Dossier na temat Anthony Fauciego/COVID-19

Ta praca została częściowo wsparta przez zbiórkę pieniędzy, w której około 330 osób przekazało fundusze na wsparcie zespołu technologicznego New Earth i Urban Global Health Alliance. Jest ona udostępniona na licencji Creative Commons CC- BY-NC-SA. Wszelkie pochodne wykorzystanie tego dossier musi być upublicznione dla dobra innych. Wszystkie dokumenty, referencje i informacje zawarte w niniejszym dokumencie, mają charakter taki jaki mają w chwili ich opublikowania. Autor nie ponosi odpowiedzialności za błędy w zapisie publicznym lub w odniesieniach do niego. W całym dokumencie, użycie terminów powszechnie przyjętych w literaturze medycznej i naukowej, nie oznacza akceptacji lub odrzucenia dogmatu, który reprezentują.

[Dossier – zbiór dokumentów dotyczących jakiejś sprawy]

SARS-CoV-2 w kontekście patentów sprzed 20 lat – dr David Martin

Wersja po angielsku – The Fauci COVID-19 Dossier

 

Dossier na temat Anthony Fauciego/COVID-19

 

Dossier na temat Anthony Fauciego-COVID-19

Tło:

Przez ostatnie dwie dekady, moja firma – M-CAM – monitorowała możliwe naruszenia Protokołu o zakazie używania gazów duszących, trujących lub innych w czasie wojny; bakteriologicznych metod prowadzenia wojny (Protokół Genewski z 1925 roku) oraz Konwencji o zakazie prowadzenia badań, produkcji i gromadzenia zapasów broni bakteriologicznej i toksycznej oraz ich zniszczeniu (BTWC z 1972 roku). W naszej Globalnej Ocenie Technologii na lata 2003-2004: Zbrojenia Wektorowe [Global Technology Assessment: VectorWeaponization]. W M-CAM zwróciliśmy uwagę na rosnące zaangażowanie Chin, w technologię łańcuchowej reakcji polimerazy (PCR), w odniesieniu do dołączenia do światowej sceny w konstrukcji chimerycznych wektorów wirusowych. Od tego czasu, co tydzień, monitorujemy rozwój badań i wysiłki komercyjne w tej dziedzinie, włączając w to, ale nie ograniczając się, do synergii badawczej tworzącej się pomiędzy amerykańskim Centrum Kontroli i Prewencji Chorób (CDC), Narodowym Instytutem Alergii i Chorób Zakaźnych (NIAID), Uniwersytetem Północnej Karoliny w Chapel Hill (UNC), Uniwersytetem Harvarda, Uniwersytetem Emory, Uniwersytetem Vanderbilta, Uniwersytetem Tsinghua, Uniwersytetem Pensylwanii oraz wieloma innymi instytucjami badawczymi i ich komercyjnymi powiązaniami.

Grant AI23946-08 przyznany przez Narodowy Instytut Zdrowia dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny w Chapel Hill (oficjalnie sklasyfikowany jako powiązany z Narodowym Instytutem Alergii i Chorób Zakaźnych [NIAID] dr Anthony’ego Fauci przynajmniej w 2003 roku) rozpoczął prace nad syntetycznym modyfikowaniem Coronaviridae (rodzina koronawirusów) w wyraźnym celu prowadzenia ogólnych badań, wzmacniania patogenów, wykrywania, manipulowania i potencjalnych interwencji terapeutycznych, skierowanych na te same czynniki. Już 21 maja 2000 roku dr Ralph Baric i Uniwersytet Północnej Karoliny [UNC] dążyli do opatentowania krytycznych sekcji rodziny koronawirusów, dla własnych korzyści komercyjnych [U.S. Provisional Application No. 60/206,537, filed May 21, 2000]. W jednej z kilku prac, powstałych w wyniku prac sponsorowanych przez ten grant, dr R. Baric opublikował to, co według niego było pełnej długości cDNA wirusa SARS CoV, w którym wyraźnie stwierdzono, że wirus SAR CoV był oparty na złożonym segmencie DNA.

“Używając panelu przylegających cDNA, które obejmują cały genom, złożyliśmy cDNA o pełnej długości szczepu SARS-CoVUrbani i uratowaliśmy molekularnie sklonowane wirusy SARS (klon zakaźny SARS-CoV), które zawierały oczekiwane mutacje markera wstawione do klonów składowych.”- PNAS October 28, 2003 100 (22) 12995-13000; Reversegenetics with a full-lengthinfectiouscDNA of severeacute respiratory syndromecoronavirus https://www.pnas.org/content/100/22/12995

Wiosną, 19 kwietnia 2002 roku, przed pierwszym wybuchem SARS w Azji – Christopher M. Curtis, Boyd Yount i Ralph Baric złożyli wniosek o patent U.S. 7279372 na metodę wytwarzania rekombinowanego koronawirusa. W pierwszym publicznym zapisie stwierdzeń, starali się oni opatentować sposób wytwarzania “zakaźnego, defektywnego w replikacji koronawirusa”. Praca ta była wspierana przez grant NIH wspomniany powyżej i GM63228. W skrócie, amerykański Departament Zdrowia i Opieki Społecznej [HHS] był zaangażowany w finansowanie wzmacniania zakaźnej natury koronawirusów w latach 1999-2002, zanim SARS został kiedykolwiek wykryty u ludzi.

Na tym tle zauważyliśmy niezwykłe wysiłki CDC w zakresie podejmowanych starań uzyskania patentów, gdy 25 kwietnia 2003 r. starało się ono o opatentowanie koronawirusa SARS wyizolowanego od ludzi, który podobno przeniósł się na ludzi podczas epidemii SARS w Azji w latach 2002-2003. Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101] dotyczący wynalazków podlegających opatentowaniu zabrania patentowania przyrody. Ten przepis nie powstrzymał CDC w ich wysiłkach. Ich wniosek, uaktualniony w 2007 roku, ostatecznie został wydany jako patent USA 7220852 i ograniczał każdego, kto nie był licencjonowany [upoważniony] przez ich patent, do manipulowania SARS CoV, rozwijania testów lub zestawów do pomiaru koronawirusa SARS u ludzi lub pracy z ich opatentowanym wirusem do użytku terapeutycznego. Prace związane z tym wirusem, prowadzone przez wybranych współpracowników, obejmowały: znaczne ilości inżynierii chimerycznej, badania typu uzyskiwania funkcji [gain-of-function], charakteryzację wirusa, wykrywanie, leczenie (zarówno szczepionki, jak i interwencje terapeutyczne) oraz badania nad bronią biologiczną.

Krótko mówiąc, dzięki patentowi dr Barica [USA 6593111] (roszczenia 1 i 5) oraz patentowi CDC o numerze 7220852 (roszczenie 1), żadne badania w Stanach Zjednoczonych nie mogły być prowadzone bez zezwolenia lub naruszenia tychże patentów.

Zauważyliśmy, że specjalista w dziedzinie badań nad uzyskiwaniem funkcji [gain-of-function], dr Ralph Baric, był zarówno odbiorcą milionów dolarów amerykańskich w postaci dotacji na badania od kilku agencji federalnych, jak i zasiadał w Międzynarodowym Komitecie Taksonomii Wirusów [International Committee on Taxonomy of Viruses (ICTV)] Światowej Organizacji Zdrowia oraz w Grupie Badawczej Coronaviridae (CSG).

Haplogrupy dzielą się na dodatkowe podgrupy - gałęzie (subklad)

Haplogrupy [A] dzielą się na dodatkowe podgrupy (subklad) [A1a i A1b, A2a i A2b].

W tym charakterze, dr Ralph Baric był odpowiedzialny za określanie “nowości” wśród kladów różnych gatunków wirusów, ale także bezpośrednio korzystał z deklarowanych nowości – w formie nowych wniosków na finansowanie badań i związanej z nimi współpracy patentowej i handlowej. Razem z CDC, NIAID, WHO, placówkami akademickimi i podmiotami komercyjnymi (w tym Johnson & Johnson; Sanofi i ich kilkoma firmami biotechnologicznymi, posiadającymi patenty na koronawirusy; Moderna; Ridgeback; Gilead; Sherlock Biosciences; i inne), potężna grupa interesów tworzyła coś, odnośnie czego sugerowalibyśmy, że jest “wzajemnym powiązaniem/zazębianiem się dyrekcji”, zgodnie z amerykańskimi prawami antymonopolowymi.

Podmioty te były również powiązane z Globalną Radą Monitorowania Gotowości [Global Preparedness Monitoring Board [GPMB)] pod WHO, której członkowie odegrali zasadniczą rolę w finansowanym przez Open Philanthropy globalnym ćwiczeniu „przy stole” odnośnie pandemii koronawirusów o nazwie “Wydarzenie 201” w październiku 2019 roku.

To wydarzenie [Event 201], sfinansowane przez głównego inwestora w Sherlock Biosciences oraz Fundację Billa i Melindy Gatesów w mandat Globalnej Rady Monitorowania Gotowości [GPMB] na globalne ćwiczenie w sprawie gotowości na choroby układu oddechowego, które ma być zakończone do września 2020 roku, zaalarmowało nas to, bo pojawiła się wskazówka dotycząca scenariusza przyszłej “epidemii”. Spodziewaliśmy się, że taki scenariusz pojawi się w Wuhan lub Guangdong w Chinach, w północnych Włoszech, w Seattle, w Nowym Jorku lub w kombinacji tych miejsc, ponieważ prace dr Zhengli Shi i dr Barica nad odzwierzęcym przenoszeniem się koronawirusa, zidentyfikowały nakładające się mutacje koronawirusa w populacjach nietoperzy znajdujących się w tych obszarach.

Dossier ten nie jest bynajmniej wyczerpujący. Wskazuje on jednak na liczne naruszenia prawa karnego, które mogą być związane z terroryzmem COVID-19. Wszystkie materiały źródłowe są w nim cytowane. Dodatkowe szczegółowe zestawienie wszystkich osób, instytucji badawczych, fundacji, źródeł finansowania i przedsiębiorstw komercyjnych jest dostępne na życzenie.

 

Spis treści:

35 U.S.C. § 101 – Wynalazki Podlegające Opatentowaniu
18 U.S.C. §2339 C i nast. – Finansowanie Aktów Terroru i Spiskowanie w Celu ich Popełnienia
18 U.S.C. § 2331 §§ 802 – Akty Terroryzmu Krajowego Skutkujące Śmiercią Obywateli Amerykańskich
18 U.S.C. § 1001 – Okłamywanie Kongresu
15 U.S.C. §1-3 – Spiskowanie w Celu Prowadzenia Przestępczej Działalności Gospodarczej
15 U.S.C. §8 – Manipulacja i Alokacja Rynku
15 U.S.C. § 19 – Wzajemne Powiązania Między Dyrekcjami
35 U.S.C. §200 – 206 – Ujawnienie Interesu Rządowego/Państwowego
21 C.F.R. § 50.24 et seq., Nielegalne Badania Kliniczne
Podmioty komercyjne

 

 

 

Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101]

 

Z opinii sędziego Clarence’a Thomasa dla większości

Paragraf 101 ustawy o patentach stanowi: „Ktokolwiek wymyśli lub odkryje nowy i użyteczny proces, maszynę, produkcję lub skład materii, lub jakiekolwiek nowe i użyteczne ich ulepszenie, może uzyskać na nie patent, z zastrzeżeniem warunków i wymagań niniejszego rozdziału.”35 U.S.C. § 101.

Od dawna “uważamy, że przepis ten zawiera ważny domyślny wyjątek: prawa natury, zjawiska naturalne i abstrakcyjne idee nie podlegają opatentowaniu”. Mayo, 566 U.S., at , 132 S.Ct., at 1293 (wewnętrzne cytaty i nawiasy pominięte). Są one raczej “podstawowymi narzędziami pracy naukowej i technologicznej”, które leżą poza domeną ochrony patentowej. Tamże 132 S.C., 1293. Jak wyjaśnił Sąd, bez tego wyjątku, istniałoby znaczne niebezpieczeństwo, że przyznanie patentów “uwięziłoby” wykorzystanie takich narzędzi i w ten sposób “zahamowałoby przyszłe innowacje oparte na nich”. Tamże, w 132 S.Ct., na 1301. Byłoby to sprzeczne z samym sensem istnienia patentów, które istnieją po to, by promować twórczość. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.C. 2204, 65 L.Ed.2d 144 (1980) (Produkty natury nie są wytwarzane, a “‘manifestacje… natury [są] wolne dla wszystkich ludzi i nie są zastrzeżone na wyłączność dla kogokolwiek'”).Association for MolecularPathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

W swojej większościowej opinii z 2013 roku Sąd Najwyższy USA wyraźnie zaznaczył, że Sąd “od dawna utrzymywał”, że natura nie podlega patentowaniu. Samo wyizolowanie DNA nie stanowi przedmiotu patentu. W swoim patencie CDC przedstawiło fałszywe i wprowadzające w błąd twierdzenia w Biurze Patentów i Znaków Towarowych Stanów Zjednoczonych, stwierdzając, że “nowo wyizolowany ludzki koronawirus został zidentyfikowany jako czynnik wywołujący SARS i nazwany SARS-CoV ” [U.S. Patent 7220852] . Na poparcie tego stwierdzenia nie przedstawiono żadnych danych “przyczynowych”.

Kiedy 25 kwietnia 2003 r. złożyli wniosek patentowy, ich pierwszym roszczeniem (i jedynym, które przetrwało do ostatecznego wydania, mimo sprzeciwu eksperta patentowego w 2006 i 2007 r.) był genom wirusa SARS CoV.

Chociaż patent ten jest wyraźnie nielegalny zgodnie z 35 U.S.C. §101, CDC nie tylko nalegało na jego przyznanie pomimo nieostatecznych i ostatecznych odrzuceń, ale także nadal płaciło opłaty za utrzymanie patentu po tym, jak decyzja Sądu Najwyższego z 2013 r. potwierdziła, że był on sprzeczny z prawem.

Ponadto CDC opatentowało wykrywanie wirusa SARS CoV przy użyciu wielu metod, w tym reakcji łańcuchowej polimerazy z odwrotną transkrypcją (RT-PCR). Dzięki temu patentowi wykluczyli oni kogokolwiek spoza ich licencjonowanych lub spiskujących interesów z legalnego angażowania się w niezależną weryfikację ich twierdzeń, że wyizolowali wirusa, że jest on czynnikiem powodującym SARS, lub że jakakolwiek terapia może być skuteczna przeciwko zgłoszonemu patogenowi.

Należy zauważyć, że wnioski patentowe CDC zostały również odrzucone w odmowach nieostatecznych i ostatecznych z powodu niekwalifikowalności na podstawie 35 U.S.C. § 102, ponieważ zostały publicznie ujawnione przed ich złożeniem. W pierwszym nieostatecznym odrzuceniu USPTO stwierdził, że genom CDC został opublikowany w czterech wpisach akcesyjnych Genbank 14, 18 i 21 kwietnia 2003 r. z identycznością od 96,8% do 99,9% identycznych sekwencji. [Źródło: USPTO Non-FinalRejection File #10822904, September 7, 2006, page 4.]

Dr Fauci wiedział i nie ujawnił dowodów na to, że patent CDC był sprzeczny z prawem, w oparciu o prace, które finansował w latach poprzedzających wybuch SARS.

Po uzyskaniu nielegalnego patentu, złożeniu petycji o unieważnienie decyzji eksperta o jego odrzuceniu, a następnie ostatecznym przyznaniu patentu, CDC okłamało opinię publiczną, twierdząc, że kontroluje patent, aby był on “publicznie dostępny”.

Rzecznik CDC Llelwyn Grant powiedział, że: „Całym celem tego patentu jest uniemożliwienie ludziom kontrolowania technologii. Robi się to po to, aby zapewnić przemysłowi i innym badaczom rozsądny dostęp do próbek.” – Źródło: 6 maj 2003, Race to Patent SARS VirusRenewsDebate]

Tragikomicznym jest fakt, że to publiczne oświadczenie obala prosty fakt, że ich własna publikacja w Genbanku w rzeczywistości uczyniła go domeną publiczną, a tym samym nie nadawała się do opatentowania. Fakt ten, potwierdzony przez inspektorów patentowych, został unieważniony przez CDC w ramach płatnej akwizycji mającej na celu obejście prawa.

Chociaż nie jest to objęte 35 U.S.C. §101, nadużycie prawa patentowego przez dr Anthony Fauciego jest szczegółowo opisany poniżej. Na uwagę zasługuje jednak jego rozmyślne i zwodnicze użycie terminu “szczepionka” w patentach i publicznych wypowiedziach, w celu wypaczenia znaczenia tego terminu dla manipulacji opinią publiczną.

W sprawie Jacobson v. Mass z 1905 roku sąd jasno stwierdził, że aby szczepionka była obowiązkowa, wymagana jest KORZYŚĆ PUBLICZNA. Ani Pfizer, ani Moderna nie udowodniły zakłócenia w transmisji [zaraźliwości] wirusa. W sprawie Jacobson v. Massachusetts, 197 U.S. 11 (1905), sąd stwierdził, że kontekst ich opinii opiera się na następującej zasadzie:

“Ten sąd więcej niż raz uznał to za fundamentalną zasadę, że ‘osoby i własność podlegają wszelkiego rodzaju ograniczeniom i obciążeniom w celu zabezpieczenia ogólnego komfortu, zdrowia i dobrobytu państwa…”.

W testach “rzekomej szczepionki” Moderna i Pfizer wyraźnie przyznali, że ich technologia terapii genowej nie ma żadnego wpływu na infekcję wirusową lub przenoszenie wirusa, a jedynie przekazuje biorcy zdolność do endogennej produkcji białka kolcowego S1 poprzez wprowadzenie syntetycznej sekwencji mRNA. Dlatego podstawa statutu Massachusetts i ustalenia Sądu Najwyższego jest w tym przypadku nieistotna.

Co więcej, Urząd Patentów i Znaków Towarowych Stanów Zjednoczonych [USPTO], podczas procesu REJESTRACJI szczepionki przeciwko HIV, który to wniosek Anthony Fauci złożył, otrzymał następującą odpowiedź na poparcie odrzucenia jego fałszywego “wynalazku”:

Wniosek/numer kontrolny: 09/869,003 Strona 5

Wniosek/numer kontrolny: 09/869,003 Strona 5

Te argumenty są przekonujące w zakresie, w jakim antygenowy peptyd stymuluje odpowiedź immunologiczną, która może wytworzyć przeciwciała wiążące się z określonym peptydem lub białkiem, ale nie są przekonujące w odniesieniu do szczepionki. Odpowiedź immunologiczna wywołana przez szczepionkę musi być czymś więcej niż tylko pewną reakcją immunologiczną, ale musi mieć charakter ochronny. Jak zauważono w poprzedniej skardze do Urzędu, w sztuce [medycznej] termin “szczepionka” oznacza środek, który zapobiega infekcji. Wnioskodawca nie wykazał, że zgłoszona szczepionka spełnia nawet niższy standard określony w specyfikacji, a tym bardziej standardową definicję sztuki, aby być skuteczną w tym zakresie.

Dlatego roszczenia 5, 7 i 9 nie są skuteczne jako szczepionka przeciw HIV-1, a zatem nie mają patentowej użyteczności.

 

18 U.S.C. §2339 C i nast. – Finansowanie Aktów Terroru i Spiskowanie w Celu ich Popełnienia

 

Pośrednio, bezprawnie i umyślnie dostarcza lub gromadzi fundusze z zamiarem ich wykorzystania lub ze świadomością, że fundusze te mają zostać wykorzystane, w całości lub w części, w celu przeprowadzenia:

(A) czynu, który stanowi przestępstwo w ramach traktatu określonego w podsekcji (e)(7), wdrożonego przez Stany Zjednoczone, lub

(B) jakiegokolwiek innego czynu mającego spowodować śmierć lub poważne uszkodzenie ciała osoby cywilnej lub każdej innej osoby nie biorącej czynnego udziału w działaniach wojennych w sytuacji konfliktu zbrojnego, jeżeli celem takiego czynu, ze względu na jego charakter lub kontekst, jest zastraszenie ludności lub zmuszenie rządu lub organizacji międzynarodowej do podjęcia lub zaniechania działania….

Nie później niż 11 kwietnia 2005 r. dr Anthony Fauci publicznie uznał związek SARS z potencjałem bioterrorystycznym. Wykorzystując strach przed bioterroryzmem wywołanym przez wąglik w 2001 roku, publicznie świętował gospodarcze dobrodziejstwo, jakie ludzie od zajmowania się terroryzmem krajowym skierowali na jego budżet. W szczególności stwierdził, że NIAID aktywnie finansuje badania nad mikromacierzą DNA “SARS Chip” do szybkiego wykrywania SARS (coś, co nie zostało udostępnione podczas obecnej “pandemii”) i dwoma kandydatami na szczepionki skoncentrowane na białku kolcowych SARS-CoV.

Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/

Pod kierownictwem trzech zatrudnionych przez siebie chińskich badaczy – Zhi-yong Yanga, Wing-pui Konga i YueHuanga – Fauci miał do 2004 roku co najmniej jedną szczepionkę DNA w trakcie badań na zwierzętach.

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/

Zespół ten, wchodzący w skład Centrum Badań nad Szczepionkami przy NIAID, koncentrował się przede wszystkim na opracowywaniu szczepionek przeciwko HIV, ale jego zadaniem było również zidentyfikowanie kandydatów na szczepionkę przeciwko SARS. We współpracy z Sanofi, ScrippsInstitute, Harvardem, MIT i NIH, decyzja dr Fauci o jednostronnym promowaniu szczepionek jako podstawowej interwencji w przypadku kilku wyznaczonych “chorób zakaźnych” uniemożliwiła zastosowanie sprawdzonych terapii u chorych i umierających.

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/

Dr Peter McCullough o blokowaniu metod leczenia Covid-19
Leczenie chorób wirusowych: czy prawdę ukrywano przez dziesięciolecia? – dr Lee D. Merritt

CDC i NIAID pod kierownictwem Anthony’ego Fauci weszły w wymianę handlową między państwami (w tym, ale nie tylko, współpraca z EcoHealth Alliance Inc.) i z obcymi narodami (w szczególności z Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk) poprzez grant z 2014 roku, o oznaczeniu R01AI110964 Narodowego Instytutu Zdrowia [NIH], w celu wykorzystania swoich praw patentowych. Wiadomo było, że badania te dotyczyły białek powierzchniowych koronawirusów, które miały zdolność do bezpośredniego zakażania ludzkich układów oddechowych. Mimo rażącego naruszenia moratorium NIH na badania typu uzyskiwania funkcji [gain of function], NIAID i dr Ralph Baric kontynuowali prace nad chimerycznymi składnikami koronawirusów, specjalnie w celu wzmocnienia patogenności materiału biologicznego.

Do października 2013 roku, w ramach prac finansowanych przez NIAID w Chinach, Instytut Wirusologii w Wuhan opisał białko kolcowe S1 1 koronawirusa. W prace te zaangażowane były NIAID, USAID oraz Peter Daszak, szef EcoHealth Alliance. Praca ta, finansowana w ramach grantu R01AI079231, była kluczowa w izolowaniu i manipulowaniu fragmentami wirusów wybranych z różnych miejsc w całych Chinach, które zawierały wysokie ryzyko poważnej reakcji u ludzi.

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
https://pubmed.ncbi.nlm.nih.gov/24172901/

Do marca 2015 r. wiadomo było, że zarówno wirulencja białka kolcowe S1, jak i receptor ACE2 stanowią znaczne zagrożenie dla zdrowia ludzkiego. NIAID, EcoHealth Alliance i liczni badacze ubolewali nad faktem, że opinia publiczna nie była wystarczająco zaniepokojona koronawirusem, aby odpowiednio finansować ich pożądane badania.

National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses https://www.ncbi.nlm.nih.gov/books/NBK349040/

Dr Peter Daszak z EcoHealth Alliance zaproponował następującą ocenę sytuacji:

“Daszak powtórzył, że dopóki kryzys związany z chorobami zakaźnymi nie stanie się bardzo realny i nie przekroczy progu sytuacji kryzysowej, jest często w dużym stopniu ignorowany. Aby utrzymać bazę finansową po zakończeniu kryzysu, musimy zwiększyć świadomość opinii publicznej odnośnie konieczności opracowania medycznych środków zapobiegawczych, takich jak powszechny program uniwersalnych szczepień przeciwko koronawirusom. Kluczowym elementem napędzającym ten proces są media, a gospodarka szybko podchwyci ten trend. Musimy wykorzystać ten szum medialny i zaadresować prawdziwe problemy. Inwestorzy się pojawią, gdy tylko wyczują potencjalne zyski z finalizacji tego procesu, stwierdził Daszak.” – Źródło: Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.

Ekonomia będzie podążać za trendem/szumem.

CDC i NIAID weszły w wymianę handlową między Stanami (w tym, ale nie ograniczając się do pracy z Uniwersytetem Północnej Karoliny w Chapel Hill [UNC]) i z zagranicą (w szczególności, Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk reprezentowanych przez Shi Zheng-Li) poprzez U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), i dofinansowanie z Narodowej Fundacji Nauk Przyrodniczych w Chinach 81290341 (Zheng-Li Shi) i wsp. 2015-2016. Projekty te miały miejsce w czasie, gdy wykonywane prace były zakazane przez amerykańskie Narodowy Instytut Zdrowia [NIH].

Wytworzony w laboratorium koronawirus wywołał debatę – Jef Akst [2015]

Opinia publiczna została wyraźnie poinformowana o niebezpieczeństwach, jakie niosą ze sobą badania finansowane przez NIAID w 2015 i 2016 roku, kiedy materiał z Instytutu Wirusologii w Wuhan był obrabiany w placówce Uniwersytetu Północnej Karoliny [UNC], czyli laboratorium dr Ralpha Barica.

“Jedynym skutkiem tej pracy, jest stworzenie w laboratorium nowego, nienaturalnego zagrożenia” – zgadza się Richard Ebright, biolog molekularny i ekspert ds. obrony biologicznej na Rutgers University w Piscataway, w stanie New Jersey. Zarówno Ebright jak i Wain-Hobson są długoletnimi krytykami badań typu gain-of-function [uzyskiwania funkcji].

W swoim artykule autorzy badania przyznają również, że fundatorzy mogą/powinni się dobrze zastanowić o dopuszczeniu takich eksperymentów w przyszłości. “Panele naukowe mogą uznać, że podobne badania, nad budową wirusów chimerycznych, opartych na krążących szczepach, są zbyt ryzykowne, aby je prowadzić” – piszą, dodając, że potrzebna jest dyskusja na temat tego, “czy tego typu badania nad wirusami chimerycznymi uzasadniają dalsze badania w porównaniu z nieodłącznym ryzykiem”.

Ale dr Baric i inni twierdzą, że badania przyniosły korzyści. Wyniki badań “przesuwają tego wirusa z kandydata na nowo pojawiający się patogen do wyraźnego i obecnego zagrożenia”, mówi dr Peter Daszak, który był współautorem pracy z 2013 roku. Peter Daszak jest prezesem EcoHealth Alliance, międzynarodowej sieci naukowców z siedzibą w Nowym Jorku, która pobiera próbki wirusów od zwierząt i ludzi w miejscach występowania nowych chorób na całym świecie.

Dr Peter Daszak zgadza się, że badania testujące hybrydowe wirusy w ludzkich hodowlach komórkowych i modelach zwierzęcych mają ograniczony zakres, jeśli chodzi o to, co mogą powiedzieć o zagrożeniu stwarzanym przez dzikiego wirusa. Twierdzi on jednak, że mogą one pomóc wskazać, które patogeny powinny być traktowane priorytetowo w dalszych badaniach.” – Nature, 12 listopad 2015, Engineered bat virus stirs debate over risky research https://www.nature.com/articles/nature.2015.18787

Anthony Fauci: „Korzyści ze zgromadzonych danych przeważają nad ryzykiem związanym z pandemią” – dr Chris Martenson
EcoHealth Alliance dr Petera Daszaka ukryło prawie 40 milionów dolarów z Pentagonu i zmilitaryzowało naukę o pandemii – Sam Husseini

Wiedząc, że amerykański Departament Zdrowia i Usług Społecznych [HHS] (poprzez CDC, NIH, NIAID oraz finansowane przez nich laboratoria i partnerów komercyjnych) miał patenty na każdy proponowany element medycznych środków zaradczych i ich finansowanie, dr Fauci, dr Gao (Chińskie CDC) i dr Elias (Fundacja Billa i Melindy Gates) spiskowali, aby popełnić akty terroru na globalnej populacji – w tym obywatelach Stanów Zjednoczonych – kiedy we wrześniu 2019 r. opublikowali następujące informacje w corocznym raporcie na temat globalnej gotowości na sytuacje kryzysowe związane ze zdrowiem:

“Kraje, darczyńcy i instytucje wielostronne muszą być przygotowane na najgorsze.

Szybko rozprzestrzeniająca się pandemia spowodowana śmiertelnym patogenem oddechowym (czy to naturalnie pojawiającym się, czy też przypadkowo lub celowo uwolnionym), stawia dodatkowe wymagania dotyczące gotowości. Darczyńcy i instytucje wielostronne muszą zapewnić odpowiednie inwestycje w rozwój innowacyjnych szczepionek i terapii, zdolności produkcyjnych, leków antywirusowych o szerokim spektrum działania oraz odpowiednich interwencji niefarmakologicznych. Wszystkie kraje muszą opracować system natychmiastowego udostępniania sekwencji genomu każdego nowego czynnika chorobotwórczego do celów zdrowia publicznego, a także środki umożliwiające wymianę ograniczonych medycznych środków zaradczych między krajami.

Wskaźnik(i) postępu do września 2020 roku:

– Darczyńcy i kraje zobowiązują się i określają harmonogramy: finansowania i opracowania uniwersalnej szczepionki przeciwko grypie, leków antywirusowych o szerokim spektrum działania i terapii celowanych. WHO i jej państwa członkowskie opracowują opcje standardowych procedur i harmonogramów udostępniania danych dotyczących sekwencji, próbek i medycznych środków zaradczych dla patogenów innych niż grypa.

– Darczyńcy, kraje i instytucje wielostronne opracowują wieloletni plan i podejście do wzmocnienia zdolności badawczych w zakresie badań i rozwoju, przed i w trakcie epidemii.

– WHO, Fundusz Narodów Zjednoczonych na rzecz Dzieci, Międzynarodowa Federacja Stowarzyszeń Czerwonego Krzyża i Czerwonego Półksiężyca, partnerzy akademiccy i inni partnerzy określają strategie zwiększania możliwości i integracji podejść i badaczy z dziedziny nauk społecznych w całym kontinuum gotowości i reagowania ” – str. 8, Annual report on global preparedness for health emergencies

Jakby na potwierdzenie użyteczności żądania z września 2019 r. o “finansowanie i rozwój” szczepionki oraz fortunnego rzekomego wybuchu SARS CoV-2 w grudniu 2019 r., dr Fauci zaczął napawać się, że jego losy w zakresie dodatkowego finansowania prawdopodobnie zmieniają się na lepsze. W wywiadzie w STAT z 10 lutego 2020 roku, został on zacytowany w następujący sposób:

“”Pojawienie się nowego wirusa zmieni tę liczbę, prawdopodobnie znacznie”, powiedział Fauci. “Nie wiem, jak dużo to będzie. Ale myślę, że to będzie generować bardziej trwałe zainteresowanie koronawirusami, ponieważ jest bardzo jasne, że koronawirusy mogą dokonywać naprawdę interesujących rzeczy.”” – Fluctuating funding and flagging interest hurt coronavirus research, leaving crucial knowledge gaps

 

18 U.S.C. § 2331 §§ 802 – Akty Terroryzmu Krajowego Skutkujące Śmiercią Obywateli Amerykańskich

 

Sekcja 802 amerykańskiej ustawy PATRIOT Act (Pub. L. No. 107-52) rozszerzyła definicję terroryzmu, aby objąć “krajowy,” w przeciwieństwie do międzynarodowego, terroryzm. Osoba angażuje się w terroryzm krajowy, jeśli dokonuje czynu “niebezpiecznego dla życia ludzkiego”, który jest pogwałceniem praw karnych stanu lub Stanów Zjednoczonych, jeśli czyn ten wydaje się być zamierzony, aby: (i) zastraszyć lub wymusić [coś] na ludności cywilnej; (ii) wywrzeć wpływ na politykę rządu poprzez zastraszenie lub wymuszenie;

Dr Anthony Fauci zastraszał i zmuszał ludność cywilną oraz próbował wpłynąć na politykę rządu poprzez zastraszenie i przymus.

Bez żadnego potwierdzenia, dr Anthony Fauci promował symulację komputerową profesora Neila Fergusona, wywodząc z niej twierdzenia, że:

“Świat stoi w obliczu najpoważniejszego kryzysu zdrowia publicznego od pokoleń. Tutaj przedstawiamy konkretne szacunki skali zagrożenia, przed jakim stoją obecnie kraje.”

“Używamy najnowszych szacunków dotkliwości, aby pokazać, że strategie polityczne, których celem jest złagodzenie epidemii, mogą zmniejszyć liczbę zgonów o połowę i ograniczyć szczyt zapotrzebowania na opiekę zdrowotną o dwie trzecie, ale to nie wystarczy, aby zapobiec przeciążeniu systemów opieki zdrowotnej. Aby ograniczyć przenoszenie choroby do niskiego poziomu, konieczne będą zatem bardziej intensywne i społecznie destrukcyjne interwencje. Jest prawdopodobnym, że takie środki – przede wszystkim dystans społeczny na dużą skalę – będą musiały być stosowane przez wiele miesięcy, być może aż do momentu, gdy dostępna będzie szczepionka.” – Imperial College London, 17 marca 2020, COVID-19: Imperial researchers model likely impact of public healthmeasures

Przegląd kodu źródłowego z modelu Fergusona
COVID – dlaczego terminologia ma znaczenie? – dr Malcolm Kendrick
Plusy i minusy środków zaradczych przeciw pandemii grypy – dr Thomas Inglesby, prof. Jennifer Nuzzo, prof. Tara O’Toole i prof. Donald Henderson [listopad 2006]
Lockdown jest ponad 10 razy bardziej śmiertelny niż sama pandemia

Informując prezydenta, że aż 2,2 miliona zgonów może być skutkiem patogenu, który nie został jeszcze wyizolowany i którego nie można było zmierzyć z żadną dokładnością, dr Fauci zastraszył i zmusił ludność oraz rząd do lekkomyślnych, niesprawdzonych i szkodliwych działań, powodujących nieodwracalne szkody dla życia i środków do życia.

Ani Imperial College, ani “niezależny” Institute for HealthMetrics and Evaluation [Instytut Mierzenia i Oceny Zdrowia] (finansowany głównie przez Fundację Billa i Melindy Gatesów)nie miały żadnych dowodów na sukces w szacowaniu wcześniejszych obciążeń spowodowanych koronawirusem, ale bez konsultacji czy wzajemnej weryfikacji dr Fauci przyjął ich przerażające szacunki za podstawę interwencji, które są wyraźnie sprzeczne z zaleceniami medycznymi.

– Nałożenie dystansu społecznego było oparte na symulacji komputerowej i modelach środowiskowych, które nie zawierały żadnych dowodów na przenoszenie chorób.

– Narzucenie noszenia masek na twarz było bezpośrednio sprzeczne z dowodami z kontrolowanych badań klinicznych i z pisemną polityką w czasopiśmie Amerykańskiego Stowarzyszenia Medycznego [AMA].

“Maski na twarz nie powinny być noszone przez zdrowe osoby w celu ochrony przed nabyciem infekcji dróg oddechowych, ponieważ nie ma dowodów sugerujących, że maski na twarz noszone przez zdrowe osoby są skuteczne w zapobieganiu chorobie.”JAMA. 2020;323(15):1517-1518; Medical Masks

– Zarówno w symulacjach Imperial College, jak i IHME, kwarantanny były modelowane dla osób chorych, a nie zdrowych.

Geneza idei zamykania kraju [Lockdown] sięga 2006 roku – Jeffrey A. Tucker [American Institute for Economic Research]
Maseczki nie działają: Przegląd literatury naukowej w kontekście zasadności polityki społecznej wobec COVID-19 – dr Denis Rancourt

Naleganie na szczepionki, przy jednoczesnym blokowaniu awaryjnego stosowania sprawdzonych interwencji farmaceutycznych, mogło przyczynić się do śmierci wielu pacjentów i zdrowych osób.

Wykorzystując władzę NIAID podczas domniemanej pandemii, dr Anthony Fauci aktywnie tłumił sprawdzone medyczne środki zaradcze, stosowane i potwierdzone w postępowaniach naukowych, które oferowały alternatywę dla produktów finansowanych przez jego spiskujące podmioty, którym zapewnił bezpośrednie finansowanie i dla których miał otrzymywać korzyści materialne i niematerialne.

Alan Jones: Biurokraci zaprzeczają, że hydroksychlorochina zmniejsza śmiertelność
Koronawirus: Jak sobie z nim poradzić? – Prof. Didier Raoult [Chlorochina]
Hydroksychlorochina – czy działa na koronawirusa? – Dr Vladimir Zelenko
Wywiad z dr Stellą Immanuel o Hydroksychlorochinie [30 lipiec 2020]
COVID-19 – Dr Richard Bartlett: Strategia oparta na leku Budezonid

 

 

18 U.S.C. § 1001 – Okłamywanie Kongresu

 

(a)O ile niniejsza sekcja nie stanowi inaczej, każdy, kto w jakiejkolwiek sprawie podlegającej jurysdykcji władzy wykonawczej, ustawodawczej lub sądowniczej Rządu Stanów Zjednoczonych, świadomie i umyślnie-

(1) fałszuje, ukrywa lub tuszuje za pomocą jakiejkolwiek sztuczki, schematu lub urządzenia istotny fakt;

(2) składa jakiekolwiek materialnie fałszywe, fikcyjne lub oszukańcze oświadczenie lub reprezentację; lub

(3) sporządza lub wykorzystuje fałszywe pismo lub dokument, wiedząc, że zawiera on fałszywe, fikcyjne lub oszukańcze oświadczenie lub wpis; podlega grzywnie na mocy niniejszego paragrafu, karze pozbawienia wolności na okres nie dłuższy niż 5 lat lub, jeśli przestępstwo wiąże się z międzynarodowym lub krajowym terroryzmem (zgodnie z definicją w sekcji 2331), karze pozbawienia wolności na okres nie dłuższy niż 8 lat, lub obu tym karom. Jeżeli sprawa dotyczy przestępstwa z rozdziału 109A, 109B, 110 lub 117, lub sekcji 1591, wówczas kara pozbawienia wolności nałożona na mocy niniejszej sekcji nie przekracza 8 lat.

 

W dniu 22 października 2020 r. Biuro Odpowiedzialności Rządu Stanów Zjednoczonych (GAO) opublikowało raport zatytułowany:

BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property.

W dokumencie tym autorzy poinformowali, że Narodowy Instytut Zdrowia (NIH) otrzymał “do 2 miliardów dolarów w tantiemach z tytułu wkładu w 34 leki sprzedane w latach 1991-2019”.

Pobieżny przegląd raportu NIH Office of Technology Transfer dotyczącego aktywnych licencji wydaje się sprzeczny z raportem GAO w odniesieniu do kilku istotnych faktów. W raporcie GAO wyraźnie brakuje ponad 30 patentów związanych z aktywnymi związkami generującymi miliardy dolarów przychodu. Dlaczego GAO i NIH nie mogły dojść do porozumienia w sprawie czegoś tak prostego, jak leki generujące dochód dla NIH?

Od czasu uchwalenia ustawy Bayh Dole Act (Pub. L. 96-517, 12 grudnia 1980 r.), badania finansowane z funduszy federalnych były ekonomiczną bonanzą dla amerykańskich uniwersytetów, agencji federalnych i ich wybranych patronów. W pierwszej dekadzie po wprowadzeniu ustawy Bayh-Dole, fundusze NIH podwoiły się z 3,4 miliarda dolarów do 7,1 miliarda dolarów. Dekadę później- podwoiły się ponownie- osiągając 15,6 miliarda dolarów. W następstwie września 2001 roku, Narodowy Instytut Alergii i Chorób Zakaźnych (NIAID) odnotował bezpośredni wzrost swojego budżetu o ponad 300%, bez uwzględnienia funduszy DARPA, które od 2005 roku wynosiły aż 1,7 miliarda dolarów rocznie. W 2020 roku budżet NIH wynosił ponad 41 miliardów dolarów.

Co się stało z 763 miliardami dolarów z funduszy podatników przeznaczonych na uczynienie Ameryki zdrowszą, odkąd wynalazcy są zachęcani do komercyjnego działania? Kto się wzbogacił?

Odpowiedź, niestety, jest taka, że skrupulatne rozliczenia nie są prowadzone, aby móc odpowiedzieć na te pytania.

Narodowy Instytut Zdrowia [NIH] jest wymienionym z nazwy właścicielem co najmniej 138 patentów od 1980 roku.

Amerykański Departament Zdrowia i Opieki Społecznej [HHS] jest wymienionym z nazwy właścicielem co najmniej 2600 patentów.

Dotacje lub współpraca z NIAID zaowocowały 2655 patentami i wnioskami patentowymi, z których tylko 95 zawiera przypisanie do Departamentu Zdrowia i Usług Społecznych jako właściciela. Większość z tych patentów jest przypisana do uniwersytetów, co sprawia, że ostateczni beneficjenci komercyjni są całkowicie nieprzejrzyści. Jednym z największych posiadaczy jest SIGA Technologies (NASDAQ: SIGA), która, choć publicznie informuje o bliskich związkach z NIAID, nie jest wymieniona w raporcie NIH GAO. Dyrektor generalny SIGA, dr Phillip L. Gomez spędził 9 lat w NIAID, rozwijając program szczepionek przeciwko HIV, SARS, Ebola, Wirusa Zachodniego Nilu i grypy, zanim przeszedł do przedsięwzięć komercyjnych. Chociaż ich technologia wyraźnie wywodzi się z osiągnieć naukowych do których przyczynił się NIAID, firma zgłasza przychody z NIAID, ale nie ma żadnych opłat licencyjnych ani płatności komercyjnych na rzecz NIH lub któregokolwiek z jego programów.

Dyrektor NIAID, dr Anthony Fauci, jest wymieniony jako wynalazca w 8 przyznanych patentach amerykańskich. Żaden z nich nie został zgłoszony w raportach NIAID, NIH lub GAO dotyczących aktywnego licencjonowania, pomimo faktu, że dr Fauci został podobno zmuszony do otrzymania zapłaty za swój “wynalazek” w postaci Interleukiny-2 – płatności, które podobno przekazał nienazwanej organizacji charytatywnej.

Z 21 patentów wymienionych w pomarańczowej księdze amerykańskiej Agencji ds. Żywności i Leków (FDA), wymienionych w raporcie GAO, żaden z patentów dr Anthony’ego Fauci nie jest wymieniony. Co więcej, żaden z patentów NIAID nie jest wymieniony pomimo wyraźnych dowodów na to, że Gilead Sciences i Janssen Pharmaceuticals (oddział Johnson & Johnson) wygenerowały ponad 2 miliardy dolarów rocznie ze sprzedaży, która była bezpośrednim rezultatem osiągnięć naukowych finansowanych przez NIAID. W raporcie GAO brakuje 2 patentów na Velclade, który od kilku lat generuje sprzedaż przekraczającą 2,18 miliarda dolarów rocznie. Żaden z patentów dla Yescarta nie jest wymieniony w raporcie GAO. Żaden z patentów na Lumoxiti nie jest wymieniony w raporcie GAO. Żaden z patentów na lek Kepivance nie został wymieniony w raporcie GAO. Z naruszeniem 37 USC §410.10 i 35 USC §202(a), ponad 13 z 21 patentów w raporcie GAO nie ujawnia interesów rządu, mimo że są one bezpośrednim wynikiem finansowania przez NIH.

Odporność i bezkarność: korupcja w relacjach Państwo-Farmacja – dr PaddyRawlinson
Prawda o firmach farmaceutycznych. Jak nas oszukują i co z tym robić – dr MarciaAngell

Własny dorobek patentowy dr Anthony’ego Fauci:

Patent US 6190656 i 6548055 Wzmocnienie immunologiczne z przerywaną terapią interleukiną-2

Metoda aktywacji układu odpornościowego ssaków obejmuje serię podań IL-2, co odbywa się z przerwami przez dłuższy okres czasu. Każde podanie IL-2 jest wystarczające, aby umożliwić wzrost i szczyt spontanicznej syntezy DNA w komórkach krwi obwodowej lub węzłów chłonnych pacjenta, a każde następne podanie następuje po poprzednim podaniu w serii przez okres czasu, który jest wystarczający, aby umożliwić ekspresję receptora IL-2 w krwi obwodowej lub węzłach chłonnych pacjenta, aby wzrosnąć, osiągnąć szczyt, a następnie zmniejszyć się do 50% wartości szczytowej. Ta przerywana terapia IL-2 może być łączona z inną terapią, która jest ukierunkowana na określony stan chorobowy, taką jak terapia antyretrowirusowa- obejmująca, na przykład, podawanie AZT, ddI lub interferonu alfa. Ponadto, podawanie IL-2 może być stosowane w celu ułatwienia transdukcji in situ limfocytów T w kontekście terapii genowej. W tym podejściu komórki są najpierw aktywowane in vivo przez wspomnianą terapię IL-2, a następnie transdukcja jest dokonywana przez dostarczenie genetycznie zmodyfikowanego wektora retrowirusowego bezpośrednio do pacjenta.

Niniejsze zgłoszenie jest kontynuacją amerykańskiego zgłoszenia patentowego nr ser. 08/487075, złożonego 7 czerwca 1995 r., obecnie zaniechanego, które jest kontynuacją w części amerykańskiego zgłoszenia patentowego nr ser. 08/063315, złożonego 19 maja 1993 r., obecnie wydanego jako patent US 5419900, oraz zgłoszenie patentowe USNr ser. 08/452440, złożone 26 maja 1995 r., obecnie wydane jako patent nr U.S. 5696079, który jest Krajowym Etapem zgłoszonego na podstawie 35 USC 371 zgłoszenia PCT/US94/05397, złożonego 19 maja 1994 r., którego treść jest włączona do niniejszego dokumentu przez przypis.

Zgłoszono 19 maja 1993 r.

Wydano Ostateczne Odrzucenie 20 stycznia 1998 r. odrzucony po odstąpieniu 14 sierpnia 1998 r. i 12 kwietnia 1999 r. ograniczone i zmodyfikowane roszczenia przyznane 8 maja 2000 r.

Ta rodzina patentów była podstawą kłamstwa Fauci’ego dla czasopisma British Medical Journal, w którym fałszywie stwierdził:

“Dr Anthony Fauci powiedział BMJ, że jako pracownik rządowy, był zobowiązany przez prawo do umieszczenia swojego nazwiska na patencie dotyczącym rozwoju interleukiny 2 [IL-2] i był również zobowiązany przez prawo do otrzymania części zapłaty, którą rząd otrzymał za wykorzystanie patentu. Powiedział, że uważa otrzymanie zapłaty za niestosowne (sic) i przekazał całą kwotę na cele charytatywne.”BMJ. 2005 Jan 22; 330(7484): 162.

Nie był “zobowiązany przez prawo” do popełnienia oszustwa wobec urzędu patentowego, a następnie otrzymania za to zapłaty!

 

Patent US 6911527 Peptydy związane z HIV

Wynalazek ten polega na odkryciu nowych specyficznych epitopów i przeciwciał związanych z długotrwałym przeżyciem infekcji HIV-1. Te epitopy i przeciwciała mają zastosowanie w przygotowywaniu szczepionek do zapobiegania infekcji HIV-1 lub do kontrolowania progresji do AIDS.

Zgłoszony 6 maja 1999 r.

Odrzucony jako niepatentowalny 22 stycznia 2003 roku. Wydane z ostatecznym odrzuceniem 15 lipca 2004 r. po złożeniu wniosków o ponowne rozpatrzenie. Zmodyfikowane i ograniczone roszczenia dopuszczone 29 września 2004 roku.

 

Patent US 7368114 Białko fuzyjne, w tym CD4

Odkryto tu nowe rekombinowane polipeptydy, które zawierają polipeptyd CD4 podwiązany na jego końcu C z częścią immunoglobuliny zawierającą region zawiasowy i stałą domenę łańcucha ciężkiego immunoglobuliny ssaków.

Część lub IgG jest połączona na swoim końcu C z polipeptydem zawierającym końcówkę z końcem C łańcucha ciężkiego przeciwciała IgA lub końcówkę z końca C łańcucha ciężkiego przeciwciała IgM. Ujawnione są tu również metody stosowania tych białek fuzyjnych CD4.

Zgłoszono 24 października 2002 r.

Odrzucony jako niepatentowalny 18 sierpnia 2006 roku. Opłacone odwołanie w celu uchylenia ustaleń eksperta 15 lutego 2007 roku. Ponownie odrzucony 11 maja 2007 roku. W dniu 10 października 2007 r. wnioskodawcy jeszcze bardziej zawęzili konstrukcję tego, co wyraźnie nie było patentem, a USPTO przyznało mniej niż połowę roszczeń, o które ubiegano się w pierwotnym zgłoszeniu.

 

Patent US 9896509, 9193790 i 9441041 Zastosowanie antagonistów interakcji pomiędzy HIV GP120 i integryną alfa 4 beta 7

Podano metody leczenia zakażenia HIV. Metody mogą obejmować podawanie podmiotowi z zakażeniem HIV terapeutycznie skutecznej ilości środka, który zakłóca interakcję gp120 i alfa 4 integryny, takiego jak antagonista alfa 4 beta 1 lub integryny alfa 4 beta 7, lecząc w ten sposób zakażenie HIV. W kilku przykładach, antagonistą integryny alfa 4 jest przeciwciało monoklonalne, które wiąże się swoiście z podjednostką integryny alfa 4, beta 1 lub beta7 lub cyklicznym heksapeptydem o sekwencji aminokwasowej CWLDVC. Przedstawiono również metody zmniejszania replikacji lub infekcji HIV. Metody obejmują kontakt komórki ze skuteczną ilością środka, który zakłóca interakcję gp120 i integryny alfa 4, takiego jak antagonista integryny alfa 4 beta 1 lub alfa 4 beta 7. Ponadto, dostarczane są metody określania, czy środek jest użyteczny w leczeniu HIV.

Odrzucony 22 maja 2017 roku jako podwójnie opatentowany. W swojej odpowiedzi wnioskodawcy przyznają się do bezprawnego działania i dążą do uzyskania tylko tych elementów swojego zgłoszenia, które wykraczają poza okres obowiązywania wydanych patentów. W dniu 11 października 2017 r. wydano ograniczone roszczenia.

 

Próbka zagmatwanego przepływu funduszy, który wymyka się publicznemu ujawnieniu.

 

US Patent 8999351 został wydany Tekmira Pharmaceuticals Corporation w Burnaby, Kolumbia Brytyjska, w Kanadzie. W swoim patencie ujawniają oni, że ich badania były wspierane przez grant z Narodowego Instytutu Alergii i Chorób Zakaźnych (Grant HHSN266200600012C). Jak na ironię, ten grant o wartości 23 milionów dolarów został przyznany w 2006 roku firmie Alnylam Pharmaceuticals, Inc, a nie firmie Tekmira.

W 2012 roku firma Alnylam zgodziła się zapłacić firmie Tekmira 65 milionów dolarów w celu rozstrzygnięcia sporów prawnych, w tym roszczenia o odszkodowanie w wysokości 1 miliarda dolarów za “bezlitosne i okrutne” przywłaszczenie tajemnic handlowych firmy Tekmira. Od najwcześniejszego pierwszeństwa zgłoszenia patentowego z 10 listopada 2008 r., nie ma żadnego publicznego zapisu wskazującego na firmę Tekmira jako beneficjenta tego grantu NIAID. Niezależnie od tego, technologia nanocząstek lipidowych opracowana w ramach tego grantu jest technologią wykorzystywaną obecnie w interwencji [szprycy] firmy Moderna na COVID-19. W swoim zgłoszeniu 10-Q firma Alnylam informuje, że posiada licencję na technologię od firmy Arbutus – dawniej Tekmira – która oskarżyła firmę Acuitas o przywłaszczenie tajemnic handlowych i przekazanie licencji na nie firmie Moderna oraz koncernowi Pfizer współpracującego z firmą BioNTech.

Dodatkowe przypisy:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

 

15 U.S.C. §1-3 – Spiskowanie w Celu Prowadzenia Przestępczej Działalności Gospodarczej

 

Każda umowa, kombinacja w formie powiernictwa lub w inny sposób, lub zmowa, w celu ograniczenia handlu pomiędzy kilkoma Stanami lub z obcymi narodami, jest uznana za nielegalną. Każda osoba, która zawrze jakąkolwiek umowę lub zaangażuje się w jakąkolwiek kombinację lub zmowę uznaną niniejszym za nielegalną, zostanie uznana za winną przestępstwa, a po skazaniu będzie podlegać karze grzywny nieprzekraczającej 100.000.000 dolarów, jeśli jest korporacją, lub, 1.000.000 dolarów jeśli jest inną osobą, lub karze pozbawienia wolności nieprzekraczającej 10 lat, lub obu tym karom, według uznania sądu.

Grant AI23946-08 z Narodowego Instytutu Zdrowia przyznany dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny w Chapel Hill (oficjalnie sklasyfikowany jako powiązany z NIAID dr Anthony’ego Fauci przynajmniej w 2003 roku) rozpoczął prace nad syntetycznym modyfikowaniem Coronaviridae (rodzina koronawirusów) w wyraźnym celu prowadzenia ogólnych badań, wzmacniania patogenności, wykrywania, manipulowania i potencjalnych interwencji terapeutycznych skierowanych na te same czynniki/patogeny. Już 21 maja 2000 roku dr R. Baric z Uniwersytetem Północnej Karoliny [UNC] dążyli do opatentowania krytycznych sekcji rodziny koronawirusów dla własnych korzyści komercyjnych [U.S. Provisional Application No. 60/206,537, filed May 21, 2000].

W jednej z kilku prac powstałych w wyniku prac sponsorowanych przez ten grant, dr Baric opublikował to, co według niego było pełnej długości cDNA wirusa SARS CoV, w którym wyraźnie stwierdzono, że wirus SAR CoV opierał się na kompozycji segmentów DNA.

Używając panelu sąsiadujących cDNA, które obejmują cały genom, złożyliśmy cDNA o pełnej długości szczepu SARS-CoVUrbani i uratowaliśmy sklonowane molekularnie wirusy SARS (klon zakaźny SARS-CoV), które zawierały oczekiwane mutacje markera wstawione do klonów składowych.”PNAS October 28, 2003 100 (22) 12995-13000; Reverse genetics with a full-length infectiousc DNA of severe acute respiratory syndrome coronavirus

Dnia 19 kwietnia 2002 roku – wiosną przed pierwszym wybuchem SARS w Azji – Christopher M. Curtis, Boyd Yount i Ralph Baric złożyli wniosek o patent nr US 7279372 na metodę produkcji rekombinowanego koronawirusa. W pierwszym publicznym zapisie roszczeń, starali się oni opatentować sposób wytwarzania “zakaźnego, defektywnego w replikacji koronawirusa”. Praca ta była wspierana przez grant NIH wspomniany powyżej i GM63228. W skrócie, amerykański Departament Zdrowia i Opieki Społecznej [HHS] był zaangażowany w finansowanie wzmacniania zakaźnej natury koronawirusa w latach 1999-2002, zanim SARS został kiedykolwiek wykryty u ludzi.

Na tym tle zauważyliśmy niezwykłe starania amerykańskiego Centrum Kontroli i Prewencji Chorób [CDC] na opatentowanie koronawirusa SARS wyizolowanego z ludzi, który według doniesień został przeniesiony na ludzi podczas epidemii SARS w Azji w latach 2002-2003. Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101] zabrania patentowania przyrody. Ten przepis nie powstrzymał CDC w ich wysiłkach. Ich wniosek, uaktualniony w 2007 roku, ostatecznie został wydany jako patent US 7220852 i ograniczał każdego, kto nie był licencjonowany przez ich patent, od manipulowania SARS CoV, rozwijania testów lub zestawów do pomiaru koronawirusa SARS u ludzi lub pracy z ich opatentowanym wirusem do użytku terapeutycznego. Prace związane z tym wirusem, prowadzone przez wybranych współpracowników, obejmowały znaczne ilości inżynierii chimerycznej, badania typu uzyskiwania funkcji [gain-of-function], charakterystykę wirusa, wykrywanie, leczenie (zarówno szczepionki, jak i interwencje terapeutyczne) oraz badania nad bronią biologiczną.

Krótko mówiąc, dzięki patentowi dr Barica US 6593111 (roszczenia 1 i 5) oraz patentowi CDC US 7220852 (roszczenie 1), żadne badania w Stanach Zjednoczonych nie mogły być prowadzone bez ich zezwolenia lub naruszenia tego patentu.

Zauważyliśmy, że specjalista w dziedzinie badań typu gain-of-function, dr Ralph Baric, był zarówno odbiorcą milionów dolarów amerykańskich dotacji na badania od kilku instytucji federalnych, jak i zasiadał w Międzynarodowym Komitecie Taksonomii Wirusów (ICTV) Światowej Organizacji Zdrowia oraz w Grupie Badawczej Coronaviridae (CSG). W ramach tej funkcji był zarówno odpowiedzialny za określanie “nowości” kladów gatunków wirusów, jak i bezpośrednio korzystał z deklaracji o nowościach w postaci nowych zezwoleń na finansowanie badań oraz związanej z nimi współpracy patentowej i komercyjnej. Razem z CDC, NIAID, WHO, placówkami akademickimi i podmiotami komercyjnymi (w tym Johnson & Johnson; Sanofi i ich kilkoma firmami biotechnologicznymi posiadającymi patenty na koronawirusy; Moderna; Ridgeback; Gilead; Sherlock Biosciences; i, inne), potężna grupa interesów tworzyła to, co sugerowalibyśmy jako “wzajemnympowiązaniem dyrekcji” zgodnie z amerykańskimi prawem antymonopolowym.

1986-1990 NIAID Grant AI 23946 prowadzący do uzyskania patentu US 7279327 “Methods for Producing Recombinant Coronavirus”. Zgłoszony w 2002 r. i wydany w 2007 roku

Praca opublikowana po raz pierwszy na podstawie grantu NIAID to:

An Experimental Model for Dilated Cardiomyopathy after Rabbit Coronavirus Infection

https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf

1990 Pfizer zgłasza patent US 6372224 na szczepionkę przeciwko koronawirusowi opartą o białko S 14 listopada 2000 r. który został porzucony w kwietniu 2010 r., co czyni go domeną publiczną.

Lata 90. Prace koncentrowały się na związku koronawirusów z kardiomiopatią (patrz wyżej)

Wczesne odniesienie do “pojawienia się” koronawirusa jako patogenu układu oddechowego:

High Recombination And Mutation Rates In Mouse Hepatitis Virus Suggest That Coronaviruses May Be Potentiall Y Important Emerging Viruses

https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf

2000Dr Ralph Baric w ramach grantów AI23946 i GM63228 z Narodowego Instytutu Zdrowia [NIH] aktywnie pracuje nad rekombinowanym koronawirusem

2001 Narodowy Instytut Zdrowia, Alergie i Choroby Zakaźne. “Reverse Genetics with a Coronavirus Infectious cDNA Construct”. 4/1/2001-3/31/005 całkowity roczny koszty to 1 milion dolarów. RS Baric, PI

2002 Wybuch epidemii koronawirusa SARS w Azji

2003 25 kwietnia 2003 CDC złożyło patent, który ostatecznie uzyskała, jego numer to US 7220852 (patent na sekwencję RNA) oraz US 7776521 (patent na metodologię badań). Patenty te dają amerykańskiemu Departamentowi Zdrowia i Usług Społecznych [HHS] możliwość kontrolowania komercyjnego wykorzystania koronawirusa SARS.

Dr Anthony Fauci zostaje mianowany członkiem Naukowej Rady Doradczej Global Grand Challenges Fundacji Billa i Melindy Gatesów (pełnił tę funkcję do 2010 roku).

28 kwietnia 2003 r. Sequoia Pharmaceuticals składa wniosek o patent US 7151163(Środki przeciwwirusowe do leczenia, kontroli i zapobiegania zakażeniom koronawirusami). Otrzymało w tym samym roku dwa granty w wysokości 953 tysięcy dolarów od HHS.

21 lipca 2003 r. zespół Ralpha Barica (wykorzystujący granty AI23946 i GM63228) zgłasza patent US 7618802 (Kompozycje koronawirusów z genomem odpornym na rekombinację), który został wydany 17 listopada 2009 roku.

Instytut Onkologii Dana-Farber w listopadzie 2003 zgłasza patent US 7750123 na przeciwciało monoklonalne neutralizujące wirusa SARS CoV. Badania te są wspierane przez kilka grantów NIH, w tym przez granty z Narodowego Instytutu Zdrowia o oznaczeniach A128785, A148436 i A1053822.

2004 6 stycznia 2004 – SARS i bioterroryzm na konferencji Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators.

Na tej konferencji termin “Nowa Normalność” został wprowadzony przez firmę Merck.

Dr FAUCI I dr BARIC zaczynają zarabiać pieniądze!!! Narodowy Instytut Alergii i Chorób Zakaźnych (NIAID). SARS Reverse Genetics. AI059136-01. Koszty całkowite 1,7 miliona dolarów, RS Baric, PI. 10% wysiłku. 4/1/04- 3/31/09. Projekt ma na celu opracowanie pełnej długości zakaźnego cDNA wirusa SARS-CoV, opracowanie cząstek replikonowych SARS-CoV wyrażających heterologiczne geny oraz adaptację SARS-CoV na myszy, co pozwoli na stworzenie mysiego modelu patogennej infekcji SARS-CoV.

Narodowy Instytut Alergii i Chorób Zakaźnych. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% nakładu pracy. 7/1/04-6/30/09. 2,1 miliona dolarów.

22 listopada 2004 Uniwersytet w Hong Kongu patentuje białko kolcowe związane z SARS i ubiega się o patent US 7491489 (Syntetyczny peptyd celujący w krytyczne miejsca na białku kolca koronawirusa związanym z SARS odpowiedzialnym za infekcję wirusową i sposób jego zastosowania).

2005 Agencja ds. Zaawansowanych Projektów Badawczych w Obszarze Obronności (DARPA).Biohacking: Biological Warfare Enabling Technologies, czerwiec 2005. Waszyngton, Dystrykt Kolumbia. Wydarzenie sponsorowane przez DARPA/MITRE.

Przegląd osi czasu z https://www.youtube.com/watch?v=rO EeYBQiQU i https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

2008 Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 rozpoczyna się od 10.189.682 milionów dolarów dla UNC w Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

2009 Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 jest kontynuowany, przekazano kolejne 5.448.656 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID)

2010 Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 8.747.142 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

Liczba wydanych patentów na koronawirus SARS osiągnęła szczyt od czasu wybuchu epidemii w Azji (391 patentów).

6 sierpnia 2010 r., Moderna (przed jej założeniem) składa wniosek o patent US 9447164, który przyciągnął inwestorów (i “wynalazców”) z Flagship Ventures. Patent ten wyrósł z pracy dr Jasona P. Schruma z Harvard Medical School, wspieranego przez National Science Foundation Grant#0434507. Podczas gdy wniosek rości sobie prawo do pierwszeństwa z sierpnia 2010 roku, wniosek nie został sfinalizowany aż do października 2015 roku. W dniu 4 listopada 2015 roku USPTO wydał nieostateczne odrzucenie tego oryginalnego patentu, odrzucając wszystkie roszczenia.

https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 z odniesieniem do finansowania w

https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

2011 Crucell dołączył do Janssen Pharmaceutical Companies będącego częścią Johnson & Johnson w lutym, zabierając ze sobą całą swoją technologię dotyczącą SARS.

Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 jest kontynuowany, przekazano 7.344.820 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

2012 MERS wyizolowany w Egipcie

Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 7.627.657 USD dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

2013 Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 7.226.237 milionów dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID)

2014 23 kwietnia 2014, Moderna zgłasza patent na szczepionkę na bazie kwasu nukleinowego, patenty US9872900 i US10022435

2015 Moderna podpisuje umowę o rozwoju szczepionki z NIAID i realizuje ją z wiodącym na rynku twórcą i wynalazcą mRNA-1273 Guiseppe Ciaramella.

https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html

2016 Narodowy Instytut Zdrowia [NIH] poprzez Scripps Institute i Dartmouth College składają wniosek patentowy WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use [Białka kolcowe koronawirusa sprzed fuzji i ich zastosowanie]” ujawniający technologię mRNA, która pokrywa się (i jest używana w tandemie z) technologią Moderny.

Główny wynalazca Barney Scott Graham był dobrze znany firmie Moderna, jako że jest on osobą w Narodowym Instytucie Zdrowia [NIH], do której Moderna “wysłała e-maila” w celu uzyskania sekwencji dla SARS CoV-2, zgodnie z raportem Moderny tutaj (“W styczniu 2020 roku, gdy odkryto, że infekcja w Wuhan była spowodowana nowym koronawirusem, Bancel szybko wysłał e-maila do dr Barneya Grahama, zastępcy dyrektora Centrum Badań nad Szczepionkami w Narodowym Instytucie Zdrowia, prosząc go o przesłanie sekwencji genetycznej wirusa.” – Źródło: Executives of vaccine developer Moderna cash in, cutcorners, 26 maj 2020)

Ponadto, współwynalazca Jason McLellan pracował z dr Barney’em Grahamem nad patentem na szczepionkę będącą wspólną własnością rządu chińskiego złożonym w Australii w 2013 roku. AU 2014231357A1 – Epitope of RSV fusion protein and antibody identifying same

2017 sierpień – Sanofi kupuje firmę Protein Science Corp posiadającą znaczne zasoby patentów na SARS

2018 czerwiec – firma Sanofi kupuje firmę Ablynx posiadającą znaczne zasoby patentów na SARS

2019 marzec, Sherlock Biosciences licencjonuje technologię Wyss, aby tworzyć przystępną cenowo diagnostykę molekularną – finansowane przez Open Philanthropy – tę samą organizację, która będzie sponsorem finansowym ćwiczeń “przy stole” o nazwie Wydarzeni 201, które ułożyło plan “pandemii” w październiku 2019 roku.

 

15 U.S.C. §8 – Manipulacja i Alokacja Rynku

 

Za sprzeczne z porządkiem publicznym, nielegalne i nieważne uznaje się wszelkie kombinacje, zmowy, powiernictwa, porozumienia lub umowy zawierane przez lub pomiędzy dwiema lub więcej osobami lub korporacjami, z których każda, jako agent lub zleceniodawca, zajmuje się importem jakiegokolwiek artykułu z jakiegokolwiek obcego kraju do Stanów Zjednoczonych, oraz gdy takie kombinacje, zmowy, powiernictwa, porozumienia lub umowy mają na celu ograniczenie legalnego handlu lub wolnej konkurencji w legalnym handlu, lub zwiększenie ceny rynkowej w jakiejkolwiek części Stanów Zjednoczonych jakiegokolwiek artykułu lub artykułów importowanych lub przeznaczonych do importu. Porozumienie lub umowa mają na celu ograniczenie handlu zgodnego z prawem lub wolnej konkurencji w handlu zgodnym z prawem, lub zwiększenie ceny rynkowej w jakiejkolwiek części Stanów Zjednoczonych artykułu lub artykułów importowanych lub przeznaczonych do importu do Stanów Zjednoczonych, lub jakiejkolwiek produkcji, do której taki importowany artykuł wchodzi lub ma wejść. Każda osoba, która zajmuje się importem jakichkolwiek towarów z jakiegokolwiek obcego kraju, z naruszeniem przepisów niniejszej sekcji, lub która łączy się lub spiskuje z innymi w celu naruszenia tych przepisów, jest winna wykroczenia i po skazaniu jej w jakimkolwiek sądzie Stanów Zjednoczonych taka osoba zostanie ukarana grzywną w wysokości nie mniejszej niż 100 dolarów i nie przekraczającej 5000 dolarów, a ponadto zostanie ukarana więzieniem, według uznania sądu, na okres nie krótszy niż trzy miesiące i nie przekraczający dwunastu miesięcy.

Poprzez niekonkurencyjne przyznawanie grantów dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny [UNC]w Chapel Hill, wybór lokalizacji laboratoriów bezpieczeństwa biologicznego poziomu 4 (BSL-4), ustalanie cen Remdesiviru i terapii mRNA firm Moderna i Pfizer, NIAID, CDC i Departament Zdrowia i Opieki Społecznej [HHS] były zaangażowane w przydzielanie funduszy federalnych spiskującym stronom bez niezależnej kontroli.

Od około 12 marca 2020 roku, w celu wzbogacenia własnych interesów ekonomicznych poprzez zapewnienie dodatkowych funduszy zarówno od podmiotów federalnych, jak i fundacji, CDC i dr Fauci z NIAID postanowili zawiesić badania i sklasyfikować COVID-19 wyłącznie na podstawie kapryśnej prezentacji objawów. Zmuszając opinię publiczną do polegania na The COVID Tracking Project – finansowanym przez Fundację Bloomberga, Zuckerberga i Gatesa i prezentowanym przez media (The Atlantic) – a nie agencję zdrowia publicznego – dr Fauci użył oszukańczej technologii testowania (RT-PCR), aby mylić “przypadki COVID” z pozytywnymi testami PCR u żywych, jednocześnie nalegając, aby zgony z powodu COVID były liczone wyłącznie na podstawie objawów. To utrwaliło popyt rynkowy na jego pożądany program szczepień, który był powtarzany przez niego i spiskujące z nim strony na całym świecie aż do chwili obecnej. Nic dziwnego, że było to konieczne z powodu widocznego spadku liczby przypadków, które stanowiły kryteria dr Fauci’ego i innych do pozbawiania obywateli ich praw wynikających z 1. Poprawki Konstytucji.

Myślenie pojęciowe, a myślenie stereotypowe – Andrzej Wronka, Kazimierz Ajdukiewicz
COVID – dlaczego terminologia ma znaczenie? – dr Malcolm Kendrick
Jak dokładne są testy na COVID? – dr Sebastian Rushworth
Testy PCR: Po 35 cyklach odcięcia nie wyhodujesz wirusa – dr Anthony Fauci
Nawet połowa testów na koronowirusa może być fałszywie pozytywna [Chiny]
Nieoczekiwane wykrycie przeciwciał na SARS-CoV-2 w okresie przed pandemicznym we Włoszech. [wrzesień 2019]

15 U.S.C. § 19 – Wzajemne Powiązania Między Dyrekcjami

 

(1) Żadna osoba nie może w tym samym czasie pełnić funkcji dyrektora lub urzędnika w dwóch korporacjach (innych niż banki, stowarzyszenia bankowe i spółki powiernicze), które są-

(A) zaangażowane w całości lub częściowo w handel; oraz

(B) ze względu na swoją działalność i miejsce prowadzenia działalności są konkurentami, tak że wyeliminowanie konkurencji w drodze porozumienia między nimi stanowiłoby naruszenie jakichkolwiek przepisów antymonopolowych; jeżeli każda z tych korporacji posiada kapitał, nadwyżkę i niepodzielne zyski o łącznej wartości przekraczającej 10.000.000 dolarów, skorygowane zgodnie z ustępem (5) niniejszej podsekcji.

Dr Anthony Fauci jest członkiem Rady Przywódczej [Leadership Council] Globalnego Planu Działań na rzecz Szczepionek [Gates Global Vaccine Action Plan] Billa i Malindy Gates.

Dr Fauci, kontrolując wydawanie federalnych funduszy na badania, był i nadal jest członkiem Rady Monitorowania Globalnej Gotowości [Global Preparedness Monitoring Board] Światowej Organizacji Zdrowia. Dołączył do niego w tej radzie skonfliktowany darczyńca z Fundacji Billa i Melindy Gates, dr Chris Elias, oraz dr George F. Gao z Chińskiej Rady Państwowej ichniego Centrum Kontroli i Prewencji Chorób. Ta Rada Monitorowania Globalnej Gotowości [GPMB] przewidywała, że wszystkie państwa członkowskie muszą wziąć udział w globalnej symulacji uwolnienia patogenu układu oddechowego.

Dr Ralph Baric jest jednym z głównych beneficjentów funduszy federalnych USA, prowadzi ośrodek BSL-4 i zasiada w grupie roboczej International Committee on Taxonomy of Virus Corona viridae, której zadaniem jest potwierdzenie obecności lub jego braku patogenu, za co otrzymuje bezpośrednie wynagrodzenie.

Jak wspomniano w części dotyczącej naruszeń 18 U.S.C. § 1001 powyżej, istnieją liczne nieujawnione relacje handlowe pomiędzy naukowcami otrzymującymi finansowanie, ich instytucjami finansującymi oraz interesami handlowymi, w których występują ujawnione i nieujawnione warunki handlowe. Pełna lista wszystkich potencjalnie zaangażowanych stron jest wymieniona w poniższej części zatytułowanej “Podmioty komercyjne”.

Wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny są sprzeczne z prawem, CDC i Narodowy Instytut Alergii i Chorób Zakaźnych kierowany przez Anthony’ego Fauci (dalej odpowiednio “NIAID” i “dr Fauci”) weszły w wymianę handlową między państwami (w tym m.in. współpracując z Ecohealth Alliance Inc. ) oraz z zagranicą (w szczególności z Instytutem Wirusologii w Wuhan oraz Chińską Akademią Nauk) za pośrednictwem grantu R01AI110964 z programu grantów Narodowego Instytutu Zdrowiaz 2014 r. i następnych, w celu wykorzystania swoich praw patentowych.

Ponadto wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny były nielegalne, CDC i Narodowy Instytut Alergii i Chorób Zakaźnych (dalej “NIAID”) weszły w wymianę handlową między stanami (w tym, ale nie tylko, współpracując z Uniwersytetem Północnej Karoliny w Chapel Hill) oraz z obcymi narodami (w szczególności z Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk reprezentowaną przez dr Shi Zheng-Li) poprzez U19AI109761 (dr Ralph S. Baric), U19AI107810 (Ralph S. Baric) oraz grant Narodowej Fundacji Nauk Przyrodniczych w Chinach o oznaczeniu 81290341 (ShiZheng-Li) i wsp. 2015-2016.

Ponadto wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny były nielegalne, CDC i NIAID weszły w wymianę handlową między Stanami (w tym, ale nie tylko, współpracując z Uniwersytetem Północnej Karoliny w Chapel Hill) i z obcymi narodami w celu prowadzenia chimerycznej konstrukcji nowatorskiego materiału koronawirusowego o specyficznych właściwościach wirulencji przed, w trakcie i po określeniu przez Narodowy Instytut Zdrowia [NIH] w październiku 17, 2014, że praca ta nie była wystarczająco zrozumiała w odniesieniu dostandardów bezpieczeństwa biologicznego tej instytucji.

Wytworzony w laboratorium koronawirus wywołał debatę – Jef Akst [2015]

W tym dochodzeniu zakłada się, że CDC i jej współpracownicy byli:
a) w pełni świadomi prac wykonywanych przy użyciu ich opatentowanej technologii;
b) zawarli wyraźne lub dorozumiane umowy obejmujące licencjonowanie, lub inne wynagrodzenie; i, c) świadomie zaangażowali jeden lub więcej zagranicznych interesów, aby kontynuować eksploatację ich zastrzeżonej technologii, gdy Sąd Najwyższy Stanów Zjednoczonych potwierdził, że takie patenty były nielegalne i gdy Narodowy Instytut Zdrowia [NIH] wydał moratorium na takie badania.

Podobno w styczniu 2018 r. ambasada USA w Chinach wysłała śledczych do Instytutu Wirusologii w Wuhan i stwierdziła, że

“Podczas interakcji z naukowcami w laboratorium Instytucie w Wuhan zauważyli oni, że nowe laboratorium ma poważny niedobór odpowiednio wyszkolonych techników i badaczy potrzebnych do bezpiecznego prowadzenia tegolaboratorium wysokiego poziomu bezpieczeństwa [szczelności biologicznej].” Gazeta Washington Post podała, że informacje te zostały zawarte w depeszy z 19 stycznia 2018 roku. Ponad rok później, w czerwcu 2019 r., CDC przeprowadziło inspekcję w Instytucie Badań Medycznych Chorób Zakaźnych Armii Stanów Zjednoczonych w Fort Detrick (zwanym dalej “USAMRIID”) i nakazało jego zamknięcie po stwierdzeniu, że ich inspekcja znalazła zagrożenia dla bezpieczeństwa biologicznego. Publikacja w czasopiśmie Nature z 2003 r. (423(6936): 103) donosi o współpracy między CDC a USAMRIID w zakresie badań nad koronawirusami, po której nastąpiła późniejsza znacząca współpraca.

„Naukowcy z NIH i armii amerykańskiej połączyli siły w systematycznym programie badań przesiewowych, aby znaleźć kandydatów na leki do zwalczania ciężkiego ostrego zespołu oddechowego (SARS). Współpraca, która już trwa, została ogłoszona na zeszłotygodniowej Międzynarodowej Konferencji na temat Badań Antywirusowych w Savannah w stanie Georgia.” – Nature, 8 maj 2003, US Army join shunt for SARS drug

CDC, ze względu na to, co wydaje się być tym samym rodzajem obaw zidentyfikowanych w Wuhan, zdecydowało się kontynuować współpracę z rządem chińskim, zamykając jednocześnie placówkę armii amerykańskiej.

CDC zgłosiło pierwszy przypadek choroby podobnej do SARS-CoV w Stanach Zjednoczonych w styczniu 2020 r., przy czym Służba Wywiadu Epidemiologicznego CDC zgłosiła 650 przypadków klinicznych i 210 testów. Biorąc pod uwagę, że podejrzany patogen po raz pierwszy pojawił się w oficjalnych raportach 31 grudnia 2019 r., można jedynie stwierdzić, że CDC:
a) posiadało mechanizm i środki do przeprowadzenia testów potwierdzających istnienie “nowego koronawirusa”; lub
b) nie posiadało takiego mechanizmu i fałszywie ogłosiło taki komunikat w styczniu.

Naiwnością jest sugerować, że WHO lub CDC mogły wyprodukować i rozprowadzić testy na “nowy” patogen, kiedy ich własne późniejsze osiągnięcia w zakresie rozwoju i wdrażania testów okazały się niewiarygodne…

Zagrożenie pandemią i wycieki z laboratoriów: Samospełniające się przepowiednie – dr Martin Furmanski
Długa historia przypadkowych ucieczek laboratoryjnych potencjalnie pandemicznych patogenów jest ignorowana w reportażach na temat COVID-19 – Sam Husseini

 

35 U.S.C. §200 – 206 – Ujawnienie Interesu Rządowego/Państwowego

 

35 U.S.C. §202 (c)(6)

Zobowiązanie wykonawcy, w przypadku złożenia wniosku patentowego w Stanach Zjednoczonych przez wykonawcę lub w jego imieniu, lub przez jakiegokolwiek cesjonariusza wykonawcy, do umieszczenia w specyfikacji takiego wniosku i każdego patentu wydanego na jego podstawie, oświadczenia określającego, że wynalazek został dokonany przy wsparciu rządu i że rząd posiada pewne prawa do wynalazku.

Ponad 5000 patentów i wniosków patentowych zawierało odniesienie do koronawirusa SARS sięgające dat pierwszeństwa z 1998 roku. Są one streszczone poniżej.

Liczba patentów związanych z koronawirusem SARS

23 lipca 2020 roku Komisja Patentowa i Odwoławcza Biura Patentów i Znaków Towarowych Stanów Zjednoczonych odrzuciła starania firmy Moderna o unieważnienie patentu US 8058069. Patent ten, będący własnością Arbutus Biopharma Corp (należącej głównie do Roivant Science Ltd), obejmuje nanocząstki lipidowe (LNP) wymagane jako medium do dostarczenia mRNA w szczepionce. Niektóre z podstawowych technologii zostały oparte na pracach wykonanych pierwotnie na Uniwersytecie Kolumbii Brytyjskiej i zostały po raz pierwszy licencjonowane w 1998 roku.

Szczepionki mRNA na COVID-19 – dr James Odell

mRNA-1273 – eksperymentalna szczepionka opracowana przez Modernę na COVID-19 – wykorzystuje technologię nanocząstek lipidowych [LNP], na którą firma Moderna uważała że ma licencje od Acuitas Therapeutics Inc, firmy utworzonej przez byłego dyrektora wcześniejszej firmy Tekmira, należącej do Arbutusa. Ta licencja nie upoważniała firmy Moderna do wykorzystania tej technologii w szczepionce COVID-19.

Firmy M-CAM i Knowledge Ecology International niezależnie potwierdziły, że Moderna naruszyła prawo amerykańskie, nie ujawniając udziału rządu USA w finansowaniu swoich patentów i wniosków patentowych. Chociaż zaniedbanie to ma wpływ na wszystkie z ponad 130 przyznanych amerykańskich patentów firmy Moderna, jest ono szczególnie problematyczne w przypadku amerykańskiego patentu US 10702600 (Beta coronavirus mRNA vaccine), który jest patentem odnoszącym się do, “informacyjnego/matrycowego kwasu rybonukleinowego (mRNA) zawierającego otwartą ramkę odczytu kodującą białko kolca [S] lub podjednostkę białka S betakoronawirusa (BetaCoV), sformułowanego w nanocząstce lipidowej”.

Konkretne roszczenia odnoszące się do kluczowego elementu koronawirusa SARS zostały opatentowane 28 marca 2019 roku – 9 miesięcy przed wybuchem epidemii SARS CoV-2! Zarówno patent, jak i finansowanie DARPA dla tej technologii zostały ujawnione w publikacji naukowej (New England Journal of Medicine), ale fundusze rządowe nie zostały wspomniane w patencie.

W 2013 r. w ramach programu Autonomiczna Diagnostyka Umożliwiająca Profilaktykę i Terapię [Autonomous Diagnostics to Enable Prevention and Therapeutics – ADEPT] przyznano grant firmie Moderna Therapeutics na opracowanie nowego typu szczepionki opartej na informacyjnym RNA [mRNA]. Pierwotny grant DARPA nosił numer W911NF-13-1-0417. Firma wykorzystała tę technologię do opracowania swojej szczepionki na COVID-19, która w momencie opublikowania tego dossier przechodziła I fazę badań klinicznych we współpracy z NIH.29

Zgodnie z przepisami Federal Acquisition Regulation (FAR), kontrahenci rządu federalnego muszą w ramach kontraktu przedstawić informacje dotyczące kwestii naruszenia własności intelektualnej. Zgodnie z FAR §27.201-1(c) i (d) rząd wymaga zarówno zawiadomienia o naruszeniu lub potencjalnym naruszeniu, jak i zachowania odpowiedzialności ekonomicznej za naruszenie patentu. Konkretnie, w FAR §52.227.3 (a),

“Wykonawca zabezpieczy rząd i jego urzędników, agentów i pracowników przed odpowiedzialnością, w tym kosztami, za naruszenie jakiegokolwiek patentu Stanów Zjednoczonych…”. Oprócz patentów cytowanych przez USPTO podczas badań, które doprowadziły do patentu US 10702600, M-CAM zidentyfikowało czternaście innych wydanych patentów poprzedzających patent US 10702600, które zostały wykorzystane przez egzaminatorów patentowych do ograniczenia patentów wynikających z tych samych finansowanych badań, w tym patentów poszukiwanych przez CureVac.

Krótko mówiąc, podczas gdy Moderna cieszy się setkami milionów dolarów finansowania i wsparcia ze strony Anthony’ego Fauci i jego NIAID, od początku swego istnienia była zaangażowana w nielegalną działalność patentową i okazywała pogardę dla amerykańskiego prawa patentowego. Co gorsza, rząd Stanów Zjednoczonych udzielił firmie Moderna wsparcia finansowego w obliczu nieujawnionego ryzyka naruszenia prawa, potencjalnie przyczyniając się do tego samego naruszenia, za które otrzymali odszkodowanie.

 

21 C.F.R. § 50.24 et seq., Nielegalne Badania Kliniczne

 

Prowadzenie badań medycznych (nawet w nagłych przypadkach) jest niezgodne z prawem bez podjęcia szeregu kroków w celu:

  1. Zorganizowania badań przez uprawnioną i instytucjonalną komisją rewizyjną;
  2. Zapewnienia świadomej zgody wszystkim uczestnikom, w tym oświadczenia o ryzyku i korzyściach; oraz,
  3. Zaangażowania się w konsultacje ze społecznością, w której badanie ma być przeprowadzone.

 

Dr Anthony Fauci wymusił na zdrowej populacji Stanów Zjednoczonych bezprawne badanie kliniczne, w którym amerykański Departament Zdrowia i Usług Społecznych [HHS] ekstrapoluje dane epidemiologiczne. Nie uzyskano ani nie zabezpieczono świadomej zgody na żaden z “medycznych środków zaradczych” narzuconych populacji i nie powołano żadnej niezależnej komisji rewizyjnej – zgodnie z definicją zawartą w ustawie.

Do kwietnia 2020 roku, oficjalne zalecenie Journal of the American Medical Association było jednoznaczne.

“Maski na twarz nie powinny być noszone przez zdrowe osoby w celu ochrony przed nabyciem infekcji dróg oddechowych, ponieważ nie ma dowodów sugerujących, że maski na twarz noszone przez zdrowe osoby są skuteczne w zapobieganiu chorobie.”JAMA. 2020;323(15):1517-1518; MedicalMasks

Część tego braku dowodów w rzeczywistości wykazała, że płócienne maski na twarz w rzeczywistości zwiększyły liczbę zachorowań związanych z grypą.

Maski z tkanin: niebezpieczne dla twojego zdrowia? – prof. Raina MacIntyre [2015]

Wbrew ustaleniom naukowym, stany, hrabstwa i przedsiębiorstwa naruszyły wymogi prawne dotyczące ogłaszania medycznych środków zaradczych podczas sytuacji zagrożenia zdrowia publicznego, wyrażając “przekonanie”, że maski na twarz ograniczają rozprzestrzenianie się wirusa SARS CoV-2. Jak dotąd, żadne z badań nie potwierdziło, że maska zapobiega przenoszeniu lub zakażeniu się SARS CoV-2.

Wydychany aerozol i maski na twarz

Wszystkie strony nakazujące stosowanie masek na twarz nie tylko świadomie ignorują ugruntowaną wiedzę z badań empirycznych, ale angażują się w coś, co jest równoznaczne z badaniem klinicznym całej populacji. Do takiego wniosku prowadzi fakt, że stosowanie masek na twarz i zapadalność na COVID-19 są omawiane w artykułach medycznych [naukowych] promowanych przez Amerykańskie Centrum Kontroli i Prewencji Chorób i inne instytucje.

2 metry czy 20 metrów, dystans nie ma większego znaczenia dla Covid-19 – prof. Martin Bazant i prof. John Bush z MIT

Dystans społeczny do 2 metrów był promowany jako środek zapobiegający przenoszeniu się wirusów grypy z osoby na osobę. Chociaż w jednym z badań wysunięto hipotezę, że do zakażenia może dojść w odległości do około 2 metrów, w badaniu tym wyraźnie stwierdzono, że nie testowano przenoszenia się wirusa między osobami, a żywotność wirusa w odległości 2 metrów nie była nawet przedmiotem badania. Nie powstrzymało to jednak przeinaczenia wyników badania, które wykorzystano jako podstawę dla niezweryfikowanego medycznego środka zaradczego, jakim jest dystans społeczny. Do tej pory żadne badanie nie wykazało skuteczności dystansu społecznego w modyfikowaniu przenoszenia wirusa SARS CoV-2. Urzędnicy zdrowia publicznego powołują się na publikację J InfectDis. 2013 Apr;207(7):1037-46:

„Wyniki: Piętnaście badań, w tym 12 modelujących i trzy epidemiologiczne, spełniło kryteria kwalifikacji. Badania epidemiologiczne wykazały, że dystans społeczny był związany z redukcją zachorowań na choroby grypopodobne i serokonwersji na grypę A (H1N1) z 2009 roku. Jednak ogólne ryzyko błędu systematycznego w badaniach epidemiologicznych było poważne. W badaniach modelujących oszacowano, że same środki dystansu społecznego w miejscu pracy spowodowały medianę obniżenia o 23% skumulowanego wskaźnika zachorowań na grypę w populacji ogólnej. Opóźniły one również i zmniejszyły szczytową częstotliwość ataków grypy. Redukcja skumulowanego wskaźnika ataków była bardziej wyraźna, gdy dystans społeczny w miejscu pracy był połączony z innymi interwencjami niefarmakologicznymi lub farmaceutycznymi. Oceniono jednak, że skuteczność zmniejszała się wraz z wyższymi wartościami podstawowej liczby reprodukcyjnej, opóźnieniem uruchomienia dystansu społecznego w miejscu pracy lub mniejszą zgodnością.

Wnioski: Badania modelowe przemawiają za stosowaniem dystansu społecznego w miejscach pracy niezwiązanych z opieką zdrowotną, ale brakuje dobrze zaprojektowanych badań epidemiologicznych.” BMC Public Health. 2018; 18: 518; Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review

Wbrew ustaleniom naukowym, państwa, powiaty i przedsiębiorstwa naruszyły wymogi prawne dotyczące ogłaszania medycznych środków zaradczych podczas zagrożenia zdrowia publicznego, wyrażając “przekonanie”, że dystans społeczny zdrowej populacji ogranicza rozprzestrzenianie się SARS CoV-2. Jak dotąd, ani jedno badanie nie potwierdziło, że dystansowanie społeczne jakiejkolwiek populacji zapobiegło rozprzestrzenianiu się lub zakażeniu SARS CoV-2.

Zgodnie z ustawą o Federalnej Komisji Handlu [FTC Act], Rozdział 15, paragraf 41 Kodeksu Stanów Zjednoczonych [15 U.S.C. § 41] i następne, niezgodne z prawem jest reklamowanie, że produkt lub usługa może zapobiegać, leczyć lub uzdrawiać choroby ludzkie, chyba że posiada się kompetentne i wiarygodne dowody naukowe, w tym, w stosownych przypadkach, rzetelne kontrolowane badania kliniczne z udziałem ludzi, potwierdzające, że twierdzenia te są prawdziwe w chwili ich wygłaszania. W związku z tym, każda strona promująca stosowanie maseczek na twarz, narusza Ustawę o Federalnej Komisji Handlu.

Wszystkie te przepisy zostały złamane. Wszystkie właściwe władze w Stanach Zjednoczonych muszą zaprzestać stosowania masek na twarz do czasu skorygowania powyższych spraw.

 

Podmioty komercyjne

 

Dla wielu osób koronawirus SARS jest nowym tematem. Od 1999 roku możliwość manipulacji i wykorzystania koronawirusów do różnych celów przyciągnęło uwagę wielu osób, instytucji i organizacji komercyjnych, zarówno w sektorze publicznym, prywatnym jak i non-profit. Poniżej znajduje się lista ponad 5100 patentów i wniosków patentowych, zgłoszonych w wyraźnym celu kontrolowania jakiegoś aspektu koronawirusa SARS.

 

 

 

 

 

PATENT Tytuł Właściciel Priorytet Data złożenia Data otrzymania
US9995706 Amperometric gas sensor Steris Corporation 25-

Jun-

12

30-

Sep

-14

12-

Jun-

18

US9995705 Amperometric gas sensor Steris Corporation 25-

Jun-

12

30-

Sep

-14

12-

Jun-

18

US9994558 Multicyclic compounds and methods of using same Karyopharm Therapeutics Inc. 20-

Sep-

13

19-

Sep

-14

12-

Jun-

18

US9994550 Heterocyclic modulators of lipid synthesis for use against cancer and viral infections 3-V Biosciences, Inc. 7-

Jan-

14

7-

Jan

-15

12-

Jun-

18

US9993543 Immunogenic compositions comprising silicified virus and methods of use Portland State University 31-

Jan-

13

31-

Jan

-14

12-

Jun-

18

US9982257 Chiral control WAVE LIFE SCIENCES LTD. 13-

Jul-12

12-

Jul-

13

29-

May

-18

US9982241 Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University 14-

May-

10

1-

Oct

-15

29-

May

-18

US9982025 Monomeric griffithsin tandemers The United States of America, as represented by the Secretary, Department of Health and Human Services 5-

Jun-

13

5-

Jun

-14

29-

May

-18

US9981036 Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 12-

Dec-

11

26-

Feb

-16

29-

May

-18

US9975885 Broad-spectrum non-covalent coronavirus protease inhibitors PURDUE RESEARCH FOUNDATION 28-

Apr-

16

28-

Apr

-17

22-

May

-18

US9974850 Immunogenic compositions and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 25-

Mar-

15

25-

Mar

-16

22-

May

-18

US9974848 Tetanus toxoid and CCL3 improve DC vaccines Duke University 14-

Nov-

13

14-

Nov

-14

22-

May

-18

US9974845 Combination of vaccination and inhibition of the PD-1 pathway CureVac AG 22-

Feb-

13

21-

Feb

-14

22-

May

-18

US9970061 Bioagent detection oligonucleotides IBIS BIOSCIENCES, INC. 27-

Dec-

11

27-

Dec

-12

15-

May

-18

US9969793 Compositions and methods for the treatment of immunodeficiency ADMA Biologics, Inc. 28-

Oct-

14

13-

Nov

-17

15-

May

-18

US9963718 LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors VIRATHERAPEUTICS GMBH 8-

Oct-

08

7-

Apr

-17

8-

May

-18

US9963611 Composition for use in decreasing the transmission of human pathogens Innonix Technologies, Incorporated 29-

May-

09

21-

May

-10

8-

May

-18

US9963427 Dithiol mucolytic agents PARION SCIENCES, INC. 23-

Aug-

13

11-

Mar

-16

8-

May

-18

US9962439 Injectable vaccine composition NITTO DENKO CORPORATION 3-

Oct-

13

2-

Oct

-14

8-

May

-18

US9957302 Treating cancer with viral nucleic acid Mayo Foundation for Medical Education and Research 20-

Feb-

07

6-

Jul-

15

1-

May

-18

US9957300 Virus-like particles, methods of preparation, and immunogenic compositions Emory University 17-

May-

02

4-

May

-15

1-

May

-18

US9957238 Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds Parion Sciences, Inc. 13-

Dec-

13

1-

Mar

-17

1-

May

-18

US9951317 Highly efficient influenza matrix (M1) proteins NOVAVAX, INC. 11-

Jul-03

6-

Oct

-16

24-

Apr-

18

 

US9951124 Antibody producing non-human mammals MERUS N.V. 27-

Jun-

08

25-

Jan

-13

24-

Apr-

18

US9951122 Antibodies against influenza virus and methods of use thereof BURNHAM INSTITUTE FOR MEDICAL RESEARCH 6-

Dec-

07

12-

Aug

-13

24-

Apr-

18

US9950062 Compounds and compositions as TLR activity modulators GLAXOSMITHKLINE BIOLOGICALS SA 2-

Sep-

09

1-

Sep

-10

24-

Apr-

18

US9945856 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V. 18-

Aug-

03

13-

Aug

-14

17-

Apr-

18

US9945780 Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer GEN-PROBE INCORPORATED 14-

Jun-

12

7-

Jun

-13

17-

Apr-

18

US9944928 Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions York Yuan Yuan Zhu 23-

Jul-07

2-

Jul-

15

17-

Apr-

18

US9944695 Antibody producing non-human mammals Menus N.V. 27-

Jun-

08

30-

Apr

-14

17-

Apr-

18

US9944686 Treatment of tumors with recombinant interferon alpha SUPERLAB FAR EAST LIMITED 28-

Feb-

01

5-

Sep

-13

17-

Apr-

18

US9944649 Compounds and compositions as toll-like receptor 7 agonists Novartis Ag 1-

May-

14

29-

Apr

-15

17-

Apr-

18

US9943614 Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods BRIGHAM YOUNG UNIVERSITY 17-

Jun-

08

16-

Jun

-09

17-

Apr-

18

US9938300 Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors Forma Therapeutics, Inc. 5-

Feb-

15

4-

Feb

-16

10-

Apr-

18

US9938275 Substituted imidazoquinolines, imidazopyridines, and i midazonaphthyridines 3M Innovative Properties Company 18-

Jun-

04

23-

Jan

-17

10-

Apr-

18

US9938258 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. 29-

Nov-

12

27-

Nov

-13

10-

Apr-

18

US9932351 Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors Forma Therapeutics, Inc. 5-

Feb-

15

4-

Feb

-16

3-

Apr-

18

US9932323 Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones Rutgers, The State University of New Jersey 11-

Sep-

12

13-

Jan

-17

3-

Apr-

18

US9931316 Antiviral activity from medicinal mushrooms and their active constituents Not Available 31-

Mar-

15

14-

Sep

-15

3-

Apr-

18

US9926340 NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH 8-

Apr-

15

1-

Apr

-16

27-

Mar

-18

US9925215 Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative UNIWERSYTET JAGIELLONSKI 29-

Jul-14

25-

Oct

-17

27-

Mar

-18

US9920314 Compositions for and methods of identifying antigens President and Fellows of Harvard College 21-

Feb-

06

6-

May

-15

20-

Mar

-18

US9920128 Synthetic antiserum for rapid-turnaround therapies The Johns Hopkins University 28-

Jan-

15

20-

Jan

-16

20-

Mar

-18

US9919034 Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V TAMIR BIOTECHNOLOGY, INC. 28-

Mar-

14

10-

Jun

-15

20-

Mar

-18

US9915613 Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector GEN-PROBE INCORPORATED 24-

Feb-

11

21-

Mar

-14

13-

Mar

-18

US9914976 Methods and compositions for prostate cancer metastasis FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA 25-

Mar-

11

27-

May

-16

13-

Mar

-18

US9913801 Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione YOUR ENERGY SYSTEMS, LLC 15-

Feb-

13

15-

Mar

-13

13-

Mar

-18

US9909176 Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq) The Johns Hopkins University 8-

Sep-

14

1-

Sep

-15

6-

Mar

-18

US9908946 Generation of binding molecules Merus N.V. 26-

Sep-

11

16-

Sep

-15

6-

Mar

-18

US9908675 Powdered pouch and method of making same MONOSOL, LLC 16-

Apr-

12

19-

Jul-

16

6-

Mar

-18

 

US9907796 Methods of treating tumoral diseases, or bacterial or viral infections INHIBIKASE THERAPEUTICS, INC. 4-

Oct-

12

15-

Sep

-16

6-

Mar

-18

US9895692 Sample-to-answer microfluidic cartridge Micronics, Inc. 29-

Jan-

10

5-

Aug

-15

20-

Feb

-18

US9895411 Analogs of C5a and methods of using same BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA 29-

Jun-

10

29-

Jun

-11

20-

Feb

-18

US9895341 Inflammation and immunity treatments Ocean Spray Cranberries, Inc. 1-

Apr-

11

30-

Mar

-12

20-

Feb

-18

US9894888 Transgenic immunodeficient mouse expressing human SIRP-alpha INSTITUT PASTEUR 26-

Mar-

12

26-

Mar

-13

20-

Feb

-18

US9890419 Nanoreporters and methods of manufacturing and use thereof NanoString Technologies, Inc. 23-

Dec-

05

20-

May

-16

13-

Feb

-18

US9890408 Multiple displacement amplification IBIS BIOSCIENCES, INC. 15-

Oct-

09

15-

Oct

-10

13-

Feb

-18

US9890362 Compositions, methods and uses for inducing viral growth Takeda Vaccines, Inc. 5-

Dec-

08

19-

Sep

-14

13-

Feb

-18

US9890361 Methods for increasing the infectivity of viruses utilizing alkyne- modified fatty acids LIFE TECHNOLOGIES CORPORATION

26-Jan-12
25-Jan-13
13-Feb-18

US9890206 H1N1 flu virus neutralizing antibodies Medigen Biotechnology Corporation
20-Aug-15
20-Aug-15
13-Feb-18

US9890169 Triazolinone compounds as HNE inhibitors CHIESI FARMACEUTICI S.P.A.
14-Dec-15
12-Dec-16
13-Feb-18
US9890124 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc.
15-Dec-15
14-Jun-17
13-Feb-18
US9889194 Immunogenic composition for MERS coronavirus infection New York Blood Center, Inc.
1-Mar-13
28-Feb-14
13-Feb-18
US9885092 Materials and methods for detection of HPV nucleic acids QIAGEN GAITHERSBURG INC.
24-Feb-11
23-Feb-12

6-Feb-18
US9885082 Embodiments of a probe and method for targeting nucleic acids University of Idaho
19-Jul-11
19-Jul-12
6-Feb-18
US9885037 Chiral control WAVE LIFE SCIENCES LTD.
13-Jul-12
12-Jul-13
6-Feb-18
US9884895 Methods and compositions for chimeric coronavirus spike proteins The University of North Carolina at Chapel Hill
20-Mar-14
20-Mar-15
6-Feb-18
US9884876 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Kineta, Inc.
9-May-14
8-May-15
6-Feb-18
US9884129 Release of agents from cells The Brigham and Women’s Hospital, Inc.
15-Oct-09
5-Jan-15
6-Feb-18
US9884032 Esters of short chains fatty acids for use in the treatment of immunogenic disorders PROPONENT BIOTECH GMBH
3-Oct-12
3-Mar-16
6-Feb-18

US9884026 Modular particles for immunotherapy YALE UNIVERSITY

1-Nov-13
31-Oct-14
6-Feb-18
US9880151 Method of determining, identifying or isolating cell-penetrating peptides Phylogica Limited
23-May-11
23-May-12
30-Jan-18

US9879026 Substituted spirocycles Boehringer Ingelheim International GmbH
12-Sep-14
29-Nov-16
30-Jan-18
US9879003 Host targeted inhibitors of dengue virus and other viruses Dana-Farber Cancer Institute, Inc.
11-Apr-12
15-Mar-13
30-Jan-18
US9878988 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC.
29-May-12
5-Jan-16
30-Jan-18
US9873678 Chemical compounds AstraZeneca AB
18-Mar-14
17-Mar-15
23-Jan-18
US9873674 C-Rel inhibitors and uses thereof CORNELL UNIVERSITY

21-Sep-12
19-Sep-13
23-Jan-18
US9872900 Nucleic acid vaccines ModernaTX, Inc.
23-Apr-14
5-Apr-16
23-Jan-18
US9872898 Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome Ohio State Innovation Founation
24-Apr-12
3-Oct-16
23-Jan-18
US9872895 TLR5 ligands, therapeutic methods, and compositions related thereto Emory University
24-Sep-10
20-Sep-11
23-Jan-18

 

US9868952 Compositions and methods for âCœresistance-proofâC SiRNA therapeutics for influenza Sirnaomics, Inc. 8-Jul-

12

7-

Jul-

13

16-

Jan-

18

US9868740 Pyrimidinone compounds which are HNE inhibitors CHIESI FARMACEUTICI S.p.A. 12-

Jun-

14

12-

Jun

-14

16-

Jan-

18

US9868736 Deubiquitinase inhibitors and methods for use of the same THE REGENTS OF THE UNIVERSITY OF MICHIGAN 10-

Oct-

13

10-

Oct

-14

16-

Jan-

18

US9867882 Carbohydrate conjugates as delivery agents for oligonucleotides Alnylam Pharmaceuticals, Inc. 4-

Dec-

07

25-

Aug

-15

16-

Jan-

18

US9867877 Methods for preparing squalene NOVARTIS AG 12-

May-

10

22-

Nov

-16

16-

Jan-

18

US9862706 Compounds CHIESI FARMACEUTICI S.p.A. 31-

May-

16

26-

May

-17

9-

Jan-

18

US9861614 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 9-

May-

12

23-

Jun

-15

9-

Jan-

18

US9856254 Alkoxy substituted imidazoquinolines 3M Innovative Properties Company 3-

Oct-

03

13-

Jun

-16

2-

Jan-

18

US9856241 Substituted benzofuranyl and benzoxazolyl compounds and uses thereof Karyopharm Therapeutics Inc. 3-Jul-

13

3-

Jul-

14

2-

Jan-

18

US9856228 Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors PROZYMEX A/S 9-

Sep-

13

8-

Sep

-14

2-

Jan-

18

US9856224 Stable sodium channel blockers PARION SCIENCES, INC. 30-

Jun-

14

30-

Jan

-17

2-

Jan-

18

US9855287 Anti-viral azide containing compounds LIFE TECHNOLOGIES CORPORATION 28-

Jul-10

20-

Aug

-15

2-

Jan-

18

US9855284 Pharmaceutical compositions and methods Pop Test Oncology LLC 3-

Aug-

15

6-

Dec

-16

2-

Jan-

18

US9849143 Broad spectrum antiviral and methods of use The Burlington HC Research Group, Inc. 17-

Apr-

06

16-

Feb

-17

26-

Dec

-17

US9845342 Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria Spogen Biotech Inc. 17-

Sep-

14

17-

Sep

-15

19-

Dec

-17

US9840731 Preservation of biological materials in non-aqueous fluid media Gentegra, LLC 14-

Mar-

13

14-

Mar

-14

12-

Dec

-17

US9840719 Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues The Children’s Hospital of Philadelphia 22-

Jul-13

22-

Jul-

14

12-

Dec

-17

US9840491 Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors FORMA Therapeutics, Inc. 5-

Feb-

15

4-

Feb

-16

12-

Dec

-17

US9839687 Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule SUZHOU M-CONJ BIOTECH CO., LTD. 15-

Jul-15

15-

Jul-

15

12-

Dec

-17

US9834812 Probe kit for detecting a single strand target nucleotide sequence Fondazione Istituto Italiano Di Tecnologia 27-

Dec-

12

27-

Dec

-13

5-

Dec

-17

US9834791 CRISPR-related methods and compositions with governing gRNAS Editas Medicine, Inc. 7-

Nov-

13

7-

Nov

-14

5-

Dec

-17

US9834757 Hand, foot, and mouth vaccines and methods of manufacture and use thereof Takeda Vaccines, Inc. 7-

Nov-

14

6-

Nov

-15

5-

Dec

-17

US9834595 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases Ablynx N.V. 5-

Jun-

08

29-

Oct

-15

5-

Dec

-17

US9833504 Virus-like particles and process for preparing same Folia Biotech Inc. 13-

May-

11

1-

May

-12

5-

Dec

-17

US9833492 Combinations of a caspase inhibitor and an antiviral agent Centre National de la Recherche Scientifique 2-

Nov-

07

15-

May

-15

5-

Dec

-17

US9832998 Antiviral compositions Long Island University 30-

May-

07

19-

Mar

-15

5-

Dec

-17

US9828382 Pyrimidinone compounds as human neutrophil elastase inhibitors Chiesi Farmaceutici S.p.A. 18-

Dec-

12

10-

May

-16

28-

Nov

-17

US9828379 Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof ABIDE THERAPEUTICS, INC. 3-Jul-

13

1-

Jul-

14

28-

Nov

-17

US9828370 Compositions and methods for inhibiting kinases INHIBIKASE THERAPEUTICS, INC. 23-

Apr-

15

22-

Apr

-16

28-

Nov

-17

US9828346 N-myristoyl transferase inhibitors University of Dundee 2-

Sep-

08

31-

Aug

-15

28-

Nov

-17

 

US9828342 Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof CITY OF HOPE 24-

Feb-

12

25-

Feb

-13

28-

Nov

-17

US9827190 Intradermal delivery of immunological compositions comprising toll­like receptor 7 agonists GLAXOSMITHKLINE BIOLOGICALS SA 1-

Feb-

13

30-

Jan

-14

28-

Nov

-17

US9822339 Means and methods for influencing the stability of antibody producing cells ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM 9-

Dec-

05

26-

Aug

-15

21-

Nov

-17

US9822173 Heterodimeric immunoglobulins AMGEN INC. 21-

Nov-

12

21-

Nov

-13

21-

Nov

-17

US9822165 Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region DANA-FARBER CANCER INSTITUTE, INC. 18-

Jun-

09

18-

Jun

-10

21-

Nov

-17

US9822155 Method of preventively treating a subject at the risk of developing infections of a respiratory virus Xiangxue Group (Hong Kong) Company Limited 9-

May-

13

23-

Aug

-16

21-

Nov

-17

US9822127 GAK modulators as antivirals The Board of Trustees of the Leland Stanford Junior University 23-

Jul-14

23-

Jul-

15

21-

Nov

-17

US9822065 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. 6-

Mar-

15

14-

Feb

-17

21-

Nov

-17

US9821052 Reverse genetics systems Seqirus UK Limited 31-

Jul-09

30-

Jul-

10

21-

Nov

-17

US9821051 Reducing hospitalization in elderly influenza vaccine recipients Seqirus UK Limited 28-

Oct-

10

21-

Oct

-11

21-

Nov

-17

US9816078 Compositions for increasing polypeptide stability and activity, and related methods SOLIS BIODYNE OAre 19-

Nov-

09

11-

Mar

-16

14-

Nov

-17

US9815886 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. 28-

Oct-

14

8-

Jan

-15

14-

Nov

-17

US9815805 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB 24-

Jan-

14

8-

Nov

-16

14-

Nov

-17

US9814777 Targeting lipids Arbutus Biopharma Corporation 4-

Dec-

07

22-

Oct

-13

14-

Nov

-17

US9810683 Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells The Regents of the University of California 6-

May-

09

25-

Nov

-13

7-

Nov

-17

US9809845 Methods and reagents for amplifying nucleic acids The United States of America, as represented by the Secretary, Department of Health and Human Services 6-

Aug-

12

6-

Aug

-12

7-

Nov

-17

US9809796 Animal protein-free media for cultivation of cells Baxalta GmbH 29-

Oct-

04

18-

May

-17

7-

Nov

-17

US9809632 Universal protein tag for double stranded nucleic acid delivery University of Washington Through its Center for Commercialization 23-

Oct-

13

22-

Oct

-14

7-

Nov

-17

US9809591 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. 8-

Mar-

11

5-

Oct

-15

7-

Nov

-17

US9808490 Induced hepatocytes and uses thereof ACCELERATED BIOSCIENCES CORP. 26-

Nov-

14

25-

Nov

-15

7-

Nov

-17

US9803236 Microarray-based assay integrated with particles for analyzing molecular interactions CapitalBio Corporation 6-

Aug-

10

6-

Aug

-10

31-

Oct-

17

US9803197 Particle-nucleic acid conjugates and therapeutic uses related thereto Emory University 25-

Jun-

12

27-

Feb

-13

31-

Oct-

17

US9802937 Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors ORIGENIS GMBH 21-

Apr-

11

23-

Apr

-12

31-

Oct-

17

US9802919 Compounds CHIESI FARMACEUTICI S.p.A. 31-

May-

16

26-

May

-17

31-

Oct-

17

US9801948 Antimicrobial compositions and methods of use thereof Yale University 21-

Sep-

11

21-

Sep

-12

31-

Oct-

17

US9801947 Methods and compositions for enhancing immune response 3M INNOVATIVE PROPERTIES COMPANY 10-

Apr-

03

6-

Oct

-14

31-

Oct-

17

US9801935 Soluble needle arrays for delivery of influenza vaccines SEQIRUS UK LIMITED 20-

Aug-

10

11-

Oct

-16

31-

Oct-

17

US9801897 Delivery of RNA to trigger multiple immune pathways GLAXOSMITHKLINE BIOLOGICALS SA 6-Jul-

10

6-

Jul-

11

31-

Oct-

17

US9797000 Non-target amplification method for detection of RNA splice-forms in a sample QIAGEN GAITHERSBURG INC. 1-

May-

09

30-

Apr

-10

24-

Oct-

17

US9796979 Oligonucleotide modulators of the toll-like receptor pathway Quark Pharmaceuticals Inc. 3-

Mar-

11

28-

Jul-

16

24-

Oct-

17

 

US9796735 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 20-

Jun-

07

7-

Nov

-14

24-

Oct-

17

US9795669 Lipidated immune response modifier compound compositions, formulations, and methods 3M INNOVATIVE PROPERTIES COMPANY 17-

Aug-

10

15-

Dec

-15

24-

Oct-

17

US9795668 Delivery of self-replicating RNA using biodegradable polymer particles GlaxoSmithKline Biologicals S.A. 6-Jul-

10

23-

Nov

-15

24-

Oct-

17

US9795666 High-yield transgenic mammalian expression system for generating virus-like particles Academia Sinica 5-

Sep-

06

11-

Feb

-15

24-

Oct-

17

US9791437 Multianalyte assay Nexus Dx, Inc. 30-

Apr-

07

15-

Jun

-15

17-

Oct-

17

US9789180 D-amino acid derivative-modified peptidoglycan and methods of use thereof The Regents of the University of California 30-

Nov-

12

31-

Mar

-16

17-

Oct-

17

US9786050 Stain-free histopathology by chemical imaging The Board of Trustees of the University of Illinois 15-

Mar-

13

14-

Mar

-14

10-

Oct-

17

US9783595 Neutralizing GP41 antibodies and their use The United States of America, as represented by the Secretary, Department of Health and Human Services 7-

Nov-

11

2-

Aug

-16

10-

Oct-

17

US9782470 Method of obtaining thermostable dried vaccine formulations Merck Sharp & Dohme Corp. 16-

Oct-

13

13-

Oct

-14

10-

Oct-

17

US9782434 Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution Sonoma Pharmaceuticals, Inc. 20-

Jan-

06

7-

Jul-

15

10-

Oct-

17

US9770504 Generating peptoid vaccines The Board of Regents of the University of Texas System 3-

May-

13

2-

May

-14

26-

Sep

-17

US9770463 Delivery of RNA to different cell types GLAXOSMITHKLINE BIOLOGICALS SA 6-Jul-

10

7-

Jun

-11

26-

Sep

-17

US9765395 System and method for DNA sequencing and blood chemistry analysis Nanomedical Diagnostics, Inc. 28-

Apr-

14

10-

Apr

-15

19-

Sep

-17

US9765133 Antibody producing non-human mammals Merus N.V. 27-

Jun-

08

29-

Apr

-14

19-

Sep

-17

US9765071 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY 25-

Nov-

03

14-

Mar

-16

19-

Sep

-17

US9764027 Outer membrane vesicles GLAXOSMITHKLINE BIOLOGICALS SA 18-

Sep-

12

18-

Sep

-13

19-

Sep

-17

US9759723 B-cell antigen presenting cell assay University of Pittsburgha€”Of the Commonwealth System of Higher Education 8-

Apr-

10

21-

Mar

-16

12-

Sep

-17

US9758840 Parasite detection via endosymbiont detection IBIS BIOSCIENCES, INC. 14-

Mar-

10

11-

Mar

-11

12-

Sep

-17

US9758820 Organism identification panel BioFire Diagnostics, LLC 2-

Apr-

07

1-

Apr

-08

12-

Sep

-17

US9758775 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. 10-

Dec-

09

14-

Apr

-14

12-

Sep

-17

US9758568 Oligopeptide-free cell culture media Baxalta GmbH 4-

Jan-

06

16-

Nov

-15

12-

Sep

-17

US9758553 Yeast strain for the production of proteins with terminal alpha-1,3- linked galactose MERCK SHARP & DOHME CORP. 30-

May-

08

2-

Jul-

14

12-

Sep

-17

US9757478 Mutant protease biosensors with enhanced detection characteristics Promega Corporation 11-

May-

10

7-

Jan

-16

12-

Sep

-17

US9757470 Peptides for assisting delivery across the blood brain barrier Children’s Medical Center Corporation 22-

May-

06

30-

Apr

-14

12-

Sep

-17

US9757446 Influenza virus vectors and uses therefor FLUGEN, INC. 17-

Mar-

14

13-

Mar

-15

12-

Sep

-17

US9757407 T reatment of viral infections by modulation of host cell metabolic pathways The Trustees of Princeton University 1-

Jun-

07

21-

Dec

-15

12-

Sep

-17

US9751945 Sortase-modified VHH domains and uses thereof Whitehead Institute for Biomedical Research 13-

Apr-

12

15-

Apr

-13

5-

Sep

-17

US9750798 Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses STICHTING WAGENINGEN RESEARCH 21-

May-

13

21-

May

-14

5-

Sep

-17

US9750797 Sustained release vaccine composition VIRBAC CORPORATION 16-

Jun-

04

16-

Jun

-05

5-

Sep

-17

US9750690 Circulation of components during microfluidization and/or homogenization of emulsions NOVARTIS AG 3-

Dec-

09

5-

Sep

-14

5-

Sep

-17

 

US9746985 System and method for detecting, collecting, analyzing, and communicating event-related information Georgetown University 25-

Feb-

08

20-

Apr

-11

29-

Aug

-17

US9746459 Antigen presenting cell assay University of Pittsburgha€”Of the Commonwealth System of Higher Education 8-

Apr-

10

11-

Oct

-13

29-

Aug

-17

US9745306 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4- D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors Respivert Li mited 15-

Mar-

13

14-

Mar

-14

29-

Aug

-17

US9744231 Quality control methods for oil-in-water emulsions containing squalene NOVARTIS AG 8-

Nov-

06

27-

Aug

-13

29-

Aug

-17

US9744229 Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 4-

Apr-

08

28-

Apr

-14

29-

Aug

-17

US9744183 Nucleic acid prodrugs and methods of use thereof WAVE LIFE SCIENCES LTD. 6-Jul-

09

6-

Jul-

10

29-

Aug

-17

US9738894 Short interfering RNA (siRNA) analogues Roche Innovation Center Copenhagen A/S 21-

Mar-

03

28-

Mar

-16

22-

Aug

-17

US9738624 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 21-

Jun-

13

20-

Jun

-14

22-

Aug

-17

US9737618 Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor The Trustees of the University of Pennsylvania 30-

Sep-

03

20-

Jul-

15

22-

Aug

-17

US9737593 Carbon nanotube compositions and methods of use thereof Yale University 19-

Mar-

08

15-

Mar

-13

22-

Aug

-17

US9730997 Alphavirus vectors for respiratory pathogen vaccines Novartis Vaccines and Diagnostics, Inc. 21-

May-

04

20-

Aug

-14

15-

Aug

-17

US9730912 Pharmaceutical compounds ASTEX THERAPEUTICS LIMITED 12-

Oct-

06

12-

Oct

-07

15-

Aug

-17

US9727810 Spatially addressable molecular barcoding Cellular Research, Inc. 27-

Feb-

15

26-

Feb

-16

8-

Aug

-17

US9726607 Systems and methods for detecting multiple optical signals GEN-PROBE INCORPORATED 10-

Mar-

05

3-

Mar

-14

8-

Aug

-17

US9725770 Methods and compositions for identification of source of microbial contamination in a sample The Regents of the University of California 6-

Mar-

12

6-

Mar

-13

8-

Aug

-17

US9725487 Compositions and methods for measles virus inhibition Autoimmune Technologies, LLC 4-

Nov-

03

13-

May

-15

8-

Aug

-17

US9719106 Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof The Trustees of the University of Pennsylvania 29-

Apr-

13

29-

Apr

-14

1-

Aug

-17

US9719083 Bioagent detection methods IBIS BIOSCIENCES, INC. 8-

Mar-

09

8-

Mar

-10

1-

Aug

-17

US9718774 Indole carboxamide derivatives as P2X7 receptor antagonist IDORSIA PHARMACEUTICALS LTD 12-

Dec-

12

11-

Dec

-13

1-

Aug

-17

US9717755 Method of treating inflammation Cytosorbents Corporation 1-

Apr-

10

1-

Apr

-11

1-

Aug

-17

US9717749 Production of stable non-polyadenylated RNAs Massachusetts Institute of Technology 16-

Oct-

12

16-

Oct

-13

1-

Aug

-17

US9717732 Drug combination VERONA PHARMA PLC 15-

Mar-

13

17-

Mar

-14

1-

Aug

-17

US9714411 Animal protein-free media for cultivation of cells Baxalta GmbH 29-

Oct-

04

30-

Nov

-15

25-

Jul-

17

US9714283 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. 28-

Oct-

14

2-

Jul-

15

25-

Jul-

17

US9714226 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 29-

Jul-11

13-

Nov

-15

25-

Jul-

17

US9713641 Anti-TIGIT antigen-binding proteins and methods of use thereof Potenza Therapeutics, Inc. 13-

Feb-

17

13-

Feb

-17

25-

Jul-

17

US9713606 Methods for treating pulmonary emphysema using substituted 2- Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides inhibitors of cathepsin C Boehringer Ingelheim International GmbH 14-

Mar-

13

1-

Dec

-15

25-

Jul-

17

US9708375 Inhibitory polypeptides specific to WNT inhibitors Amgen Inc. 15-

Mar-

13

14-

Mar

-14

18-

Jul-

17

US9707278 Methods of modulating immune responses by modifying Akt3 bioactivity Augusta University Research Institute, Inc. 17-

Apr-

14

17-

Apr

-15

18-

Jul-

17

 

US9701736 Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection New York Blood Center, Inc. 20-

Oct-

10

9-

Oct

-14

11-

Jul-

17

US9701638 Therapeutic hydroxyquinolones Rutgers, The State University of New Jersey 9-

Nov-

12

8-

Nov

-13

11-

Jul-

17

US9700616 Arranging interaction and back pressure chambers for microfluidization NOVARTIS AG 3-

Dec-

09

22-

Mar

-16

11-

Jul-

17

US9700614 Intranasal vaccination dosage regimen Eurocine Vaccines AB 17-

Dec-

12

17-

Dec

-13

11-

Jul-

17

US9700558 Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist VERONA PHARMA PLC 15-

Mar-

13

17-

Mar

-14

11-

Jul-

17

US9696247 Sample fixation and stabilization RNASSIST LTD. 1-

Mar-

13

28-

Feb

-14

4-

Jul-

17

US9695445 Method for production of reprogrammed cell using chromosomally unintegrated virus vector ID Pharma Co., Ltd. 16-

Jul-08

29-

Jul-

15

4-

Jul-

17

US9695135 Therapeutic catechols Rutgers, The State University of New Jersey 12-

May-

14

11-

May

-15

4-

Jul-

17

US9695134 3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine- 2-carboxamide compounds Parion Sciences, Inc. 17-

Dec-

12

8-

Jan

-15

4-

Jul-

17

US9689018 Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses Diagnostic Hybrids, Inc. 24-

Apr-

98

4-

Aug

-14

27-

Jun-

17

US9688982 Methods and compositions for the treatment of cancer or other diseases CITY OF HOPE 26-

Jan-

07

11-

Oct

-13

27-

Jun-

17

US9687536 Methods and compositions for intranasal delivery SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. 15-

Apr-

10

15-

Apr

-11

27-

Jun-

17

US9683256 Biological specimen collection and transport system Longhorn Vaccines and Diagnostics, LLC 1-

Oct-

07

15-

Dec

-15

20-

Jun-

17

US9683017 Inhibitory peptides of viral infection UNIVERSITY TENNESSEE RESEARCH FOUNDATION 17-

Jul-14

16-

Jul-

15

20-

Jun-

17

US9682133 Disrupted adenovirus-based vaccine against drugs of abuse CORNELL UNIVERSITY 17-

Mar-

10

17-

Mar

-11

20-

Jun-

17

US9677089 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor The Trustees of the University of Pennsylvania 17-

Dec-

01

30-

Mar

-16

13-

Jun-

17

US9676867 Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody Dana-Farber Cancer Institute Inc. 2-

Dec-

05

8-

May

-13

13-

Jun-

17

US9676857 Soluble engineered monomeric Fc The United States of America, as represented by the Secretary, Department of Health and Human Services 16-

Mar-

12

14-

Mar

-13

13-

Jun-

17

US9676727 Myxovirus therapeutics, compounds, and uses related thereto Children’s Healthcare of Atlanta, Inc. 24-

Oct-

11

7-

Jul-

16

13-

Jun-

17

US9675550 Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 26-

Jul-10

25-

Jan

-13

13-

Jun-

17

US9670507 Directed evolution and in vivo panning of virus vectors The University of North Carolina at Chapel Hill CO 1 1 28-

Jun

-16

6-

Jun-

17

US9670166 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 6-

Feb-

13

5-

Aug

-16

6-

Jun-

17

US9669092 Antagonism of the VIP signaling pathway Emory University 2-

Feb-

11

31-

Jan

-12

6-

Jun-

17

US9669089 Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen CureVac AG 15-

Feb-

12

15-

Feb

-13

6-

Jun-

17

US9669088 Vaccination with multiple clades of H5 influenza A virus Seqirus UK Limited 26-

Nov-

07

25-

Nov

-08

6-

Jun-

17

US9661856 Synergy of plant antimicrobials with silver The Arizona Board of Regents on Behalf of The University of Arizona 24-

Aug-

12

26-

Aug

-13

30-

May

-17

US9657278 Methods to produce bunyavirus replicon particles Stichting Dienst Landbouwkundig Onderzoek 20-

Sep-

10

10-

Jul-

15

23-

May

-17

US9657076 GM-CSF and IL-4 conjugates, compositions, and methods related thereto Children’s Healthcare of Atlanta, Inc. 23-

Oct-

12

23-

Oct

-13

23-

May

-17

US9657048 Enantiomers of the 1a€2,6a€2-isomer of neplanocin A Auburn University 4-

Aug-

14

4-

Aug

-15

23-

May

-17

 

US9657015 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 31-

Jul-14

27-

Jul-

15

23-

May

-17

US9655896 Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity PARION SCIENCES, INC. 27-

Jun-

11

12-

Jan

-15

23-

May

-17

US9655845 Oil-in-water emulsions that contain nucleic acids GlaxoSmithKline Biologicals, S.A. 6-Jul-

11

6-

Jul-

12

23-

May

-17

US9655367 Disinfecting composition and wipes with reduced contact time LONZA, INC. 6-

Nov-

13

4-

Nov

-14

23-

May

-17

US9651543 Malaria antigen screening method The United States of America as Represented by the Secretary of the Navy 31-

Aug-

05

19-

Apr

-13

16-

May

-17

US9650685 Selective detection of human rhinovirus The United States of America, as represented by the Secretary, Department of Health and Human Services 5-

Dec-

08

15-

Dec

-14

16-

May

-17

US9650649 LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors VIRATHERAPEUTICS GMBH 8-

Oct-

08

8-

Oct

-09

16-

May

-17

US9649324 Use of tylvalosin as antiviral agent CAMBRIDGE UNIVERSITY TECHNICAL SERVICES 13-

Jul-06

8-

Jun

-15

16-

May

-17

US9649309 Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity The University of North Carolina at Chapel Hill 11-

Apr-

14

3-

Apr

-15

16-

May

-17

US9644180 Synthetic membrane-receiver complexes RUBIUS THERAPEUTICS, INC. 18-

Nov-

13

12-

Jun

-15

9-

May

-17

US9642876 Method of preventing or treating sinusitis with oxidative reductive potential water solution SONOMA PHARMACEUTICALS, INC. 30-

Dec-

03

27-

Oct

-15

9-

May

-17

US9642873 Combinations of TGFÎ2 and COX-2 inhibitors and methods for their therapeutic application Sirnaomics, Inc. 4-

May-

10

4-

May

-11

9-

May

-17

US9637524 Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector The Regents of the University of California 27-

Feb-

09

5-

Nov

-14

2-

May

-17

US9637491 Pyrazolo[4,3-D]pyrimidines as kinase inhibitors ORIGENIS GMBH 19-

Oct-

12

18-

Oct

-13

2-

May

-17

US9636410 Cationic oil-in-water emulsions GLAXOSMITHKLINE BIOLOGICALS SA 6-Jul-

11

6-

Jul-

12

2-

May

-17

US9636397 Adjuvant compositions and related methods Vaxliant, LLC 24-

Mar-

15

24-

Mar

-16

2-

May

-17

US9636370 AAV vectors targeted to oligodendrocytes The University of North Carolina at Chapel Hill 28-

Sep-

12

27-

Sep

-13

2-

May

-17

US9629907 Compositions for and methods of inducing mucosal immune responses The Trustees of the University of Pennsylvania 19-

Nov-

04

28-

Oct

-11

25-

Apr-

17

US9624173 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. 8-

Mar-

11

19-

Mar

-15

18-

Apr-

17

US9623040 Immunomodulation by controlling expression levels of microRNAs in dendritic cells The Board of Trustees of the Leland Stanford Junior University 14-

Jul-14

10-

Jul-

15

18-

Apr-

17

US9618508 Flow cytometry analysis of materials adsorbed to metal salts GlaxoSmithKline Biologicals SA 14-

Dec-

10

14-

Dec

-11

11-

Apr-

17

US9618476 System and method for electronic biological sample analysis NANOMEDICAL DIAGNOSTICS, INC. 28-

Apr-

14

28-

Apr

-14

11-

Apr-

17

US9618429 Polymer stabilization of chromogen solutions Ventana Medical Systems, Inc. 23-

Jan-

12

18-

Jan

-13

11-

Apr-

17

US9611481 Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof UNIVERSITE DE MONTPELLIER 24-

Sep-

09

23-

Sep

-10

4-

Apr-

17

US9611474 Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof QUARK PHARMACEUTICALS, INC. 12-

Sep-

12

12-

Sep

-13

4-

Apr-

17

US9605276 Replication defective adenovirus vector in vaccination Etubics Corporation 24-

Aug-

12

15-

Mar

-13

28-

Mar

-17

US9603864 Substituted nucleosides, nucleotides and analogs thereof Alios BioPharma, Inc. 24-

Jun-

14

22-

Jun

-15

28-

Mar

-17

US9603850 MerTK-specific pyrazolopyrimidine compounds The University of North Carolina at Chapel Hill 11-

Apr-

14

3-

Apr

-15

28-

Mar

-17

US9599606 ADP-ribose detection reagents The Board of Regents of the University of Texas System 10-

Jun-

14

9-

Jun

-15

21-

Mar

-17

US9598459 Pharmaceutical compositions and methods Pop Test Oncology LLC 3-

Aug-

15

28-

Jul-

16

21-

Mar

-17

 

US9597333 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. 6-

Mar-

15

28-

Sep

-16

21-

Mar

-17

US9593334 Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting authophagy University of Pittsburgh—Of the Commonwealth System of Higher Education 7-

Mar-

12

6-

Mar

-13

14-

Mar

-17

US9593331 Double-stranded nucleic acid molecule for gene expression control Osaka City University 2-

Nov-

11

1-

Nov

-12

14-

Mar

-17

US9593084 Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity Parion Sciences, Inc. 17-

Dec-

12

13-

Dec

-13

14-

Mar

-17

US9592284 Immunization regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boost The Trustees of the University of Pennsylvania 28-

Apr-

04

27-

Apr

-05

14-

Mar

-17

US9592277 Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases Avirid, Inc. 14-

Apr-

04

14-

Apr

-05

14-

Mar

-17

US9588069 Methods for performing thermal melt analysis GEN-PROBE INCORPORATED 31-

Jul-12

31-

Jul-

13

7-

Mar

-17

US9587250 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor Trustees of the University of Pennsylvania 17-

Dec-

01

16-

Jan

-15

7-

Mar

-17

US9586998 Methods of propagating monkey adenoviral vectors GenVec, Inc. 9-

Nov-

09

4-

Aug

-15

7-

Mar

-17

US9586911 Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds Parion Sciences, Inc. 13-

Dec-

13

19-

Dec

-14

7-

Mar

-17

US9586910 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-

pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra

zine-2-carboxamide

Parion Sciences, Inc. 27-

Jun-

11

18-

Dec

-13

7-

Mar

-17

US9585968 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom 3M Innovative Properties Company 3-

Jun-

11

14-

Aug

-15

7-

Mar

-17

US9585953 Immunogenic compositions in particulate form and methods for producing the same MUCOSIS B.V. 22-

Mar-

11

22-

Mar

-12

7-

Mar

-17

US9585874 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 9-

May-

12

6-

Jan

-16

7-

Mar

-17

US9585849 Broad spectrum antiviral and methods of use The Burlington HC Research Group, Inc. 17-

Apr-

06

17-

Apr

-07

7-

Mar

-17

US9580474 Polyionic papilloma virus-like particle (VLP) vaccines THE JOHNS HOPKINS UNIVERSITY 8-

Sep-

10

8-

Sep

-11

28-

Feb

-17

US9580468 Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells CENTRE DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER BBN) 13-

Jan-

11

13-

Jan

-12

28-

Feb

-17

US9580429 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy AstraZeneca AB 6-

Dec-

04

15-

Sep

-14

28-

Feb

-17

US9574189 Enzymatic encoding methods for efficient synthesis of large libraries Nuevolution A/S 1-

Dec-

05

1-

Dec

-06

21-

Feb

-17

US9574181 Influenza virus reassortment method Seqirus UK Limited 21-

May-

10

24-

Oct

-14

21-

Feb

-17

US9573955 Compounds Chiese Farmaceutici S.p.A. 16-

Dec-

13

16-

Dec

-14

21-

Feb

-17

US9573938 Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones Rutgers, The State University of New Jersey 11-

Sep-

12

11-

Sep

-13

21-

Feb

-17

US9572899 Compositions for enhancing transport of molecules into cells AVI BIOPHARMA, INC. 29-

Apr-

03

5-

Nov

-08

21-

Feb

-17

US9572864 Compositions and uses of lectins Emory University 12-

Feb-

10

11-

Dec

-15

21-

Feb

-17

US9572823 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

5-

Apr

-16

21-

Feb

-17

US9567336 Conjugated TLR7 and/or TLR8 and TLR2 agonists INVIVOGEN 19-

Nov-

12

15-

Mar

-13

14-

Feb

-17

US9566326 Adjuvanted influenza vaccines for pediatric use Seqirus UK Limited 22-

Feb-

08

21-

Jun

-13

14-

Feb

-17

US9566291 Nutritional composition comprising indigestible oligosaccharides N.V. Nutricia 24-

Aug-

04

24-

Aug

-05

14-

Feb

-17

US9566290 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

20-

Apr

-16

14-

Feb

-17

 

US9566289 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

17-

Feb

-16

14-

Feb

-17

US9565857 Antimicrobial solutions Board of Regents, The University of Texas System 10-

Sep-

10

9-

Sep

-11

14-

Feb

-17

US9562110 Bispecific antibody Wuhan YZY Biopharma Co., Ltd. 21-

Nov-

12

21-

Nov

-12

7-

Feb

-17

US9561263 Treatment of inflammatory illnesses with ACE2 Apeiron Biologics AG 18-

Dec-

07

18-

Dec

-08

7-

Feb

-17

US9556237 Antiviral rift valley fever virus peptides and methods of use The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases 6-

Dec-

12

4-

Jun

-15

31-

Jan-

17

US9556229 Modification of peptides using a bis(thioether)arylbridge approach The Regents of the University of California 18-

May-

12

17-

May

-13

31-

Jan-

17

US9556184 Phosphoinositide 3-kinase inhibitors Respivert, Ltd. 15-

Mar-

13

4-

Dec

-15

31-

Jan-

17

US9556117 Indole carboxamide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. 18-

Dec-

12

17-

Dec

-13

31-

Jan-

17

US9555031 Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill 11-

Apr-

14

3-

Apr

-15

31-

Jan-

17

US9555030 Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity The University of North Carolina at Chapel Hill 11-

Apr-

14

3-

Apr

-15

31-

Jan-

17

US9550773 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M Innovative Properties Company 18-

Jun-

04

13-

Apr

-15

24-

Jan-

17

US9550757 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 5-

Mar-

10

28-

Jun

-13

24-

Jan-

17

US9549949 Antiviral agent NBC MESHTEC, INC. 3-

Sep-

08

31-

Aug

-09

24-

Jan-

17

US9549938 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

11-

Mar

-16

24-

Jan-

17

US9546371 Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE 18-

Mar-

08

18-

Mar

-09

17-

Jan-

17

US9546184 Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 13-

Aug-

08

8-

Jun

-15

17-

Jan-

17

US9546150 Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7 HYBRIGENICS SA 2-

Sep-

11

29-

Aug

-12

17-

Jan-

17

US9545440 Methods for preparing squalene NOVARTIS AG 12-

May-

10

23-

Oct

-15

17-

Jan-

17

US9540373 Substituted spirocycles Boehringer Ingelheim International GmbH 12-

Sep-

14

10-

Sep

-15

10-

Jan-

17

US9539321 HMGBl-derived peptides enhance immune response to antigens The Regents of the University of California 27-

Jul-10

9-

Mar

-15

10-

Jan-

17

US9539217 Nanoparticle compositions Allertein Therapeutics, LLC 3-

Apr-

13

3-

Apr

-14

10-

Jan-

17

US9533978 Pyrimidine derivatives and their use in the treatment of cancer and further diseases Sumitomo Dainippon Pharma Co., Ltd 21-

May-

09

26-

Aug

-14

3-

Jan-

17

US9533037 Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes Declion Holdings LLC 16-

Oct-

07

16-

Oct

-08

3-

Jan-

17

US9529974 System and method for detecting, collecting, analyzing, and communicating event-related information Georgetown University 25-

Feb-

08

27-

Jul-

11

27-

Dec

-16

US9527903 Engineered antibody constant domain molecules The United States of America, as represent by the Secretary, Department of Health and Human Services 31-

Jan-

08

1-

Oct

-13

27-

Dec

-16

US9526803 Diagnostic chewing gum for pathogens Julius-Maximilians-Universitaet Wuerzburg 8-

Mar-

12

8-

Mar

-13

27-

Dec

-16

US9526700 Composition for inactivating an enveloped virus VIROBLOCK SA 19-

May-

06

17-

Nov

-14

27-

Dec

-16

US9522962 Peptides, conjugates and method for increasing immunogenicity of a vaccine Academisch Ziekenhuis Leiden h.o.d.n. LUMC 15-

Mar-

10

15-

Mar

-11

20-

Dec

-16

US9522894 Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors AstraZeneca AB 24-

Jan-

14

21-

Jan

-15

20-

Dec

-16

 

US9522171 EV576 for use in the treatment of viral infections of the respiratory tra ct Volution Immuno Pharmaceuticals SA 8-

Jan-

10

2-

Jan

-15

20-

Dec

-16

US9518093 Topical formulation of arginine-rich cyclic antimicrobial peptides NOVABIOTICS LIMITED 24-

Feb-

06

9-

Nov

-15

13-

Dec

-16

US9518083 Gadd45beta targeting agents Imperial Innovations Limited 22-

Oct-

09

10-

Feb

-15

13-

Dec

-16

US9517263 Benzonaphthyridine-containing vaccines GlaxoSmithKline Biologicals SA 10-

Jun-

09

10-

Jun

-10

13-

Dec

-16

US9517205 Soluble needle arrays for delivery of influenza vaccines Seqirus UK Limited 20-

Aug-

10

19-

Aug

-11

13-

Dec

-16

US9512471 Methods and kits for detecting human papillomavirus DIACARTA Inc 30-

Jun-

10

30-

Jun

-10

6-

Dec

-16

US9512443 Recombinant expression of multiprotein complexes using polygenes ETH ZURICH 8-

Nov-

05

6-

Nov

-06

6-

Dec

-16

US9512181 Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor Tetragenetics, Inc. 27-

May-

11

29-

May

-12

6-

Dec

-16

US9511070 Heterocyclyl carboxamides for treating viral diseases NovaDrug, LLC 31-

Aug-

12

30-

Aug

-13

6-

Dec

-16

US9506063 SiRNA compositions and methods for treatment of HPV and other infections Sirnaomics, Inc. 29-

Jul-10

29-

Jan

-13

29-

Nov

-16

US9504747 Lipids and lipid compositions for the delivery of active agents Novartis AG 8-

Mar-

13

7-

Mar

-14

29-

Nov

-16

US9504673 Agent for the prophylaxis and treatment of highly pathogenic infectious diseases LTD “Valenta-Intellekt†21-

May-

09

10-

May

-10

29-

Nov

-16

US9504255 Physical antimicrobial method NMS TECHNOLOGIES CO., LTD. 1-

Aug-

12

16-

Jul-

13

29-

Nov

-16

US9499799 Cells and methodology to generate non-segmented negative-strand RNA viruses Centre National De La Recherche Scientifique 22-

Dec-

06

15-

Oct

-13

22-

Nov

-16

US9499535 Kinase inhibitors ORIGENIS GMBH 21-

Apr-

11

23-

Apr

-12

22-

Nov

-16

US9499489 Myxovirus therapeutics, compounds, and uses related thereto Children’s Healthcare of Atlanta, Inc. 24-

Oct-

11

24-

Oct

-12

22-

Nov

-16

US9498548 Method of using oxidative reductive potential water solution in dental applications Oculus Innovative Sciences, Inc. 2-

May-

05

2-

May

-06

22-

Nov

-16

US9498544 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents Tissue Regeneration Therapeutics Inc. 21-

Apr-

08

13-

Mar

-15

22-

Nov

-16

US9498527 Vaccine composition NITTO DENKO CORPORATION 4-

Apr-

12

3-

Apr

-13

22-

Nov

-16

US9494571 Methods of testing for intracellular pathogens Novartis AG 8-

Mar-

10

7-

Mar

-11

15-

Nov

-16

US9493788 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor The Trustees of the University of Pennsylvania 17-

Dec-

01

16-

Jan

-15

15-

Nov

-16

US9493572 GITR antibodies and methods of inducing or enhancing an immune response GITR, Inc. 25-

Mar-

05

23-

Mar

-15

15-

Nov

-16

US9493518 Compositions and methods for treating clostridium difficile- associated diseases National Health Research Institutes 14-

Mar-

13

13-

Mar

-14

15-

Nov

-16

US9492528 Influenza virus-like particles (VLPS) comprising hemagglutinin MEDICAGO INC. 13-

Jul-07

2-

Jul-

09

15-

Nov

-16

US9492413 Use of salt of an acetylsalicylic acid for the treatment of viral infections Ventaleon GMBH 14-

Jan-

08

14-

Jan

-09

15-

Nov

-16

US9489495 System and method for detecting, collecting, analyzing, and communicating event-related information GEORGETOWN UNIVERSITY 25-

Feb-

08

28-

Aug

-08

8-

Nov

-16

US9487838 Oligonucleotide probe for the detection of adenovirus QIAGEN HAMBURG GMBH 28-

Dec-

10

28-

Dec

-10

8-

Nov

-16

US9487837 Exosome-mediated diagnosis of hepatitis virus infections and diseases MOREHOUSE SCHOOL OF MEDICINE 6-

Oct-

08

21-

Jan

-14

8-

Nov

-16

US9487778 Oligonucleotide modulators of the toll-like receptor pathway QUARK PHARMACEUTICALS, INC. 3-

Mar-

11

1-

Mar

-12

8-

Nov

-16

US9487749 Use of methylsulfonylmethane (MSM) to modulate microbial activity Biogenic Innovations, LLC 30-

Oct-

09

12-

Aug

-14

8-

Nov

-16

 

US9487528 Compounds Chiesi Farmaceutici S.p.A. 9-

Jun-

14

5-

Jun

-15

8-

Nov

-16

US9486479 Antimicrobial solutions containing dichloride monoxide and methods of making and using the same Oculus Innovative Sciences, Inc. 13-

Mar-

07

21-

Jul-

14

8-

Nov

-16

US9481912 Compositions and methods for detecting and identifying nucleic acid sequences in biological samples Longhorn Vaccines and Diagnostics, LLC 12-

Sep-

06

8-

Oct

-13

1-

Nov

-16

US9481724 hDC-sign binding peptides Sloan-Kettering Institute for Cancer Research 19-

Dec-

11

10-

Dec

-12

1-

Nov

-16

US9481630 Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY 19-

Oct-

11

28-

Sep

-12

1-

Nov

-16

US9476090 Signal propagation biomolecules, devices and methods STC.UNM 21-

May-

13

21-

May

-14

25-

Oct-

16

US9476032 Attenuated viruses useful for vaccines The Research Foundation for The State University of New York 30-

Mar-

07

31-

Mar

-08

25-

Oct-

16

US9475872 Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F ImmunoQure AG 28-

Dec-

11

2-

Jan

-13

25-

Oct-

16

US9475862 Neutralizing GP41 antibodies and their use The United States of America, as represented by the Secretary, Department of Health and Human Services 7-

Nov-

11

7-

Nov

-12

25-

Oct-

16

US9475832 Phosphonates with reduced toxicity for treatment of viral infections The Regents of the University of California 14-

Apr-

10

29-

Sep

-14

25-

Oct-

16

US9475804 Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom 3M Innovative Properties Company 3-

Jun-

11

1-

Jun

-12

25-

Oct-

16

US9475779 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 31-

Jul-14

27-

Jul-

15

25-

Oct-

16

US9475775 Benzazepine dicarboxamide compounds Hoffmann-La Roche Inc. 6-

Mar-

15

4-

Mar

-16

25-

Oct-

16

US9474844 Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto Hemalux LLC 22-

Oct-

14

29-

Dec

-15

25-

Oct-

16

US9474759 Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses Kansas State University Research Foundation 27-

Sep-

11

27-

Sep

-12

25-

Oct-

16

US9469876 Circulating biomarkers for metastatic prostate cancer Caris Life Sciences Switzerland Holdings GmbH 6-

Apr-

10

6-

Apr

-11

18-

Oct-

16

US9464276 Highly efficient influenza matrix (M1) proteins Novavax, Inc. 11-

Jul-03

23-

Feb

-15

11-

Oct-

16

US9464123 Peptides having activity of inhibiting infections of respiratory viruses and use of the same XIANGXUE GROUP (HONG KONG) COMPANY LIMITED 9-

May-

13

21-

Feb

-14

11-

Oct-

16

US9463240 Arranging interaction and back pressure chambers for microfluidization NOVARTIS AG 3-

Dec-

09

11-

Jul-

14

11-

Oct-

16

US9459247 Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry Academia Sinica 29-

Mar-

10

29-

Mar

-11

4-

Oct-

16

US9459233 Amperometric gas sensor Steris Corporation 25-

Jun-

12

26-

Feb

-13

4-

Oct-

16

US9458492 Methods and cells for identifying RIG-I pathway regulators Kineta, Inc. 25-

Feb-

11

23-

Feb

-12

4-

Oct-

16

US9458470 Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin MEDICAGO INC. 21-

Jan-

08

23-

Jan

-13

4-

Oct-

16

US9458184 Compositions of TLR7 and/or TLR8 agonists conjugated to lipids INVIVOGEN 15-

Jun-

12

15-

Mar

-13

4-

Oct-

16

US9458113 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 31-

Jul-14

27-

Jul-

15

4-

Oct-

16

US9457074 Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome Ohio State Innovation Foundation 24-

Apr-

12

23-

Feb

-15

4-

Oct-

16

US9453043 Nucleic acid chemical modifications ALNYLAM PHARMACEUTICALS, INC. 2-

Mar-

09

22-

Jan

-15

27-

Sep

-16

US9452973 Modulators of the relaxin receptor 1 THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES 4-

May-

12

15-

Mar

-13

27-

Sep

-16

US9452210 Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant MEDICAGO INC. 13-

Jul-07

4-

Jan

-13

27-

Sep

-16

 

US9447462 Methods for concurrent identification and quantification of an unknown bioagent IBIS BIOSCIENCES, INC. 18-

Feb-

04

27-

Jan

-14

20-

Sep

-16

US9447132 Highly active nucleoside derivative for the treatment of HCV Achillion Pharmaceuticals, Inc. 12-

Apr-

13

14-

Apr

-14

20-

Sep

-16

US9447097 4-amino-imidazoquinoline compounds Hoffmann-La Roche Inc. 22-

Apr-

14

7-

Apr

-16

20-

Sep

-16

US9446062 Methods of treating ischemia-reperfusion injury with siRNAs Quark Pharmaceuticals, Inc. 25-

Oct-

06

8-

Jan

-15

20-

Sep

-16

US9442107 Antibody-nanoparticle conjugates and methods for making and using such conjugates Ventana Medical Systems, Inc. 27-

Apr-

10

21-

Apr

-15

13-

Sep

-16

US9441247 TC-83-derived alphavirus vectors, particles and methods ALPHAVAX, INC. 18-

May-

04

6-

Jul-

15

13-

Sep

-16

US9440960 Substituted oxetanes and their use as inhibitors of cathepsin C Boehringer Ingelheim International GmbH 1-

Aug-

14

31-

Jul-

15

13-

Sep

-16

US9440930 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 31-

Jul-14

27-

Jul-

15

13-

Sep

-16

US9435795 Enhanced deposition of chromogens utilizing pyrimidine analogs Ventana Medical Systems, Inc. 30-

Dec-

10

6-

Oct

-14

6-

Sep

-16

US9435000 Primate T-lymphotropic viruses Johns Hopkins University 21-

Feb-

05

20-

Sep

-13

6-

Sep

-16

US9434997 Methods, compounds and systems for detecting a microorganism in a sample Lawrence Livermore National Security, LLC 24-

Aug-

07

21-

Aug

-08

6-

Sep

-16

US9434769 Peptide compositions and methods for inhibiting herpesvirus infection The Administrators of the Tulane Educational Fund 30-

Oct-

09

9-

Jul-

14

6-

Sep

-16

US9433672 Compositions and methods for activating innate and allergic immunity ID Biomedical Corporation of Quebec 26-

Apr-

12

28-

Apr

-14

6-

Sep

-16

US9430610 Re-sequencing pathogen microarray The United States of America, as represented by the Secretary of the Navy 2-Jul-

04

10-

Apr

-08

30-

Aug

-16

US9428739 Norovirus and Sapovirus antigens NOVARTIS VACCINES AND DIAGNOSTICS, INC. 24-

Mar-

01

27-

Nov

-12

30-

Aug

-16

US9428574 Polypeptides and uses thereof for treatment of autoimmune disorders and infection COMPUGEN LTD. 30-

Jun-

11

1-

Jul-

12

30-

Aug

-16

US9428571 Antibodies and processes for preparing the same TAIGA BIOTECHNOLOGIES, INC. 16-

May-

08

18-

Mar

-15

30-

Aug

-16

US9428490 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 29-

Jul-11

26-

Jul-

12

30-

Aug

-16

US9428439 Hydrobenzamide derivatives as inhibitors of Hsp90 ASTEX THERAPEUTICS LTD. 12-

Oct-

06

7-

Jan

-14

30-

Aug

-16

US9426989 Organic peroxide compounds for microorganism inactivation NOVARTIS AG 6-

May-

10

6-

May

-11

30-

Aug

-16

US9422367 Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. 7-

Feb-

06

26-

Nov

-13

23-

Aug

-16

US9421254 Immunostimulatory combinations of TLR ligands and methods of use The United States of America, as represented by the Secretary, Department of Health and Human Services 24-

Sep-

07

24-

Sep

-08

23-

Aug

-16

US9416416 Biological specimen collection/transport compositions and methods Longhorn Vaccines and Diagnostics, LLC 1-

Oct-

07

16-

Dec

-11

16-

Aug

-16

US9416409 Capture primers and capture sequence linked solid supports for molecular diagnostic tests IBIS BIOSCIENCES, INC. 31-

Jul-09

30-

Jul-

10

16-

Aug

-16

US9416396 Covalently linked thermostable kinase for decontamination process validation The Secretary of State for Health 20-

Feb-

08

18-

Feb

-09

16-

Aug

-16

US9415392 Slip chip device and methods The University of Chicago 24-

Mar-

09

23-

Mar

-10

16-

Aug

-16

US9415087 Compositions and methods for treating coronavirus infection Ludwig-Maximilians-Universitaet Muenchen 11-

Mar-

14

8-

May

-15

16-

Aug

-16

US9415033 Esters of short chains fatty acids for use in the treatment of immunogenic disorders PROPONENT BIOTECH GMBH 3-

Oct-

12

3-

Oct

-13

16-

Aug

-16

US9409987 Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer COMPUGEN LTD 15-

Apr-

11

16-

Apr

-12

9-

Aug

-16

US9409917 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. 20-

Jan-

12

18-

Jan

-13

9-

Aug

-16

 

US9409870 Compounds CHIESI FARMACEUTICI S.p.A. 15-

Dec-

14

27-

Nov

-15

9-

Aug

-16

US9408908 Combination adjuvant formulation Not Available 16-

Oct-

08

15-

Feb

-13

9-

Aug

-16

US9408907 Homogenous suspension of immunopotentiating compounds and uses thereof GlaxoSmithKline Biologicals SA 15-

Dec-

09

15-

Dec

-10

9-

Aug

-16

US9404160 Methods for the detection of microorganisms Becton, Dickinson and Company 22-

Dec-

09

21-

Dec

-10

2-

Aug

-16

US9403868 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. 20-

Mar-

09

5-

Mar

-15

2-

Aug

-16

US9402921 Directed evolution and in vitro panning of virus vectors The University of North Carolina at Chapel Hill 30-

Apr-

08

22-

Oct

-14

2-

Aug

-16

US9402878 Depsipeptide and uses thereof NovoBiotic Pharmaceuticals, LLC 3-

Dec-

12

1-

Jul-

15

2-

Aug

-16

US9402812 Methods for the preparation of liposomes Indu Javeri 23-

Sep-

09

23-

Sep

-10

2-

Aug

-16

US9394092 Powdered pouch and method of making same MONOSOL, LLC 16-

Apr-

12

14-

Mar

-13

19-

Jul-

16

US9393564 Bioagent detection systems, devices, and methods IBIS BIOSCIENCES, INC. 30-

Mar-

09

30-

Mar

-10

19-

Jul-

16

US9393295 Nanoparticles for use in pharmaceutical compositions Novartis AG 28-

Apr-

08

28-

Apr

-09

19-

Jul-

16

US9393215 Nanoparticles for use in immunogenic compositions Novartis AG 2-

Dec-

05

1-

Dec

-06

19-

Jul-

16

US9388429 Method for propagating adenoviral vectors encoding inhibitory gene products GenVec, Inc. 10-

Nov-

05

28-

May

-14

12-

Jul-

16

US9388234 Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds Not Available 6-

Jun-

03

19-

Jun

-13

12-

Jul-

16

US9388198 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. 21-

Jan-

14

21-

Jan

-14

12-

Jul-

16

US9388197 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. 22-

Jan-

13

21-

Jan

-14

12-

Jul-

16

US9387242 Chimeric viruses presenting non-native surface proteins and uses thereof Icahn School of Medicine at Mount Sinai 2-

Dec-

05

1-

Dec

-06

12-

Jul-

16

US9382590 Methods and compositions for prostate cancer metastasis FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU) 25-

Mar-

11

20-

May

-15

5-

Jul-

16

US9382545 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity COLEY PHARMACEUTICAL GMBH 27-

Sep-

06

4-

Oct

-13

5-

Jul-

16

US9382288 Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action Justus-Liebig-Universitat Giessen 6-

Oct-

10

6-

Oct

-11

5-

Jul-

16

US9381244 VISTA modulators for diagnosis and treatment of cancer KING’S COLLEGE LONDON 7-

Sep-

12

9-

Sep

-13

5-

Jul-

16

US9381239 VLPS derived from cells that do not express a viral matrix or core protein Novavax, Inc. 25-

May-

07

14-

Apr

-14

5-

Jul-

16

US9381226 Methods and compositions related to inhibition of viral entry UNIVERSITY OF UTAH RESEARCH FOUNDATION 8-

Feb-

07

8-

Feb

-08

5-

Jul-

16

US9381220 Sceletium extract and uses thereof H. L. Hall & Sons Limited 20-

Mar-

09

15-

Jul-

14

5-

Jul-

16

US9380785 Antiviral resin member NBC MESHTEC, INC. 6-Jul-

11

6-

Jul-

12

5-

Jul-

16

US9376486 Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof DSO National Laboratories 14-

Dec-

10

14-

Dec

-11

28-

Jun-

16

US9376398 Carboxylic acid compounds Astrazeneca Aktiebolag 18-

May-

12

17-

May

-13

28-

Jun-

16

US9375465 Conjugates of GM-CSF and IL-7, compositions and methods related thereto Children’s Healthcare of Atlanta, Inc. 14-

Nov-

11

13-

Nov

-12

28-

Jun-

16

US9372156 System for processing contents of a receptacle to detect an optical signal emitted by the contents GEN-PROBE INCORPORATED 10-

Mar-

05

22-

Feb

-11

21-

Jun-

16

US9371563 Nanoreporters and methods of manufacturing and use thereof NanoString Technologies, Inc. 23-

Dec-

05

11-

Mar

-13

21-

Jun-

16

 

US9370582 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. 4-

Dec-

07

11-

Jul-

14

21-

Jun-

16

US9370581 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. 4-

Dec-

07

11-

Jul-

14

21-

Jun-

16

US9370570 Polychlorinated biphenyls and squalene-containing adjuvants Novartis AG 28-

Dec-

07

10-

Dec

-13

21-

Jun-

16

US9370531 Method of providing patient specific immune response in amyloidoses and protein aggregation disorders New York University 31-

Aug-

07

1-

Sep

-08

21-

Jun-

16

US9365577 Pyrimidinone compounds as human neutrophil elastase inhibitors Chiesi Farmaceutici S.p.A. 18-

Dec-

12

17-

Dec

-13

14-

Jun-

16

US9365567 Alkoxy substituted imidazoquinolines 3M Innovative Properties Company 3-

Oct-

03

30-

Sep

-14

14-

Jun-

16

US9365523 Imidazolyl amide compounds and uses related thereto Children’s Healthcare of Atlanta, Inc. 31-

Mar-

11

28-

Mar

-12

14-

Jun-

16

US9365506 Compounds and compositions as TLR2 agonists NOVARTIS AG 23-

Mar-

10

9-

Jul-

14

14-

Jun-

16

US9364511 Antiviral preparations obtained from a natural cinnamon extract RAMOT AT TEL-AVIV UNIVERSITY LTD. 24-

Dec-

03

22-

Jun

-06

14-

Jun-

16

US9359360 TLR agonists The Regents of The University of California 22-

Aug-

05

20-

Nov

-12

7-

Jun-

16

US9358280 Decreasing potential iatrogenic risks associated with influenza vaccines Novartis AG 9-

Sep-

04

11-

Jan

-13

7-

Jun-

16

US9353133 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

7-

Mar

-14

31-

May

-16

US9352048 Carbohydrate conjugates as delivery agents for oligonucleotides ALNYLAM PHARMACEUTICALS, INC. 4-

Dec-

07

22-

Jul-

14

31-

May

-16

US9347055 Method and kit for preparation of sample for use in nucleic acid amplification EIKEN KAGAKU KABUSHIKI KAISHA 5-

Nov-

07

5-

Nov

-08

24-

May

-16

US9346866 Inhibition of tace activity with cyclic peptides The Regents of the University of California 2-

Jun-

11

19-

Sep

-14

24-

May

-16

US9346794 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 23-

Aug-

12

29-

Dec

-15

24-

May

-16

US9346769 Tetrazolones as inhibitors of fatty acid synthase Infinity Pharmaceuticals, Inc. 5-

May-

10

23-

Aug

-13

24-

May

-16

US9346753 Dithiol mucolytic agents PARION SCIENCES, INC. 23-

Aug-

13

13-

Aug

-14

24-

May

-16

US9345760 IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same Advanced Bionutrition Corporation 9-

Sep-

11

7-

Sep

-12

24-

May

-16

US9340507 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 23-

Aug-

12

2-

Sep

-15

17-

May

-16

US9339561 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION 11-

May-

10

5-

May

-14

17-

May

-16

US9339525 Inhibition of biofilm organisms Novabiotics Limited 31-

Mar-

09

31-

Mar

-10

17-

May

-16

US9334268 4-amino-imidazoquinoline compounds HOFFMAN-LA ROCHE INC. 22-

Apr-

14

22-

Apr

-15

10-

May

-16

US9328110 Substituted imidazo ring systems and methods 3M INNOVATIVE PROPERTIES COMPANY 25-

Nov-

03

11-

Mar

-14

3-

May

-16

US9328093 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA 15-

Jan-

10

17-

Sep

-14

3-

May

-16

US9326972 Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression Ohio University 16-

Mar-

04

9-

Feb

-12

3-

May

-16

US9322827 B-cell antigen presenting cell assay University of Pittsburgh – Of the Commonwealth System of Higher Education 8-

Apr-

10

8-

Apr

-11

26-

Apr-

16

US9321999 Compositions for increasing polypeptide stability and activity, and related methods SOLIS BIODYNE OAre 19-

Nov-

09

19-

Nov

-10

26-

Apr-

16

US9321847 Activatable toxin complexes comprising a cleavable inhibitory peptide RAMOT at Tel Aviv University Ltd. 20-

Sep-

10

22-

Aug

-11

26-

Apr-

16

 

US9321831 RSV-specific binding molecules and means for producing them MedImmune Limited 1-

Jun-

07

13-

Sep

-13

26-

Apr-

16

US9320784 Peptides shared among lethal cancers and therapeutic compositions comprising said peptides Not Available 7-

Aug-

09

19-

Jul-

12

26-

Apr-

16

US9320748 Immunologically useful arginine salts Novartis AG 7-

Mar-

12

7-

Mar

-13

26-

Apr-

16

US9315530 Adsorption of immunopotentiators to insoluble metal salts Novartis AG 1-

Sep-

10

1-

Sep

-11

19-

Apr-

16

US9310375 Luminophore-labeled molecules coupled with particles for microarray-based assays CapitalBio Corporation 27-

Oct-

10

27-

Oct

-10

12-

Apr-

16

US9310088 Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matter Technical University of Denmark 17-

Jul-09

14-

Jul-

10

12-

Apr-

16

US9309325 Antibodies and methods of use thereof The Regents of the University of California 7-

May-

09

4-

May

-10

12-

Apr-

16

US9303068 D-amino acid derivative-modified peptidoglycan and methods of use thereof The Regents of the University of California 30-

Nov-

12

27-

Nov

-13

5-

Apr-

16

US9303000 Olefin containing nuclear transport modulators and uses thereof KARYOPHARM THERAPEUTICS INC. 17-

Jan-

11

16-

Jan

-12

5-

Apr-

16

US9297010 Short interfering RNA (siRNA) analogues Roche Innovation Center Copenhagen A/S 21-

Mar-

03

11-

Feb

-14

29-

Mar

-16

US9295732 Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists INVIVOGEN 22-

Feb-

13

22-

Feb

-13

29-

Mar

-16

US9295708 Modified release formulations for oprozomib Onyx Therapeutics, Inc. 24-

Oct-

12

24-

Oct

-13

29-

Mar

-16

US9295646 Cationic oil-in-water emulsions Novartis AG 6-Jul-

10

18-

Sep

-11

29-

Mar

-16

US9291628 Direct clone analysis and selection technology Dublin City University 13-

Jul-10

13-

Jul-

11

22-

Mar

-16

US9291597 Detecting targets using mass tags and mass spectrometry VENTANA MEDICAL SYSTEMS, INC. 2-Jul-

10

1-

Jul-

11

22-

Mar

-16

US9290794 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION 11-

May-

10

12-

Nov

-12

22-

Mar

-16

US9290786 Monoclonal antibody production by EBV transformation of B cells Institute for Research in Biomedicine 26-

Feb-

03

25-

Apr

-13

22-

Mar

-16

US9290760 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. 15-

Sep-

10

14-

Sep

-11

22-

Mar

-16

US9290745 Luciferase biosensor PROMEGA CORPORATION 10-

Oct-

03

14-

Feb

-14

22-

Mar

-16

US9290545 Compositions and methods for the treatment of viral infections Dana-Farber Cancer Institute, Inc. 23-

Jan-

08

23-

Jul-

10

22-

Mar

-16

US9290459 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 6-

Feb-

13

9-

Nov

-15

22-

Mar

-16

US9290457 Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 31-

Jul-14

27-

Jul-

15

22-

Mar

-16

US9289487 II-key/antigenic epitope hybrid peptide vaccines Antigen Express, Inc. 14-

Sep-

99

11-

Jan

-05

22-

Mar

-16

US9284560 Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAs Biocross Institute of Molecular Medicine (Nantong) Co., Ltd. 19-

Sep-

11

19-

Sep

-11

15-

Mar

-16

US9278128 Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same The Trustees of the University of Pennsylvania 14-

Sep-

09

6-

Jan

-14

8-

Mar

-16

US9278126 Influenza vaccines with reduced amounts of squalene Seqirus UK Limited 10-

Feb-

09

10-

Feb

-10

8-

Mar

-16

US9272024 Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same The Trustees of the University of Pennsylvania 12-

Dec-

11

11-

Dec

-12

1-

Mar

-16

US9271494 Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions Ecolab USA, Inc. 30-

Aug-

07

30-

Aug

-07

1-

Mar

-16

US9266844 Suppression of SARS replication by SARS helicase inhibitors The Curators of the University of Missouri 15-

Jun-

12

17-

Jun

-13

23-

Feb

-16

 

US9266843 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 9-

May-

12

9-

May

-13

23-

Feb

-16

US9265876 Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto Hemalux Technologies LLC 22-

Oct-

14

22-

Oct

-14

23-

Feb

-16

US9260398 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC. 29-

May-

12

9-

Dec

-14

16-

Feb

-16

US9255144 Anti-IL-18 antibodies and their uses MedImmune Limited 20-

Dec-

10

20-

Dec

-11

9-

Feb

-16

US9255140 Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus NEW YORK BLOOD CENTER, INC. 15-

Jun-

04

23-

Mar

-09

9-

Feb

-16

US9254315 Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds Not Available 28-

Apr-

04

3-

Feb

-10

9-

Feb

-16

US9254265 Small liposomes for delivery of immunogen encoding RNA NOVARTIS AG 31-

Aug-

10

31-

Aug

-11

9-

Feb

-16

US9249427 Recombinant HCMV and RHCMV vectors and uses thereof Oregon Health & Science University 14-

May-

10

14-

Nov

-12

2-

Feb

-16

US9249195 Reovirus vaccines and methods of use therefor Vanderbilt University 7-

Apr-

10

4-

Apr

-11

2-

Feb

-16

US9248201 Mutant protease biosensors with enhanced detection characteristics PROMEGA CORPORATION 11-

May-

10

5-

May

-14

2-

Feb

-16

US9248178 Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens Not Available 8-

Jun-

09

8-

Jun

-10

2-

Feb

-16

US9242980 Lipidated immune response modifier compound compositions, formulations, and methods 3M Innovative Properties Company 17-

Aug-

10

16-

Aug

-11

26-

Jan-

16

US9238809 Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material QIAGEN GAITHERSBURG, INC. 24-

Sep-

09

5-

Aug

-10

19-

Jan-

16

US9234175 Creating bioengineered lymph nodes H. Lee Moffitt Cancer Center and Research Institute, Inc. 17-

Nov-

09

16-

Nov

-10

12-

Jan-

16

US9233148 Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza Not Available 9-

Jan-

09

16-

Oct

-09

12-

Jan-

16

US9227977 Phosphoinositide 3-kinase inhibitors Respivert Ltd. 15-

Mar-

13

14-

Mar

-14

5-

Jan-

16

US9222075 Animal protein-free media for cultivation of cells Baxalta GmbH 29-

Oct-

04

2-

May

-14

29-

Dec

-15

US9221832 Heterocyclic amide derivatives as P2X7 receptor antagonists ACTELION PHARMACEUTICALS LTD. 22-

Jul-11

20-

Jul-

12

29-

Dec

-15

US9221807 Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 21-

Feb-

14

12-

Feb

-15

29-

Dec

-15

US9220768 Decreasing potential iatrogenic risks associated with influenza vaccines Novartis AG 9-

Sep-

04

14-

Oct

-11

29-

Dec

-15

US9217745 Arrayed detector system for measurement of influenza immune response University of Rochester 2-

May-

08

11-

Jul-

13

22-

Dec

-15

US9217157 Recombinant influenza viruses and uses thereof Icahn School of Medicine at Mount Sinai 27-

Jul-09

27-

Jul-

10

22-

Dec

-15

US9216192 Toll-like receptor agonist formulations and their use VentiRx Pharmaceuticals, Inc. 1-

Aug-

08

16-

Jul-

12

22-

Dec

-15

US9213027 Lipoparticles comprising proteins, methods of making, and using the same Integral Molecular, Inc. 30-

Jul-03

1-

Nov

-13

15-

Dec

-15

US9212399 Biological specimen collection and transport system and method of use Longhorn Vaccines and Diagnostics, LLC 1-

Oct-

07

7-

Jan

-14

15-

Dec

-15

US9212205 Nucleic acid binding compounds and methods of use University of Rochester 26-

Jul-07

28-

Jul-

08

15-

Dec

-15

US9206396 Methods and devices for quantitative viral assays Wisconsin Alumni Research Foundation 16-

Nov-

05

16-

Nov

-06

8-

Dec

-15

US9206158 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 29-

Jul-11

10-

Jun

-15

8-

Dec

-15

US9200329 Rapid epidemiologic typing of bacteria BioFire Diagnostics, LLC 19-

May-

08

18-

May

-09

1-

Dec

-15

 

US9200287 Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity AdiuTide Pharmaceuticals GmbH 18-

May-

07

15-

May

-08

1-

Dec

-15

US9200280 Methods and compositions for the treatment of cancer or other diseases CITY OF HOPE 26-

Jan-

07

9-

Jun

-14

1-

Dec

-15

US9200279 Methods and compositions for the treatment of cancer or other diseases CITY OF HOPE 26-

Jan-

07

14-

Jan

-14

1-

Dec

-15

US9200074 Antibodies to IL-1 R1 and methods of making them MEDIMMUNE LIMITED 7-

Nov-

08

16-

Apr

-14

1-

Dec

-15

US9199981 Compounds and compositions as C-kit kinase inhibitors NOVARTIS AG 1-

Sep-

11

27-

Aug

-12

1-

Dec

-15

US9199897 Methods for preparing squalene NOVARTIS AG 12-

May-

10

12-

May

-11

1-

Dec

-15

US9198927 Targeting opposite strand replication intermediates of single­stranded viruses by RNAI ALNYLAM PHARMACEUTICALS, INC. 24-

Sep-

04

1-

Mar

-10

1-

Dec

-15

US9193780 Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases Ablynx N.V. 5-

Jun-

08

5-

Jun

-09

24-

Nov

-15

US9192661 Delivery of self-replicating RNA using biodegradable polymer particles Novartis AG 6-Jul-

10

7-

Jun

-11

24-

Nov

-15

US9187748 Compositions and methods for silencing ebola virus gene expression Not Available 20-

Jul-09

28-

Mar

-14

17-

Nov

-15

US9187426 Organic compounds Novartis AG 27-

Jun-

08

25-

Jun

-09

17-

Nov

-15

US9186419 Directed evolution and in vitro panning of virus vectors The University of North Carolina at Chapel Hill 30-

Apr-

08

17-

Jan

-14

17-

Nov

-15

US9186399 Immune stimulatory oligonucleotide analogs containing modified sugar moieties AdiutTide Pharmaceuticals GmbH 9-

Oct-

07

29-

Sep

-08

17-

Nov

-15

US9181303 Treatment of bacterial infections with cyclic antimicrobial peptides NovaBiotics Limited 22-

Dec-

05

20-

Jun

-14

10-

Nov

-15

US9181290 Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranose CHANG GUNG UNIVERSITY 17-

Jun-

11

19-

Sep

-11

10-

Nov

-15

US9175047 Peptidomimetic macrocycles Aileron Therapeutics, Inc. 14-

Jan-

09

14-

Jan

-10

3-

Nov

-15

US9174925 Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY 26-

Oct-

11

28-

Sep

-12

3-

Nov

-15

US9169318 Neutralizing molecules to viral antigens Sea Lane Biotechnologies, Inc. 28-

Mar-

08

18-

Jul-

11

27-

Oct-

15

US9168318 Oxidative reductive potential water solution and methods of using the same Oculus Innovative Sciences, Inc. 30-

Dec-

03

11-

Aug

-04

27-

Oct-

15

US9168299 Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies LIPUM AB 8-

Apr-

09

30-

Oct

-13

27-

Oct-

15

US9168269 Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals THE TRUSTEES OF PRINCETON UNIVERSITY 18-

Feb-

10

18-

Feb

-11

27-

Oct-

15

US9163222 Mutations in OAS1 genes Kineta Two, LLC 4-

May-

05

14-

Nov

-12

20-

Oct-

15

US9163065 Depsipeptide and uses thereof NovoBiotic Pharmaceuticals, LLC 3-

Dec-

12

3-

Dec

-13

20-

Oct-

15

US9161976 Immunotherapy comprising TLR9 ligand and CD40 ligand Trustees of Dartmouth College 30-

Dec-

02

22-

Oct

-12

20-

Oct-

15

US9156811 N-myristoyl transferase inhibitors Univeristy of Dundee 2-

Sep-

08

29-

Aug

-09

13-

Oct-

15

US9155309 Virus inactivating sheet NBC MESHTEC, INC. 2-

Oct-

09

4-

Oct

-10

13-

Oct-

15

US9149473 Targeted whole genome amplification method for identification of pathogens IBIS BIOSCIENCES, INC. 14-

Sep-

06

14-

Sep

-07

6-

Oct-

15

US9149445 Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections THE TRUSTEES OF PRINCETON UNIVERSITY 27-

Jul-09

27-

Jul-

10

6-

Oct-

15

US9145588 Generation of binding molecules MERUS BIOPHARMACEUTICALS B.V. 26-

Sep-

11

26-

Sep

-12

29-

Sep

-15

 

US9145585 Method for using permuted nucleic acid probes Ventana Medical Systems, Inc. 1-

Sep-

06

5-

Aug

-14

29-

Sep

-15

US9145410 Pyrazolopyridines and analogs thereof 3M Innovative Properties Company 3-

Oct-

03

26-

Jan

-12

29-

Sep

-15

US9144575 Anti-viral azide containing compounds LIFE TECHNOLOGIES CORPORATION 28-

Jul-10

28-

Jul-

11

29-

Sep

-15

US9139833 Modified small interfering RNA molecules and methods of use Arrowhead Research Corporation 26-

Jul-02

12-

Mar

-13

22-

Sep

-15

US9139647 Diagnosis and treatment of cancer using anti-TM4SF20 antibody FORERUNNER PHARMA RESEARCH CO., LTD. 25-

Dec-

08

25-

Dec

-09

22-

Sep

-15

US9139620 Feline morbillivirus and uses thereof THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA 20-

Jan-

12

22-

Jan

-13

22-

Sep

-15

US9138472 CD40L vaccines, compositions, and methods related thereto EMORY UNIVERSITY 28-

Sep-

10

28-

Sep

-11

22-

Sep

-15

US9134247 Method and apparatus for two-step surface-enhanced raman spectroscopy REAL-TIME ANALYZERS, INC. 16-

Dec-

11

16-

Dec

-11

15-

Sep

-15

US9133248 Methods of propagating monkey adenoviral vectors GenVec, Inc. 9-

Nov-

09

9-

Nov

-10

15-

Sep

-15

US9132423 Sample-to-answer microfluidic cartridge Micronics, Inc. 29-

Jan-

10

28-

Jan

-11

15-

Sep

-15

US9132175 Bacillus based delivery system and methods of use The Curators of the University of Missouri 18-

Apr-

11

18-

Apr

-11

15-

Sep

-15

US9128101 Biomarkers for theranostics Caris Life Sciences Switzerland Holdings GmbH 1-

Mar-

10

1-

Mar

-11

8-

Sep

-15

US9127256 Method for production of reprogrammed cell using chromosomally unintegrated virus vector DNAVEC CORPORATION 16-

Jul-08

16-

Jul-

09

8-

Sep

-15

US9127251 Means and methods for influencing the stability of antibody producing cells ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM 9-

Dec-

05

8-

Dec

-06

8-

Sep

-15

US9127028 Substrates for chromogenic detection and methods of use in detection assays and kits Ventana Medical Systems, Inc. 16-

Aug-

10

12-

Aug

-11

8-

Sep

-15

US9125952 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes Industry Academic Cooperation Foundation, Hallym University 17-

Jul-09

13-

Aug

-14

8-

Sep

-15

US9115093 Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 4-

Mar-

13

20-

Feb

-14

25-

Aug

-15

US9115065 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses Kineta, Inc. 6-

Dec-

04

26-

Feb

-13

25-

Aug

-15

US9109199 Methods to produce bunyavirus replicon particles STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK 20-

Sep-

10

20-

Sep

-11

18-

Aug

-15

US9107970 Method and a filter for capturing airborne agents Not Available 15-

Jul-08

13-

Jul-

09

18-

Aug

-15

US9107958 Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom 3M Innovative Properties Company 3-

Jun-

11

1-

Jun

-12

18-

Aug

-15

US9107906 Compositions and methods for the treatment of immunodeficiency ADMA BIOLOGICS, INC. 28-

Oct-

14

8-

Jan

-15

18-

Aug

-15

US9107904 Immunostimulatory compositions and methods of use thereof Massachusetts Institute of Technology 5-

Apr-

12

15-

Mar

-13

18-

Aug

-15

US9102938 2â€2 and 5â€2 modified monomers and oligonucleotides ALNYLAM PHARMACEUTICALS, INC. 31-

Mar-

11

31-

Mar

-11

11-

Aug

-15

US9102911 High density self-contained biological analysis BioFire Diagnostics, LLC 15-

May-

09

28-

Jan

-13

11-

Aug

-15

US9102741 GAS57 mutant antigens and GAS57 antibodies Novartis AG 12-

Sep-

07

13-

Oct

-14

11-

Aug

-15

US9102740 Cna-B domain antigens in vaccines against gram positive bacteria NOVARTIS AG 12-

Jan-

09

7-

Jun

-13

11-

Aug

-15

US9102633 Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds Parion Sciences, Inc. 13-

Dec-

13

13-

Dec

-13

11-

Aug

-15

US9102624 Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity Boehringer Ingelheim International GmbH 23-

Aug-

12

20-

Aug

-13

11-

Aug

-15

 

US9101597 Immunoprotective primary mesenchymal stem cells and methods Autoimmune Technologies, LLC 14-

Mar-

13

14-

Mar

-13

11-

Aug

-15

US9101582 Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention 31-

Jul-08

27-

Mar

-13

11-

Aug

-15

US9096585 Antiviral compounds and uses thereof Icahn School of Medicine at Mount Sinai 28-

May-

10

31-

May

-11

4-

Aug

-15

US9096543 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 9-

May-

12

9-

May

-13

4-

Aug

-15

US9090897 Production of IFN-lambda by conventional dendritic cells Bavarian Nordic A/S 18-

Dec-

09

17-

Dec

-10

28-

Jul-

15

US9085641 Peptides regulating the surface expression of the T cell receptor Max-Delbruck-Centrum Fur Molekulare Medizin 23-

Jun-

06

23-

Jun

-07

21-

Jul-

15

US9084808 Modified small interfering RNA molecules and methods of use Arrowhead Research Corporation 1-

Oct-

04

9-

May

-14

21-

Jul-

15

US9084758 Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof The Catholic University of Korea Industry-Academic Cooperation Foundation 24-

Jul-12

25-

Aug

-14

21-

Jul-

15

US9080209 Non-mass determined base compositions for nucleic acid detection IBIS BIOSCIENCES, INC. 6-

Aug-

09

6-

Aug

-10

14-

Jul-

15

US9080204 Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009 Longhorn Vaccines and Diagnostics, LLC 12-

Sep-

06

30-

Dec

-11

14-

Jul-

15

US9079965 Bispecific antibody Wuhan YZY Biopharma Co., LTD. 21-

Nov-

12

13-

Mar

-14

14-

Jul-

15

US9079943 TC-83-derived alphavirus vectors, particles and methods ALPHAVAX, INC. 18-

May-

04

28-

Mar

-14

14-

Jul-

15

US9079865 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 29-

Jul-11

29-

Jul-

12

14-

Jul-

15

US9078885 Respiratory disease treatment Pulmagen Therapeutics (Inflammation) Limited 7-

Aug-

08

7-

Apr

-14

14-

Jul-

15

US9078868 Therapeutic agent for accelerating recovery of animal under medical treatment DAIICHI SANKYO COMPANY, LIMITED 15-

Jan-

10

14-

Jan

-11

14-

Jul-

15

US9073869 Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C Boehringer Ingelheim International GmbH 14-

Mar-

13

11-

Sep

-14

7-

Jul-

15

US9072738 Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity PARION SCIENCES, INC. 27-

Jun-

11

27-

Jun

-12

7-

Jul-

15

US9072726 Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution Oculus Innovative Sciences, Inc. 20-

Jan-

06

21-

Dec

-09

7-

Jul-

15

US9072702 Reverse genetics using non-endogenous pol I promoters Novartis AG 21-

May-

09

21-

May

-10

7-

Jul-

15

US9067873 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Kineta Four, LLC 6-

Dec-

04

19-

Dec

-13

30-

Jun-

15

US9066964 Use of tylvalosin as antiviral agent Cambridge University Technical Services 13-

Jul-06

13-

Jul-

07

30-

Jun-

15

US9063150 Method for detection of antigen-specific antibodies in biological samples The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention 2-

Sep-

08

25-

Aug

-09

23-

Jun-

15

US9061001 Combination adjuvant formulation Dalhousie University 16-

Oct-

08

15-

Oct

-09

23-

Jun-

15

US9056900 Compositions and methods for coronavirus inhibition Autoimmune Technologies, LLC. 4-

Nov-

03

8-

Aug

-13

16-

Jun-

15

US9056898 Attenuated RNA virus and applications thereof Washington University 20-

Sep-

07

22-

Sep

-08

16-

Jun-

15

US9056071 Compounds and methods for preventing or treating a viral infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) 2-

Nov-

07

19-

Jun

-13

16-

Jun-

15

US9051619 Methods and compositions for prostate cancer metastasis FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU) 25-

Mar-

11

23-

Mar

-12

9-

Jun-

15

US9051564 Compositions for and methods of identifying antigens President and Fellows of Harvard College 21-

Feb-

06

21-

Feb

-07

9-

Jun-

15

US9051353 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. 20-

Mar-

09

24-

Sep

-13

9-

Jun-

15

 

US9050376 Conjugates of synthetic TLR agonists and uses therefor The Regents of the University of California 7-

Feb-

07

19-

Jun

-14

9-

Jun-

15

US9046523 Rapid bioluminescence detection system THE SECRETARY OF STATE FOR HEALTH 7-

Jan-

09

2-

Aug

-13

2-

Jun-

15

US9045855 Anti-viral member NBC Meshtec, Inc. 26-

Dec-

08

28-

Dec

-09

2-

Jun-

15

US9045727 Virus-like particles, methods of preparation, and immunogenic compositions EMORY UNIVERSITY 17-

May-

02

4-

Apr

-06

2-

Jun-

15

US9045472 Imidazoquinoline compounds ASTRAZENECA AB 16-

Dec-

10

16-

Dec

-11

2-

Jun-

15

US9045470 Compounds and compositions as TLR activity modulators IRM LLC 2-

Sep-

09

1-

Sep

-10

2-

Jun-

15

US9044420 Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses IMMUNE DESIGN CORP. 8-

Apr-

11

6-

Apr

-12

2-

Jun-

15

US9040310 Antibody-nanoparticle conjugates and methods for making and using such conjugates Ventana Medical Systems, Inc. 27-

Apr-

10

27-

Apr

-11

26-

May

-15

US9034646 Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD. 25-

May-

10

26-

Nov

-12

19-

May

-15

US9034313 Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same Inovio Pharmaceuticals, Inc. 8-

Feb-

10

8-

Feb

-11

19-

May

-15

US9029413 T reatment of viral infections by modulation of host cell metabolic pathways The Trustees of Princeton University 1-

Jun-

07

3-

Apr

-12

12-

May

-15

US9029382 3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds Parion Sciences, Inc. 17-

Dec-

12

13-

Dec

-13

12-

May

-15

US9029315 Soluble PD-1 variants, fusion constructs, and uses thereof The University of Hong Kong 11-

Nov-

10

11-

Nov

-11

12-

May

-15

US9028841 Synergistic bacterial compositions and methods of production and use thereof Seres Health, Inc. 23-

Nov-

12

20-

Mar

-14

12-

May

-15

US9028837 Methods and compositions for poxvirus A35R protein East Carolina University 7-

Jun-

12

20-

Dec

-12

12-

May

-15

US9028823 Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies GITR, Inc. 25-

Mar-

05

1-

Mar

-13

12-

May

-15

US9024001 Alphavirus replicon packaging constructs Novartis Vaccines and Diagnostics, Inc. 25-

May-

04

20-

May

-05

5-

May

-15

US9023855 Compounds Chiesi Farmaceutici S.p.A. 14-

Sep-

11

11-

Feb

-14

5-

May

-15

US9023839 Compounds and compositions as c-kit kinase inhibitors IRM LLC 1-

Sep-

11

22-

Apr

-14

5-

May

-15

US9017699 Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus New York Blood Center, Inc. 15-

Jun-

04

18-

Feb

-10

28-

Apr-

15

US9017696 Adenovirus vectors Isis Innovation Limited 10-

Apr-

07

10-

Apr

-08

28-

Apr-

15

US9012622 Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer Not Available 31-

Dec-

08

31-

Dec

-09

21-

Apr-

15

US9011767 Transportable vacuum assisted decontamination unit and decontamination process STERIS Inc. 1-

Apr-

13

31-

Mar

-14

21-

Apr-

15

US9006264 Substituted imidazoquinolines, imidazopyridines, and i midazonaphthyridines 3M Innovative Properties Company 18-

Jun-

04

9-

Sep

-13

14-

Apr-

15

US9006194 Compositions and methods for diminishing viral infection and inflammation associated with viral infection Drexel University 19-

Dec-

08

17-

Dec

-09

14-

Apr-

15

US9005974 Means and methods for influencing the stability of cells Academish Medisch Centrum Bij de Universiteit van Amsterdam 9-

Dec-

05

9-

Dec

-05

14-

Apr-

15

US9005665 Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome Ohio State Innovation Foundation 24-

Apr-

12

24-

Apr

-13

14-

Apr-

15

US9005599 Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents Tissue Regeneration Therapeutics Inc. 21-

Apr-

08

20-

Apr

-09

14-

Apr-

15

US8999996 Hydrazide containing nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. 29-

Jul-11

19-

Mar

-14

7-

Apr-

15

 

US8999975 Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C Boehringer Ingelheim International GmbH 19-

Sep-

11

14-

Sep

-12

7-

Apr-

15

US8999678 Method of increasing the function of an AAV vector The Trustees of the University of Pennsylvania 7-

Apr-

05

7-

Apr

-06

7-

Apr-

15

US8999349 HMGBl-derived peptides enhance immune response to antigens The Regents of the University of California 27-

Jul-10

27-

Jul-

11

7-

Apr-

15

US8999316 Antiviral compounds Long Island University 30-

May-

07

30-

May

-08

7-

Apr-

15

US8993717 Gadd45beta targeting agents Imperial Innovations Limited 22-

Oct-

09

22-

Oct

-10

31-

Mar

-15

US8993581 Methods for treating viral disorders Trustees of Boston University 24-

Sep-

09

11-

Jun

-13

31-

Mar

-15

US8993295 Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting The General Hospital Corporation 20-

Jul-06

20-

Jul-

07

31-

Mar

-15

US8992939 Highly efficient influenza matrix (M1) proteins Novavax, Inc. 11-

Jul-03

24-

Oct

-11

31-

Mar

-15

US8987249 Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of Cathepsin C Boehringer Ingelheim International GmbH 14-

Mar-

13

12-

Mar

-14

24-

Mar

-15

US8987191 Bioactive peptides and methods of using same Compugen Ltd. 12-

Jul-07

21-

Jun

-13

24-

Mar

-15

US8986933 Selective detection of human rhinovirus The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control 5-

Dec-

08

5-

Dec

-08

24-

Mar

-15

US8986926 Compositions comprising oriented, immobilized macromolecules and methods for their preparation NanoString Technologies, Inc. 23-

Dec-

05

22-

Dec

-06

24-

Mar

-15

US8986702 Antibodies and processes for preparing the same Taiga Biotechnologies, Inc. 16-

May-

08

18-

May

-09

24-

Mar

-15

US8980898 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases Parion Sciences, Inc. 29-

May-

12

29-

May

-13

17-

Mar

-15

US8980338 Sceletium extract and uses thereof H.L. Hall & Sons Limited 20-

Mar-

09

16-

Mar

-10

17-

Mar

-15

US8980281 High-yield transgenic mammalian expression system for generating virus-like particles Academia Sinica 5-

Sep-

06

12-

Feb

-10

17-

Mar

-15

US8975389 Nucleic acid chemical modifications Alnylam Pharmaceuticals, Inc. 2-

Mar-

09

2-

Mar

-10

10-

Mar

-15

US8969362 9-substituted 8-oxoadenine compound AstraZeneca Aktiebolag 26-

Mar-

04

21-

Oct

-13

3-

Mar

-15

US8969350 Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient Astrazeneca AB 18-

Dec-

08

17-

Dec

-09

3-

Mar

-15

US8962580 Chemical modifications of monomers and oligonucleotides with cycloaddition Alnylam Pharmaceuticals, Inc. 23-

Sep-

08

23-

Sep

-09

24-

Feb

-15

US8962332 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor The Trustees of the University of Pennsylvania 17-

Dec-

01

13-

Sep

-13

24-

Feb

-15

US8962330 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor The Trustees of the University of Pennsylvania 17-

Dec-

01

31-

Oct

-07

24-

Feb

-15

US8961983 Mucosal vaccine using cationic nanogel National University Corporation Tokyo Medical and Dental University 31-

Oct-

08

5-

Sep

-14

24-

Feb

-15

US8961477 Delivery of immune response modifier compounds 3M Innovative Properties Company 25-

Aug-

03

25-

Aug

-04

24-

Feb

-15

US8956863 Agents from cells The Brigham and Women’s Hospital, Inc. 15-

Oct-

09

15-

Oct

-10

17-

Feb

-15

US8956616 Constructs binding to phosphatidylserine and their use in disease treatment Board of Regents, The University of Texas System 24-

Jan-

05

24-

Jan

-06

17-

Feb

-15

US8951768 Mutations in OAS1 genes Kineta Two, LLC 4-

May-

05

11-

Jul-

11

10-

Feb

-15

US8951528 Immune response modifier conjugates 3M Innovative Properties Company 22-

Feb-

06

21-

Feb

-07

10-

Feb

-15

US8945943 Personal glucose meters for detection and quantification of a broad range of analytes The Board of Trustees of the University of Illinois 26-

May-

10

26-

May

-11

3-

Feb

-15

US8945904 Influenza virus reassortment Novartis AG 21-

May-

10

20-

May

-11

3-

Feb

-15

 

US8945610 Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics BASF SE 14-

Nov-

07

11-

Nov

-08

3-

Feb

-15

US8940864 Stabilized therapeutic small helical antiviral peptides New York Blood Center, Inc. 5-

Oct-

06

2-

Oct

-07

27-

Jan-

15

US8940501 Methods for ligation and uses thereof Whitehead Institute for Biomedical Research 30-

Jan-

09

1-

Feb

-10

27-

Jan-

15

US8937154 Stabilized therapeutic small helical antiviral peptides New York Blood Center, Inc. 5-

Oct-

06

2-

Feb

-12

20-

Jan-

15

US8933210 Label-free functional nucleic acid sensors for detecting target agents The Board of Trustees of the University of Illinois 6-

Oct-

10

6-

Oct

-11

13-

Jan-

15

US8933019 Antiviral cell-penetrating peptides New York Blood Center, Inc. 6-

May-

08

31-

Oct

-12

13-

Jan-

15

US8916552 Pharmaceutical combinations Astex Therapeutics Limited 12-

Oct-

06

12-

Oct

-07

23-

Dec

-14

US8916340 Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay The John Hopkins University 6-

Jan-

06

8-

Jan

-07

23-

Dec

-14

US8906872 Antisense antiviral compound and method for treating ssRNA viral infection Sarepta Therapeutics, Inc. 16-

Sep-

04

22-

Dec

-11

9-

Dec

-14

US8906863 Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector The Regents of the University of California 27-

Feb-

09

1-

Sep

-11

9-

Dec

-14

US8906862 Multiple antigen delivery system using hepatitis E virus-like particle National Institute of Infectious Disease 27-

Feb-

09

29-

Aug

-11

9-

Dec

-14

US8901071 Compounds and their use Novabiotics Limited 31-

Mar-

10

30-

Mar

-11

2-

Dec

-14

US8900585 Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection New York Blood Center, Inc. 20-

Oct-

10

20-

Oct

-11

2-

Dec

-14

US8895629 Circulation of components during homogenization of emulsions Novartis AG 3-

Dec-

09

3-

Dec

-10

25-

Nov

-14

US8895577 Compounds and compositions as TLR activity modulators Not Available 3-

Mar-

08

22-

Apr

-13

25-

Nov

-14

US8895570 Purine derivatives AstraZeneca AB 17-

Dec-

10

14-

Dec

-11

25-

Nov

-14

US8895534 Boron containing small molecules Anacor Pharmaceuticals, Inc. 20-

Jun-

07

30-

Jul-

10

25-

Nov

-14

US8895295 High density self-contained biological analysis Biofire Diagnostics, LLC 15-

Nov-

06

14-

Nov

-07

25-

Nov

-14

US8889708 Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C Boehringer Ingelheim International GmbH 14-

Mar-

13

12-

Mar

-14

18-

Nov

-14

US8889692 Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses AstraZeneca AB 27-

Jun-

07

14-

Sep

-12

18-

Nov

-14

US8889656 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

30-

Apr

-13

18-

Nov

-14

US8889398 Composition for inactivating an enveloped virus Viroblock SA 19-

May-

06

18-

May

-07

18-

Nov

-14

US8889181 Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes Industry Academic Cooperation Foundation, Hallym University 17-

Jul-09

16-

Jun

-10

18-

Nov

-14

US8889118 Anticancer agent containing dendritic cell having RNA virus transferred thereinto DNA VEC Research Inc. 24-

Jun-

04

28-

Apr

-05

18-

Nov

-14

US8889117 Modular nanoparticles for adaptable vaccines Yale University 15-

Feb-

07

15-

Feb

-08

18-

Nov

-14

US8884020 Indole compounds Ironwood Pharmaceuticals, Inc. 7-

Aug-

06

7-

Aug

-07

11-

Nov

-14

US8883790 Pharmaceutical combinations Astex Therapeutics Limited 12-

Oct-

06

12-

Oct

-07

11-

Nov

-14

US8883500 Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy Northeastern University 5-

Dec-

08

7-

Dec

-09

11-

Nov

-14

US8883481 Reverse genetics methods for virus rescue Novartis AG 20-

Oct-

09

20-

Oct

-10

11-

Nov

-14

US8883477 Oligoadenylate synthetase (OAS) Kineta Two, LLC 23-

Nov-

05

14-

Jun

-13

11-

Nov

-14

 

US8882484 Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells Bayer Healthcare LLC 28-

May-

08

27-

May

-09

11-

Nov

-14

US8881040 System and method for detecting, collecting, analyzing, and communicating event-related information Georgetown University 28-

Aug-

08

2-

Dec

-09

4-

Nov

-14

US8877775 Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of cathepsin C Boehringer Ingelheim International GmbH 14-

Mar-

13

12-

Mar

-14

4-

Nov

-14

US8877187 Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases Avianax, LLC 25-

Jul-05

23-

Nov

-10

4-

Nov

-14

US8877060 Methods for removing pathogens from a platelet preparation Biovec Transfusion, LLC 23-

Nov-

10

31-

Oct

-11

4-

Nov

-14

US8871816 Methods for producing vaccine adjuvants Novartis AG 3-

Dec-

09

3-

Dec

-10

28-

Oct-

14

US8871790 Heterocyclic modulators of lipid synthesis 3-V Biosciences, Inc. 8-

Mar-

11

8-

Mar

-12

28-

Oct-

14

US8871783 Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides inhibitors of cathepsin C Boehringer Ingelheim International GmBh 14-

Mar-

13

12-

Mar

-14

28-

Oct-

14

US8871782 Alkoxy substituted imidazoquinolines 3M Innovative Properties Company 3-

Oct-

03

1-

Oct

-04

28-

Oct-

14

US8871503 Construct Isis Innovation Limited 28-

Mar-

06

28-

Mar

-07

28-

Oct-

14

US8871487 Compositions, methods and uses for inducing viral growth Takeda Vaccines, Inc. 5-

Dec-

08

4-

Dec

-09

28-

Oct-

14

US8871442 Enhanced deposition of chromogens Ventana Medical Systems, Inc. 30-

Dec-

10

28-

Dec

-11

28-

Oct-

14

US8865865 N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic Philipps-Universitat Marburg 29-

Oct-

08

29-

Oct

-09

21-

Oct-

14

US8865166 Antibodies to IL-17A and uses thereof MedImmune Limited 23-

Jun-

06

22-

Jun

-07

21-

Oct-

14

US8859568 Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy Astrazeneca AB 6-

Dec-

04

3-

Nov

-10

14-

Oct-

14

US8859251 Oligoadenylate synthetase (OAS) Kineta Two, LLC 23-

Nov-

05

1-

Jul-

13

14-

Oct-

14

US8858958 Adjuvant comprising aluminum, oligonucleotide and polycation Novartis AG 27-

Aug-

09

27-

Aug

-10

14-

Oct-

14

US8858957 GAS57 mutant antigens and GAS57 antibodies Novartis AG 12-

Sep-

07

14-

Mar

-13

14-

Oct-

14

US8854617 Compounds and markers for surface-enhanced Raman scattering Julius-Maximilians-Universitat Wurzburg 24-

Sep-

07

24-

Sep

-08

7-

Oct-

14

US8853382 Expression of antibody or a fragment thereof in lactobacillus Hera Pharmaceuticals, Inc. 5-

Aug-

10

4-

Aug

-11

7-

Oct-

14

US8846710 Method of preferentially inducing the biosynthesis of interferon 3M Innovative Properties Company 23-

Feb-

05

22-

Feb

-06

30-

Sep

-14

US8846697 Purine analogs The Regents of the University of California 31-

May-

06

23-

Apr

-07

30-

Sep

-14

US8846643 Phosphonates with reduced toxicity for treatment of viral infections The Regents of the University of California 14-

Apr-

10

11-

Oct

-12

30-

Sep

-14

US8846051 Modulation of replicative fitness by deoptimization of synonymous codons The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention 8-

Oct-

04

7-

Oct

-05

30-

Sep

-14

US8841100 Use of methylsulfonylmethane (MSM) to modulate microbial activity Biogenic Innovations, LLC 30-

Oct-

09

16-

Feb

-11

23-

Sep

-14

US8840899 Use of mTOR inhibitors to enhance T cell immune responses Emory University 5-

Aug-

08

5-

Aug

-09

23-

Sep

-14

US8840890 Rapid expression cloning of human monoclonal antibodies from memory B cells University of Maryland, Baltimore 12-

Nov-

08

12-

Nov

-09

23-

Sep

-14

US8840873 Method of treating second and third degree burns using oxidative reductive potential water solution Oculus Innovative Sciences, Inc. 23-

Mar-

05

23-

Mar

-06

23-

Sep

-14

US8840774 Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode Board of Regents of the University of Texas System 3-

Jun-

05

28-

Oct

-13

23-

Sep

-14

US8835107 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics Amsterdam Institute of Viral Genomics B.V. 18-

Aug-

03

26-

Jul-

10

16-

Sep

-14

 

US8834445 Methods of treating or preventing peritonitis with oxidative reductive potential water solution Oculus Innovative Sciences, Inc. 20-

Jan-

06

30-

Mar

-12

16-

Sep

-14

US8828962 SiRNA compositions and methods for potently inhibiting viral infection Xiangxue Group (Hong Kong) Company Limited 11-

Dec-

08

12-

Dec

-11

9-

Sep

-14

US8828956 Carbohydrate conjugates as delivery agents for oligonucleotides Alnylam Pharmaceuticals, Inc. 4-

Dec-

07

4-

Dec

-12

9-

Sep

-14

US8828940 Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands Compugen Ltd. 18-

Sep-

06

14-

Dec

-10

9-

Sep

-14

US8828929 Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof Japan as Represented by Director-General of National Institute of Infectious Diseases 28-

Nov-

08

27-

Nov

-09

9-

Sep

-14

US8828673 Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses Diagnostic Hybrids Inc 24-

Apr-

98

1-

Mar

-12

9-

Sep

-14

US8828659 Method for producing nucleic acid probes Ventana Medical Systems, Inc. 1-

Sep-

06

11-

Mar

-13

9-

Sep

-14

US8828407 Chimaeric protein The Pirbright Institute 7-Jul-

09

5-

Jul-

10

9-

Sep

-14

US8828406 Influenza viruses and uses thereof Icahn School of Medicine at Mount Sinai 30-

Jul-09

29-

Jul-

10

9-

Sep

-14

US8822512 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. 20-

Mar-

09

20-

Sep

-11

2-

Sep

-14

US8822409 Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith Phylogica Limited 20-

Jun-

07

20-

Jun

-08

2-

Sep

-14

US8821897 Viral adjuvants The University of North Carolina at Chapel Hill 9-Jul-

04

24-

Nov

-10

2-

Sep

-14

US8816089 Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Masatoshi Hagiwara 26-

Dec-

03

19-

Nov

-12

26-

Aug

-14

US8816053 Methods for treating viral infection using IL-28 and IL-29 cysteine mutants ZymoGenetics, Inc. 2-

Apr-

04

7-

Sep

-12

26-

Aug

-14

US8815837 Respiratory disease treatment Pulmagen Therapeutics (Inflammation) Limited 7-

Aug-

08

29-

Jun

-12

26-

Aug

-14

US8815831 Treatment of Acinetobacter with alginate oligomers and antibiotics Algipharma AS 3-

Jun-

09

3-

Jun

-10

26-

Aug

-14

US8815611 Surface for label independent detection and method thereof Corning Incorporated 10-

Apr-

08

3-

Apr

-09

26-

Aug

-14

US8815249 Ii-key/antigenic epitope hybrid peptide vaccines Antigen Express, Inc. 4-

Sep-

99

26-

Jul-

10

26-

Aug

-14

US8815244 Method for production of antibody using ostrich Japan Science and Technology Agency 29-

Aug-

05

16-

Aug

-11

26-

Aug

-14

US8809377 Deubiquitinase inhibitors and methods for use of the same The Regents of the University of Michigan 24-

Sep-

10

23-

Sep

-11

19-

Aug

-14

US8808703 Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc Not Available 23-

Mar-

10

23-

Mar

-11

19-

Aug

-14

US8808686 Adjuvant-sparing multi-dose influenza vaccination regimen Novartis AG 15-

Jun-

06

19-

Sep

-11

19-

Aug

-14

US8802853 Arylalkenyl and arylalkynyl substituted imidazoquinolines 3M Innovative Properties Company 29-

Dec-

03

17-

Dec

-04

12-

Aug

-14

US8802647 Materials and methods for prevention and treatment of RNA viral diseases University of South Florida 30-

Apr-

02

17-

Sep

-12

12-

Aug

-14

US8802106 Peptide compositions and methods for inhibiting herpesvirus infection The Administrators of the Tulane Educational Fund 30-

Oct-

09

29-

Oct

-10

12-

Aug

-14

US8796423 Anti-TSG101 antibodies and their uses for treatment of viral infections Eli Lilly and Company 15-

Nov-

06

18-

Apr

-08

5-

Aug

-14

US8790655 Conjugates of synthetic TLR agonists and uses therefor The Regents of The University of California 7-

Feb-

07

8-

Jan

-13

29-

Jul-

14

US8785408 Compositions and methods for reducing or protecting against delayed graft function (DGF) Quark Pharmaceuticals, Inc. 27-

Jun-

07

26-

Jun

-08

22-

Jul-

14

US8785375 Cyclic antimicrobial peptides for treating bacterial infections Novabiotics Ltd. 22-

Dec-

05

22-

Aug

-12

22-

Jul-

14

 

US8784900 Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same Oculus Innovative Sciences, Inc. 13-

Mar-

07

13-

Mar

-08

22-

Jul-

14

US8779132 Pharmaceutical compounds Astex Therapeutics Limited 12-

Oct-

06

12-

Oct

-07

15-

Jul-

14

US8778963 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M Innovative Properties Company 25-

Nov-

03

24-

Nov

-04

15-

Jul-

14

US8778846 Composition, device and associated method General Electric Company 4-

Dec-

06

1-

Mar

-07

15-

Jul-

14

US8778845 Composition, device and associated method Genral Electric Company 15-

Dec-

05

1-

Mar

-07

15-

Jul-

14

US8778358 Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae Novartis Vaccines and Diagnostics, Inc. 29-

Jul-04

18-

Oct

-10

15-

Jul-

14

US8778275 Methods for producing vaccine adjuvants Novartis AG 3-

Dec-

09

3-

Dec

-10

15-

Jul-

14

US8772471 Targeted delivery of siRNA Immune Disease Institute 26-

Jan-

07

25-

Jan

-08

8-

Jul-

14

US8765939 Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers AstraZeneca AB 22-

Nov-

07

16-

Aug

-12

1-

Jul-

14

US8765704 Modified small interfering RNA molecules and methods of use Novartis AG 28-

Feb-

08

14-

Dec

-11

1-

Jul-

14

US8765643 Composition, device and associated method General Electric Company 4-

Dec-

06

1-

Mar

-07

1-

Jul-

14

US8765146 Adenoviral vector-based malaria vaccines GenVec, Inc. 31-

Aug-

05

31-

Aug

-06

1-

Jul-

14

US8765138 Antiviral and antibacterial activity from medicinal mushrooms Not Available 6-

Jan-

04

24-

Sep

-08

1-

Jul-

14

US8765133 Method of producing anti-CD166 antibody in ostrich Japan Science and Technology Agency 29-

Aug-

05

16-

Aug

-11

1-

Jul-

14

US8759307 Oligonucleotide compound and method for treating nidovirus infections Sarepta Therapeutics, Inc. 24-

Dec-

03

25-

Apr

-08

24-

Jun-

14

US8758763 Archaeal polar lipid aggregates for administration to animals National Research Council of Canada 15-

Dec-

06

23-

Jan

-13

24-

Jun-

14

US8758680 Method and device for cleaning air Not Available 29-

Sep-

10

27-

Sep

-11

24-

Jun-

14

US8754071 Compounds and compositions as c-kit kinase inhibitors Not Available 1-

Sep-

11

19-

Sep

-13

17-

Jun-

14

US8754015 Modified phage for displaying post-translationally modified proteins and uses thereof University of Rochester 21-

Nov-

06

20-

Nov

-07

17-

Jun-

14

US8748567 Method for delivery across the blood brain barrier Children’s Medical Center Corporation 22-

May-

06

22-

May

-07

10-

Jun-

14

US8748464 Use of SIRT1 activators or inhibitors to modulate an immune response The J. David Gladstone Institutes 7-

Feb-

08

16-

Jul-

10

10-

Jun-

14

US8748405 Methods and compositions for the treatment of cancer or other diseases City of Hope 26-

Jan-

07

9-

Sep

-11

10-

Jun-

14

US8748156 Animal protein-free media for cultivation of cells Baxter Healthcare SA 29-

Oct-

04

16-

Apr

-13

10-

Jun-

14

US8741813 Composition, device and associated method General Electric Company 15-

Dec-

05

28-

Feb

-07

3-

Jun-

14

US8741653 Single recombination system and methods of use Emergent Product Development GmbH 22-

Dec-

08

16-

Dec

-09

3-

Jun-

14

US8741604 Nucleic acid molecule encoding a specific IL-1R1 antibody Medimmune Limited 7-

Nov-

08

14-

Sep

-12

3-

Jun-

14

US8741564 Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements HTG Molecular Diagnostics, Inc. 4-

May-

11

26-

Apr

-12

3-

Jun-

14

US8741311 Methods and compositions for immunization against virus Academia Sinica 27-

Mar-

09

26-

Mar

-10

3-

Jun-

14

US8735567 Multi-targeted RNAi therapeutics for scarless wound healing of skin Not Available 6-

Nov-

07

6-

Nov

-08

27-

May

-14

US8735559 Mutant protease biosensors with enhanced detection characteristics Promega Corporation 11-

May-

10

11-

May

-11

27-

May

-14

 

US8735421 Imidazoquinolinyl sulfonamides 3M Innovative Properties Company 30-

Dec-

03

23-

Dec

-04

27-

May

-14

US8735410 Quinazoline derivatives as tyrosine kinase inhibitors AstraZeneca AB 26-

Feb-

05

24-

Feb

-06

27-

May

-14

US8735348 Casein derived peptides and uses thereof Peptera Ltd. 1-

Mar-

00

5-

Sep

-12

27-

May

-14

US8734823 Device including altered microorganisms, and methods and systems of use The Invention Science Fund I, LLC 14-

Dec-

05

28-

May

-10

27-

May

-14

US8728793 Amphipathic alpha-helical peptide compositions as antiviral agents The Board of Trustees of the Leland Stanford Junior University 19-

Jul-07

14-

Jul-

08

20-

May

-14

US8722917 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

23-

Jan

-12

13-

May

-14

US8722741 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease AstraZeneca AB 24-

Aug-

04

6-

Dec

-11

13-

May

-14

US8722725 Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory 23-

Mar-

07

21-

Mar

-08

13-

May

-14

US8718948 Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector Gen-Probe Incorporated 24-

Feb-

11

24-

Feb

-12

6-

May

-14

US8716464 Compositions and methods for silencing Ebola virus gene expression Not Available 20-

Jul-09

20-

Jul-

10

6-

May

-14

US8716461 Human parvovirus Blood Systems, Inc. 24-

May-

04

24-

May

-05

6-

May

-14

US8710224 Heterocyclic compounds as CCR2B antagonists AstraZeneca AB 24-

Dec-

04

13-

Sep

-13

29-

Apr-

14

US8709730 Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteins Icahn School of Medicine at Mount Sinai 5-

Apr-

07

7-

Apr

-08

29-

Apr-

14

US8709496 Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract D2 Bioscience Group Ltd. 6-

Jan-

10

23-

May

-12

29-

Apr-

14

US8709447 Compositions and methods for activating innate and allergic immunity ID Biomedical Corporation of Quebec 22-

Oct-

03

26-

Apr

-12

29-

Apr-

14

US8709441 TC-83-derived alphavirus vectors, particles and methods Alphavax, Inc. 18-

May-

04

6-

Jul-

10

29-

Apr-

14

US8704169 Direct impact ionization (DII) mass spectrometry The United States of America, as represented by the Secretary, Department of Health and Human Services 11-

Oct-

11

11-

Oct

-11

22-

Apr-

14

US8703748 Cleaning composition for treating tissue for transplantation derived from human/animal CG BIO Co., Ltd. 11-

Feb-

09

10-

Feb

-10

22-

Apr-

14

US8703467 Inactivation of a pathogen in a sample by a treatment with formalin and UV light Baxter Healthcare SA 27-

May-

04

26-

May

-05

22-

Apr-

14

US8702958 Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode Board of Regents of the University of Texas System 3-

Jun-

05

31-

May

-12

22-

Apr-

14

US8697873 Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines 3M Innovative Properties Company 24-

Mar-

04

24-

Mar

-05

15-

Apr-

14

US8697853 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. 10-

Dec-

09

10-

Jan

-13

15-

Apr-

14

US8697659 Analogues of glycolipids useful as immunoadjuvants Luigi Panza 12-

Oct-

07

10-

Oct

-08

15-

Apr-

14

US8697140 Virucidal disinfectant B. Braun Medical AG 28-

Jan-

05

28-

May

-09

15-

Apr-

14

US8697088 VLPs derived from cells that do not express a viral matrix or core protein Novavax, Inc. 25-

May-

07

27-

May

-08

15-

Apr-

14

US8697087 Influenza vaccines including combinations of particulate adjuvants and immunopotentiators Novartis AG 4-

Nov-

05

6-

Nov

-06

15-

Apr-

14

US8691837 Substituted imidazo ring systems and methods 3M Innovative Properties Company 25-

Nov-

03

24-

Nov

-04

8-

Apr-

14

US8691826 Compounds Chiesi Farmaceutici S.p.A. 14-

Sep-

11

13-

Sep

-12

8-

Apr-

14

US8691781 Compositions for treating respiratory viral infections and their use Sirnaomics, Inc. 5-

Nov-

04

4-

Nov

-05

8-

Apr-

14

 

US8691777 Combination therapy Emory University 27-

Jan-

11

25-

Jan

-12

8-

Apr-

14

US8686152 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1) Janssen Pharmaceutica NV 10-

Mar-

10

9-

Mar

-11

1-

Apr-

14

US8682619 Device including altered microorganisms, and methods and systems of use The Invention Science Fund I, LLC 14-

Dec-

05

28-

May

-10

25-

Mar

-14

US8679839 Cell line from rousettus as host cell for pathogen amplification Probiogen AG 4-

Mar-

08

4-

Mar

-09

25-

Mar

-14

US8678184 Methods for producing vaccine adjuvants Novartis AG 3-

Dec-

09

3-

Dec

-10

25-

Mar

-14

US8678002 Devices and methods for decreasing human pathogen transmission Filligent Limited 26-

Jun-

07

25-

Jun

-08

25-

Mar

-14

US8673983 Melanins synthesized chemically or via enzyme catalysis Loyola University Chicago 21-

Dec-

07

22-

Dec

-08

18-

Mar

-14

US8673932 Oxime substituted imidazo-containing compounds 3M Innovative Properties Company 12-

Aug-

03

12-

Aug

-04

18-

Mar

-14

US8673907 Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their use in therapy AstraZeneca AB 17-

Dec-

07

16-

Dec

-08

18-

Mar

-14

US8673904 Epoxide inhibitors of cysteine proteases The Board of Trustees of the Leland Stanford Junior University 13-

Jun-

06

13-

Jun

-07

18-

Mar

-14

US8673558 Luciferase biosensor Promega Corporation 10-

Oct-

03

24-

Apr

-12

18-

Mar

-14

US8673331 Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof GP&E 18-

Nov-

11

18-

Nov

-11

18-

Mar

-14

US8669263 Use of TAM receptor inhibitors as antimicrobials Salk Institute for Biological Studies 9-

Nov-

07

8-

Mar

-13

11-

Mar

-14

US8669262 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-

pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra

zine-2-carboxamide

Parion Sciences, Inc. 27-

Jun-

11

26-

Jun

-12

11-

Mar

-14

US8669240 Biological specimen collection and transport system and method of use Longhorn Vaccines & Diagnostics, LLC 1-

Oct-

07

19-

Mar

-13

11-

Mar

-14

US8664274 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses Siga Technologies, Inc. 6-

Dec-

04

6-

Jul-

11

4-

Mar

-14

US8664218 Pharmaceutical compounds Astex Therapeutics Ltd. 11-

Apr-

08

30-

Jan

-13

4-

Mar

-14

US8664188 siRNA compositions and methods for potently inhibiting viral infection Xiangxue Group (Hong Kong) Company Limited 11-

Dec-

08

11-

Dec

-09

4-

Mar

-14

US8663922 Systems and methods for detecting multiple optical signals Gen-Probe Incorporated 10-

Mar-

05

1-

Jun

-10

4-

Mar

-14

US8658767 Lipidated polyepitope vaccines National Health Research Institutes 15-

Nov-

10

15-

Nov

-11

25-

Feb

-14

US8658697 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Siga Technologies, Inc. 6-

Dec-

04

26-

Oct

-10

25-

Feb

-14

US8658666 Substituted imidazoquinolines and imidazonaphthyridines 3M Innovative Properties Company 11-

Feb-

05

10-

Feb

-06

25-

Feb

-14

US8658178 Carbon nanotube compositions and methods of use thereof Yale University 19-

Mar-

08

19-

Mar

-09

25-

Feb

-14

US8653252 Short interfering RNA (siRNA) analogues Santaris Pharma A/S 21-

Mar-

03

22-

Mar

-04

18-

Feb

-14

US8653084 Hydrobenzamide derivatives as inhibitors of Hsp90 Astex Therapeutics Ltd. 12-

Oct-

06

12-

Oct

-07

18-

Feb

-14

US8653034 Compositions and methods comprising phosphatidylethanolamine­binding peptide derivatives Board of Regents, The University of Texas System 15-

Jul-02

8-

May

-08

18-

Feb

-14

US8652836 Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response Providence Health System 29-

Jul-05

27-

Jul-

06

18-

Feb

-14

 

US8652782 Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids Longhorn Vaccines & Diagnostics, LLC 12-

Sep-

06

26-

Apr

-11

18-

Feb

-14

US8652533 Durable biocides and disinfectants Mitsui Norin Co., Ltd. 7-Jul-

04

5-

Jul-

05

18-

Feb

-14

US8648076 Cysteine protease inhibitors and their therapeutic applications Hybrigenics SA 5-

Aug-

05

26-

Jul-

06

11-

Feb

-14

US8647676 Antimicrobial composition from copepods Nofima Ingrediens 28-

Oct-

08

28-

Oct

-09

11-

Feb

-14

US8642596 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses Siga Technologies, Inc. 6-

Dec-

04

6-

Dec

-05

4-

Feb

-14

US8642260 Single quantum-dot based aptameric nanosensors The Research Foundation of the City University of New York 21-

Oct-

08

21-

Oct

-09

4-

Feb

-14

US8633322 Alkynyl derivatives useful as DPP-1 inhibitors Janssen Pharmaceutica NV 29-

Oct-

09

28-

Oct

-10

21-

Jan-

14

US8633308 Compounds for preventing or treating viral infections and methods of use thereof The Governors of The University of Alberta 28-

Feb-

07

27-

Feb

-08

21-

Jan-

14

US8632764 Directed evolution and in vivo panning of virus vectors University of North Carolina at Chapel Hill 30-

Apr-

08

29-

Apr

-09

21-

Jan-

14

US8629283 Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof Icahn School of Medicine at Mount Sinai 6-

Mar-

08

6-

Mar

-09

14-

Jan-

14

US8629271 Compounds AstraZeneca AB 6-

Feb-

08

2-

Apr

-12

14-

Jan-

14

US8629098 Compositions and methods for adoptive and active immunotherapy Yale University 15-

Jan-

08

14-

Jan

-09

14-

Jan-

14

US8628786 Polychlorinated biphenyls and squalene-containing adjuvants Novartis AG 28-

Dec-

07

2-

Dec

-11

14-

Jan-

14

US8624011 Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same The Trustees of the University of Pennsylvania 14-

Sep-

09

14-

Sep

-10

7-

Jan-

14

US8623419 Technology for preparation of macromolecular microspheres Ansun Biopharma, Inc. 24-

Jan-

06

4-

Nov

-11

7-

Jan-

14

US8623382 Immunogenic compositions for inducing an immune response to HIV Wyeth LLC 17-

Jun-

04

18-

Jan

-11

7-

Jan-

14

US8623364 Antigenic GM-CSF peptides and antibodies to GM-CSF Morphotek, Inc. 8-

Feb-

06

24-

Oct

-12

7-

Jan-

14

US8617838 Fluorescent proteins and related methods and compounds University of Massachusetts 20-

Sep-

04

20-

Sep

-05

31-

Dec

-13

US8615368 Method for determining the amount of an analyte in a sample Gen-Probe Incorporated 10-

Mar-

05

10-

Mar

-06

24-

Dec

-13

US8609370 Highly active glycoproteins-process conditions and an efficient method for their production Glycotope GmbH 13-

Feb-

04

14-

Feb

-05

17-

Dec

-13

US8609101 Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies Theraclone Sciences, Inc. 23-

Apr-

09

23-

Apr

-10

17-

Dec

-13

US8604215 Crystalline tripeptide epoxy ketone protease inhibitors Onyx Therapeutics, Inc. 20-

Mar-

09

22-

Mar

-10

10-

Dec

-13

US8603469 Methods of treating cancer with human monoclonal antibodies against interleukin 8 Genmab A/S 16-

Dec-

02

27-

Dec

-11

10-

Dec

-13

US8599383 Optical cytometry The Regents of the University of California 6-

May-

09

6-

May

-09

3-

Dec

-13

US8598192 Hydroxylamine substituted imidazoquinolines 3M Innovative Properties Company 14-

Nov-

03

12-

Nov

-04

3-

Dec

-13

US8598134 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof South Alabama Medical Science Foundation 22-

Oct-

04

23-

Jul-

10

3-

Dec

-13

US8598116 Treatment of influenza virus infection Educational Fund and Autoimmune Technologies, LLC 4-

Nov-

03

29-

May

-12

3-

Dec

-13

US8598106 Anti-microbial composition exhibiting residual anti-microbial properties on a surface Byotrol PLC 17-

Sep-

07

5-

Jul-

11

3-

Dec

-13

US8597650 Methods for treating rheumatoid arthritis with anti-bile salt- stimulated lipase (BSSL) antibodies HERNELL OLLE 8-

Apr-

09

6-

Apr

-10

3-

Dec

-13

 

US8592567 Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same The Trustees of the University of Pennsylvania 13-

Jan-

06

3-

May

-12

26-

Nov

-13

US8592391 Method for therapeutic, clinical and veterinary use poly-ICLC SALAZAR ANDRES 1-Jul-

03

17-

Oct

-08

26-

Nov

-13

US8586770 Unsaturated steroid compounds Harbor Therapeutics, Inc. 29-

Sep-

04

18-

Feb

-11

19-

Nov

-13

US8586364 Cells and methodology to generate non-segmented negative-strand RNA viruses Institut Pasteur 22-

Dec-

06

21-

Dec

-07

19-

Nov

-13

US8586363 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. 10-

Dec-

09

10-

Dec

-10

19-

Nov

-13

US8581584 Membrane proteins, mechanisms of action and uses thereof Florida State University Research Foundation 26-

May-

10

26-

May

-11

12-

Nov

-13

US8580927 Engineered antibody constant domain molecules The United States of America, as represented by the Secretary, Department of Health and Human Services 31-

Jan-

08

30-

Jan

-09

12-

Nov

-13

US8580268 CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity Coley Pharmaceutical GmbH 27-

Sep-

06

27-

Sep

-07

12-

Nov

-13

US8569283 Compounds and compositions as c-Kit kinase inhibitors LIU XIAODONG 1-

Sep-

11

29-

Aug

-12

29-

Oct-

13

US8562996 RSV-specific binding molecules and means for producing them MedImmune Limited 1-

Jun-

07

30-

May

-08

22-

Oct-

13

US8562943 Quality control methods for oil-in-water emulsions containing squalene Novartis AG 8-

Nov-

06

6-

Nov

-07

22-

Oct-

13

US8560339 System and method to predict the global spread of infectious agents via commercial air travel Kamran Khan 2-

Apr-

07

2-

Apr

-08

15-

Oct-

13

US8557767 Synthetic apolipoprotein E mimicking polypeptides and methods of use UAB Research Foundation 28-

Aug-

07

27-

Aug

-08

15-

Oct-

13

US8557248 Methods and compositions for treating malaria Cyvax, Inc. 9-

Aug-

10

9-

Aug

-11

15-

Oct-

13

US8552051 Use of pharmaceutical compositions containing mesembrenone H. L. Hall & Sons Limited 20-

Mar-

09

16-

Mar

-10

8-

Oct-

13

US8552032 Bicyclic derivatives useful as inhibitors of DPP-1 Janssen Pharmaceutica NV 18-

Dec-

09

16-

Dec

-10

8-

Oct-

13

US8551968 Methods for generation of antibodies National Jewish Health 13-

Mar-

07

13-

Mar

-08

8-

Oct-

13

US8551756 Avian influenza chimeric VLPS Novavax, Inc. 11-

Jul-03

19-

Jan

-10

8-

Oct-

13

US8551750 Device including bone cage and method for treatment of disease in a subject The Invention Science Fund I, LLC 23-

Apr-

09

28-

Jul-

09

8-

Oct-

13

US8551749 Device including bone cage and method for treatment of disease in a subject The Invention Science Fund I, LLC 23-

Apr-

09

23-

Apr

-09

8-

Oct-

13

US8551738 Systems and methods for rapid identification of nucleic acid variants Ibis Biosciences, Inc. 21-

Jul-05

11-

Nov

-09

8-

Oct-

13

US8551469 Treatment of tumors and viral diseases with recombinant interferon alpha Superlab Far East Limited 28-

Feb-

01

6-

Oct

-08

8-

Oct-

13

US8546432 Tetrazolones as inhibitors of fatty acid synthase Infinity Pharmaceuticals, Inc. 5-

May-

10

5-

May

-11

1-

Oct-

13

US8546383 Chiral fused [1,2]imidazo[4,5-c] ring compounds 3M Innovative Properties Company 30-

Dec-

04

25-

May

-12

1-

Oct-

13

US8546082 Methods for identification of sepsis-causing bacteria Ibis Biosciences, Inc. 11-

Sep-

03

25-

May

-07

1-

Oct-

13

US8541568 Compositions and methods using siRNA molecules for treatment of gliomas BIGNER DARELL D 24-

May-

08

26-

May

-09

24-

Sep

-13

US8541457 Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors Xenon Pharmaceuticals Inc. 3-

Jun-

05

5-

Jun

-06

24-

Sep

-13

US8541438 Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M Innovative Properties Company 18-

Jun-

04

21-

Dec

-10

24-

Sep

-13

US8541221 Primate T-lymphotropic viruses Johns Hopkins University 21-

Feb-

05

1-

Jul-

10

24-

Sep

-13

US8541003 Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using Protein Sciences Corporation 20-

Jun-

03

21-

Jun

-04

24-

Sep

-13

 

US8529968 Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said composition Hightech Bio-Activities Holding GmbH 29-

Mar-

04

29-

Mar

-05

10-

Sep

-13

US8524715 Phenoxyacetic acid derivatives useful for treating respiratory diseases Astrazeneca AB 23-

Nov-

04

22-

Nov

-05

3-

Sep

-13

US8524488 Methods and devices for determining a cell characteristic, and applications employing the same The Regents of the University of California 10-

Sep-

02

9-

Mar

-05

3-

Sep

-13

US8524241 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A The General Hospital Corporation 20-

Jul-07

18-

Jul-

08

3-

Sep

-13

US8519106 Monoclonal human tumor-specific antibody University of Zurich 13-

Mar-

07

13-

Mar

-08

27-

Aug

-13

US8507545 Cytotoxic T cell activator comprising EP4 agonist National University Corporation, Hamamatsu University School of Medicine 8-

May-

07

7-

May

-08

13-

Aug

-13

US8507544 Bi-aryl amide compounds as CRTh2 receptor modulators Astrazeneca AB 5-Jul-

07

3-

Jul-

08

13-

Aug

-13

US8507455 Folate conjugates Alnylam Pharmaceuticals, Inc. 4-

Dec-

07

4-

Dec

-08

13-

Aug

-13

US8506968 SARS vaccine compositions and methods of making and using them Eli Lilly and Company 29-

Jun-

00

28-

Dec

-09

13-

Aug

-13

US8506966 Adjuvanted influenza vaccines for pediatric use Novartis AG 22-

Feb-

08

20-

Feb

-09

13-

Aug

-13

US8501746 Organic compounds Novartis AG 5-

Jun-

06

4-

Jun

-07

6-

Aug

-13

US8501699 Bicyclic nucleosides and nucleotides as therapeutic agents Biota Scientific Management Pty Ltd 3-Jul-

08

7-

Sep

-12

6-

Aug

-13

US8501461 System for performing multi-formatted assays Gen-Probe Incorporated 10-

Mar-

05

3-

Dec

-09

6-

Aug

-13

US8497405 Process for dispersing vaporous hydrogen peroxide STERIS Inc. 6-

Mar-

07

28-

Feb

-13

30-

Jul-

13

US8497112 Method for producing viral vaccines Baxter Healthcare SA 28-

Aug-

07

28-

Aug

-08

30-

Jul-

13

US8494781 Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds BOGOCH ELENORE S 6-

Jun-

03

10-

Dec

-10

23-

Jul-

13

US8492329 Bioactive peptides and methods of using same Compugen Ltd. 12-

Jul-07

11-

Jul-

08

23-

Jul-

13

US8486959 Dibenzo[f,h]isoquinoline derivatives National Health Research Institutes 14-

Jan-

10

14-

Jan

-11

16-

Jul-

13

US8486678 Pharmaceutical compositions for the treatment of virus infection Kineta Two, LLC 23-

Nov-

05

1-

Feb

-12

16-

Jul-

13

US8486619 Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses University of Rochester 2-

May-

08

1-

May

-09

16-

Jul-

13

US8486420 Live virus vaccines Children’s Hospital, Inc. 15-

Feb-

05

15-

Feb

-06

16-

Jul-

13

US8481547 Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1 Janssen Pharmaceutica NV 18-

Dec-

09

16-

Dec

-10

9-

Jul-

13

US8481270 Method for chromogenic detection of two or more target molecules in a single sample Ventana Medical Systems, Inc. 22-

Aug-

08

21-

Aug

-09

9-

Jul-

13

US8481255 Scytovirin domain 1 related polypeptides The United States of America, as represented by the Secretary, Department of Health and Human Services 25-

May-

05

30-

Sep

-11

9-

Jul-

13

US8476292 Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-

dimethylethyl}methanesulfonamide and methods

3M Innovative Properties Company 9-

Sep-

05

8-

Sep

-06

2-

Jul-

13

US8476288 Salts 756 AstraZeneca AB 21-

May-

09

20-

May

-10

2-

Jul-

13

US8476265 Compounds-801 AstraZeneca AB 30-

Jul-10

14-

Sep

-12

2-

Jul-

13

US8470771 Method and medicament for inhibiting the infection of influenza virus Institute of Microbiology, Chinese Academy of Sciences 14-

Nov-

07

18-

Dec

-07

25-

Jun-

13

US8470769 Method of treatment of bacterial infection by administration of poly­lysine Novabiotics, Ltd. 18-

Aug-

04

30-

Nov

-11

25-

Jun-

13

 

US8470346 Anti-viral pharmaceutical compositions Mast Therapeutics, Inc. 10-

Dec-

03

19-

May

-11

25-

Jun-

13

US8470335 Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation 13-

Jun-

08

13-

Jun

-08

25-

Jun-

13

US8466284 Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase Astra Zeneca AB 6-

Nov-

07

5-

Nov

-08

18-

Jun-

13

US8466167 Compounds and compositions as TLR activity modulators IRM LLC 3-

Mar-

08

27-

Feb

-09

18-

Jun-

13

US8466124 RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles Coley Pharmaceutical GmbH 13-

Aug-

07

12-

Jun

-12

18-

Jun-

13

US8465751 Cna—B domain antigens in vaccines against gram positive bacteria Novartis AG 12-

Jan-

09

12-

Jan

-10

18-

Jun-

13

US8461125 Compositions and methods to treat asthma The Children’s Hospital of Philadelphia 14-

Feb-

08

13-

Aug

-10

11-

Jun-

13

US8460914 Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens Novartis AG 9-

Sep-

04

10-

Jan

-13

11-

Jun-

13

US8460605 Decontaminant dispenser suitable for use as a projectile STERIS Inc. 6-

Mar-

07

20-

Feb

-08

11-

Jun-

13

US8455483 Compounds—801 AstraZeneca AB 31-

Jul-09

30-

Jul-

10

4-

Jun-

13

US8450471 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. 10-

Dec-

09

22-

Mar

-12

28-

May

-13

US8450467 Carbohydrate conjugates as delivery agents for oligonucleotides Alnylam Pharmaceuticals, Inc. 4-

Dec-

07

14-

Dec

-11

28-

May

-13

US8450350 Triazoles as inhibitors of fatty acid synthase Infinity Pharmaceuticals, Inc. 5-

May-

10

5-

May

-11

28-

May

-13

US8450284 Coiled-coil lipopeptide helical bundles and synthetic virus-like particles Universitaet Zuerich 9-

Dec-

06

6-

Dec

-07

28-

May

-13

US8450055 Malaria antigen screening method The United States of America as Represented by the Secretary of the Navy 31-

Aug-

05

25-

Aug

-06

28-

May

-13

US8445650 Mutant botulinum neurotoxin serotype A polypeptide and uses thereof Thomas Jefferson University 25-

Sep-

07

25-

Sep

-08

21-

May

-13

US8445447 B7-DC variants immunogenic compositions and methods of use thereof The Johns Hopkins University 13-

Jul-07

7-

Mar

-12

21-

May

-13

US8444961 RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor Sekisui Chemical Co., Ltd. 16-

Jun-

09

16-

Jun

-10

21-

May

-13

US8440704 Quercetin-containing compositions Quercegen Pharmaceuticals LLC 17-

Jul-06

16-

Dec

-09

14-

May

-13

US8440649 Phenanthroindolizidine analogues National Health Research Institutes 24-

Feb-

09

11-

Feb

-10

14-

May

-13

US8440642 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

1-

Sep

-11

14-

May

-13

US8440432 Tal effector-mediated DNA modification Iowa State University Research Foundation, Inc. 10-

Dec-

09

22-

Mar

-12

14-

May

-13

US8440431 TAL effector-mediated DNA modification Iowa State University Research Foundation, Inc. 10-

Dec-

09

22-

Mar

-12

14-

May

-13

US8440408 Animal protein-free media for cultivation of cells Baxter Healthcare S.A. 29-

Oct-

04

10-

Dec

-10

14-

May

-13

US8436178 Imidazoquinolines with immuno-modulating properties AstraZeneca AB 8-

May-

07

6-

May

-08

7-

May

-13

US8436024 2-pyridone compounds Astrazeneca AB 2-

Oct-

09

1-

Oct

-10

7-

May

-13

US8431160 Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions Novartis AG 24-

Feb-

06

24-

Feb

-07

30-

Apr-

13

US8431134 Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention 31-

Jul-08

31-

Jul-

09

30-

Apr-

13

US8426565 Dendritic cell marker and uses thereof Walter and Eliza Hall Institute of Medical Research 30-

Aug-

07

29-

Aug

-08

23-

Apr-

13

US8420798 Method for producing nucleic acid probes Ventana Medical Systems, Inc. 1-

Sep-

06

31-

Aug

-07

16-

Apr-

13

 

US8420784 Interleukin 10 receptor, (IL-10R) antibodies Kyowa Hakko Kirin Co., Ltd. 27-

May-

08

27-

May

-09

16-

Apr-

13

US8420096 Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling Vanderbilt University 4-

Mar-

04

4-

Mar

-05

16-

Apr-

13

US8420094 Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A The General Hospital Corporation 20-

Jul-07

18-

Jul-

08

16-

Apr-

13

US8415394 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease Astrazeneca AB 6-

Oct-

05

21-

Dec

-11

9-

Apr-

13

US8415361 Use of TAM receptor inhibitors as antimicrobials The Salk Institute for Biological Studies 9-

Nov-

07

7-

Nov

-08

9-

Apr-

13

US8415330 Biological specimen collection and transport system and method of use Longhorn Vaccines & Diagnostics, LLC 1-

Oct-

07

1-

Oct

-12

9-

Apr-

13

US8415309 Bicyclic nucleosides and nucleotides as therapeutic agents Biota Scientific Managment Pty Ltd 1-Jul-

09

11-

Jan

-12

9-

Apr-

13

US8415118 Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof Virginia Tech Intellectual Properties, Inc. 29-

Oct-

07

29-

Oct

-08

9-

Apr-

13

US8415102 Methods and computer systems for identifying target-specific sequences for use in nanoreporters NanoString Technologies, Inc. 10-

Apr-

07

10-

Apr

-08

9-

Apr-

13

US8410149 Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses Siga Technologies Inc. 6-

Dec-

04

28-

Oct

-10

2-

Apr-

13

US8410114 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial AstraZeneca AB 8-

May-

06

6-

Jan

-12

2-

Apr-

13

US8409589 Mutant forms of streptolysin O Novartis AG 21-

Dec-

07

14-

Sep

-11

2-

Apr-

13

US8399651 Nucleic acids encoding GAS57 mutant antigens Novartis AG 12-

Sep-

07

10-

Sep

-12

19-

Mar

-13

US8398992 Methods and compositions for polytopic vaccination Polytopos LLC 29-

Apr-

05

22-

Dec

-11

19-

Mar

-13

US8394986 Phenoxiacetic acid derivatives AstraZeneca AB 21-

Aug-

03

26-

Jul-

11

12-

Mar

-13

US8394945 Compositions for use in identification of bacteria Ibis Biosciences, Inc. 11-

Sep-

03

7-

Mar

-07

12-

Mar

-13

US8394386 Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations The Trustees of the University of Pennsylvania 28-

Apr-

04

27-

Apr

-05

12-

Mar

-13

US7829712 Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase Xenon Pharmaceuticals Inc. 20-

Sep-

04

20-

Sep

-05

9-

Nov

-10

US7829707 Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy AstraZeneca AB 6-

Dec-

04

5-

Dec

-05

9-

Nov

-10

US7829302 Method for detecting the specificity of activated lymphocyte HU JUN 8-

Dec-

03

7-

Dec

-04

9-

Nov

-10

US7820210 Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers Inhalation, Inc. 3-

Apr-

00

18-

Mar

-08

26-

Oct-

10

US7812135 GITR-binding antibodies TOLERRX, Inc. 25-

Mar-

05

27-

Mar

-06

12-

Oct-

10

US7803918 Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics Amsterdam Institute of Viral Genomics B.V. 18-

Aug-

03

18-

Aug

-04

28-

Sep

-10

US7803796 Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus Sungkyunkwan University Foundation For Corporate Collaboration 22-

Dec-

06

20-

Dec

-07

28-

Sep

-10

US7803765 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom Phylogica Limited 20-

Feb-

04

20-

Feb

-04

28-

Sep

-10

US7799800 Lipid-modified immune response modifiers 3M Innovative Properties Company 30-

Oct-

03

12-

Aug

-04

21-

Sep

-10

US7794998 Primate T-lymphotropic viruses Johns Hopkins University 21-

Feb-

05

24-

Feb

-07

14-

Sep

-10

US7794659 Signal measuring system having a movable signal measuring device Gen-Probe Incorporated 10-

Mar-

05

10-

Mar

-06

14-

Sep

-10

US7790878 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof Alnylam Pharmaceuticals, Inc. 22-

Oct-

04

25-

Jun

-09

7-

Sep

-10

 

US7790449 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor The Trustees of the University of Pennsylvania 17-

Dec-

01

6-

Sep

-07

7-

Sep

-10

US7790159 Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

7-

Sep

-10

US7786290 Double-stranded ribonucleic acid with increased effectiveness in an organism Alnylam Pharmaceuticals, Inc. 13-

Jun-

03

14-

Jun

-04

31-

Aug

-10

US7785775 Human virus causing severe acute respiratory syndrome (SARS) and uses thereof Versitech Limited 24-

Mar-

03

8-

Jun

-07

31-

Aug

-10

US7785612 Polyamino acid for use as adjuvant Masanori Baba 20-

Apr-

05

19-

Apr

-06

31-

Aug

-10

US7781226 Particle on membrane assay system The Board of Regents of the University of Texas System 27-

Feb-

04

22-

Dec

-04

24-

Aug

-10

US7781203 Supports for assaying analytes and methods of making and using thereof Corning Incorporated 29-

Dec-

05

7-

Jun

-06

24-

Aug

-10

US7777036 Heterocyclic derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 20-

Sep-

04

20-

Sep

-05

17-

Aug

-10

US7777022 Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof Rosetta Genomics, Ltd. 26-

Nov-

02

26-

May

-04

17-

Aug

-10

US7776521 Coronavirus isolated from humans The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention 25-

Apr-

03

14-

May

-07

17-

Aug

-10

US7767817 Water soluble boronic acid fluorescent reporter compounds and methods of use thereof FANG HAO 5-

Sep-

03

7-

Sep

-04

3-

Aug

-10

US7767677 Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors Xenon Pharmaceuticals Inc. 20-

Sep-

04

20-

Sep

-05

3-

Aug

-10

US7767658 Vaccine composition Aventis Pasteur SA 17-

Nov-

03

9-

Jan

-08

3-

Aug

-10

US7767657 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

16-

Aug

-06

3-

Aug

-10

US7767210 RNA virus vaccines and methods The Board of Regents of the University of Oklahoma 14-

Dec-

05

14-

Dec

-06

3-

Aug

-10

US7763618 Pyridyl derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 29-

Jul-03

29-

Jul-

04

27-

Jul-

10

US7758868 Modified polymerases and attenuated viruses and methods of use thereof The Penn State Research Foundation 22-

Dec-

06

24-

Dec

-07

20-

Jul-

10

US7754711 Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 30-

Jul-03

9-

Feb

-05

13-

Jul-

10

US7750123 Antibodies against SARS-CoV and methods of use thereof Dana Farber Cancer Institute, Inc. 25-

Nov-

03

24-

Nov

-04

6-

Jul-

10

US7749445 Method and apparatus for analyzing bioprocess fluids BioScale, Inc. 2-

May-

05

19-

Dec

-06

6-

Jul-

10

US7745486 Quercetin-containing compositions Quercegen Pharma LLC 17-

Jul-06

16-

Jul-

07

29-

Jun-

10

US7745442 Methods of reducing risk of infection from pathogens Parion Sciences, Inc. 20-

Aug-

03

18-

Aug

-04

29-

Jun-

10

US7745147 Methods and uses of antibodies in the purification of interferon ViraNative AB 12-

Feb-

05

13-

Feb

-06

29-

Jun-

10

US7745119 System for detecting polynucleotides Investigen, Inc. 20-

May-

03

21-

Nov

-05

29-

Jun-

10

US7745118 Comparative genomic resequencing Roche Nimblegen, Inc. 8-

Apr-

04

8-

Apr

-05

29-

Jun-

10

US7741450 Antibodies to GM-CSF Morphotek Inc. 8-

Feb-

06

8-

Feb

-07

22-

Jun-

10

US7741360 Bi-aryl or aryl-heteroaryl substituted indoles AstraZeneca AB 26-

May-

06

25-

May

-07

22-

Jun-

10

US7740858 SARS-CoV-specific B-cell epitope and applications thereof National Taiwan University 21-

Sep-

04

21-

Sep

-04

22-

Jun-

10

US7737135 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease AstraZeneca AB 24-

Aug-

04

22-

Aug

-05

15-

Jun-

10

US7736850 Strain of SARS-associated coronavirus and applications thereof Centre National de la Recherche Scientifique 2-

Dec-

03

2-

Dec

-04

15-

Jun-

10

 

US7732177 Oligoadenylate Synthetase (OAS) Illumigen Biosciences, Inc. 23-

Nov-

05

17-

Nov

-06

8-

Jun-

10

US7731978 Mutant forms of streptolysin O Novartis AG 21-

Dec-

07

19-

Dec

-08

8-

Jun-

10

US7728110 Antibodies to SARS coronavirus Amgen, Inc. 19-

May-

06

21-

May

-07

1-

Jun-

10

US7725565 System and method for detecting, collecting, analyzing, and communicating event related information Georgetown University 25-

Feb-

08

19-

Nov

-08

25-

May

-10

US7723570 Edible vaccines expressed in soybeans SoyMeds, Inc. 12-

Oct-

04

12-

Oct

-05

25-

May

-10

US7723041 Assay for SARS coronavirus by amplification and detection of the replicase sequence Becton, Dickinson and Company 12-

Sep-

03

3-

Feb

-09

25-

May

-10

US7722886 Compositions and methods for treatment of severe acute respiratory syndrome (SARS) Wyeth 20-

May-

04

20-

May

-04

25-

May

-10

US7714109 Combinations and kits for cancer treatment using selected antibodies to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

11-

May

-10

US7713515 Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis R.E.D. Laboratories N.V. 27-

May-

03

26-

May

-04

11-

May

-10

US7709521 Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases AstraZeneca AB 18-

Aug-

03

16-

Aug

-04

4-

May

-10

US7709511 Benzothiazolone derivatives AstraZeneca AB 9-

Aug-

05

3-

Aug

-06

4-

May

-10

US7709188 Multi-allelic detection of SARS-associated coronavirus Birch Biomedical Research LLC 22-

Aug-

03

13-

Aug

-04

4-

May

-10

US7700782 Compounds 569 AstraZeneca AB 19-

Dec-

07

19-

Dec

-07

20-

Apr-

10

US7700728 Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors Schering Corporation 24-

Mar-

05

24-

Mar

-06

20-

Apr-

10

US7700727 Compositions and kits for detecting pathogen infection Biokit, S.A. 23-

Dec-

03

27-

Apr

-05

20-

Apr-

10

US7700273 Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor The United States of America as represented by the Department of Health and Human Services 9-

Apr-

04

11-

Apr

-05

20-

Apr-

10

US7700120 Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus New York Blood Center 15-

Jun-

04

15-

Jun

-05

20-

Apr-

10

US7696406 Expression of a recombinant transgene Board of Trustees Operating Michigan State University 3-Jul-

03

2-

Jul-

04

13-

Apr-

10

US7696330 Binding molecules against SARS-coronavirus and uses thereof Crucell Holland B.V. 22-

Jul-03

20-

Jan

-06

13-

Apr-

10

US7691877 Pharmaceuticals Pfizer Inc. 17-

Feb-

06

16-

Feb

-07

6-

Apr-

10

US7691646 Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof Daikin Industries, Ltd. 28-

Mar-

03

21-

Nov

-08

6-

Apr-

10

US7691599 Mammalian genes involved in viral infection and tumor suppression Zirus, Inc. 2-

May-

02

2-

May

-03

6-

Apr-

10

US7691390 Viral protein CHANG MING-FU 2-

Mar-

04

19-

Sep

-07

6-

Apr-

10

US7687535 Substituted 3-sulfur indoles AstraZeneca AB 27-

May-

03

25-

May

-04

30-

Mar

-10

US7687475 RNA interference in respiratory epithelial cells University of Iowa Research Foundation 9-Jul-

04

16-

Oct

-07

30-

Mar

-10

US7682688 Microporous materials, methods, and articles for localizing and quantifying analytes University of Utah Research Foundation 26-

Nov-

02

20-

Nov

-03

23-

Mar

-10

US7678774 Treating severe acute respiratory syndrome Hemispherx Biopharma 16-

May-

03

26-

Jan

-07

16-

Mar

-10

US7678386 Liposomes coated with selected antibodies that bind to aminophospholipids Board of Regents the University of Texas 15-

Jul-02

15-

Aug

-03

16-

Mar

-10

US7674795 Fluorene derivatives, composition containing said derivatives and the use thereof Aventis Pharma SA 19-

May-

05

14-

Nov

-07

9-

Mar

-10

 

US7670807 RNA-dependent DNA polymerase from Geobacillus stea rothermophilus East Tennessee State Univ. Research Foundation 10-

Mar-

04

10-

Mar

-04

2-

Mar

-10

US7670565 Building decontamination with vaporous hydrogen peroxide Steris Inc 31-

Jan-

03

3-

Mar

-08

2-

Mar

-10

US7666996 Casein derived peptides and uses thereof Peptera Pharmaceuticals Ltd 1-

Mar-

00

1-

Mar

-04

23-

Feb

-10

US7666592 Methods for concurrent identification and quantification of an unknown bioagent Ibis Biosciences, Inc. 18-

Feb-

04

17-

Feb

-05

23-

Feb

-10

US7662860 3D-structure model of SARS coronavirus 3CL protease and anti- SARS drugs Shanghai Institute of Materia Medica, Chinese Academy of Sciences 4-

Jun-

03

2-

Dec

-05

16-

Feb

-10

US7648997 Hydroxylamine substituted imidazoquinolines Coley Pharmaceutical Group, Inc. 12-

Aug-

03

12-

Aug

-04

19-

Jan-

10

US7648844 Method and apparatus for detection of analyte using an acoustic device BioScale, Inc. 2-

May-

05

2-

May

-06

19-

Jan-

10

US7645881 Methods for treating hepatitis C PTC Therapeutics, Inc. 22-

Jul-04

14-

Jul-

05

12-

Jan-

10

US7642350 Purine derivatives Pfizer Limited 4-

May-

05

3-

May

-06

5-

Jan-

10

US7636637 Variable length probe selection Roche NimbleGen, Inc. 18-

Jun-

04

20-

Jun

-05

22-

Dec

-09

US7635557 Enzymatic diagnostic test for SARS and other viral diseases MND Diagnostic Ltd. 23-

Jun-

03

23-

Jun

-04

22-

Dec

-09

US7635485 Method of accelerated vaccination against Ebola viruses The United States of America as represented by the Department of Health and Human Services 1-

Aug-

03

17-

Jan

-06

22-

Dec

-09

US7632638 Methods and apparatus for detecting viruses using an acoustic device BioScale, Inc. 2-

May-

05

2-

May

-06

15-

Dec

-09

US7629443 Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus New York Blood Center, Inc. 2-

Jun-

04

8-

Feb

-06

8-

Dec

-09

US7629385 Sphingolipid-derived pharmaceutical compositions Jado Technologies GmbH 29-

Jun-

04

29-

Jun

-05

8-

Dec

-09

US7629137 Methods and apparatus for detecting bacteria using an acoustic device BioScale, Inc. 2-

May-

05

2-

May

-06

8-

Dec

-09

US7629114 Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer World Sense Technology Limited 26-

Aug-

03

20-

Aug

-04

8-

Dec

-09

US7625563 Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

1-

Dec

-09

US7625492 Charge-based water filtration systems The University of Wyoming Research Corporation 28-

Jan-

03

28-

Jan

-04

1-

Dec

-09

US7625428 Bioagent air filtration systems The University of Wyoming Research Corporation 28-

Jan-

03

28-

Jan

-04

1-

Dec

-09

US7623997 Computer-implemented biological sequence identifier system and method The United States of America as represented by the Secretary of the Navy 2-Jul-

04

6-

Jun

-06

24-

Nov

-09

US7622559 Human monoclonal antibodies against interleukin 8 (IL-8) Genmab A/S 16-

Dec-

02

27-

Jun

-07

24-

Nov

-09

US7622125 Polycistronic HIV vector constructs Novartis Vaccines and Diagnostics, Inc. 5-

May-

04

5-

May

-05

24-

Nov

-09

US7622118 Cancer treatment methods using selected antibodies to a minophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

24-

Nov

-09

US7622112 Anti-SARS monoclonal antibodies Not Available 5-

Dec-

03

6-

Dec

-04

24-

Nov

-09

US7619067 Evolved interferon-alpha polypeptides Maxygen, Inc. 18-

May-

05

17-

May

-06

17-

Nov

-09

US7618802 Compositions of coronaviruses with a recombination-resistant genome The University of North Carolina at Chapel Hill 21-

Jul-03

19-

Jan

-06

17-

Nov

-09

US7618788 Proteome epitope tags and methods of use thereof in protein modification analysis Millipore Corporation 10-

May-

02

5-

Feb

-04

17-

Nov

-09

US7618635 Super-antigen fusion proteins and the use thereof Healthbanks Biotech Co., Ltd. 21-

Jul-04

19-

Jul-

05

17-

Nov

-09

US7615381 Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device BioScale, Inc. 2-

May-

05

2-

May

-06

10-

Nov

-09

 

US7615223 Selected immunoconjugates for binding to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

10-

Nov

-09

US7611908 Method and apparatus for therapeutic drug monitoring using an acoustic device BioScale, Inc. 2-

May-

05

2-

May

-06

3-

Nov

-09

US7611704 Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

3-

Nov

-09

US7605161 Pyridyl derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 30-

Jul-03

29-

Jul-

04

20-

Oct-

09

US7605135 Baicalin as a treatment for SARS infection The University of Hong Kong 10-

Nov-

03

8-

Nov

-04

20-

Oct-

09

US7604960 Transient protein expression methods Crucell Holland B.V. 15-

Apr-

99

1-

Jun

-07

20-

Oct-

09

US7604801 Methods for detecting parvovirus infections The Research Foundation of State University of New York 5-

May-

03

16-

Oct

-08

20-

Oct-

09

US7598382 Aryl substituted imidazoquinolines Coley Pharmaceutical Group, Inc. 20-

Dec-

02

13-

Jan

-06

6-

Oct-

09

US7598094 Methods and apparatus for detecting cardiac injury markers using an acoustic device BioScale, Inc. 2-

May-

05

2-

May

-06

6-

Oct-

09

US7598072 Assay to detect viral uncoating Wisconsin Alumni Research Foundation 9-

Dec-

03

8-

Dec

-04

6-

Oct-

09

US7597936 Method of producing a pigmented composite microporous material University of Utah Research Foundation 26-

Nov-

02

26-

May

-04

6-

Oct-

09

US7595381 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha 27-

Jun-

03

10-

Jun

-08

29-

Sep

-09

US7595163 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha 27-

Jun-

03

10-

Jun

-08

29-

Sep

-09

US7592343 Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors Xenon Pharmaceuticals Inc. 20-

Sep-

04

20-

Sep

-05

22-

Sep

-09

US7592322 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof Alnylam Pharmaceuticals, Inc. 22-

Oct-

04

14-

Jun

-05

22-

Sep

-09

US7592008 Membrane scaffold proteins The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois 20-

Nov-

00

11-

Jan

-05

22-

Sep

-09

US7589092 Prodrugs of heteroaryl compounds Koronis Pharmaceuticals, Incorporated 20-

Jun-

03

27-

Dec

-06

15-

Sep

-09

US7585647 Nucleic acid encoding recombinant interferon WEI GUANGWEN 28-

Aug-

03

26-

Aug

-04

8-

Sep

-09

US7582740 Methods and kits for detecting SARS-associated coronavirus The Trustees of Columbia University In the City of New York 17-

Apr-

03

23-

Jan

-04

1-

Sep

-09

US7582621 Boron-containing small molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

16-

Feb

-06

1-

Sep

-09

US7579396 Polymer composite Eastman Kodak Company 31-

Jan-

07

31-

Jan

-07

25-

Aug

-09

US7579359 1-alkoxy lH-imidazo ring systems and methods 3M Innovative Properties Company 2-

Sep-

04

1-

Sep

-05

25-

Aug

-09

US7572621 Detection, characterization and treatment of viral infection and methods thereof Canadian Blood Services 9-

Apr-

03

11-

Oct

-05

11-

Aug

-09

US7572448 Combined cancer treatment methods using selected antibodies to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

11-

Aug

-09

US7572442 Selected antibody compositions for binding to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Jul-

03

11-

Aug

-09

US7569536 Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity Masatoshi Hagiwara 26-

Dec-

03

24-

Dec

-04

4-

Aug

-09

US7569384 Albumin fusion proteins Human Genome Sciences, Inc. 9-

Feb-

04

8-

Aug

-06

4-

Aug

-09

US7550140 Antibody to the human OX40 receptor Crucell Holland B.V. 13-

Jun-

02

13-

Jun

-03

23-

Jun-

09

US7547698 Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD) Xenon Pharmaceuticals Inc. 20-

Sep-

04

20-

Sep

-05

16-

Jun-

09

US7547516 Method for reducing the presence of amplification inhibitors in a reaction receptacle Gen-Probe Incorporated 10-

Mar-

05

10-

Mar

-06

16-

Jun-

09

 

US7547512 High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS) The University of Hong Kong 24-

Mar-

03

24-

Mar

-04

16-

Jun-

09

US7544697 Pyrazolopyridines and analogs thereof Coley Pharmaceutical Group, Inc. 3-

Oct-

03

1-

Apr

-05

9-

Jun-

09

US7541436 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 19-

May-

04

4-

May

-07

2-

Jun-

09

US7541163 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 19-

May-

04

14-

Aug

-07

2-

Jun-

09

US7531630 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 19-

May-

04

13-

Sep

-06

12-

May

-09

US7531324 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 19-

May-

04

13-

Sep

-06

12-

May

-09

US7521424 Albumin fusion proteins Human Genome Sciences, Inc. 22-

Jan-

03

7-

Jul-

05

21-

Apr-

09

US7521185 Assay for SARS coronavirus by amplification and detection of the replicase sequence Becton, Dickinson and Company 12-

Sep-

03

13-

Sep

-04

21-

Apr-

09

US7514436 Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 30-

Jul-03

29-

Jul-

04

7-

Apr-

09

US7511124 Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

31-

Mar

-09

US7504384 Use of lipid conjugates in the treatment of infection Yissum Research Development Company of the Hebrew University of Jerusalem 10-

Jan-

00

8-

Sep

-05

17-

Mar

-09

US7504382 Protease inhibitors for coronaviruses and SARS-CoV and the use thereof Cytovia, Inc. 6-

May-

03

6-

May

-04

17-

Mar

-09

US7504205 Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for SARS therapy The Burnham Institute 17-

May-

04

17-

May

-05

17-

Mar

-09

US7504097 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 18-

Nov-

02

30-

Oct

-06

17-

Mar

-09

US7498409 Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists Schering Corporation 24-

Mar-

05

23-

Mar

-06

3-

Mar

-09

US7498152 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 18-

Nov-

02

30-

Oct

-06

3-

Mar

-09

US7495011 Anti-coronavirus drug aRigen Pharmaceuticals, Inc. 15-

Jul-03

14-

Jul-

04

24-

Feb

-09

US7491793 Influenza virus inhibiting peptides The Administrators of the Tulane Educational Fund 4-

Nov-

03

3-

Nov

-04

17-

Feb

-09

US7491706 Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof Changchun Huapu Biotechnology Co., Ltd. 25-

Jul-03

26-

Jul-

04

17-

Feb

-09

US7491508 Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses The Trustees of the University of Pennsylvania 20-

Jun-

03

15-

Jun

-04

17-

Feb

-09

US7491489 Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof The University of Hong Knog 22-

Nov-

04

28-

Oct

-05

17-

Feb

-09

US7491397 Receptor binding polypeptides National Health Research Institutes 9-

Jan-

04

10-

Jan

-05

17-

Feb

-09

US7488801 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 18-

Nov-

02

30-

Oct

-06

10-

Feb

-09

US7488589 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 18-

Nov-

02

30-

Oct

-06

10-

Feb

-09

US7488473 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 18-

Nov-

02

30-

Oct

-06

10-

Feb

-09

US7485432 Selective modulation of TLR-mediated biological activity 3M Innovative Properties Company 27-

Feb-

03

27-

Feb

-04

3-

Feb

-09

US7482334 Therapeutic treatment methods Hollis-Eden Pharmaceuticals, Inc. 28-

Aug-

02

12-

Feb

-07

27-

Jan-

09

US7482149 Inhibition of SARS coronavirus infection with clinically approved antiviral drugs Genome Institute of Singapore 9-

Jun-

03

9-

Jun

-04

27-

Jan-

09

US7479484 Peptides and peptidomimetics having immune-modulating, anti­inflammatory, and anti-viral activity Takeda Pharmaceutical Company Limited 25-

Jun-

03

25-

Jun

-04

20-

Jan-

09

US7470666 Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome Guangdong Techpool Biochem. Pharma. Co., Ltd. 26-

May-

03

25-

May

-04

30-

Dec

-08

 

US7470548 Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof Daikin Industries, Ltd. 28-

Mar-

03

26-

Mar

-04

30-

Dec

-08

US7468418 Compositions for enhancing transport of molecules into cells AVI BioPharma., Inc. 29-

Apr-

03

29-

Apr

-04

23-

Dec

-08

US7465836 Hydrolytically-resistant boron-containing therapeutics and methods of use Anacor Pharmaceuticals, Inc. 16-

Jun-

03

15-

Jun

-04

16-

Dec

-08

US7462615 Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications Hybrigenics SA 8-

Dec-

05

8-

Dec

-05

9-

Dec

-08

US7460960 Proteome epitope tags and methods of use thereof in protein modification analysis Epitome Biosystems, Inc. 10-

May-

02

13-

Nov

-03

2-

Dec

-08

US7456180 Piperazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 30-

Jul-03

29-

Jul-

04

25-

Nov

-08

US7455833 Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

25-

Nov

-08

US7452542 Live attenuated coronavirus vaccines Vanderbilt University 21-

May-

04

23-

May

-05

18-

Nov

-08

US7445889 Methods for detecting parvovirus infections The Research Foundation of State University of New York 5-

May-

03

5-

May

-04

4-

Nov

-08

US7442761 Replikin peptides and uses thereof BOGOCH ELENORE S 6-

Jun-

03

4-

Jun

-04

28-

Oct-

08

US7442508 Methods for detection and production of influenza viruses Diagnostic Hybrids, Inc. 24-

Apr-

98

28-

Apr

-06

28-

Oct-

08

US7439349 Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof Not Available 3-Jul-

02

1-

Jul-

03

21-

Oct-

08

US7439052 Method of making modified immunodeficiency virus particles Lipid Sciences 29-

Jun-

00

10-

Apr

-06

21-

Oct-

08

US7435588 Systems for detection and production of respiratory, herpes and enteric viruses Diagnostic Hybrids, Inc. 20-

Sep-

05

28-

Apr

-06

14-

Oct-

08

US7435538 High throughput screening method of drug for physiologically active protein CellFree Sciences Co., Ltd. 8-

Sep-

03

8-

Sep

-04

14-

Oct-

08

US7432045 Method of inhibiting influenza infection with antiviral peptides Wisconsin Alumni Research Foundation 1-

Dec-

03

1-

Dec

-04

7-

Oct-

08

US7429656 Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference The University of Hong Kong 19-

May-

03

14-

Jun

-06

30-

Sep

-08

US7427479 Methods and kits for identifying target nucleotides in mixed populations Applera Corporation 30-

Apr-

04

29-

Apr

-05

23-

Sep

-08

US7424370 Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential Council of Scientific and Industrial Research 20-

Jul-04

7-

Feb

-05

9-

Sep

-08

US7407663 Modified immunodeficiency virus particles Lipid Sciences, Inc. 29-

Jun-

00

20-

Jun

-03

5-

Aug

-08

US7407662 Modified viral particles with immunogenic properties and reduced lipid content Lipid Sciences, Inc. 29-

Jun-

00

21-

Jun

-04

5-

Aug

-08

US7405207 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof Epigenesis Pharmaceuticals, Inc. 17-

Jun-

02

17-

Jun

-03

29-

Jul-

08

US7405046 Compositions and methods for treatment of rhinovirus The Quigley Corporation 6-

Aug-

01

27-

Oct

-06

29-

Jul-

08

US7399588 Method for detecting SARS coronavirus Eiken Kagaku Kabushiki Kaisha 27-

Jun-

03

15-

Jun

-04

15-

Jul-

08

US7396914 SARS nucleic acids, proteins, antibodies, and uses thereof University of Massachusetts 4-

Aug-

03

4-

Aug

-04

8-

Jul-

08

US7393856 Anti-viral uses of borinic acid complexes Anacor Pharmaceuticals, Inc. 14-

Jun-

04

14-

Jun

-05

1-

Jul-

08

US7393638 Assay system and methods for detecting SARS-CV AsiaGEN Corporation 1-Jul-

03

1-

Jul-

03

1-

Jul-

08

US7387271 Immunostimulatory combinations 3M Innovative Properties Company 30-

Dec-

02

30-

Dec

-03

17-

Jun-

08

 

US7384909 Anti-viral treatment methods using phosphatidylethanolamine­binding peptides linked to anti-viral agents Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

10-

Jun-

08

US7378386 Anti-viral treatment methods using phosphatidylethanolamine­binding peptide derivatives Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

27-

May

-08

US7375210 PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the same Samsung Electronics Co., Ltd. 12-

Dec-

03

24-

Nov

-04

20-

May

-08

US7375202 Human virus causing severe acute respiratory syndrome (SARS) and uses thereof The University of Hong Kong 24-

Mar-

03

24-

Mar

-04

20-

May

-08

US7375180 Methods and compositions related to IRM compounds and Toll-like receptor 8 3M Innovative Properties Company 13-

Feb-

03

12-

Feb

-04

20-

May

-08

US7374883 Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS) QIAGEN Diagnostics GmbH 30-

Apr-

03

30-

Apr

-04

20-

May

-08

US7371850 Method and composition for reducing expression of ROCK-II Myriad Genetics, Inc. 20-

Aug-

03

20-

Aug

-04

13-

May

-08

US7371837 Human virus causing respiratory tract infection and uses thereof The University of Hong Kong 21-

Jul-04

16-

May

-05

13-

May

-08

US7371525 Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS) The Chinese University of Hong Kong 29-

Jul-03

28-

Jul-

04

13-

May

-08

US7361747 Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus The University of Hong Kong 22-

May-

03

24-

May

-04

22-

Apr-

08

US7361304 Building decontamination with vaporous hydrogen peroxide Steris Inc. 31-

Jan-

03

29-

Jan

-04

22-

Apr-

08

US7358068 Antiviral oligonucleotides Replicor, Inc. 13-

Sep-

02

12-

Sep

-03

15-

Apr-

08

US7354908 Materials and methods for prevention and treatment of RNA viral diseases University of South Florida 30-

Apr-

02

30-

Apr

-03

8-

Apr-

08

US7354551 Room decontamination with hydrogen peroxide vapor Steris Inc 8-Jul-

04

8-

Jul-

04

8-

Apr-

08

US7344740 Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers Inhalation, Inc. 3-

Apr-

00

27-

Nov

-04

18-

Mar

-08

US7344720 Vaccine composition Sanofi Pasteur SA 17-

Nov-

03

15-

Nov

-04

18-

Mar

-08

US7339051 Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) Isis Pharmaceuticals, Inc. 28-

Apr-

03

26-

Apr

-04

4-

Mar

-08

US7335658 Pyridazine derivatives and their use as therapeutic agents Xenon Pharmaceuticals Inc. 30-

Jul-03

29-

Jul-

04

26-

Feb

-08

US7332475 Preventive or therapeutic composition for viral infectious disease Kyowa Hakko Kogyo Co., Ltd. 22-

Jul-03

22-

Jul-

04

19-

Feb

-08

US7332294 CXCL10-based diagnosis and treatment of respiratory illnesses University Health Network 17-

Aug-

04

17-

Aug

-04

19-

Feb

-08

US7320857 Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof Chinese National Human Genome Center at Shanghai 9-Jul-

04

9-

Jul-

04

22-

Jan-

08

US7318918 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 19-

May-

04

18-

May

-05

15-

Jan-

08

US7314613 Interferon-alpha polypeptides and conjugates Maxygen, Inc. 18-

Nov-

02

19-

May

-04

1-

Jan-

08

US7312036 Compositions for use in identification of viral hemorrhagic fever viruses ISIS Pharmaceuticals, Inc. 22-

Mar-

04

21-

Mar

-05

25-

Dec

-07

US7297786 RNA interference in respiratory epitheial cells University of Iowa Research Foundation 9-Jul-

04

11-

Jul-

05

20-

Nov

-07

US7291498 Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses The Trustees of the University of Pennsylvania 20-

Jun-

03

20-

Jun

-03

6-

Nov

-07

US7282568 Human monoclonal antibodies against interleukin 8 (IL-8) Genmab A/S 16-

Dec-

02

16-

Dec

-03

16-

Oct-

07

US7282199 Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor The Trustees of the University of Pennsylvania 17-

Dec-

01

25-

Apr

-03

16-

Oct-

07

US7267942 Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS) The University of Hong Kong 24-

Mar-

03

24-

Mar

-04

11-

Sep

-07

 

US7261867 Production of silver sulfate grains using organo-sulfate or organo- sulfonate additives Eastman Kodak Company 7-

Apr-

06

7-

Apr

-06

28-

Aug

-07

US7247303 Selected antibody CDRs for binding to aminophospholipids Board of Regents, The University of Texas System 15-

Jul-02

15-

Aug

-03

24-

Jul-

07

US7244732 Prodrugs of heteroaryl compounds Koronis Pharmaceuticals, Incorporated 20-

Jun-

03

31-

Mar

-04

17-

Jul-

07

US7223787 Prenylation inhibitors reduce host cell permissiveness to viral replication Board of Regents, The University of Texas System 21-

Oct-

03

21-

Oct

-03

29-

May

-07

US7220852 Coronavirus isolated from humans The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention 25-

Apr-

03

12-

Apr

-04

22-

May

-07

US7183300 Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof AGARWAL ATUL 11-

Nov-

04

10-

Nov

-05

27-

Feb

-07

US7166435 Compositions and methods for reducing the transmissivity of illnesses The Quigley Corporation 6-

Aug-

01

14-

Dec

-04

23-

Jan-

07

US7163947 1-Amino lH-imidazoquinolines 3M Innovative Properties Company 7-

Mar-

03

3-

Sep

-04

16-

Jan-

07

US7151163 Antiviral agents for the treatment, control and prevention of infections by coronaviruses Sequoia Pharmaceuticals, Inc. 28-

Apr-

03

28-

Apr

-04

19-

Dec

-06

US7151091 Compositions and methods for preventing infection La Jolla Biosciences LLC 20-

Sep-

02

22-

Sep

-03

19-

Dec

-06

US7148248 Method of treating or inhibiting the development of brain inflammation and sepsis NOZAKI MASAKO 29-

Nov-

02

26-

Nov

-03

12-

Dec

-06

US7129223 Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference The University of HongKong 19-

May-

03

19-

May

-04

31-

Oct-

06

US7129042 Compositions and methods for detecting severe acute respiratory syndrome coronavirus Diagnostic Hybrids, Inc. 3-

Nov-

03

3-

Nov

-03

31-

Oct-

06

US7115563 Composition and its therapeutic use Insignion Holding Limited 29-

May-

02

29-

May

-03

3-

Oct-

06

US7091214 Aryl substituted Imidazoquinolines 3M Innovative Properties Co. 20-

Dec-

02

18-

Dec

-03

15-

Aug

-06

US7048953 Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS) Inhalation, Inc. 3-

Apr-

00

2-

May

-03

23-

May

-06

US7023593 Apparatus for forming nano-grating device Industrial Technology Research Institute 28-

Nov-

03

17-

Mar

-04

4-

Apr-

06

US6946291 Mixed cell diagnostic systems Diagnostic Hybrids, Inc. 24-

Apr-

98

30-

Mar

-04

20-

Sep

-05

US20200176

079

METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES Not Available 19-

Jul-17

18-

Jul-

18

4-

Jun-

20

US20200173

925

MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION DEVICE JAPAN SCIENCE AND TECHNOLOGY AGENCY 29-

Mar-

17

28-

Mar

-18

4-

Jun-

20

US20200172

883

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS Not Available 19-

Nov-

09

13-

Sep

-19

4-

Jun-

20

US20200172

879

DHFR TUNABLE PROTEIN REGULATION Not Available 3-

Mar-

17

2-

Sep

-19

4-

Jun-

20

US20200172

600

RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME GLAXOSMITHKLINE BIOLOGICALS, SA 15-

Jul-09

16-

Aug

-17

4-

Jun-

20

US20200172

513

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc. 12-

Jun-

16

5-

Feb

-20

4-

Jun-

20

US20200172

480

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS HANGZHOU DAC BIOTECH CO., LTD. 12-

Jul-12

5-

Feb

-20

4-

Jun-

20

US20200171

085

Method of Treating Respiratory Tract Infection Not Available 19-

May-

17

18-

May

-18

4-

Jun-

20

US20200171

060

FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES Not Available 31-

Jul-17

26-

Jan

-18

4-

Jun-

20

US20200166

505

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS The U.S.A., as represented by the Secretary, Department of Health and Human Services 1-

Sep-

15

30-

Jan

-20

28-

May

-20

US20200165

632

ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION Spark Therapeutics, Inc. 7-

Jun-

17

6-

Jun

-18

28-

May

-20

 

US20200165

630

COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available 29-

Apr-

16

28-

Apr

-17

28-

May

-20

US20200165

613

VIRUS LIKE PARTICLE The University of Leeds 1-

Jun-

17

31-

May

-18

28-

May

-20

US20200165

594

CRISPR SYSTEM BASED ANTIVIRAL THERAPY MASSACHUSETTS INSTITUTE OF TECHNOLOGY 7-Jul-

17

6-

Jul-

18

28-

May

-20

US20200165

585

NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS Not Available 27-

Jul-17

27-

Jul-

18

28-

May

-20

US20200165

357

CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF Not Available 2-

Dec-

05

21-

Oct

-19

28-

May

-20

US20200164

334

MICROSPOTTING DEVICE Not Available 18-

Apr-

12

11-

Oct

-19

28-

May

-20

US20200164

067

Methods and Compositions for Inhibiting Akt3 Not Available 15-

Jan-

16

5-

Feb

-20

28-

May

-20

US20200164

058

TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS King Abdulaziz University 27-

Nov-

18

27-

Nov

-18

28-

May

-20

US20200164

020

PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION Not Available 12-

Apr-

17

12-

Apr

-17

28-

May

-20

US20200163

878

LIPID NANOPARTICLE MRNA VACCINES Not Available 26-

Oct-

16

26-

Oct

-17

28-

May

-20

US20200157

600

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION Not Available 19-

Nov-

18

19-

Nov

-18

21-

May

-20

US20200157

222

ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available 29-

Mar-

18

29-

Mar

-19

21-

May

-20

US20200157

221

ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES Not Available 30-

Jun-

16

28-

Jan

-20

21-

May

-20

US20200155

704

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 30-

Sep-

03

30-

Jan

-20

21-

May

-20

US20200155

699

MODIFIED VIRUS-LIKE PARTICLES OF CMV Not Available 22-

Oct-

14

26-

Nov

-19

21-

May

-20

US20200155

667

VACCINE COMPOSITIONS Not Available 27-

Jul-17

24-

Jan

-20

21-

May

-20

US20200155

664

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE Not Available 10-

Feb-

09

26-

Jun

-19

21-

May

-20

US20200155

662

COMBINATION IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS Not Available 26-

May-

17

25-

May

-18

21-

May

-20

US20200155

660

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY Not Available 23-

Sep-

15

22-

Nov

-19

21-

May

-20

US20200155

646

EV576 For Use in the Treatment of Viral Infections of the Respiratory Tract Volution Immuno Pharmaceuticals SA 8-

Jan-

10

7-

Jun

-19

21-

May

-20

US20200149

062

ENGINEERED TSC2 Not Available 14-

Jul-17

13-

Jul-

18

14-

May

-20

US20200149

048

Transbiotic Regulation of Bacterial Gene Expression Not Available 22-

May-

17

22-

May

-18

14-

May

-20

US20200148

749

ANTIBODIES AND PROCESSES FOR PREPARING THE SAME Not Available 16-

May-

08

10-

Oct

-19

14-

May

-20

US20200147

203

VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Not Available 26-

Sep-

14

10-

Jan

-20

14-

May

-20

US20200147

193

COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS Not Available 2-

Jun-

17

2-

Jun

-18

14-

May

-20

US20200147

171

COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS Not Available 18-

Sep-

18

18-

Sep

-19

14-

May

-20

US20200140

547

MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE Not Available 26-

May-

17

25-

May

-18

7-

May

-20

US20200140

493

Engineering Virus-like Nanocarriers for Biomolecule Delivery Not Available 26-

Oct-

18

25-

Oct

-19

7-

May

-20

US20200140

398

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS AZIENDA OSPEDALIERA UNIVERSITARIA SENESE 13-

Feb-

15

6-

Jan

-20

7-

May

-20

 

US20200138

937

Genetically Attenuated Nucleic Acid Vaccine Not Available 2-

Jun-

17

1-

Jun

-18

7-

May

-20

US20200138

936

Phenotypically Wild-Type and Genetically Attenuated Viruses Not Available 2-

Jun-

17

1-

Jun

-18

7-

May

-20

US20200138

818

METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB Not Available 7-

Nov-

18

6-

Nov

-19

7-

May

-20

US20200138

780

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C Not Available 14-

Mar-

13

19-

Dec

-19

7-

May

-20

US20200131

518

CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE Not Available 14-

Mar-

17

14-

Mar

-18

30-

Apr-

20

US20200129

487

CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND TAIHO PHARMACEUTICAL CO., LTD. 30-

Jun-

17

29-

Jun

-18

30-

Apr-

20

US20200127

954

RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies 22-

Aug-

17

31-

Dec

-18

23-

Apr-

20

US20200124

599

ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL CELLEMEDY CO., LTD 13-

Apr-

17

13-

Apr

-18

23-

Apr-

20

US20200123

233

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES Ablynx N.V. 5-

Jun-

08

1-

Aug

-19

23-

Apr-

20

US20200123

205

Inhibition Of TCR Signaling With Peptide Variants Not Available 22-

Oct-

18

18-

Dec

-19

23-

Apr-

20

US20200123

203

COMPOSITIONS COMPRISING CURONS AND USES THEREOF FLAGSHIP PIONEERING INNOVATIONS V, INC. 13-

Jun-

17

13-

Jun

-18

23-

Apr-

20

US20200115

448

CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF Not Available 26-

Apr-

17

22-

Oct

-19

16-

Apr-

20

US20200115

434

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF Not Available 23-

Oct-

15

29-

Oct

-19

16-

Apr-

20

US20200113

996

CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES Not Available 23-

Jun-

17

21-

Jun

-18

16-

Apr-

20

US20200113

967

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS Not Available 26-

May-

17

26-

May

-17

16-

Apr-

20

US20200113

831

LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES GLAXOSMITHKLINE BIOLOGICALS SA 6-Jul-

11

16-

Dec

-19

16-

Apr-

20

US20200113

830

PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA GLAXOSMITHKLINE BIOLOGICALS S.A. 31-

Aug-

11

16-

Dec

-19

16-

Apr-

20

US20200109

403

IN VIVO DELIVERY OF OLIGONUCLEOTIDES Not Available 12-

Dec-

11

18-

Dec

-19

9-

Apr-

20

US20200108

136

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available 6-

Apr-

07

22-

Nov

-19

9-

Apr-

20

US20200102

558

TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY Not Available 3-

Apr-

17

3-

Oct

-19

2-

Apr-

20

US20200102

550

TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available 10-

Dec-

09

28-

Aug

-19

2-

Apr-

20

US20200102

544

POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING THE SAME Not Available 30-

Dec-

13

11-

Sep

-19

2-

Apr-

20

US20200102

362

TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY Not Available 6-

Apr-

17

5-

Apr

-18

2-

Apr-

20

US20200102

292

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Not Available 3-Jul-

13

10-

Jul-

19

2-

Apr-

20

US20200101

158

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF Not Available 1-

Oct-

15

22-

Oct

-19

2-

Apr-

20

US20200101

153

MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN Not Available 6-

Apr-

17

6-

Apr

-18

2-

Apr-

20

US20200101

142

PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY Not Available 12-

Jun-

17

12-

Jun

-18

2-

Apr-

20

 

US20200101

119

METHODS OF TREATMENT OF INFECTIONS USING BACTERIA Not Available 27-

Sep-

18

26-

Sep

-19

2-

Apr-

20

US20200101

087

PHARMACEUTICAL COMPOSITIONS AND METHODS Not Available 3-

Aug-

15

21-

Nov

-19

2-

Apr-

20

US20200100

480

TRAIT SELECTION IN AVIANS Not Available 31-

May-

17

31-

May

-18

2-

Apr-

20

US20200095

324

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF Not Available 30-

Mar-

17

30-

Mar

-18

26-

Mar

-20

US20200093

919

MODIFIED PEDV SPIKE PROTEIN Not Available 20-

Sep-

18

18-

Sep

-19

26-

Mar

-20

US20200093

909

PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO Not Available 19-

Apr-

17

19-

Apr

-18

26-

Mar

-20

US20200093

855

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE Not Available 11-

Sep-

17

3-

Jun

-19

26-

Mar

-20

US20200093

841

Broad Spectrum Antiviral and Methods of Use Not Available 17-

Apr-

06

30-

Apr

-19

26-

Mar

-20

US20200087

655

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES Not Available 14-

Jul-15

22-

Nov

-19

19-

Mar

-20

US20200087

646

OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE Not Available 31-

May-

17

31-

May

-18

19-

Mar

-20

US20200087

630

INFLUENZA VIRUS AND TYPE 1 DIABETES Istituto Zooprofilattico Sperimentale delle Venezie 10-

Oct-

12

25-

Jul-

19

19-

Mar

-20

US20200087

359

GRIFFITHSIN MUTANTS The United States of America,as represented by the Secretary,Department of Health and Human Services 10-

Feb-

15

27-

Nov

-19

19-

Mar

-20

US20200087

313

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 29-

Jul-11

25-

Apr

-19

19-

Mar

-20

US20200087

298

Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups Not Available 1-

Mar-

17

27-

Feb

-18

19-

Mar

-20

US20200087

280

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

25-

Nov

-19

19-

Mar

-20

US20200086

324

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION Not Available 30-

Jun-

16

27-

Dec

-18

19-

Mar

-20

US20200085

984

APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 7-

Mar-

11

25-

Nov

-19

19-

Mar

-20

US20200085

947

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available 7-

Sep-

12

14-

May

-19

19-

Mar

-20

US20200085

943

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN CureVac AG 31-

Jan-

12

29-

Aug

-19

19-

Mar

-20

US20200085

872

IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS Not Available 19-

Apr-

17

19-

Apr

-18

19-

Mar

-20

US20200085

852

EPIDERMAL MRNA VACCINE Not Available 5-

Aug-

15

5-

Aug

-16

19-

Mar

-20

US20200085

756

NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF Not Available 14-

Sep-

18

12-

Jul-

19

19-

Mar

-20

US20200080

141

METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS Not Available 11-

Dec-

13

19-

Nov

-19

12-

Mar

-20

US20200080

111

Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions Thereof Not Available 18-

Sep-

15

19-

Sep

-16

12-

Mar

-20

US20200079

820

DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE Hangzhou DAC Biotech Co., Ltd. 20-

Apr-

16

20-

Apr

-16

12-

Mar

-20

US20200079

781

Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases Not Available 5-

Sep-

18

1-

Aug

-19

12-

Mar

-20

US20200078

335

COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS Not Available 1-

May-

17

1-

May

-18

12-

Mar

-20

US20200072

836

MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF Not Available 5-

May-

14

2-

Apr

-19

5-

Mar

-20

US20200071

723

RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL Not Available 30-

Aug-

18

29-

Aug

-19

5-

Mar

-20

 

US20200071

421

BISPECIFIC ANTIBODY Not Available 20-

Nov-

13

8-

Apr

-19

5-

Mar

-20

US20200069

814

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE Hangzhou DAC Biotech Co., Ltd. 6-

Apr-

17

6-

Apr

-17

5-

Mar

-20

US20200062

764

ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME Not Available 17-

Nov-

16

17-

Nov

-17

27-

Feb

-20

US20200061

187

METHODS FOR PREPARING SQUALENE Not Available 12-

May-

10

4-

Nov

-19

27-

Feb

-20

US20200061

185

PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE The Scripps Research Institute 25-

Oct-

16

25-

Oct

-17

27-

Feb

-20

US20200060

981

CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES Not Available 9-

Dec-

16

11-

Dec

-17

27-

Feb

-20

US20200056

221

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA Not Available 8-

Nov-

13

25-

Oct

-19

20-

Feb

-20

US20200056

159

NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR Not Available 28-

Feb-

17

27-

Feb

-18

20-

Feb

-20

US20200055

927

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION Not Available 8-

Sep-

16

25-

Oct

-19

20-

Feb

-20

US20200055

926

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION Not Available 8-

Sep-

16

25-

Oct

-19

20-

Feb

-20

US20200054

731

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF Not Available 7-

Jan-

14

15-

Jul-

19

20-

Feb

-20

US20200054

660

DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY St. Jude Children’s Research Hospital 9-

Dec-

16

7-

Dec

-17

20-

Feb

-20

US20200054

259

HIGH DENSITY ANALOG MULTIPEXING EnLiSense, LLC 17-

Aug-

18

16-

Aug

-19

20-

Feb

-20

US20200048

722

METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS Not Available 8-

May-

15

24-

Aug

-19

13-

Feb

-20

US20200048

649

VIRUS-LIKE PARTICLES AND USES THEREOF Not Available 13-

Mar-

17

13-

Mar

-18

13-

Feb

-20

US20200048

636

IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA GLAXOSMITHKLINE BIOLOGICALS SA 6-Jul-

10

18-

Oct

-19

13-

Feb

-20

US20200046

865

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION Not Available 29-

Dec-

17

22-

Aug

-19

13-

Feb

-20

US20200046

826

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS Academia Sinica 27-

Mar-

09

4-

Jun

-19

13-

Feb

-20

US20200046

692

SPECIFIC AKT3 INHIBITOR AND USES THEREOF Not Available 15-

Jan-

16

2-

Oct

-19

13-

Feb

-20

US20200040

408

HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION Not Available 8-

Feb-

16

6-

May

-19

6-

Feb

-20

US20200040

042

CHIMERIC MOLECULES AND USES THEREOF Not Available 30-

Mar-

17

29-

Mar

-18

6-

Feb

-20

US20200038

871

DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS Not Available 29-

Mar-

17

29-

Mar

-18

6-

Feb

-20

US20200038

373

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 9-

May-

12

16-

May

-19

6-

Feb

-20

US20200033

343

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES Not Available 6-

Oct-

08

14-

Oct

-19

30-

Jan-

20

US20200032

255

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES Not Available 26-

Jan-

07

6-

Mar

-19

30-

Jan-

20

US20200031

871

NOVEL DEPSIPEPTIDES AND USES THEREOF Not Available 4-

Apr-

17

30-

Mar

-18

30-

Jan-

20

US20200031

819

COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available 23-

Apr-

15

26-

Jun

-19

30-

Jan-

20

US20200030

441

Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods Not Available 17-

Aug-

10

8-

Jul-

19

30-

Jan-

20

 

US20200030

432

ZOONOTIC DISEASE RNA VACCINES ModernaTX, Inc. 17-

Mar-

17

16-

Mar

-18

30-

Jan-

20

US20200030

422

COMBINATION OF VACCINATION AND OX40 AGONISTS CureVac AG 9-

Sep-

16

15-

Apr

-19

30-

Jan-

20

US20200024

616

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM Not Available 30-

Mar-

18

29-

Mar

-19

23-

Jan-

20

US20200024

310

NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available 3-

Dec-

12

1-

Aug

-19

23-

Jan-

20

US20200020

420

Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application Thereof Not Available 8-

Dec-

16

7-

Dec

-17

16-

Jan-

20

US20200017

926

CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF Not Available 7-

Nov-

13

28-

Aug

-19

16-

Jan-

20

US20200017

832

COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES THEREOF Not Available 5-

Apr-

17

5-

Apr

-18

16-

Jan-

20

US20200017

588

MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM Not Available 14-

Oct-

16

16-

Oct

-17

16-

Jan-

20

US20200017

554

SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINS Not Available 23-

Mar-

17

22-

Mar

-18

16-

Jan-

20

US20200017

514

ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION Not Available 12-

Jul-18

12-

Jul-

18

16-

Jan-

20

US20200017

455

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Not Available 24-

Jan-

14

19-

Mar

-19

16-

Jan-

20

US20200016

589

LOADING VIALS Not Available 10-

Nov-

11

24-

Sep

-19

16-

Jan-

20

US20200016

286

Production of Immune-Response-Stimulating Aerosols By Non­Thermal Plasma Treatment Of Airborne Pathogens Not Available 13-

Jul-18

12-

Jul-

19

16-

Jan-

20

US20200016

280

Compositions For Enhancing Transport Of Molecules Into Cells Not Available 29-

Apr-

03

9-

Apr

-19

16-

Jan-

20

US20200016

161

METHODS FOR TREATING VIRAL DISORDERS TRUSTEES OF BOSTON UNIVERSITY 24-

Sep-

09

22-

Jul-

19

16-

Jan-

20

US20200010

883

METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS Not Available 9-

Oct-

15

7-

Jun

-19

9-

Jan-

20

US20200010

519

NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION Not Available 10-

Mar-

17

9-

Mar

-18

9-

Jan-

20

US20200009

244

NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS Not Available 13-

Jun-

18

13-

Jun

-19

9-

Jan-

20

US20200002

674

ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE Not Available 18-

Nov-

13

16-

Sep

-19

2-

Jan-

20

US20200000

931

SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS Not Available 15-

Jul-16

10-

Apr

-19

2-

Jan-

20

US20190391

150

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES Not Available 1-

May-

15

10-

Sep

-19

26-

Dec

-19

US20190390

249

BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM Longhorn Vaccines and Diagnostics, LLC 1-

Oct-

07

19-

Jun

-17

26-

Dec

-19

US20190390

229

GENE EDITING REAGENTS WITH REDUCED TOXICITY Not Available 21-

Apr-

16

20-

Apr

-17

26-

Dec

-19

US20190390

179

SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF Not Available 12-

Apr-

16

12-

Apr

-17

26-

Dec

-19

US20190390

176

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM Not Available 2-

Dec-

15

3-

Jul-

19

26-

Dec

-19

US20190389

816

ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited 26-

Jun-

03

29-

Aug

-19

26-

Dec

-19

US20190388

473

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION Not Available 1-

Apr-

14

30-

Aug

-19

26-

Dec

-19

US20190382

799

VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS Not Available 27-

Oct-

16

19-

Apr

-19

19-

Dec

-19

 

US20190382

433

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY THE UNIVERSITY OF NOTTINGHAM 4-

Apr-

14

25-

Jul-

19

19-

Dec

-19

US20190381

180

HYBRID CARRIERS FOR NUCLEIC ACID CARGO Not Available 9-

Jun-

16

9-

Jun

-17

19-

Dec

-19

US20190381

162

PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING Not Available 28-

Mar-

16

27-

Mar

-17

19-

Dec

-19

US20190381

155

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY CureVac AG 22-

Feb-

13

29-

Aug

-19

19-

Dec

-19

US20190380

995

PREVENTION AND TREATMENT OF VIRAL INFECTIONS Not Available 2-

Jun-

16

3-

Jul-

19

19-

Dec

-19

US20190380

891

MOBILE CLINICS Baylor College of Medicine 12-

Nov-

14

28-

Aug

-19

19-

Dec

-19

US20190376

151

MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS Not Available 4-

Apr-

12

8-

Feb

-19

12-

Dec

-19

US20190376

034

PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF Not Available 18-

Nov-

13

23-

Aug

-19

12-

Dec

-19

US20190375

801

HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR TREATMENT OF INFECTIOUS DISEASE Not Available 9-

Sep-

16

8-

Sep

-17

12-

Dec

-19

US20190374

650

COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER/BIOMACROMOLECULE CONJUGATES Not Available 22-

Feb-

17

21-

Feb

-18

12-

Dec

-19

US20190374

610

MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSIS Not Available 20-

Dec-

16

20-

Dec

-17

12-

Dec

-19

US20190374

576

VIRAL METHODS OF T CELL THERAPY Not Available 27-

Oct-

16

19-

Apr

-19

12-

Dec

-19

US20190370

834

SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS PATHOGENS Not Available 1-

Jun-

18

1-

Jun

-18

5-

Dec

-19

US20190367

553

COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1 Not Available 27-

Oct-

17

26-

Apr

-19

5-

Dec

-19

US20190367

525

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 30-

Dec-

14

19-

Jul-

19

5-

Dec

-19

US20190367

453

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS HANGZHOU DAC BIOTECH CO., LTD. 12-

Jul-12

13-

Aug

-19

5-

Dec

-19

US20190365

925

AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM Not Available 21-

Nov-

14

13-

Jun

-19

5-

Dec

-19

US20190365

756

PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS Not Available 4-

Jun-

18

3-

Jun

-19

5-

Dec

-19

US20190359

990

VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF Not Available 25-

Jan-

17

25-

Jan

-18

28-

Nov

-19

US20190359

635

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

18-

Jul-

19

28-

Nov

-19

US20190359

629

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

18-

Jul-

19

28-

Nov

-19

US20190358

335

STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER CONJUGATES Not Available 12-

Jan-

17

12-

Jan

-18

28-

Nov

-19

US20190358

312

ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE Not Available 19-

Dec-

17

19-

Dec

-18

28-

Nov

-19

US20190358

304

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTESNIONS, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPOERIMENTALLY INDUCED OCULAR DISORDERS Not Available 18-

Oct-

13

29-

May

-19

28-

Nov

-19

US20190358

170

Lipids and Lipid Compositions for the Delivery of Active Agents Not Available 19-

Dec-

13

12-

Aug

-19

28-

Nov

-19

US20190352

639

GENOME EDITING REAGENTS AND THEIR USE Not Available 10-

Feb-

17

12-

Feb

-18

21-

Nov

-19

US20190352

615

METHOD FOR PURIFYING VIRUS Not Available 22-

Dec-

16

21-

Dec

-17

21-

Nov

-19

 

US20190352

608

CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION Not Available 16-

Sep-

13

30-

Jan

-19

21-

Nov

-19

US20190352

357

HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS Colorado State University Research Foundation 7-

Nov-

14

7-

Aug

-19

21-

Nov

-19

US20190346

443

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES Not Available 6-

Oct-

08

28-

Jun

-19

14-

Nov

-19

US20190345

504

ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG 30-

Dec-

14

26-

Jul-

19

14-

Nov

-19

US20190345

503

CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION Not Available 20-

Jun-

16

15-

Jun

-17

14-

Nov

-19

US20190345

481

PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM OXIDES Not Available 14-

Jul-15

5-

Jul-

19

14-

Nov

-19

US20190345

221

BROAD SPECTRUM VACCINE, PREPARING METHOD AND APPLICATION THEREOF Tianjin Dongya Biological Technology Co., Ltd. 9-

May-

18

9-

May

-18

14-

Nov

-19

US20190345

166

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS Not Available 1-

May-

14

24-

Jul-

19

14-

Nov

-19

US20190343

862

DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS GLAXOSMITHKLINE BIOLOGICALS, SA 6-Jul-

10

16-

Jul-

19

14-

Nov

-19

US20190337

990

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY Not Available 13-

Feb-

15

5-

Jun

-19

7-

Nov

-19

US20190336

969

PARALLELIZED SAMPLE HANDLING Not Available 19-

Apr-

13

27-

Mar

-19

7-

Nov

-19

US20190336

611

HYBRID CARRIERS FOR NUCLEIC ACID CARGO CureVac AG 9-

Jun-

16

9-

Jun

-17

7-

Nov

-19

US20190336

608

CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY CureVac AG 9-

Jun-

16

9-

Jun

-17

7-

Nov

-19

US20190336

597

METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES Not Available 8-

Jan-

13

17-

May

-19

7-

Nov

-19

US20190336

456

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS ABIOGEN PHARMA S.P.A. 15-

Jul-16

13-

Jul-

17

7-

Nov

-19

US20190330

618

ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES Not Available 1-

Dec-

05

22-

Jan

-19

31-

Oct-

19

US20190330

572

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available 8-

Sep-

16

21-

Jun

-19

31-

Oct-

19

US20190330

245

Boron-Containing Small Molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

12-

Jul-

19

31-

Oct-

19

US20190330

187

Chemical Compounds Not Available 18-

Mar-

14

10-

May

-19

31-

Oct-

19

US20190330

164

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 29-

Jul-11

28-

Nov

-18

31-

Oct-

19

US20190330

149

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS HANGZHOU DAC BIOTECH CO., LTD. 12-

Jul-12

9-

May

-19

31-

Oct-

19

US20190328

869

IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPY Transgene SA 10-

Oct-

16

10-

Oct

-17

31-

Oct-

19

US20190328

865

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION Not Available 28-

Jul-14

17-

Nov

-17

31-

Oct-

19

US20190328

804

AAV Vectors Targeted to Oligodendrocytes Not Available 28-

Sep-

12

15-

Jul-

19

31-

Oct-

19

US20190323

068

PCR Ready Compositions and Methods for Screening Biological Samples Longhorn Vaccines and Diagnostics, LLC 12-

Sep-

06

28-

Jun

-19

24-

Oct-

19

US20190322

989

PRODUCTION OF VIRUSES IN CELL CULTURE Not Available 24-

Nov-

15

25-

Jan

-19

24-

Oct-

19

US20190322

725

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF Not Available 13-

May-

14

2-

Jul-

19

24-

Oct-

19

US20190321

481

IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS NantBio, Inc. 11-

Nov-

16

9-

Nov

-17

24-

Oct-

19

US20190321

403

ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODS Juno Therapeutics, Inc. 2-

Dec-

16

30-

Nov

-17

24-

Oct-

19

 

US20190316

109

COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY DEPLETES P16 POSITIVE SENESCENT CELLS Not Available 17-

Apr-

12

10-

Jun

-19

17-

Oct-

19

US20190316

091

ERYTHROID CELLS COMPRISING ARGINASE Not Available 18-

Nov-

13

30-

May

-19

17-

Oct-

19

US20190316

090

ERYTHROID CELLS COMPRISING ARGININE DEIMINASE RUBIUS THERAPEUTICS, INC. 18-

Nov-

13

30-

May

-19

17-

Oct-

19

US20190316

089

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

10-

May

-19

17-

Oct-

19

US20190315

840

ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE Not Available 16-

Sep-

16

10-

Jun

-19

17-

Oct-

19

US20190315

807

VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCING THE EXPRESSION OF ANTIBODIES Not Available 27-

Jul-16

26-

Jul-

17

17-

Oct-

19

US20190314

496

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT CureVac AG 1-

Apr-

14

18-

Jun

-19

17-

Oct-

19

US20190314

483

Vaccines Including Antigen From Four Strains of Influenza Virus Not Available 6-

Dec-

06

30-

Nov

-18

17-

Oct-

19

US20190314

482

VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES Medigen, Inc. 28-

Nov-

16

21-

Nov

-17

17-

Oct-

19

US20190314

480

IMMUNOGENIC COMPOSITIONS AND USES THEREOF Not Available 25-

Mar-

15

23-

Apr

-19

17-

Oct-

19

US20190314

471

MOLECULAR VACCINES FOR INFECTIOUS DISEASE Not Available 2-

Oct-

08

27-

Jun

-19

17-

Oct-

19

US20190314

455

CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES Not Available 3-

Aug-

17

7-

Jun

-19

17-

Oct-

19

US20190314

372

PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS Not Available 5-

Dec-

16

25-

Mar

-19

17-

Oct-

19

US20190310

168

AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS Not Available 22-

Jul-14

4-

Mar

-19

10-

Oct-

19

US20190309

357

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 9-

Dec-

16

25-

Feb

-19

10-

Oct-

19

US20190309

262

ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE Not Available 18-

Nov-

13

4-

Jun

-19

10-

Oct-

19

US20190309

261

ERYTHROID CELLS COMPRISING LYSINE OXIDASE Not Available 18-

Nov-

13

4-

Jun

-19

10-

Oct-

19

US20190309

048

Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use Not Available 6-

Feb-

15

20-

May

-19

10-

Oct-

19

US20190309

039

CRYPTIC POLYPEPTIDES AND USES THEREOF Not Available 29-

Jan-

15

22-

Apr

-19

10-

Oct-

19

US20190308

980

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 30-

Dec-

14

24-

Jun

-19

10-

Oct-

19

US20190308

969

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available 11-

Nov-

16

13-

Nov

-17

10-

Oct-

19

US20190308

943

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS Parion Sciences, Inc. 17-

Dec-

12

13-

Mar

-19

10-

Oct-

19

US20190307

878

IMMUNE COMPLEX The Rockefeller University 20-

Mar-

15

10-

May

-19

10-

Oct-

19

US20190307

722

ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES Not Available 21-

Oct-

16

20-

Oct

-17

10-

Oct-

19

US20190298

824

ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv 4-

May-

16

4-

May

-17

3-

Oct-

19

US20190298

752

METHODS FOR THE USE OF 5′-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) Invirsa, Inc. 27-

Mar-

18

26-

Mar

-19

3-

Oct-

19

US20190298

750

Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto Not Available 11-

Sep-

13

21-

Nov

-18

3-

Oct-

19

US20190293

656

NON-RADIOACTIVE CYTOTOXICITY ASSAYS Not Available 19-

Sep-

16

19-

Sep

-17

26-

Sep

-19

US20190292

580

DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR BIOCHEMICAL SENSING Rutgers, The State University of New Jersey 23-

Mar-

18

22-

Mar

-19

26-

Sep

-19

 

US20190292

563

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR The Trustees of the University of Pennsylvania 17-

Dec-

01

8-

Apr

-19

26-

Sep

-19

US20190292

561

SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO- ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE SPARK THERAPEUTICS, INC. 1-

Dec-

15

1-

Dec

-16

26-

Sep

-19

US20190292

236

MODULATION OF IFI16 AND STING ACTIVITY Not Available 9-

Aug-

16

9-

Aug

-17

26-

Sep

-19

US20190292

216

Cyclic Di-Nucleotide Induction of Type I Interferon Not Available 3-

May-

13

19-

Feb

-19

26-

Sep

-19

US20190292

178

HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES Dana-Farber Cancer Institute, Inc. 11-

Apr-

12

26-

Jan

-18

26-

Sep

-19

US20190290

674

Composition for Promoting Production of Immunostimulatory Factor Kyoto University 2-

Aug-

16

31-

Jul-

17

26-

Sep

-19

US20190285

632

METABALOMICS AND VIRAL DIAGNOSTICS SUITE Excision Biotherapeutics, Inc. 24-

May-

16

24-

May

-17

19-

Sep

-19

US20190284

575

REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS Not Available 21-

May-

09

30-

Jan

-19

19-

Sep

-19

US20190284

531

DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL COSTIMULATION AND USES THEREOF Not Available 15-

May-

15

24-

May

-19

19-

Sep

-19

US20190284

230

ASSEMBLED GLYCOPROTEINS Not Available 29-

Sep-

16

22-

Sep

-17

19-

Sep

-19

US20190282

694

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS AUTOIMMUNE TECHNOLOGIES, LLC 14-

Mar-

13

30-

May

-19

19-

Sep

-19

US20190282

608

Method Of Treating Inflammation Not Available 1-

Apr-

10

29-

May

-19

19-

Sep

-19

US20190276

523

COMPOSITION AND METHODS OF TREATING B CELL DISORDERS Not Available 2-

Sep-

16

5-

Sep

-17

12-

Sep

-19

US20190275

519

SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS Not Available 8-

Nov-

16

8-

Nov

-17

12-

Sep

-19

US20190275

101

STRUCTURE OF GII.4 NOROVIRUS PROTEASE – DESIGN OF BROAD- SPECTRUM PROTEASE INHIBITORS Not Available 5-

Oct-

16

5-

Oct

-17

12-

Sep

-19

US20190269

694

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available 8-

Mar-

11

11-

Oct

-18

5-

Sep

-19

US20190269

672

Specific Akt3 Inhibitor and Uses Thereof Not Available 15-

Jan-

16

20-

May

-19

5-

Sep

-19

US20190264

267

PHASING Wave Life Sciences Ltd. 25-

Jul-16

24-

Jul-

17

29-

Aug

-19

US20190264

177

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

10-

May

-19

29-

Aug

-19

US20190263

934

FC VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED HALF-LIFE Not Available 26-

Jan-

18

25-

Jan

-19

29-

Aug

-19

US20190262

448

Cationic Oil-In-Water Emulsions GLAXOSMITHKLINE BIOLOGICALS, SA 18-

Sep-

11

7-

Mar

-19

29-

Aug

-19

US20190262

371

METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS Not Available 20-

Oct-

16

20-

Oct

-17

29-

Aug

-19

US20190256

585

ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE PEPTIDE Not Available 10-

Jun-

15

10-

Jun

-16

22-

Aug

-19

US20190256

579

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE The U.S.A., as represented by the Secretary, Department of Health and Human Services 24-

Feb-

15

3-

May

-19

22-

Aug

-19

US20190255

085

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS Not Available 16-

Sep-

15

1-

Feb

-19

22-

Aug

-19

US20190254

968

OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS S.A. 6-Jul-

11

2-

May

-19

22-

Aug

-19

US20190250

153

MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING SAME Board of Regents, The University of Texas System 20-

Oct-

16

19-

Oct

-17

15-

Aug

-19

US20190248

883

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available 16-

Dec-

02

20-

Feb

-19

15-

Aug

-19

US20190248

866

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION Not Available 30-

Jun-

11

30-

Apr

-18

15-

Aug

-19

 

US20190248

865

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF Not Available 23-

Oct-

15

21-

Oct

-16

15-

Aug

-19

US20190247

529

METHOD AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURES Not Available 29-

Dec-

17

23-

Apr

-19

15-

Aug

-19

US20190247

489

ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING Not Available 20-

Oct-

11

16-

Nov

-18

15-

Aug

-19

US20190247

485

Dimethyl Fumarate and Vaccination Regimens Biogen MA Inc. 14-

Mar-

14

23-

Apr

-19

15-

Aug

-19

US20190247

440

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION Not Available 1-

Apr-

14

12-

Apr

-19

15-

Aug

-19

US20190247

367

TREATMENT OF INFECTIOUS DISEASES CHILDREN’S MEDICAL CENTER CORPORATION 26-

Jan-

15

23-

Apr

-19

15-

Aug

-19

US20190241

646

ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION Not Available 15-

Mar-

17

15-

Apr

-19

8-

Aug

-19

US20190241

618

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS Not Available 30-

Sep-

09

22-

Oct

-18

8-

Aug

-19

US20190240

317

HPIV3 RNA VACCINES ModernaTX, Inc. 22-

Oct-

15

28-

Mar

-19

8-

Aug

-19

US20190233

447

PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS Not Available 28-

Aug-

15

25-

Feb

-19

1-

Aug

-19

US20190232

282

METHODS AND COMPOSITIONS FOR DETECTING ANALYTES Not Available 23-

Sep-

16

20-

Sep

-17

1-

Aug

-19

US20190231

004

MASK NBC MESHTEC INC. 17-

Oct-

16

13-

Oct

-17

1-

Aug

-19

US20190225

986

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

Not Available 28-

Oct-

05

30-

Nov

-18

25-

Jul-

19

US20190225

971

METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE Not Available 10-

Aug-

15

4-

Aug

-16

25-

Jul-

19

US20190224

339

COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available 29-

Apr-

16

28-

Apr

-17

25-

Jul-

19

US20190223

445

ANTIMICROBIAL GEOPOLYMER COMPOSITIONS Not Available 14-

Jul-16

13-

Jul-

17

25-

Jul-

19

US20190220

524

DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN KNOWLEDGE GRAPHS Not Available 16-

Jan-

18

29-

Mar

-18

18-

Jul-

19

US20190219

563

Assay for Detecting TH1 and TH2 Cell Populations Not Available 16-

May-

14

17-

Dec

-18

18-

Jul-

19

US20190218

574

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR The Trustees of the University of Pennsylvania 2-

Oct-

07

28-

Mar

-19

18-

Jul-

19

US20190218

277

ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE Not Available 16-

Sep-

16

15-

Sep

-17

18-

Jul-

19

US20190218

207

3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NaMPT Modulators Not Available 17-

Aug-

15

17-

Aug

-16

18-

Jul-

19

US20190216

951

METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS CureVac AG 21-

Aug-

13

1-

Apr

-19

18-

Jul-

19

US20190216

917

HMPV RNA VACCINES ModernaTX, Inc. 22-

Oct-

15

28-

Mar

-19

18-

Jul-

19

US20190216

915

TRANSGENIC VERO-CD4/CCR5 CELL LINE Not Available 2-

Oct-

15

15-

Feb

-19

18-

Jul-

19

US20190216

841

Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens Not Available 20-

Apr-

11

20-

Mar

-19

18-

Jul-

19

US20190211

361

COMPOSITIONS COMPRISING CURONS AND USES THEREOF Not Available 13-

Jun-

17

27-

Mar

-19

11-

Jul-

19

US20190211

355

DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF Not Available 5-

Jan-

15

4-

Jan

-16

11-

Jul-

19

US20190211

024

SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES General Research Laboratory 19-

Aug-

16

19-

Aug

-17

11-

Jul-

19

 

US20190209

678

MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITY Not Available 2-

Dec-

14

12-

Mar

-19

11-

Jul-

19

US20190209

604

OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. 3-

Jun-

16

2-

Jun

-17

11-

Jul-

19

US20190207

890

RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies 22-

Aug-

17

31-

Dec

-18

4-

Jul-

19

US20190204

330

APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS Not Available 28-

Jun-

16

19-

Dec

-18

4-

Jul-

19

US20190203

268

LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED ASSAY FOR DETECTING MICROBES Not Available 2-

Jan-

18

31-

Dec

-18

4-

Jul-

19

US20190203

186

PRODUCTION OF VIRUSES IN AVIAN EGGS Not Available 24-

Nov-

15

25-

Jan

-19

4-

Jul-

19

US20190203

170

Avian Cells for Improved Virus Production Not Available 5-

Jun-

13

21-

Dec

-18

4-

Jul-

19

US20190202

929

COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS Not Available 20-

Sep-

16

20-

Sep

-17

4-

Jul-

19

US20190202

868

CORONAVIRUS PROTEINS AND ANTIGENS Phibro Animal Health Corporation 7-

Feb-

14

15-

Mar

-19

4-

Jul-

19

US20190202

854

ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN A Not Available 4-

Aug-

14

8-

Mar

-19

4-

Jul-

19

US20190201

565

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION Not Available 29-

Dec-

17

11-

Sep

-18

4-

Jul-

19

US20190201

564

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION Not Available 29-

Dec-

17

29-

Dec

-17

4-

Jul-

19

US20190201

552

Aptamer Compositions and Methods of Use Thereof Not Available 28-

Dec-

17

28-

Dec

-18

4-

Jul-

19

US20190201

433

2′-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT Atea Pharmaceuticals, Inc. 7-

Sep-

16

5-

Mar

-19

4-

Jul-

19

US20190201

352

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY Not Available 30-

Jan-

15

12-

Mar

-19

4-

Jul-

19

US20190201

337

HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS Not Available 3-

Dec-

09

3-

Jan

-19

4-

Jul-

19

US20190194

728

Systemic inflammatory and pathogen biomarkers and uses therefor Not Available 24-

Aug-

16

24-

Aug

-17

27-

Jun-

19

US20190194

717

METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM JAPAN SCIENCE AND TECHNOLOGY AGENCY 5-

Sep-

16

4-

Sep

-17

27-

Jun-

19

US20190194

628

METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION Takeda Pharmaceutical Company Limited 1-

Sep-

16

1-

Sep

-17

27-

Jun-

19

US20190194

322

IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY BIO-TECHNE CORPORATION 3-

Aug-

16

3-

Aug

-17

27-

Jun-

19

US20190194

299

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF Not Available 25-

Apr-

14

19-

Nov

-18

27-

Jun-

19

US20190194

226

FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS Not Available 26-

Aug-

16

1-

Aug

-17

27-

Jun-

19

US20190194

150

COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION Arrakis Therapeutics, Inc. 1-Jul-

16

30-

Jun

-17

27-

Jun-

19

US20190192

691

REGULATED BIOCIRCUIT SYSTEMS Not Available 11-

Apr-

16

11-

Apr

-17

27-

Jun-

19

US20190192

581

Methods of Populating a Gastrointestinal Tract Not Available 4-

Feb-

13

1-

Aug

-18

27-

Jun-

19

US20190187

151

ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING STABLE ISOTOPE STANDARDS UVic Industry Partnerships Inc. 6-

Jun-

16

7-

Apr

-17

20-

Jun-

19

US20190187

130

COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI­DYE QUINONE METHIDE AND TYRAMIDE CONJUGATES Not Available 28-

Jun-

16

19-

Dec

-18

20-

Jun-

19

US20190185

922

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS CapitalBio Corporation 5-

Dec-

13

20-

Nov

-18

20-

Jun-

19

 

US20190185

832

DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING CAS9 NUCLEASE AND USES THEREOF Not Available 3-

Jun-

16

2-

Jun

-17

20-

Jun-

19

US20190184

067

MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS Not Available 1-

Nov-

15

28-

Feb

-19

20-

Jun-

19

US20190184

018

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES Not Available 4-

Dec-

07

20-

Nov

-18

20-

Jun-

19

US20190183

968

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS Not Available 13-

Jan-

11

27-

Feb

-19

20-

Jun-

19

US20190183

918

SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES Not Available 12-

Jun-

13

29-

Oct

-18

20-

Jun-

19

US20190177

739

RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS Not Available 21-

Jan-

08

13-

Dec

-18

13-

Jun-

19

US20190175

716

Adenoviral Vector Not Available 23-

Jun-

16

23-

Jun

-17

13-

Jun-

19

US20190175

528

INHIBITION OF BIOFILM ORGANISMS Not Available 31-

Mar-

09

13-

Feb

-19

13-

Jun-

19

US20190169

677

PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR THE DETECTION OF TARGET VIRUSES Click Diagnostics, Inc. 9-

Nov-

17

9-

Nov

-18

6-

Jun-

19

US20190169

639

CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS EDITAS MEDICINE, INC. 7-

Nov-

13

24-

Jan

-19

6-

Jun-

19

US20190169

595

RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies 22-

Aug-

17

25-

Jan

-19

6-

Jun-

19

US20190167

787

Methods and Compositions for Inhibiting Akt3 Not Available 15-

Jan-

16

6-

Feb

-19

6-

Jun-

19

US20190167

786

EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES Not Available 4-

Nov-

05

9-

Jul-

18

6-

Jun-

19

US20190167

636

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C Not Available 14-

Mar-

13

8-

Feb

-19

6-

Jun-

19

US20190166

866

METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A CRUSTACEAN CATCH Not Available 4-

Dec-

17

30-

Nov

-18

6-

Jun-

19

US20190160

129

Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents Not Available 1-

Oct-

15

1-

Feb

-19

30-

May

-19

US20190160

063

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 31-

Dec-

15

30-

Dec

-16

30-

May

-19

US20190154

687

DETECTION DEVICE AND DETECTION METHOD Kabushiki Kaisha Toshiba 17-

Nov-

17

7-

Mar

-18

23-

May

-19

US20190154

550

BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE Not Available 6-

Apr-

16

6-

Apr

-17

23-

May

-19

US20190153

471

COMPOSITIONS FOR THE TREATMENT OF DISEASE Not Available 29-

Apr-

16

28-

Apr

-17

23-

May

-19

US20190153

086

Heterodimeric Immunoglobulins Not Available 21-

Nov-

12

5-

Feb

-19

23-

May

-19

US20190151

844

DEVICES AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELL Click Diagnostics, Inc. 29-

Jun-

16

21-

Dec

-18

23-

May

-19

US20190151

474

RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULES Kyoto University 8-

Sep-

14

8-

Sep

-15

23-

May

-19

US20190144

930

ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION Not Available 6-

Dec-

13

9-

Jan

-19

16-

May

-19

US20190144

929

DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS Not Available 15-

Mar-

17

15-

Mar

-18

16-

May

-19

US20190144

827

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES RUBIUS THERAPEUTICS, INC. 18-

Nov-

13

19-

Nov

-18

16-

May

-19

US20190144

556

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES Not Available 13-

May-

16

12-

May

-17

16-

May

-19

US20190144

484

ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Not Available 28-

Apr-

16

28-

Apr

-17

16-

May

-19

 

US20190142

929

INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED STRAINS Not Available 10-

Feb-

09

15-

Oct

-18

16-

May

-19

US20190142

927

LOW-ADDITIVE INFLUENZA VACCINES Not Available 27-

Jun-

07

26-

Jun

-18

16-

May

-19

US20190136

226

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION Not Available 11-

May-

16

9-

Nov

-18

9-

May

-19

US20190136

215

Replication Conditional Virus that Specifically Kills Senescent Cells Not Available 17-

Apr-

12

6-

Jul-

18

9-

May

-19

US20190135

875

TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS Not Available 18-

May-

16

17-

May

-17

9-

May

-19

US20190135

873

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE Not Available 19-

Dec-

16

19-

Dec

-18

9-

May

-19

US20190135

788

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS Hoffmann-La Roche Inc. 12-

Jun-

16

7-

Dec

-18

9-

May

-19

US20190134

214

GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof Not Available 6-

May-

16

4-

May

-17

9-

May

-19

US20190134

193

USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS SALK INSTITUTE FOR BIOLOGICAL STUDIES 9-

Nov-

07

9-

Aug

-18

9-

May

-19

US20190134

186

INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT Not Available 4-

Nov-

05

10-

Jul-

18

9-

May

-19

US20190134

062

PHARMACEUTICAL COMPOSITIONS AND METHODS Not Available 3-

Aug-

15

8-

Jan

-19

9-

May

-19

US20190128

893

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Not Available 24-

Feb-

14

7-

Nov

-18

2-

May

-19

US20190128

810

SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR PERFORMANCE Not Available 31-

Dec-

15

13-

Dec

-18

2-

May

-19

US20190127

441

METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY University of Vermont and State Agricultural College 13-

Apr-

16

13-

Apr

-17

2-

May

-19

US20190127

405

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Not Available (Ml)

LL

7-

Nov

-18

2-

May

-19

US20190127

401

CHARGED LINKERS AND THEIR USES FOR CONJUGATION HANGZHOU DAC BIOTECH CO., LTD. 12-

Aug-

16

20-

Dec

-18

2-

May

-19

US20190127

400

CHARGED LINKERS AND THEIR USES FOR CONJUGATION HANGZHOU DAC BIOTECH CO., LTD. 12-

Aug-

16

20-

Dec

-18

2-

May

-19

US20190127

399

CHARGED LINKERS AND THEIR USES FOR CONJUGATION HANGZHOU DAC BIOTECH CO., LTD. 12-

Aug-

16

20-

Dec

-18

2-

May

-19

US20190125

858

COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE

ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY

Not Available 18-

Apr-

16

18-

Apr

-17

2-

May

-19

US20190125

806

Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing Antimicrobial and Antiviral Agent Murata Manufacturing Co., Ltd. 13-

Jun-

16

13-

Dec

-18

2-

May

-19

US20190125

724

PREVENTION AND TREATMENT OF VIRAL INFECTIONS Not Available 2-

Jun-

16

27-

Nov

-18

2-

May

-19

US20190119

744

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS Not Available 31-

Jul-09

5-

Nov

-18

25-

Apr-

19

US20190119

743

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS Not Available 15-

Aug-

16

26-

Oct

-18

25-

Apr-

19

US20190119

701

METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF Not Available 8-

Sep-

17

7-

Sep

-18

25-

Apr-

19

US20190119

266

COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available 23-

Apr-

15

24-

Oct

-18

25-

Apr-

19

US20190119

220

CARBOXYLIC ACID COMPOUNDS Sumitomo Dainippon Pharma Co., Ltd. 18-

May-

12

23-

Oct

-18

25-

Apr-

19

US20190117

793

MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES Not Available 15-

Feb-

07

1-

Oct

-18

25-

Apr-

19

US20190117

702

USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS Indiana University Research and Technology Corporation 6-

May-

14

31-

Oct

-18

25-

Apr-

19

US20190112

596

TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS Not Available 4-

Apr-

12

12-

Apr

-18

18-

Apr-

19

US20190112

394

USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATION Whitehead Institute for Biomedical Research 28-

Jun-

11

24-

Sep

-18

18-

Apr-

19

 

US20190111

141

A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE Ewha University – Industry Collaboration Foundation 6-

Apr-

16

6-

Apr

-17

18-

Apr-

19

US20190105

653

PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING WATERBORNE PATHOGENS Not Available 5-

Oct-

17

5-

Oct

-18

11-

Apr-

19

US20190105

381

METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING CANCER Not Available 16-

Mar-

16

16-

Mar

-16

11-

Apr-

19

US20190105

334

Anti-Viral Azide Containing Compounds Not Available 28-

Jul-10

3-

Dec

-18

11-

Apr-

19

US20190100

586

Humanized Anti-Claudin-1 Antibodies and Uses Thereof Chu Strasbourg, Les HA’pitaux Universitaires de Strasbourg 22-

Mar-

16

21-

Mar

-17

4-

Apr-

19

US20190099

493

Targeting Lipids Arbutus Biopharma Corporation 4-

Dec-

07

10-

Oct

-17

4-

Apr-

19

US20190099

479

RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF Not Available 14-

May-

10

27-

Apr

-18

4-

Apr-

19

US20190094

224

METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL RECEPTOR AFFINITY AND SEQUENCE Not Available 11-

Apr-

16

6-

Apr

-17

28-

Mar

-19

US20190091

329

CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS, SA 6-Jul-

11

6-

Dec

-18

28-

Mar

-19

US20190091

221

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS TRUSTEES OF BOSTON UNIVERSITY 11-

Mar-

10

23-

Apr

-18

28-

Mar

-19

US20190085

057

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION Not Available 8-

Sep-

16

15-

Nov

-18

21-

Mar

-19

US20190085

024

Alpha-Ketoamide Inhibitors Of Cysteine Proteases Not Available 15-

Sep-

17

17-

Sep

-18

21-

Mar

-19

US20190085

013

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Not Available 7-

Mar-

16

7-

Mar

-17

21-

Mar

-19

US20190084

943

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL

SODIUM CHANNEL BLOCKING ACTIVITY

Parion Sciences, Inc. 17-

Dec-

12

23-

Aug

-18

21-

Mar

-19

US20190083

602

METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS Not Available 22-

Dec-

15

22-

Dec

-16

21-

Mar

-19

US20190083

592

IMMUNOSTIMULATORY COMBINATIONS Not Available 30-

Dec-

02

22-

Oct

-18

21-

Mar

-19

US20190083

569

MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS Not Available 11-

Jun-

15

24-

Jul-

18

21-

Mar

-19

US20190083

525

COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS Not Available 11-

Jul-17

10-

Jul-

18

21-

Mar

-19

US20190083

520

N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto Not Available 10-

Mar-

16

10-

Mar

-17

21-

Mar

-19

US20190083

408

CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF Not Available 2-

Dec-

11

4-

Dec

-18

21-

Mar

-19

US20190083

397

OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID NOVARTIS AG 23-

Dec-

15

21-

Dec

-16

21-

Mar

-19

US20190078

060

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES Novartis AG 9-

Sep-

04

8-

Nov

-18

14-

Mar

-19

US20190078

051

Animal Protein-Free Media for Cultivation of Cells Baxalta GmbH 29-

Oct-

04

29-

Oct

-18

14-

Mar

-19

US20190077

847

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES Ablynx N.V. 5-

Jun-

08

17-

Oct

-17

14-

Mar

-19

US20190077

764

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION Hoffmann-La Roche Inc. 23-

May-

16

13-

Nov

-18

14-

Mar

-19

US20190077

763

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION Hoffmann-La Roche Inc. 23-

May-

16

13-

Nov

-18

14-

Mar

-19

US20190076

520

VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING Not Available 4-

Apr-

08

11-

Sep

-18

14-

Mar

-19

US20190076

468

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE Not Available 11-

Sep-

17

11-

Sep

-17

14-

Mar

-19

 

US20190071

423

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

422

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

421

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

420

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

419

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

418

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190062

785

MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES Not Available 4-

Apr-

16

31-

Mar

-17

28-

Feb

-19

US20190062

724

RNA TARGETING METHODS AND COMPOSITIONS Salk Institute for Biological Studies 22-

Aug-

17

27-

Mar

-18

28-

Feb

-19

US20190062

713

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS Not Available 11-

Jul-03

22-

Mar

-18

28-

Feb

-19

US20190062

408

CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USE Not Available 25-

Aug-

08

20-

Jun

-18

28-

Feb

-19

US20190062

380

FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE THEREOF Not Available 7-

Sep-

12

28-

Aug

-18

28-

Feb

-19

US20190062

326

2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A] PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS BAYER PHARMA AKTIENGESELLSCHAFT 10-

Dec-

15

7-

Dec

-16

28-

Feb

-19

US20190062

323

PI-Kinase Inhibitors with Anti-Infective Activity Not Available 26-

Feb-

16

24-

Feb

-17

28-

Feb

-19

US20190060

435

PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE The United States of America, as represented by the Secretary, Dept of Health and Human Service 27-

Feb-

16

27-

Feb

-17

28-

Feb

-19

US20190060

364

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY Not Available 31-

Jul-15

6-

Nov

-18

28-

Feb

-19

US20190060

363

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY Not Available 31-

Jul-15

6-

Nov

-18

28-

Feb

-19

US20190060

262

ENHANCED EXPRESSION OF RNA VECTORS UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH 25-

Mar-

13

5-

Sep

-18

28-

Feb

-19

US20190060

239

Technology for the Preparation of Microparticles Not Available 24-

Jul-07

17-

Oct

-18

28-

Feb

-19

US20190056

122

Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and Methods of Use Thereof Synexis LLC 20-

Apr-

15

20-

Apr

-16

21-

Feb

-19

US20190055

256

ANTI-VIRAL DRUG DORING INTERNATIONAL GMBH 24-

Feb-

16

24-

Feb

-17

21-

Feb

-19

US20190055

241

GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS Not Available 31-

Aug-

15

22-

Oct

-18

21-

Feb

-19

US20190055

234

COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available 23-

Apr-

15

24-

Oct

-18

21-

Feb

-19

US20190054

188

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 30-

Sep-

03

2-

Oct

-18

21-

Feb

-19

US20190054

127

ANTIVIRAL AGENT AND ANTIVIRAL FOOD EDUCATIONAL CORPORATION MUKOGAWA GAKUIN 4-

Mar-

16

22-

Nov

-16

21-

Feb

-19

US20190054

122

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY Not Available 31-

Jul-15

5-

Nov

-18

21-

Feb

-19

US20190049

378

CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS Not Available 10-

Mar-

05

21-

Jun

-18

14-

Feb

-19

US20190048

344

CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION Not Available 23-

Sep-

08

16-

Aug

-18

14-

Feb

-19

US20190048

082

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES Not Available 30-

Jun-

16

25-

Oct

-18

14-

Feb

-19

 

US20190048

049

CARGOMERS CERENIS THERAPEUTICS HOLDING SA 10-

Aug-

17

10-

Aug

-18

14-

Feb

-19

US20190048

026

Boron-Containing Small Molecules Anacor Pharmaceuticals, Inc. 16-

Feb-

05

18-

Oct

-18

14-

Feb

-19

US20190046

690

MATERIALS WITH IMPROVED PROPERTIES Not Available 1-

Nov-

15

2-

Nov

-16

14-

Feb

-19

US20190046

654

ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF Not Available 9-

Aug-

17

9-

Aug

-18

14-

Feb

-19

US20190046

635

COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL COMPOSITION NITTO DENKO CORPORATION 2-

Feb-

16

1-

Feb

-17

14-

Feb

-19

US20190040

451

FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC NUCLEIC ACID SEQUENCES Not Available 8-

Jan-

16

9-

Jan

-17

7-

Feb

-19

US20190040

378

NOVEL NUCLEIC ACID MOLECULES Not Available 4-Jul-

17

3-

Jul-

18

7-

Feb

-19

US20190040

370

TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9 Not Available 23-

Nov-

15

3-

Aug

-18

7-

Feb

-19

US20190040

105

Method for Preventing and Treating Hyperpermeability Not Available 5-

Mar-

09

19-

Oct

-18

7-

Feb

-19

US20190038

742

MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME Longeveron LLC 4-

Feb-

16

2-

Feb

-17

7-

Feb

-19

US20190032

077

ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG 30-

Dec-

13

9-

Jul-

18

31-

Jan-

19

US20190032

041

COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS Not Available 21-

Feb-

06

12-

Feb

-18

31-

Jan-

19

US20190031

740

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF Not Available 13-

May-

14

15-

Oct

-18

31-

Jan-

19

US20190031

679

NOVEL MONOTHIOL MUCOLYTIC AGENTS Not Available 30-

Jan-

15

5-

Sep

-18

31-

Jan-

19

US20190031

605

TETRAHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. 29-

Jan-

16

27-

Jan

-17

31-

Jan-

19

US20190030

187

sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection Sirnaomics, Inc. 8-

Sep-

15

7-

Sep

-16

31-

Jan-

19

US20190030

094

BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR TREATING RESPIRATORY DISORDERS Not Available 27-

Jan-

16

27-

Jan

-17

31-

Jan-

19

US20190025

292

ANTIGEN PRESENTING CELL ASSAY University of Pittsburgh – Of the Com monwealth System of Higher Education 8-

Apr-

10

25-

Sep

-18

24-

Jan-

19

US20190024

096

PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL Not Available 7-

Aug-

15

7-

Aug

-15

24-

Jan-

19

US20190023

799

GITR Antibodies And Methods Of Inducing Or Enhancing An Immune Response Not Available 25-

Mar-

05

28-

Jun

-18

24-

Jan-

19

US20190023

779

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY Not Available 28-

Dec-

11

5-

Oct

-18

24-

Jan-

19

US20190023

769

COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION Not Available 29-

Oct-

12

21-

Sep

-18

24-

Jan-

19

US20190022

249

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 30-

Sep-

03

2-

Oct

-18

24-

Jan-

19

US20190022

216

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF Not Available 23-

Oct-

15

4-

Sep

-18

24-

Jan-

19

US20190022

214

Attenuated Infectious Bronchitis Virus Not Available 27-

Jan-

16

26-

Jan

-17

24-

Jan-

19

US20190022

213

MERS-CoV Vaccine Not Available 29-

Nov-

13

29-

Jun

-18

24-

Jan-

19

US20190022

116

N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto Not Available 26-

Dec-

14

16-

Dec

-15

24-

Jan-

19

US20190017

112

METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTION HTG Molecular Diagnostics, Inc. 11-

Feb-

16

10-

Feb

-17

17-

Jan-

19

US20190017

068

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 17-

Dec-

01

26-

Sep

-18

17-

Jan-

19

 

US20190017

000

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available 8-

Sep-

16

19-

Sep

-18

17-

Jan-

19

US20190016

785

ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS

AND USES THEREOF

Not Available 7-

Oct-

15

7-

Oct

-16

17-

Jan-

19

US20190016

772

GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto Not Available 23-

Oct-

12

2-

Oct

-18

17-

Jan-

19

US20190016

710

MULTICYCLIC COMPOUNDS AND USES THEREOF Not Available 31-

Dec-

15

29-

Dec

-16

17-

Jan-

19

US20190016

690

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 31-

Dec-

15

30-

Dec

-16

17-

Jan-

19

US20190015

527

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 30-

Sep-

03

25-

Jul-

18

17-

Jan-

19

US20190015

522

IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF Not Available 5-

Apr-

12

19-

Jul-

18

17-

Jan-

19

US20190015

501

NUCLEIC ACID VACCINES ModernaTX, Inc. 23-

Apr-

14

27-

Sep

-18

17-

Jan-

19

US20190015

432

Lipid Disulfide Prodrugs and Uses Related Thereto Not Available 13-

Jul-17

13-

Jul-

18

17-

Jan-

19

US20190010

469

ATTENUATED VIRUSES USEFUL FOR VACCINES Not Available 30-

Mar-

07

16-

Jul-

18

10-

Jan-

19

US20190010

240

COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND Not Available 15-

Mar-

13

2-

Aug

-18

10-

Jan-

19

US20190010

132

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS Parion Sciences, Inc. 13-

Dec-

13

4-

Apr

-18

10-

Jan-

19

US20190008

954

NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION CureVac AG 31-

Jan-

12

11-

Jun

-18

10-

Jan-

19

US20190008

948

NUCLEIC ACID VACCINES ModernaTX, Inc. 23-

Apr-

14

16-

Jul-

18

10-

Jan-

19

US20190008

833

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 9-

May-

12

17-

Jul-

18

10-

Jan-

19

US20190004

061

DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY Not Available 2-Jul-

10

4-

Aug

-18

3-

Jan-

19

US20190002

477

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Kineta, Inc. 9-

May-

14

31-

Jan

-18

3-

Jan-

19

US20190002

448

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Not Available 31-

Dec-

15

29-

Dec

-16

3-

Jan-

19

US20190002

393

Lipids and Lipid Compositions for the Delivery of Active Agents Not Available 5-

Sep-

14

19-

Sep

-18

3-

Jan-

19

US20190001

010

ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF Not Available 8-

Dec-

14

13-

Jul-

18

3-

Jan-

19

US20190000

959

NUCLEIC ACID VACCINES ModernaTX, Inc. 23-

Apr-

14

27-

Jul-

18

3-

Jan-

19

US20190000

745

POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF eXion labs Inc. 28-

Jul-16

4-

Sep

-18

3-

Jan-

19

US20180372

747

METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR TISSUE Not Available 22-

Nov-

15

21-

May

-18

27-

Dec

-18

US20180372

733

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES Not Available 27-

Apr-

10

21-

Jun

-18

27-

Dec

-18

US20180371

536

METHODS FOR RNA QUANTIFICATION Not Available 1-

Jun-

15

26-

May

-16

27-

Dec

-18

US20180371

461

APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS VIRUSES AND TREATING PRRS VIRUS INFECTION Not Available 10-

Dec-

15

1-

Dec

-16

27-

Dec

-18

US20180371

410

MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS Not Available 4-

Dec-

09

28-

Aug

-18

27-

Dec

-18

US20180369

386

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Not Available 8-

Mar-

13

29-

Aug

-18

27-

Dec

-18

US20180369

364

RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG PROTEIN Not Available 2-Jul-

15

1-

Jul-

16

27-

Dec

-18

 

US20180368

417

ANTIMICROBIAL COMPOSITIONS AND METHODS Not Available 23-

Sep-

14

19-

Jun

-18

27-

Dec

-18

US20180365

375

METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC CLASSIFICATION Not Available 24-

Apr-

15

4-

Oct

-17

20-

Dec

-18

US20180363

027

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID Not Available 6-

Oct-

06

15-

May

-18

20-

Dec

-18

US20180362

625

REGULATION OF CYTOKINE PRODUCTION Not Available 4-

Dec-

15

2-

Dec

-16

20-

Dec

-18

US20180360

877

METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTURE Not Available 8-

Dec-

15

8-

Dec

-16

20-

Dec

-18

US20180360

736

FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES Intelgenx Corp. 2-

Dec-

13

23-

Aug

-18

20-

Dec

-18

US20180355

017

COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES Not Available 7-

Jun-

17

6-

Jun

-18

13-

Dec

-18

US20180353

594

METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available 26-

Jul-13

21-

Aug

-18

13-

Dec

-18

US20180346

574

ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available 13-

Jun-

16

9-

Aug

-18

6-

Dec

-18

US20180346

573

ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available 13-

Jun-

16

9-

Aug

-18

6-

Dec

-18

US20180346

522

HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME Not Available 10-

Apr-

12

6-

Aug

-18

6-

Dec

-18

US20180346

516

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS Not Available 27-

Nov-

15

28-

Nov

-16

6-

Dec

-18

US20180346

485

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

27-

Feb

-18

6-

Dec

-18

US20180346

480

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

1-

Mar

-18

6-

Dec

-18

US20180344

877

RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF Children’s Healthcare of Atlanta, Inc. 16-

Apr-

15

8-

Aug

-18

6-

Dec

-18

US20180344

832

METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY Not Available 20-

Apr-

15

20-

Apr

-16

6-

Dec

-18

US20180344

751

Broad Spectrum Antiviral and Methods of Use Not Available 17-

Apr-

06

26-

Dec

-17

6-

Dec

-18

US20180340

219

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 9-

Dec-

16

9-

Mar

-18

29-

Nov

-18

US20180340

218

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 9-

Dec-

16

9-

Mar

-18

29-

Nov

-18

US20180340

215

SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET SEQUENCE Not Available 28-

Aug-

15

26-

Aug

-16

29-

Nov

-18

US20180340

154

PRODUCTION OF VIRUSES IN AVIAN EGGS Not Available 24-

Nov-

15

23-

Nov

-16

29-

Nov

-18

US20180340

153

PRODUCTION OF VIRUSES IN CELL CULTURE Not Available 24-

Nov-

15

23-

Nov

-16

29-

Nov

-18

US20180339

991

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 30-

Dec-

14

24-

May

-18

29-

Nov

-18

US20180339

988

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 30-

Dec-

14

18-

Jan

-18

29-

Nov

-18

US20180339

014

PEPTIDOMIMETIC MACROCYCLES Not Available 14-

Jan-

09

7-

Jun

-18

29-

Nov

-18

US20180334

480

CORONAVIRUSES EPITOPE-BASED VACCINES RAMOT AT TEL-AVIV UNIVERSITY LTD. 17-

Sep-

15

15-

Sep

-16

22-

Nov

-18

US20180333

485

Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same Not Available 12-

Dec-

11

9-

May

-18

22-

Nov

-18

US20180327

800

MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS Not Available 26-

Feb-

03

21-

May

-18

15-

Nov

-18

 

US20180327

738

STABILIZED REAGENTS FOR GENOME MODIFICATION Not Available 20-

Nov-

15

18-

Nov

-16

15-

Nov

-18

US20180327

697

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available 8-

Sep-

16

12-

Jun

-18

15-

Nov

-18

US20180327

484

RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM Not Available 1-

Jun-

07

23-

Jul-

18

15-

Nov

-18

US20180326

070

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES Not Available 4-

Dec-

07

20-

Nov

-17

15-

Nov

-18

US20180326

051

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS Not Available 17-

Aug-

10

24-

Jul-

18

15-

Nov

-18

US20180326

045

COMBINATION PIV3/HMPV RNA VACCINES ModernaTX, Inc. 22-

Oct-

15

20-

Jul-

18

15-

Nov

-18

US20180326

044

NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONS Not Available 13-

Oct-

15

13-

Oct

-16

15-

Nov

-18

US20180326

039

VACCINE COMPOSITIONS Not Available 16-

Sep-

15

16-

Sep

-16

15-

Nov

-18

US20180325

076

ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM OXISCIENCE, LLC 28-

Aug-

14

24-

Jul-

18

15-

Nov

-18

US20180321

242

VIRAL BIOMARKERS AND USES THEREFOR Not Available 6-

Nov-

15

4-

Nov

-16

8-

Nov

-18

US20180319

811

DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS Not Available 30-

Oct-

15

28-

Oct

-16

8-

Nov

-18

US20180319

779

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Not Available 3-Jul-

13

4-

Dec

-17

8-

Nov

-18

US20180318

447

COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY Not Available 3-

Dec-

15

30-

Nov

-16

8-

Nov

-18

US20180318

366

METHOD OF TREATMENT USING ONCOLYTIC VIRUSES Not Available 15-

Jun-

15

15-

Jun

-16

8-

Nov

-18

US20180318

350

Immune Cells with DNMT3A Gene Modifications and Methods Related Thereto Not Available 4-

Nov-

15

4-

Nov

-16

8-

Nov

-18

US20180312

575

ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF Not Available 6-

Dec-

07

20-

Mar

-18

1-

Nov

-18

US20180312

545

OPTIMIZED NUCLEIC ACID MOLECULES Not Available 9-

Nov-

15

9-

Nov

-16

1-

Nov

-18

US20180312

544

RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND USES THEREOF The United States of America, as represented by the Secretary, Dept. of Health and Human Services 20-

Jan-

15

20-

Jan

-16

1-

Nov

-18

US20180311

338

MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME Not Available 11-

Jan-

16

11-

Jul-

18

1-

Nov

-18

US20180311

273

Method of Treating Inflammation Not Available 1-

Apr-

10

26-

Jun

-18

1-

Nov

-18

US20180305

773

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA DETECTION Not Available 12-

Apr-

17

12-

Apr

-18

25-

Oct-

18

US20180305

760

Pathogen biomarkers and uses therefor Not Available 30-

Sep-

15

30-

Sep

-16

25-

Oct-

18

US20180305

451

HIDE1 COMPOSITIONS AND METHODS Not Available 13-

Jul-15

13-

Jul-

16

25-

Oct-

18

US20180305

412

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE Not Available 19-

Dec-

16

9-

Jul-

18

25-

Oct-

18

US20180305

357

IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS Not Available 22-

Dec-

06

25-

Jun

-18

25-

Oct-

18

US20180305

356

NOVEL KINASE INHIBITORS Not Available 19-

Oct-

12

18-

May

-18

25-

Oct-

18

US20180303

874

Compositions and Methods for the Prevention of Microbial Infections Not Available 10-

Nov-

11

30-

Nov

-17

25-

Oct-

18

US20180303

768

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY Not Available 30-

Jan-

15

2-

Jul-

18

25-

Oct-

18

US20180303

090

TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT Not Available 30-

Oct-

15

17-

Oct

-16

25-

Oct-

18

 

US20180267

031

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS The U.S.A., as represented by the Secretary, Department of Health and Human Services 1-

Sep-

15

8-

Aug

-16

20-

Sep

-18

US20180265

847

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

29-

Mar

-18

20-

Sep

-18

US20180265

822

LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available 8-

Sep-

16

21-

May

-18

20-

Sep

-18

US20180265

574

Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection Not Available 15-

Mar-

17

15-

Mar

-17

20-

Sep

-18

US20180265

507

HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES Dana-Farber Cancer Institute, Inc. 11-

Apr-

12

26-

Jan

-18

20-

Sep

-18

US20180264

098

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS The Government of the USA as represented by the Secretary of the Dept. of Health and Human Service 8-

Oct-

04

31-

May

-18

20-

Sep

-18

US20180258

162

Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections Not Available 2-

Jan-

15

22-

May

-18

13-

Sep

-18

US20180258

160

Optimized Crosslinkers for Trapping a Target on a Substrate Not Available 13-

Nov-

15

11-

May

-18

13-

Sep

-18

US20180258

159

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY Not Available 28-

Oct-

14

14-

May

-18

13-

Sep

-18

US20180258

151

RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF Not Available 28-

Feb-

01

2-

Mar

-18

13-

Sep

-18

US20180251

737

COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH Not Available 5-

Dec-

08

28-

Dec

-17

6-

Sep

-18

US20180251

540

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available 16-

Dec-

02

30-

Apr

-18

6-

Sep

-18

US20180251

436

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Not Available 24-

Jan-

14

19-

Sep

-17

6-

Sep

-18

US20180250

602

PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE IMMUNE RESPONSE Not Available 11-

Feb-

14

1-

May

-18

6-

Sep

-18

US20180250

381

SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available 20-

Aug-

10

12-

Oct

-17

6-

Sep

-18

US20180245

056

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS Not Available 19-

Nov-

09

9-

Oct

-17

30-

Aug

-18

US20180245

053

VIRAL VACCINES AND METHODS OF FORMING THE SAME Not Available 27-

Feb-

17

27-

Feb

-18

30-

Aug

-18

US20180244

759

NOVEL METHODS OF GENERATING ANTIBODIES Rutgers, The State University of New Jersey 19-

Aug-

15

18-

Aug

-16

30-

Aug

-18

US20180244

756

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE The United States of America, as Represented by the Secretary, Dept. of Health and Human Services 24-

Feb-

15

24-

Feb

-16

30-

Aug

-18

US20180244

669

IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS Not Available 31-

Aug-

15

26-

Aug

-16

30-

Aug

-18

US20180244

660

CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS Not Available 17-

Aug-

15

17-

Aug

-16

30-

Aug

-18

US20180243

347

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF Not Available 25-

Aug-

15

22-

Aug

-16

30-

Aug

-18

US20180237

835

METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS American International Biotechnology, LLC 31-

Jul-15

29-

Jul-

16

23-

Aug

-18

US20180237

788

IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION The Regents of the University of California 8-

Aug-

15

5-

Aug

-16

23-

Aug

-18

US20180237

786

ARTIFICIAL NUCLEIC ACID MOLECULES CUREVAC AG 28-

Aug-

15

22-

Aug

-16

23-

Aug

-18

US20180237

502

PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY COCKTAILS Integrated BioTherapeutics, Inc. 11-

Mar-

15

11-

Mar

-16

23-

Aug

-18

US20180237

435

GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS Not Available 31-

Aug-

15

26-

Aug

-16

23-

Aug

-18

US20180236

058

REVERSE GENETICS SYSTEMS Not Available 31-

Jul-09

16-

Oct

-17

23-

Aug

-18

US20180236

054

Tetanus Toxoid and CCL3 Improve DC Vaccines Duke University 14-

Nov-

13

19-

Apr

-18

23-

Aug

-18

 

US20180235

948

(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3- METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4- FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE TREATMENT OF CANCER Not Available 18-

Aug-

15

18-

Aug

-16

23-

Aug

-18

US20180230

521

BIOAGENT DETECTION OLIGONUCLEOTIDES Not Available 27-

Dec-

11

13-

Apr

-18

16-

Aug

-18

US20180230

447

ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) Northwestern University 24-

Jan-

17

24-

Jan

-18

16-

Aug

-18

US20180228

695

DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS Not Available 11-

Aug-

15

11-

Aug

-16

16-

Aug

-18

US20180223

290

METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS GenVec, Inc. 10-

Nov-

05

7-

Sep

-17

9-

Aug

-18

US20180222

906

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES 3M Innovative Properties Company 18-

Jun-

04

9-

Apr

-18

9-

Aug

-18

US20180221

464

IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE RESPONSES Not Available 3-

Aug-

15

3-

Aug

-16

9-

Aug

-18

US20180216

164

HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS Not Available 15-

Nov-

06

19-

Mar

-18

2-

Aug

-18

US20180216

067

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

29-

Mar

-18

2-

Aug

-18

US20180215

831

Antibody Derivatives with Conditionally Enabled Effector Function Not Available 27-

Jul-15

27-

Jul-

16

2-

Aug

-18

US20180215

801

CRYPTIC POLYPEPTIDES AND USES THEREOF Not Available 29-

Jan-

15

29-

Jan

-16

2-

Aug

-18

US20180215

794

TREATING CANCER WITH VIRAL NUCLEIC ACID Mayo Foundation for Medical Education and Research 20-

Feb-

07

27-

Mar

-18

2-

Aug

-18

US20180214

430

Selective Inhibitors Of i-NOS For Use Against Viral Infection UCL Business PLC 17-

Jul-15

15-

Jul-

16

2-

Aug

-18

US20180209

960

Method of Determining, Identifying or Isolating Cell-Penetrating Peptides Not Available 23-

May-

11

11-

Dec

-17

26-

Jul-

18

US20180208

897

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

19-

Mar

-18

26-

Jul-

18

US20180208

659

ANTI-PD-L1 ANTIBODIES AND USES THEREOF Not Available 13-

Jun-

16

13-

Jun

-17

26-

Jul-

18

US20180208

653

METHODS FOR ENHANCING AN IMMUNE RESPONSE Not Available 20-

Jan-

17

19-

Jan

-18

26-

Jul-

18

US20180207

258

ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE Not Available 22-

Feb-

08

5-

Mar

-18

26-

Jul-

18

US20180207

145

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES GlaxoSmithKline Intellectual Property (No. 2) Limited 12-

May-

14

19-

Mar

-18

26-

Jul-

18

US20180201

998

COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC DEAFNESS GENE MUTATION CapitalBio Corporation 14-

Jul-15

14-

Jul-

15

19-

Jul-

18

US20180201

907

METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES Not Available 26-

Jan-

12

13-

Mar

-18

19-

Jul-

18

US20180201

687

ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES THEREOF Not Available 7-Jul-

15

7-

Jul-

16

19-

Jul-

18

US20180200

365

Methods and Compositions for Inhibiting Akt3 Not Available 17-

Jan-

17

20-

Feb

-18

19-

Jul-

18

US20180200

364

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS 3M Innovative Properties Company 17-

Aug-

10

27-

Nov

-17

19-

Jul-

18

US20180200

224

Antiviral Activity from Medicinal Mushrooms and Their Active Constituents Not Available 31-

Mar-

15

12-

Mar

-18

19-

Jul-

18

US20180200

196

Modular Particulars for Immunotherapy Not Available 1-

Nov-

13

3-

Jan

-18

19-

Jul-

18

US20180196

061

INFLUENZA POTENCY ASSAYS Not Available 7-Jul-

15

7-

Jul-

16

12-

Jul-

18

US20180195

048

METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION Takeda Vaccines, Inc. 13-

Feb-

15

12-

Feb

-16

12-

Jul-

18

 

US20180194

850

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES Not Available 15-

May-

15

13-

May

-16

12-

Jul-

18

US20180194

829

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER Not Available 15-

Apr-

11

13-

Nov

-17

12-

Jul-

18

US20180194

735

Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines Hoffmann La-Roche Inc. 17-

Sep-

15

8-

Mar

-18

12-

Jul-

18

US20180193

477

DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS Not Available 15-

Jul-15

15-

Jul-

16

12-

Jul-

18

US20180187

213

Variant AAV and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and Tissues The Children’s Hospital of Philadelphia 22-

Jul-13

6-

Dec

-17

5-

Jul-

18

US20180187

211

METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY Not Available 9-

Jan-

15

7-

Jan

-16

5-

Jul-

18

US20180187

165

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF Takeda Vaccines, Inc. 7-

Nov-

14

27-

Oct

-17

5-

Jul-

18

US20180187

154

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

20-

Feb

-18

5-

Jul-

18

US20180187

153

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

20-

Feb

-18

5-

Jul-

18

US20180187

131

DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME AND USE THEREOF COMMISSARIAT A L’ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES 16-

Jun-

15

15-

Jun

-16

5-

Jul-

18

US20180186

897

NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA Not Available 26-

Jun-

15

24-

Jun

-16

5-

Jul-

18

US20180186

821

PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN EMBEDDED TISSUE USING CAGED HAPTENS Not Available 28-

Aug-

15

28-

Feb

-18

5-

Jul-

18

US20180186

802

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS Not Available 1-

May-

14

27-

Feb

-18

5-

Jul-

18

US20180186

792

HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM 3M Innovative Properties Company 3-

Jun-

11

26-

Feb

-18

5-

Jul-

18

US20180186

534

Powdered Pouch And Method Of Making Same MONOSOL, LLC 16-

Apr-

12

29-

Dec

-17

5-

Jul-

18

US20180185

469

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME Not Available 24-

Apr-

12

14-

Dec

-17

5-

Jul-

18

US20180185

392

Pharmaceutical Compositions and Methods Not Available 3-

Aug-

15

29-

Nov

-17

5-

Jul-

18

US20180185

345

METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONS Not Available 19-

Jun-

15

17-

Jun

-16

5-

Jul-

18

US20180180

544

USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A FLUOROMETER Not Available 14-

Jun-

12

22-

Feb

-18

28-

Jun-

18

US20180179

300

GENERATION OF BINDING MOLECULES Merus N.V. 26-

Sep-

11

22-

Nov

-17

28-

Jun-

18

US20180179

274

PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES THEREOF Not Available 26-

Jun-

15

24-

Jun

-16

28-

Jun-

18

US20180177

863

METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES Not Available 23-

Sep-

15

31-

Oct

-17

28-

Jun-

18

US20180177

862

ANTIGENICALLY MATCHED INFLUENZA VACCINES Not Available 26-

Jun-

15

24-

Jun

-16

28-

Jun-

18

US20180177

860

VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION METHOD THEREFOR Not Available 11-

Jun-

15

7-

Jun

-16

28-

Jun-

18

US20180163

182

PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS Human Services 10-

Jun-

15

10-

Jun

-16

14-

Jun-

18

US20180162

838

Chemical Compounds Not Available 18-

Mar-

14

13-

Dec

-17

14-

Jun-

18

US20180162

835

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

11-

Dec

-17

14-

Jun-

18

US20180161

425

NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY PRODUCTION IN IMMUNIZATION Not Available 10-

Dec-

14

10-

Dec

-15

14-

Jun-

18

 

US20180161

422

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM- LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN CureVac AG 15-

Feb-

12

8-

Feb

-18

14-

Jun-

18

US20180161

279

GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF Not Available 14-

Dec-

16

13-

Dec

-17

14-

Jun-

18

US20180160

662

Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha Institut Pasteur 26-

Mar-

12

25-

Jan

-18

14-

Jun-

18

US20180149

659

DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE Not Available 4-

Jun-

15

3-

Jun

-16

31-

May

-18

US20180148

727

ARTIFICIAL NUCLEIC ACID MOLECULES Not Available 30-

Dec-

14

29-

Dec

-15

31-

May

-18

US20180142

239

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES Not Available 26-

Jan-

07

14-

Jun

-17

24-

May

-18

US20180142

198

DELIVERY OF BIOMOLECULES TO IMMUNE CELLS Not Available 31-

Oct-

14

30-

Oct

-15

24-

May

-18

US20180142

006

ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. 27-

Jun-

08

12-

Jan

-18

24-

May

-18

US20180142

005

ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. 27-

Jun-

08

12-

Jan

-18

24-

May

-18

US20180142

004

ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. 27-

Jun-

08

11-

Jan

-18

24-

May

-18

US20180142

003

ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. 27-

Jun-

08

9-

Jan

-18

24-

May

-18

US20180142

002

ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. 27-

Jun-

08

5-

Jan

-18

24-

May

-18

US20180140

659

ANALOGS OF C5a AND METHODS OF USING SAME Not Available 29-

Jun-

10

12-

Jan

-18

24-

May

-18

US20180140

625

PRODUCTION OF STABLE NON-POLYADENYLATED RNAS Massachusetts Institute of Technology 16-

Oct-

12

31-

Jul-

17

24-

May

-18

US20180140

580

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS Not Available 29-

Nov-

02

23-

Oct

-17

24-

May

-18

US20180135

099

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF Not Available 23-

Dec-

05

2-

Jan

-18

17-

May

-18

US20180135

012

MEMBRANE-RECEIVER COMPLEX THERAPEUTICS Not Available 13-

May-

15

13-

May

-16

17-

May

-18

US20180134

783

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available 16-

Dec-

02

26-

Apr

-16

17-

May

-18

US20180134

770

ANTIBODY PRODUCING NON-HUMAN ANIMALS Merus N.V. 27-

Jun-

08

12-

Jan

-18

17-

May

-18

US20180133

246

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES Not Available 7-

Mar-

12

1-

Nov

-17

17-

May

-18

US20180127

836

IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF VIRUSES Not Available 7-

May-

15

6-

May

-16

10-

May

-18

US20180127

783

CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS EDITAS MEDICINE, INC. 7-

Nov-

13

29-

Nov

-17

10-

May

-18

US20180127

384

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 29-

Jul-11

21-

Jun

-17

10-

May

-18

US20180125

965

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF Takeda Vaccines, Inc. 7-

Nov-

14

6-

Nov

-15

10-

May

-18

US20180125

952

PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT Not Available 15-

May-

15

13-

May

-16

10-

May

-18

US20180125

883

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES Not Available 7-

Mar-

12

20-

Sep

-17

10-

May

-18

US20180112

270

C-CBL MUTATIONS AND USES THEREOF Not Available 4-

Jun-

10

22-

Mar

-16

26-

Apr-

18

US20180111

991

MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS Not Available 2-

Dec-

14

2-

Jun

-17

26-

Apr-

18

 

US20180U1

907

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER

MUCOSAL DISEASES

Not Available 29-

May-

12

20-

Dec

-17

26-

Apr-

18

US20180110

845

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS Not Available 31-

Aug-

07

18-

Dec

-17

26-

Apr-

18

US20180105

815

Bivalent siRNA Chimeras and Methods of Use Thereof Not Available 18-

Oct-

16

6-

Oct

-17

19-

Apr-

18

US20180105

596

ANTI-TYRO3 ANTIBODIES AND USES THEREOF Not Available 17-

Apr-

15

15-

Apr

-16

19-

Apr-

18

US20180105

514

HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS Not Available 7-

Apr-

16

3-

Jan

-18

19-

Apr-

18

US20180104

241

CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY PARION SCIENCES, INC. 27-

Jun-

11

15-

Dec

-17

19-

Apr-

18

US20180100

181

METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME Not Available 17-

Apr-

15

15-

Apr

-16

12-

Apr-

18

US20180099

999

FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA Not Available 17-

Sep-

14

14-

Dec

-17

12-

Apr-

18

US20180098

972

TREATMENT OF INFECTIOUS DISEASES CHILDREN’S MEDICAL CENTER CORPORATION 26-

Jan-

15

26-

Jan

-16

12-

Apr-

18

US20180092

932

Anti-Viral Azide Containing Compounds Not Available 28-

Jul-10

7-

Dec

-17

5-

Apr-

18

US20180087

049

MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN RAPID CLOT TUBES Not Available 27-

Sep-

16

7-

Sep

-17

29-

Mar

-18

US20180086

818

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY Not Available 28-

Oct-

14

13-

Nov

-17

29-

Mar

-18

US20180085

457

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF Not Available 23-

Oct-

15

1-

Dec

-17

29-

Mar

-18

US20180085

432

STING (Stimulator of Interferon Genes), A Regulator of Innate Immune Responses Not Available 4-

Aug-

08

15-

Sep

-17

29-

Mar

-18

US20180085

388

DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS GLAXOSMITHKLINE BIOLOGICALS, SA 6-Jul-

10

5-

Oct

-17

29-

Mar

-18

US20180079

746

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available 19-

Mar-

15

15-

Mar

-16

22-

Mar

-18

US20180078

625

COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS Not Available 25-

Mar-

15

25-

Mar

-16

22-

Mar

-18

US20180078

532

IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB AMGEN INC. 21-

Sep-

16

18-

Sep

-17

22-

Mar

-18

US20180078

507

BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Not Available 16-

Sep-

16

15-

Sep

-17

22-

Mar

-18

US20180073

073

METHODS AND COMPOSITIONS FOR LABELING TARGETS AND HAPLOTYPE PHASING Not Available 18-

Mar-

15

16-

Mar

-16

15-

Mar

-18

US20180072

813

CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF Not Available 2-

Dec-

05

9-

May

-17

15-

Mar

-18

US20180072

796

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION Not Available 8-

Sep-

16

17-

Nov

-17

15-

Mar

-18

US20180072

752

COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE Not Available 30-

Mar-

15

2-

Feb

-16

15-

Mar

-18

US20180071

219

Technology for Preparation of Macromolecular Microspheres Not Available 24-

Jan-

06

25-

Sep

-17

15-

Mar

-18

US20180067

299

ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION MONITORING ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE 7-

Sep-

16

31-

May

-17

8-

Mar

-18

US20180066

228

Detection of T Cell Exhaustion or Lack of T Cell Costimulation and Uses Thereof Not Available 15-

May-

15

15-

Nov

-17

8-

Mar

-18

US20180066

216

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF Not Available 8-

Sep-

16

6-

Sep

-17

8-

Mar

-18

US20180065

981

HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR Not Available 26-

Mar-

15

21-

Mar

-16

8-

Mar

-18

 

US20180064

790

Composition for Treatment or Prevention of Infectious Inflammatory Diseases, or Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase as an Active Ingredient Not Available 26-

Feb-

15

25-

Aug

-17

8-

Mar

-18

US20180064

752

ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE Not Available 29-

Jul-14

25-

Oct

-17

8-

Mar

-18

US20180058

988

SAMPLE FIXATION AND STABILISATION Not Available 1-

Mar-

13

14-

Aug

-17

1-

Mar

-18

US20180057

871

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS Not Available 15-

Aug-

16

1-

Nov

-17

1-

Mar

-18

US20180057

841

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR Not Available 7-

Apr-

05

27-

Oct

-17

1-

Mar

-18

US20180057

817

Particle-Nucleic Acid Conjugates and Therapeutic Uses Related Thereto Not Available 25-

Jun-

12

9-

Oct

-17

1-

Mar

-18

US20180057

594

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES Not Available 30-

Jun-

16

29-

Sep

-17

1-

Mar

-18

US20180057

509

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES Not Available 9-

Feb-

05

2-

Nov

-17

1-

Mar

-18

US20180057

488

COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available 23-

Apr-

15

7-

Nov

-17

1-

Mar

-18

US20180055

925

DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS The United States of America, as represented by the Secretary, Department of Health and Human Serv 3-

Mar-

15

7-

Aug

-15

1-

Mar

-18

US20180055

769

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS Not Available 3-

Dec-

09

26-

Jun

-17

1-

Mar

-18

US20180051

267

TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available 10-

Dec-

09

5-

Oct

-17

22-

Feb

-18

US20180051

266

TAL EFFECTOR-MEDIATED DNA MODIFICATION Not Available 10-

Dec-

09

21-

Aug

-17

22-

Feb

-18

US20180050

059

DELIVERY OF RNA TO DIFFERENT CELL TYPES GLAXOSMITHKLINE BIOLOGICALS, SA 6-Jul-

10

30-

Aug

-17

22-

Feb

-18

US20180044

687

ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION Not Available 12-

Dec-

14

11-

Dec

-15

15-

Feb

-18

US20180044

328

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS Prozymex A/S 5-

Mar-

15

4-

Mar

-16

15-

Feb

-18

US20180043

007

INFLUENZA VIRUS VECTORS AND USES THEREFOR Not Available 17-

Mar-

14

21-

Aug

-17

15-

Feb

-18

US20180037

952

SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS Nanomedical Diagnostics, Inc. 28-

Apr-

14

21-

Aug

-17

8-

Feb

-18

US20180037

942

ENZYME-INDEPENDENT MOLECULAR INDEXING Not Available 3-

Aug-

16

1-

Aug

-17

8-

Feb

-18

US20180037

871

CANCER INITIATING CELL AND USE THEREOF Not Available 8-

Aug-

16

8-

Aug

-16

8-

Feb

-18

US20180037

636

STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. 18-

Jun-

09

21-

Sep

-17

8-

Feb

-18

US20180037

634

ENGINEERED POLYPEPTIDES AND USES THEREOF Not Available 2-

Aug-

16

2-

Aug

-17

8-

Feb

-18

US20180037

617

METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS Institute of Biophysics, Chinese Academy of Sciences 22-

Aug-

14

21-

Aug

-15

8-

Feb

-18

US20180036

398

FLAVIVIRUS REPLICONS Not Available 27-

Feb-

15

25-

Feb

-16

8-

Feb

-18

 

US20180036

237

OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION GLAXOSMITHKLINE BIOLOGICALS, SA 23-

Feb-

15

23-

Feb

-16

8-

Feb

-18

US20180031

555

METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES Menus N.V. 27-

Jun-

08

18-

Jul-

17

1-

Feb

-18

US20180030

429

Polypeptide Assemblies and Methods for the Production Thereof Not Available 27-

Feb-

15

29-

Feb

-16

1-

Feb

-18

US20180030

411

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

13-

Oct

-17

1-

Feb

-18

US20180028

677

Peptides for Assisting Delivery Across the Blood Brain Barrier Children’s Medical Center Corporation 22-

May-

06

30-

Jun

-17

1-

Feb

-18

US20180028

626

IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY Tnansgene SA 13-

Feb-

15

12-

Feb

-16

1-

Feb

-18

US20180028

562

METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL

WATER SOLUTION

SONOMA PHARMACEUTICALS, INC. 20-

Jan-

06

10-

Oct

-17

1-

Feb

-18

US20180028

449

Technology for the Preparation of Microparticles Not Available 24-

Jul-07

27-

Jun

-17

1-

Feb

-18

US20180028

431

POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF eXion labs Inc. 28-

Jul-16

27-

Jul-

17

1-

Feb

-18

US20180023

048

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS Not Available 29-

Oct-

04

22-

Sep

-17

25-

Jan-

18

US20180022

781

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 13-

Feb-

15

12-

Feb

-16

25-

Jan-

18

US20180021

448

Conjugates of Cell Binding Molecules with Cytotoxic Agents Hangzhou DAC Biotech Co., Ltd. 12-

Jul-12

16-

Apr

-14

25-

Jan-

18

US20180016

307

GRIFFITHSIN MUTANTS The United States of America, as represented by the Secretary, Department of Health and Human Serv 10-

Feb-

15

10-

Feb

-16

18-

Jan-

18

US20180016

285

Boron-Containing Small Molecules Not Available 20-

Jun-

07

28-

Sep

-17

18-

Jan-

18

US20180016

243

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS Not Available 13-

Feb-

15

12-

Feb

-16

18-

Jan-

18

US20180015

174

SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS Not Available 15-

Jul-16

14-

Jul-

17

18-

Jan-

18

US20180015

052

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY Not Available 30-

Jan-

15

28-

Jan

-16

18-

Jan-

18

US20180010

167

ORGANISM IDENTIFICATION PANEL Not Available 2-

Apr-

07

26-

Jul-

17

11-

Jan-

18

US20180010

125

DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF Quark Pharmaceuticals Inc. 12-

Sep-

12

15-

Feb

-17

11-

Jan-

18

US20180009

787

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. 31-

May-

16

22-

Sep

-17

11-

Jan-

18

US20180008

689

RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL ROBUSTNESS AND SEQUENCE SPACE Not Available 28-

Jan-

15

28-

Jan

-16

11-

Jan-

18

US20180002

743

FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE DETECTION OF TARGET RNA SEQUENCES Not Available 18-

Jun-

16

16-

Jun

-17

4-

Jan-

18

US20180002

406

NEUTRALIZING GP41 ANTIBODIES AND THEIR USE The United States of America, as represented by the Secretary, Department of Health and Human 7-

Nov-

11

8-

Sep

-17

4-

Jan-

18

US20180000

929

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF Not Available 30-

Nov-

12

14-

Sep

-17

4-

Jan-

18

US20180000

926

METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS Not Available 15-

Jan-

15

15-

Jan

-16

4-

Jan-

18

US20180000

868

Induced Hepatocytes and Uses Thereof Not Available 26-

Nov-

14

15-

Sep

-17

4-

Jan-

18

US20180000

724

METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE Not Available 26-

Jul-10

10-

May

-17

4-

Jan-

18

US20170369

843

SYNTHETIC MEMBRANE-RECEIVER COMPLEXES Not Available 18-

Nov-

13

29-

Mar

-17

28-

Dec

-17

US20170369

470

Cyclic Compounds and Uses Thereof Not Available 16-

Dec-

14

16-

Dec

-15

28-

Dec

-17

 

US20170368

203

Compositions For Enhancing Transport Of Molecules Into Cells Not Available 29-

Apr-

03

10-

Jan

-17

28-

Dec

-17

US20170368

201

SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM The Children’s Hospital of Philadelphia 15-

Mar-

13

8-

Sep

-17

28-

Dec

-17

US20170368

167

COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS Not Available 21-

Aug-

12

6-

Jun

-16

28-

Dec

-17

US20170362

300

OLIGOPEPTIDE-FREE CELL CULTURE MEDIA Not Available 4-

Jan-

06

7-

Aug

-17

21-

Dec

-17

US20170362

297

CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF Not Available 19-

Dec-

14

21-

Dec

-15

21-

Dec

-17

US20170362

187

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS Parion Sciences, Inc. 17-

Dec-

12

29-

Jun

-17

21-

Dec

-17

US20170362

170

HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS Not Available 3-

Aug-

07

29-

Jun

-17

21-

Dec

-17

US20170360

962

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES Not Available 16-

Feb-

16

18-

Aug

-17

21-

Dec

-17

US20170360

960

AAV Vectors Targeted to the Central Nervous System Not Available 21-

Nov-

14

20-

Nov

-15

21-

Dec

-17

US20170360

908

VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED IMMUNITY CONTAINING BISPHOSPHONATES NITTO DENKO CORPORATION 3-

Sep-

14

2-

Sep

-15

21-

Dec

-17

US20170360

881

PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF Not Available 17-

Jun-

16

16-

Jun

-17

21-

Dec

-17

US20170360

875

METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS MIDDLE TENNESSEE STATE UNIVERSITY 22-

Dec-

14

22-

Dec

-15

21-

Dec

-17

US20170358

082

STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING Not Available 15-

Mar-

13

2-

Aug

-17

14-

Dec

-17

US20170354

727

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS Not Available 8-

Oct-

04

23-

Aug

-17

14-

Dec

-17

US20170348

433

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES The Board of Trustees of the Leland Stanford Junior University 16-

Feb-

16

16-

Feb

-17

7-

Dec

-17

US20170348

402

SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR PROTEIN TO CELLS Not Available 30-

Jul-14

30-

Jul-

15

7-

Dec

-17

US20170348

369

Plant Extract and Its Therapeutic Use Not Available 16-

May-

08

18-

Jul-

17

7-

Dec

-17

US20170342

442

RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES GLAXOSMITHKLINE BIOLOGICALS, SA 11-

Oct-

11

15-

Aug

-17

30-

Nov

-17

US20170342

405

MOLECULAR INDEXING OF INTERNAL SEQUENCES Not Available 31-

May-

16

16-

May

-17

30-

Nov

-17

US20170342

056

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. 31-

May-

16

26-

May

-17

30-

Nov

-17

US20170340

735

Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof Not Available 1-

Oct-

15

19-

Jun

-17

30-

Nov

-17

US20170340

725

COMBINATION PIV3/HMPV RNA VACCINES ModernaTX, Inc. 22-

Oct-

15

11-

Aug

-17

30-

Nov

-17

US20170340

721

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES Not Available 3-

Sep-

14

3-

Sep

-15

30-

Nov

-17

US20170340

611

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. 31-

May-

16

26-

May

-17

30-

Nov

-17

US20170337

459

SPATIALLY ADDRESSABLE MOLECULAR BARCODING Not Available 27-

Feb-

15

2-

Aug

-17

23-

Nov

-17

US20170336

412

Multiplex Immuno Screening Assay Institut Pasteur 4-

May-

12

19-

Jul-

17

23-

Nov

-17

US20170336

411

B-CELL ANTIGEN PRESENTING CELL ASSAY The University of Pittsburgh – Of the Commonwealth System of Higher Education 8-

Apr-

10

9-

Aug

-17

23-

Nov

-17

US20170335

408

Methods and Systems of Multi-Assay Processing and Analysis Not Available 15-

Mar-

16

15-

Mar

-17

23-

Nov

-17

 

US20170335

374

METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE OF MICROBIAL CONTAMINATION IN A SAMPLE Not Available 6-

Mar-

12

6-

Jul-

17

23-

Nov

-17

US20170334

984

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) Not Available 16-

Dec-

02

26-

Apr

-16

23-

Nov

-17

US20170334

973

NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINS Not Available 28-

Oct-

14

27-

Oct

-15

23-

Nov

-17

US20170334

941

2′,2′-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER Not Available 31-

Oct-

14

30-

Oct

-15

23-

Nov

-17

US20170334

919

2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H- PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS RESPIVERT LTD. 15-

Mar-

13

27-

Jul-

17

23-

Nov

-17

US20170334

864

3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-

PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)

CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE

Parion Sciences, Inc. 27-

Jun-

11

1-

Mar

-17

23-

Nov

-17

US20170333

586

ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF Not Available 8-

Dec-

14

23-

May

-15

23-

Nov

-17

US20170333

553

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS Not Available 21-

May-

13

1-

Aug

-17

23-

Nov

-17

US20170333

494

PROBIOTIC THERAPEUTIC APPLICATIONS Not Available 10-

Nov-

14

9-

Nov

-15

23-

Nov

-17

US20170333

457

Anti-Viral Azide Containing Compounds Not Available 28-

Jul-10

8-

Aug

-17

23-

Nov

-17

US20170333

267

MOBILE CLINICS Baylor College of Medicine 12-

Nov-

14

11-

Nov

-15

23-

Nov

-17

US20170328

819

SAMPLE FIXATION AND STABILISATION Not Available 1-

Mar-

13

30-

May

-17

16-

Nov

-17

US20170327

543

POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES Not Available 8-

Sep-

10

31-

Jan

-17

16-

Nov

-17

US20170327

472

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL

SODIUM CHANNEL BLOCKING ACTIVITY

Parion Sciences, Inc. 17-

Dec-

12

7-

Mar

-17

16-

Nov

-17

US20170327

439

DIHYDRONAPHTHALENE DERIVATIVE ONO PHARMACEUTICAL CO., LTD. 3-

Dec-

14

3-

Dec

-14

16-

Nov

-17

US20170326

256

RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF Children’s Healthcare of Atlanta, Inc. 16-

Apr-

15

15-

Apr

-16

16-

Nov

-17

US20170326

123

Throat solution for treatment of cold, flu and sore throat Not Available 12-

May-

16

12-

May

-16

16-

Nov

-17

US20170322

682

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT-RELATED INFORMATION Georgetown University 25-

Feb-

08

27-

Jul-

17

9-

Nov

-17

US20170322

201

ANTIGEN PRESENTING CELL ASSAY University of Pittsburgh – Of the Com monwealth System of Higher Education 8-

Apr-

10

20-

Jul-

17

9-

Nov

-17

US20170321

192

Recombinant RNA Viruses and Uses Thereof Icahn School of Medicine at Mount Sinai 6-

Jun-

10

6-

Apr

-17

9-

Nov

-17

US20170319

712

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE 3M INNOVATIVE PROPERTIES COMPANY 10-

Apr-

03

27-

Jul-

17

9-

Nov

-17

US20170319

673

TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS Not Available 13-

Nov-

14

12-

Nov

-15

9-

Nov

-17

US20170319

551

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 9-

May-

12

24-

Jan

-17

9-

Nov

-17

US20170313

765

DIRECT EXPRESSION OF ANTIBODIES Not Available 29-

Oct-

14

28-

Oct

-15

2-

Nov

-17

US20170313

685

BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS Purdue Research Foundation 28-

Apr-

16

28-

Apr

-17

2-

Nov

-17

US20170312

371

MODIFIED VIRUS-LIKE PARTICLES OF CMV SAIBA GMBH 22-

Oct-

14

20-

Oct

-15

2-

Nov

-17

 

US20170312

357

MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS Not Available 2-

Dec-

14

2-

Dec

-15

2-

Nov

-17

US20170308

679

BIOSECURITY SCREENING SYSTEM AND METHOD Not Available 16-

Oct-

14

12-

Oct

-15

26-

Oct-

17

US20170307

562

CHEMICALLY DIFFERENTIATED SENSOR ARRAY Nanomedical Diagnostics, Inc. 28-

Apr-

14

8-

May

-17

26-

Oct-

17

US20170306

354

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 17-

Dec-

01

1-

May

-17

26-

Oct-

17

US20170306

293

MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS Not Available 9-

Dec-

05

2-

Jun

-17

26-

Oct-

17

US20170306

001

CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS MULTIPLE INFLUENZA A H5N1 CLADES NATIONAL UNIVERSITY OF SINGAPORE 27-

Mar-

14

27-

Mar

-15

26-

Oct-

17

US20170305

868

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS Parion Sciences, Inc. 13-

Dec-

13

1-

Mar

-17

26-

Oct-

17

US20170304

829

PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION MODULE Click Diagnostics, Inc. 22-

Apr-

16

21-

Apr

-17

26-

Oct-

17

US20170304

466

AAV-Based Gene Therapy Not Available 6-

Oct-

14

6-

Oct

-15

26-

Oct-

17

US20170304

459

METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE Not Available 10-

Oct-

14

7-

Oct

-15

26-

Oct-

17

US20170304

429

VACCINATION OF IMMUNOCOMPROMISED SUBJECTS Not Available 26-

Sep-

14

25-

Sep

-15

26-

Oct-

17

US20170304

420

POLYMER ADJUVANT Oxford University Innovation Limited 10-

Oct-

14

9-

Oct

-15

26-

Oct-

17

US20170304

354

TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS Marine Polymer Technologies, Inc. 15-

Apr-

11

13-

Mar

-17

26-

Oct-

17

US20170299

591

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES Not Available 6-

Oct-

08

13-

Dec

-16

19-

Oct-

17

US20170298

100

ANTI-VIRAL PEPTIDES Not Available 1-

Oct-

14

30-

Sep

-15

19-

Oct-

17

US20170296

663

Conjugates of Cell Binding Molecules with Cytotoxic Agents Hangzhou DAC Biotech Co., Ltd. 16-

Apr-

14

16-

Apr

-14

19-

Oct-

17

US20170296

574

Method of Treating Inflammation Not Available 1-

Apr-

10

28-

Jun

-17

19-

Oct-

17

US20170292

132

TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF Not Available 29-

Apr-

13

20-

Jun

-17

12-

Oct-

17

US20170290

909

METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING FLAGELLIN Bavarian Nordic A/S 26-

Sep-

14

25-

Sep

-15

12-

Oct-

17

US20170281

966

Device to Kill Micro-Organisms Inside the Respiratory Tract Not Available 1-

Apr-

16

28-

Mar

-17

5-

Oct-

17

US20170281

759

BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITY NITTO DENKO CORPORATION 3-

Sep-

14

2-

Sep

-15

5-

Oct-

17

US20170275

621

CHIRAL CONTROL Not Available 13-

Jul-12

17-

Mar

-17

28-

Sep

-17

US20170275

592

CULTURE MEDIUM Koninklijke Nederlandse Akademie Van Wetenschappen 27-

Nov-

14

27-

Nov

-15

28-

Sep

-17

US20170275

323

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY THE UNIVERSITY OF NOTTINGHAM 4-

Apr-

14

7-

Apr

-15

28-

Sep

-17

US20170275

253

BENZAZEPINE SULFONAMIDE COMPOUNDS Hoffmann-La Roche Inc. 18-

Dec-

14

14-

Jun

-17

28-

Sep

-17

US20170275

243

Lipids and Lipid Compositions for the Delivery of Active Agents Novartis AG 5-

Sep-

14

4-

Sep

-15

28-

Sep

-17

US20170274

064

MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES Not Available 5-

Sep-

14

4-

Sep

-15

28-

Sep

-17

US20170274

024

AAV Vectors Targeted to Oligodendrocytes Not Available 28-

Sep-

12

17-

Apr

-17

28-

Sep

-17

 

US20170267

969

Animal Protein-Free Media for Cultivation of Cells Baxalta GmbH 29-

Oct-

04

18-

May

-17

21-

Sep

-17

US20170267

722

INHIBITORY PEPTIDES OF VIRAL INFECTION Not Available 17-

Jul-14

25-

May

-17

21-

Sep

-17

US20170267

649

STABLE SODIUM CHANNEL BLOCKERS PARION SCIENCES, INC. 30-

Jun-

14

30-

Jan

-17

21-

Sep

-17

US20170266

272

TRANSGENIC VERO-CD4/CCR5 CELL LINE Not Available 2-

Oct-

15

6-

Apr

-17

21-

Sep

-17

US20170266

190

DRUG COMBINATION Not Available 15-

Mar-

13

5-

Jun

-17

21-

Sep

-17

US20170266

160

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C Not Available 14-

Mar-

13

6-

Jun

-17

21-

Sep

-17

US20170261

431

CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS Not Available 10-

Mar-

05

19-

May

-17

14-

Sep

-17

US20170260

223

ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN A Not Available 4-

Aug-

14

17-

May

-17

14-

Sep

-17

US20170260

147

ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited 26-

Jun-

03

23-

May

-17

14-

Sep

-17

US20170259

976

DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME MONOSOL, LLC 3-

Oct-

14

2-

Oct

-15

14-

Sep

-17

US20170258

904

Antagonism of the VIP Signaling Pathway Not Available 2-

Feb-

11

22-

May

-17

14-

Sep

-17

US20170258

893

MERS-CoV Vaccine Not Available 29-

Nov-

13

26-

Nov

-14

14-

Sep

-17

US20170253

861

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS Not Available 11-

Jul-03

6-

Oct

-16

7-

Sep

-17

US20170252

430

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT Not Available 1-

Apr-

14

1-

Apr

-15

7-

Sep

-17

US20170252

417

PROTEIN-CHAPERONED T-CELL VACCINES Not Available 7-

Mar-

16

7-

Mar

-17

7-

Sep

-17

US20170247

688

ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES NUEVOLUTION A/S 1-

Dec-

05

12-

Dec

-16

31-

Aug

-17

US20170247

453

SOLUBLE ENGINEERED MONOMERIC FC The United States of America, as represented by the Secretary, Department of Health and Human Serv 16-

Mar-

12

9-

May

-17

31-

Aug

-17

US20170247

423

STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION Not Available 29-

Feb-

16

28-

Feb

-17

31-

Aug

-17

US20170246

347

MATERIALS WITH IMPROVED PROPERTIES Not Available 1-

Nov-

15

5-

May

-17

31-

Aug

-17

US20170241

998

METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES Not Available 22-

Feb-

16

17-

Feb

-17

24-

Aug

-17

US20170240

639

ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY Not Available 22-

Feb-

16

22-

Feb

-17

24-

Aug

-17

US20170239

397

MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS Not Available 1-

Nov-

15

5-

May

-17

24-

Aug

-17

US20170239

364

METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY Not Available 28-

Mar-

11

2-

Mar

-17

24-

Aug

-17

US20170239

349

COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS Not Available 20-

Feb-

15

6-

Jun

-16

24-

Aug

-17

US20170239

291

METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION SONOMA PHARMACEUTICALS, INC. 30-

Dec-

03

9-

May

-17

24-

Aug

-17

US20170234

781

MEMBRANE-ASSISTED PURIFICATION Accelerate Diagnostics, Inc. 7-

Mar-

11

3-

May

-17

17-

Aug

-17

US20170226

593

HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION Not Available 8-

Feb-

16

8-

Feb

-16

10-

Aug

-17

US20170226

511

APTAMERS FOR BINDING FLAVIVIRUS PROTEINS National University of Singapore 13-

Nov-

13

13-

Nov

-14

10-

Aug

-17

US20170226

232

MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS Not Available 1-

Nov-

15

2-

Nov

-16

10-

Aug

-17

 

US20170226

222

BISPECIFIC ANTIBODY Not Available 20-

Nov-

13

18-

Jan

-17

10-

Aug

-17

US20170226

173

GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto Not Available 23-

Oct-

12

19-

Apr

-17

10-

Aug

-17

US20170224

813

VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL NITTO DENKO CORPORATION 4-

Aug-

14

4-

Aug

-15

10-

Aug

-17

US20170224

812

LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG NITTO DENKO CORPORATION 4-

Aug-

14

4-

Aug

-15

10-

Aug

-17

US20170224

616

OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS GLAXOSMITHKLINE BIOLOGICALS SA 6-Jul-

11

24-

Apr

-17

10-

Aug

-17

US20170219

560

MALARIA ANTIGEN SCREENING METHOD United States of America as Represented by the Secretary of the Navy 31-

Aug-

05

10-

Apr

-17

3-

Aug

-17

US20170216

431

VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION NITTO DENKO CORPORATION 2-

Oct-

14

1-

Oct

-15

3-

Aug

-17

US20170216

430

IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL COMPOSITION NITTO DENKO CORPORATION 4-

Aug-

14

4-

Aug

-15

3-

Aug

-17

US20170216

429

COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION NITTO DENKO CORPORATION 4-

Aug-

14

4-

Aug

-15

3-

Aug

-17

US20170216

427

Coronavirus Not Available 23-

Jul-14

23-

Jul-

15

3-

Aug

-17

US20170216

348

METAL NANOCLUSTERS AND USES THEREOF Not Available 7-

Aug-

14

7-

Aug

-15

3-

Aug

-17

US20170216

347

ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE UNIWERSYTET JAGIELLONSKI 29-

Jul-14

29-

Jul-

15

3-

Aug

-17

US20170212

116

BIOSENSORS FOR THE DETECTION OF INFECTION AND ASSOCIATED MALADIES ULISSE BIOMED SRL 31-

Jan-

14

26-

Jan

-15

27-

Jul-

17

US20170212

019

POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS Not Available 23-

Jan-

12

10-

Apr

-17

27-

Jul-

17

US20170211

096

LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus- Producing Cells for the Therapy of Tumors Not Available 29-

Jun-

11

7-

Apr

-17

27-

Jul-

17

US20170211

069

USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY University of Pittsburgh – Of the Com monwealth System of Higher Education 7-

Mar-

12

27-

Jan

-17

27-

Jul-

17

US20170211

058

METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF POOLED SAMPLES Not Available 6-

Aug-

14

5-

Aug

-15

27-

Jul-

17

US20170209

844

MICROSPOTTING DEVICE Not Available 18-

Apr-

12

5-

Jan

-17

27-

Jul-

17

US20170209

595

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULE Suzhou M-Conj Biotech Co., Ltd. 15-

Jul-15

5-

Apr

-17

27-

Jul-

17

US20170209

590

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS Not Available 13-

Jan-

11

10-

Jan

-17

27-

Jul-

17

US20170209

570

Carbon Nanotube Compositions and Methods of Use Thereof Not Available 19-

Mar-

08

17-

Mar

-17

27-

Jul-

17

US20170209

376

COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASES Not Available 14-

Apr-

04

10-

Mar

-17

27-

Jul-

17

US20170205

399

POLYMERS AND CONJUGATES COMPRISING THE SAME Not Available 2-

Oct-

14

31-

Mar

-17

20-

Jul-

17

 

US20170204

143

Constrained proteins and uses therefor Not Available 21-

Jul-14

21-

Jul-

15

20-

Jul-

17

US20170204

083

THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 11-

Sep-

12

13-

Jan

-17

20-

Jul-

17

US20170202

975

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULE Suzhou M-Conj Biotech Co., Ltd. 15-

Jul-15

5-

Apr

-17

20-

Jul-

17

US20170202

960

CATIONIC OIL-IN-WATER EMULSIONS GLAXOSMITHKLINE BIOLOGICALS, SA 6-Jul-

11

23-

Mar

-17

20-

Jul-

17

US20170202

959

ADJUVANT COMPOSITIONS AND RELATED METHODS Not Available 24-

Mar-

15

23-

Mar

-17

20-

Jul-

17

US20170202

956

Methods and Compositions for Inhibiting Akt3 Not Available 15-

Jan-

16

17-

Jan

-17

20-

Jul-

17

US20170202

955

Adjuvanted Influenza Vaccines for Pediatric Use Not Available 22-

Feb-

08

30-

Dec

-16

20-

Jul-

17

US20170202

949

DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE Providence Health & Services – Oregon 29-

Jul-05

29-

Dec

-16

20-

Jul-

17

US20170202

829

Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications Not Available 15-

Jan-

16

17-

Jan

-17

20-

Jul-

17

US20170196

979

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG 8-

Mar-

13

27-

Sep

-16

13-

Jul-

17

US20170196

954

PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR Not Available 15-

Jul-14

14-

Jul-

15

13-

Jul-

17

US20170191

933

Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal Detector Not Available 31-

Dec-

15

23-

Dec

-16

6-

Jul-

17

US20170191

079

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR Not Available 7-

Apr-

05

18-

Jan

-17

6-

Jul-

17

US20170190

770

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8) CORMORANT PHARMACEUTICALS AB 16-

Dec-

02

26-

Apr

-16

6-

Jul-

17

US20170189

521

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS 3M Innovative Properties Company 17-

Aug-

10

19-

Aug

-16

6-

Jul-

17

US20170175

140

METHODS FOR USING A 5′-EXONUCLEASE TO INCREASE HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLS Not Available 16-

Dec-

15

14-

Dec

-16

22-

Jun-

17

US20170173

585

POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTION Not Available 11-

Jul-14

10-

Jul-

15

22-

Jun-

17

US20170173

176

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD. 15-

Jul-15

3-

Mar

-17

22-

Jun-

17

US20170173

168

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD. 15-

Jul-15

3-

Mar

-17

22-

Jun-

17

US20170173

164

HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM Not Available 3-

Jun-

11

6-

Mar

-17

22-

Jun-

17

US20170168

052

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES Not Available 6-

Oct-

08

13-

Dec

-16

15-

Jun-

17

US20170168

044

QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE MEASURING XIAMEN UNIVERSITY 9-

Jun-

14

24-

Sep

-14

15-

Jun-

17

US20170166

574

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. 14-

Dec-

15

12-

Dec

-16

15-

Jun-

17

US20170165

366

Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof Not Available 1-

Oct-

15

13-

Feb

-17

15-

Jun-

17

US20170165

359

IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE Not Available 11-

Aug-

10

23-

Aug

-16

15-

Jun-

17

US20170165

341

REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION Not Available 24-

Aug-

12

15-

Feb

-17

15-

Jun-

17

US20170165

230

USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY Not Available 9-

Apr-

14

9-

Apr

-15

15-

Jun-

17

US20170160

218

APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT ANALYSES AND AMPLIFICATIONS Not Available 31-

Jul-12

23-

Feb

-17

8-

Jun-

17

 

US20170159

027

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 30-

Sep-

03

15-

Feb

-17

8-

Jun-

17

US20170159

026

Novel Recombinant Adeno-Associated Virus Capsids with Enhanced Human Skeletal Muscle Tropism Not Available 2-

Dec-

15

2-

Dec

-16

8-

Jun-

17

US20170158

752

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF Not Available 25-

Apr-

14

27-

Apr

-15

8-

Jun-

17

US20170157

262

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS Not Available 12-

Jul-12

12-

Jul-

12

8-

Jun-

17

US20170157

151

Broad Spectrum Antiviral and Methods of Use Not Available 17-

Apr-

06

16-

Feb

-17

8-

Jun-

17

US20170152

274

CHARGED LINKERS AND THEIR USES FOR CONJUGATION Hangzhou DAC Biotech Co., Ltd. 28-

Feb-

14

28-

Feb

-14

1-

Jun-

17

US20170152

271

GAK MODULATORS AS ANTIVIRALS Katholieke Universiteit Leuven 23-

Jul-14

23-

Jul-

15

1-

Jun-

17

US20170151

346

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD. 15-

Jul-15

13-

Feb

-17

1-

Jun-

17

US20170151

291

SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF Not Available 25-

Nov-

13

25-

Nov

-14

1-

Jun-

17

US20170145

394

TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9 Not Available 23-

Nov-

15

22-

Nov

-16

25-

May

-17

US20170144

984

MODULATORS OF THE RELAXIN RECEPTOR 1 Not Available 4-

May-

12

25-

Aug

-16

25-

May

-17

US20170143

845

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE SUZHOU M-CONJ BIOTECH CO., LTD 15-

Jul-15

3-

Feb

-17

25-

May

-17

US20170143

820

IMMUNOGENIC COMBINATIONS GLAXOSMITHKLINE SA 13-

Jun-

14

12-

Jun

-15

25-

May

-17

US20170143

758

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES Advanced Inhalation Therapies (AIT) Ltd. 11-

Sep-

13

4-

Jan

-17

25-

May

-17

US20170143

749

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Not Available 24-

Jun-

14

2-

Feb

-17

25-

May

-17

US20170137

527

GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN IMMUNE RESPONSE Not Available 25-

Mar-

05

7-

Nov

-16

18-

May

-17

US20170137

430

Nuclear Transport Modulators And Uses Thereof Not Available 29-

Jul-11

22-

Jul-

16

18-

May

-17

US20170136

118

NEUTRALIZING MOLECULES TO VIRAL ANTIGENS Not Available 28-

Mar-

08

8-

Jun

-16

18-

May

-17

US20170136

043

THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY The University of North Carolina at Chapel Hill 11-

Apr-

14

30-

Jan

-17

18-

May

-17

US20170131

271

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES Not Available 27-

Apr-

10

12-

Sep

-16

11-

May

-17

US20170130

200

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY Not Available 31-

Jul-15

29-

Jul-

16

11-

May

-17

US20170129

947

REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE Kolltan Pharmaceuticals, Inc. 25-

Jul-12

20-

Sep

-16

11-

May

-17

US20170129

891

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES Not Available 18-

Jun-

04

23-

Jan

-17

11-

May

-17

US20170128

465

Pharmaceutical Compositions and Methods Not Available 3-

Aug-

15

6-

Dec

-16

11-

May

-17

US20170122

853

PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV 8-

Aug-

14

7-

Aug

-15

4-

May

-17

US20170121

372

NOVEL DEPSIPEPTIDE AND USES THEREOF Not Available 3-

Dec-

12

15-

Jun

-16

4-

May

-17

US20170119

872

SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES Not Available 20-

Aug-

10

11-

Oct

-16

4-

May

-17

US20170119

871

LOW-ADDITIVE INFLUENZA VACCINES Not Available 27-

Jun-

07

24-

Jun

-16

4-

May

-17

US20170119

820

MODIFIED CELLS AND METHODS OF THERAPY Not Available 31-

Jul-15

29-

Jul-

16

4-

May

-17

 

US20170119

786

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS Not Available 8-

Mar-

11

11-

Nov

-16

4-

May

-17

US20170119

734

TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE Not Available 5-

May-

10

22-

Apr

-16

4-

May

-17

US20170118

995

MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE SAME, AND METHOD FOR CONTROLLING UNICELLULAR ORGANISMS AND/OR VIRUSES Riken Techno System Co., Ltd. 17-

Sep-

14

6-

Dec

-16

4-

May

-17

US20170114

053

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF The United States of America, as represented by the Secretary, Department of Health and Human Serv 12-

Jun-

14

12-

Jun

-15

27-

Apr-

17

US20170112

929

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER Not Available 7-

Sep-

12

6-

Jun

-16

27-

Apr-

17

US20170107

254

Modified Antimicrobial Peptides Not Available 2-

Apr-

14

2-

Apr

-15

20-

Apr-

17

US20170107

195

Chemical Compounds AstraZeneca AB 18-

Mar-

14

17-

Mar

-15

20-

Apr-

17

US20170106

077

INFLUENZA VIRUS VECTORS AND USES THEREFOR Not Available 17-

Mar-

14

13-

Mar

-15

20-

Apr-

17

US20170101

459

CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES Not Available 6-

Jun-

14

5-

Jun

-15

13-

Apr-

17

US20170101

413

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. 12-

Jun-

14

12-

Jun

-14

13-

Apr-

17

US20170100

474

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES Not Available 6-

Apr-

07

22-

Jul-

16

13-

Apr-

17

US20170100

385

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED 12-

May-

14

8-

May

-15

13-

Apr-

17

US20170096

646

Modified Adenovirus Hexon Protein and Uses Thereof Not Available 28-

Apr-

06

20-

Dec

-16

6-

Apr-

17

US20170096

455

METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS The University of North Carolina at Chapel Hill 20-

Mar-

14

20-

Mar

-15

6-

Apr-

17

US20170096

441

PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS Not Available 14-

Apr-

10

9-

Sep

-16

6-

Apr-

17

US20170096

417

Multicyclic Compounds And Methods Of Using Same Karyopharm Therapeutics Inc. 20-

Sep-

13

19-

Sep

-14

6-

Apr-

17

US20170095

818

INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION AND MICROARRAY DETECTION CapitalBio Corporation 31-

Mar-

14

31-

Mar

-15

6-

Apr-

17

US20170095

521

Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents Not Available 1-

Oct-

15

30-

Sep

-16

6-

Apr-

17

US20170089

911

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION Not Available 24-

Feb-

14

24-

Aug

-16

30-

Mar

-17

US20170088

858

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 17-

Dec-

01

20-

Oct

-16

30-

Mar

-17

US20170088

848

Recombinant Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants Expressing Hemagglutinin Medicago Inc. 21-

Jan-

08

2-

Sep

-16

30-

Mar

-17

US20170088

559

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES Not Available 9-

Feb-

05

12-

Dec

-16

30-

Mar

-17

US20170086

463

ANTIVIRAL AGENT Not Available 3-

Sep-

08

12-

Dec

-16

30-

Mar

-17

US20170082

608

Assay for Detecting TH1 and TH2 Cell Populations Not Available 16-

May-

14

15-

May

-15

23-

Mar

-17

US20170082

607

MALARIA ANTIGEN SCREENING METHOD Not Available 31-

Aug-

05

19-

Apr

-13

23-

Mar

-17

US20170081

655

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES Not Available 14-

Jul-15

13-

Jul-

16

23-

Mar

-17

US20170081

393

ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES The U.S.A., as represented by the Secretary, Department of Health and Human Services 31-

Jan-

08

2-

Dec

-16

23-

Mar

-17

US20170081

392

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF Not Available 13-

May-

14

13-

May

-15

23-

Mar

-17

 

US20170080

084

OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION Not Available 17-

Mar-

14

17-

Mar

-15

23-

Mar

-17

US20170080

079

METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES Not Available 23-

Sep-

15

23-

Sep

-16

23-

Mar

-17

US20170080

078

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME Not Available 24-

Apr-

12

3-

Oct

-16

23-

Mar

-17

US20170079

920

Technology for the Preparation of Microparticles Not Available 24-

Jul-07

5-

Dec

-16

23-

Mar

-17

US20170079

916

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY Not Available 23-

Sep-

15

23-

Sep

-16

23-

Mar

-17

US20170079

253

TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS INSTITUT PASTEUR 30-

Jul-03

17-

Jul-

12

23-

Mar

-17

US20170073

738

Compositions and Methods for Detecting and Quantifying Nucleic Acid Sequences in Blood Samples Longhorn Vaccines and Diagnostics, LLC 1-

Oct-

07

25-

Nov

-16

16-

Mar

-17

US20170073

730

METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION Not Available 11-

Sep-

15

8-

Sep

-16

16-

Mar

-17

US20170073

727

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA Not Available 8-

Nov-

13

2-

Nov

-16

16-

Mar

-17

US20170073

390

Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding Assay Not Available 6-

Jan-

06

5-

Dec

-14

16-

Mar

-17

US20170073

352

NOVEL SUBSTITUTED SPIROCYCLES Not Available 12-

Sep-

14

29-

Nov

-16

16-

Mar

-17

US20170072

053

METHODS FOR PREPARING SQUALENE Not Available 12-

May-

10

22-

Nov

-16

16-

Mar

-17

US20170071

980

METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION IN DENTAL APPLICATIONS OCULUS INNOVATIVE SCIENCES, INC. 2-

May-

05

22-

Nov

-16

16-

Mar

-17

US20170071

964

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS Not Available 16-

Sep-

15

16-

Sep

-16

16-

Mar

-17

US20170071

867

NOVEL NANOPARTICLE COMPOSITIONS Not Available 3-

Apr-

13

28-

Nov

-16

16-

Mar

-17

US20170067

030

ATTENUATED VIRUSES USEFUL FOR VACCINES Not Available 30-

Mar-

07

7-

Sep

-16

9-

Mar

-17

US20170067

021

MODIFIED CELLS AND METHODS OF THERAPY Not Available 31-

Jul-15

2-

Sep

-16

9-

Mar

-17

US20170066

788

BORON-CONTAINING SMALL MOLECULES Not Available 16-

Feb-

05

18-

Nov

-16

9-

Mar

-17

US20170066

787

BORON-CONTAINING SMALL MOLECULES Not Available 16-

Feb-

05

18-

Nov

-16

9-

Mar

-17

US20170066

731

SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS Not Available 7-

Mar-

14

5-

Mar

-15

9-

Mar

-17

US20170065

706

METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS Not Available 2-Jul-

07

14-

Sep

-16

9-

Mar

-17

US20170065

693

Sequential administration of a replication defective adenovirus vector in vaccination protocols Not Available 2-Jul-

07

14-

Sep

-16

9-

Mar

-17

US20170065

677

EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT Volution Immuno Pharmaceuticals SA 8-

Jan-

10

22-

Jul-

16

9-

Mar

-17

US20170065

636

MODIFIED CELLS AND METHODS OF THERAPY Not Available 31-

Jul-15

29-

Aug

-16

9-

Mar

-17

US20170058

430

BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS Not Available 18-

Feb-

14

18-

Feb

-15

2-

Mar

-17

US20170058

365

SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS Not Available 1-

Sep-

15

3-

Feb

-16

2-

Mar

-17

US20170057

978

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF Kineta, Inc. 9-

May-

14

8-

May

-15

2-

Mar

-17

US20170057

968

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS NOVARTIS AG 1-

May-

14

29-

Apr

-15

2-

Mar

-17

US20170057

938

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS Not Available 24-

Jan-

14

8-

Nov

-16

2-

Mar

-17

 

US20170052

190

Covalently Linked Thermostable Kinase for Decontamination Process Validation Not Available 20-

Feb-

08

8-

Jul-

16

23-

Feb

-17

US20170051

053

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY Not Available 28-

Dec-

11

7-

Sep

-16

23-

Feb

-17

US20170051

046

H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES MEDIGEN BIOTECHNOLOGY CORPORATION 20-

Aug-

15

20-

Aug

-15

23-

Feb

-17

US20170051

022

ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY Not Available 30-

Apr-

14

30-

Apr

-15

23-

Feb

-17

US20170051

007

PHARMACEUTICAL COMPOSITIONS AND METHODS Not Available 3-

Aug-

15

28-

Jul-

16

23-

Feb

-17

US20170049

813

ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE SAME OCULUS INNOVATIVE SCIENCES, INC. 13-

Mar-

07

8-

Nov

-16

23-

Feb

-17

US20170044

603

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS Not Available 31-

Jul-09

15-

Aug

-16

16-

Feb

-17

US20170044

595

PCR Ready Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences Longhorn Vaccines and Diagnostics, LLC 24-

Aug-

07

26-

Oct

-16

16-

Feb

-17

US20170044

237

ANTIBODIES AND PROCESSES FOR PREPARING THE SAME Not Available 16-

May-

08

23-

Aug

-16

16-

Feb

-17

US20170044

168

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS NOVARTIS AG 1-

May-

14

29-

Apr

-15

16-

Feb

-17

US20170042

994

COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS ASSISTANCE PUBLIQUE – HOPITAUX DE PARIS 22-

Jul-11

29-

Jul-

16

16-

Feb

-17

US20170042

898

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONS HEMAQUEST PHARMACEUTICALS, INC. 11-

Mar-

10

27-

Oct

-16

16-

Feb

-17

US20170039

316

Compositions, processes and algorithms for microbial detection Not Available 12-

Nov-

03

25-

Oct

-04

9-

Feb

-17

US20170039

314

BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING IOGENETICS, LLC 23-

Mar-

10

13-

Sep

-12

9-

Feb

-17

US20170038

085

AIR CURTAIN DEVICE Not Available 7-

Aug-

15

19-

Nov

-15

9-

Feb

-17

US20170037

457

NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME Not Available 5-

Feb-

14

29-

Jan

-15

9-

Feb

-17

US20170037

379

CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS AND USES THEREOF Icahn School of Medicine at Mount Sinai 2-

Dec-

05

3-

Mar

-16

9-

Feb

-17

US20170037

376

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, COMPOSITION USED IN METHOD, AND USES THEREOF GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES 15-

Nov-

13

12-

Nov

-14

9-

Feb

-17

US20170037

090

RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING POLYGENES Not Available 8-

Nov-

05

26-

Oct

-16

9-

Feb

-17

US20170037

045

HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM 3M Innovative Properties Company 3-

Jun-

11

24-

Oct

-16

9-

Feb

-17

US20170035

878

Multi-Functional Mucosal Vaccine Platform Not Available 11-

Feb-

14

11-

Feb

-15

9-

Feb

-17

US20170035

845

Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression Not Available 7-

Aug-

15

5-

Aug

-16

9-

Feb

-17

US20170029

877

POLYTAG PROBES Not Available 26-

Feb-

10

31-

Mar

-16

2-

Feb

-17

US20170029

847

ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG 30-

Dec-

13

28-

Jun

-16

2-

Feb

-17

US20170029

489

HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF Not Available 14-

Dec-

10

1-

Jun

-16

2-

Feb

-17

US20170028

082

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 30-

Sep-

03

3-

Aug

-16

2-

Feb

-17

US20170028

054

VACCINE COMPOSITION NITTO DENKO CORPORATION 4-

Apr-

12

11-

Oct

-16

2-

Feb

-17

US20170027

975

Methods of Treating Coronavirus Infection United States Government as represented by the Secretary, Department of Health and Human Services 7-

Apr-

14

7-

Apr

-15

2-

Feb

-17

 

US20170027

944

METHODS FOR TREATING VIRAL DISORDERS Not Available 24-

Sep-

09

18-

Feb

-15

2-

Feb

-17

US20170022

577

METHODS OF TESTING FOR INTRACELLULAR PATHOGENS Novartis AG 8-

Mar-

10

23-

Sep

-16

26-

Jan-

17

US20170022

242

NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D 17-

Apr-

14

17-

Apr

-15

26-

Jan-

17

US20170021

013

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF Not Available 30-

Nov-

12

31-

Mar

-16

26-

Jan-

17

US20170020

926

METHODS AND COMPOSITIONS FOR IMMUNOMODULATION Not Available 1-

Apr-

14

13-

Mar

-15

26-

Jan-

17

US20170016

048

COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF NUCLEIC ACIDS Not Available 18-

May-

15

17-

May

-16

19-

Jan-

17

US20170015

716

STABILIZED ANTI-MICROBIAL PEPTIDES Not Available 2-Jul-

15

1-

Jul-

16

19-

Jan-

17

US20170014

496

COMBINATION OF VACCINATION AND OX40 AGONISTS Not Available 12-

Mar-

14

12-

Mar

-14

19-

Jan-

17

US20170014

423

Benzazepine Dicarboxamide Compounds Hoffmann-La Roche Inc. 6-

Mar-

15

28-

Sep

-16

19-

Jan-

17

US20170011

131

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT RELATED INFORMATION Georgetown University 25-

Feb-

08

23-

Sep

-16

12-

Jan-

17

US20170010

264

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES Not Available 6-

Oct-

08

20-

Sep

-16

12-

Jan-

17

US20170009

237

Short Interfering RNA (siRNA) Analogues Not Available 21-

Mar-

03

28-

Mar

-16

12-

Jan-

17

US20170007

577

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS Not Available 29-

Nov-

02

19-

Sep

-16

12-

Jan-

17

US20170002

042

PEPTIDOMIMETIC MACROCYCLES Not Available 1-Jul-

15

1-

Jul-

16

5-

Jan-

17

US20170000

878

CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR Not Available 23-

Jun-

10

9-

Aug

-16

5-

Jan-

17

US20170000

873

Dimethyl Fumarate and Vaccination Regimens Not Available 14-

Mar-

14

13-

Mar

-15

5-

Jan-

17

US20160376

596

COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS Bavarian Nordic A/S 28-

Nov-

13

25-

Nov

-14

29-

Dec

-16

US20160376

321

A NOVEL SARS IMMUNOGENIC COMPOSITION BAYLOR COLLEGE OF MEDICINE 26-

Nov-

13

21-

Nov

-14

29-

Dec

-16

US20160375

137

TARGETING LIPIDS Tekmira Pharmaceuticals Corporation 4-

Dec-

07

22-

Oct

-13

29-

Dec

-16

US20160375

132

HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF Not Available 15-

Dec-

09

5-

Jul-

16

29-

Dec

-16

US20160369

268

TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES AND METHODS OF SYNTHESIS AND USE The Board of Regents of the University of Texas System 1-Jul-

13

25-

Jun

-14

22-

Dec

-16

US20160368

956

METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS Not Available 9-

May-

13

23-

Aug

-16

22-

Dec

-16

US20160368

904

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF Not Available 3-Jul-

13

3-

Jul-

14

22-

Dec

-16

US20160367

587

Systemic In Vivo Delivery of Oligonucleotides OncoImmunin, Inc. 12-

Jun-

13

12-

Jun

-14

22-

Dec

-16

US20160367

188

ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND DEVELOPERS’ TOOL KIT Not Available 17-

Jun-

15

10-

Sep

-15

22-

Dec

-16

US20160363

557

AMPEROMETRIC GAS SENSOR Not Available 25-

Jun-

12

25-

Aug

-16

15-

Dec

-16

US20160362

730

PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS Not Available 26-

Feb-

14

26-

Aug

-16

15-

Dec

-16

US20160362

454

Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses Not Available 7-

Oct-

11

10-

Jun

-16

15-

Dec

-16

US20160361

382

MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS Not Available 11-

Jun-

15

13-

Jun

-16

15-

Dec

-16

 

US20160361

259

Methods for the Preparation of Liposomes Not Available 23-

Sep-

09

2-

Aug

-16

15-

Dec

-16

US20160354

451

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS Not Available 31-

Aug-

07

9-

Jun

-16

8-

Dec

-16

US20160354

428

METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY Not Available 8-

Feb-

07

2-

Jun

-16

8-

Dec

-16

US20160354

347

Nuclear Transport Modulators and Uses Thereof Not Available 9-

May-

12

6-

Jan

-16

8-

Dec

-16

US20160348

153

EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENS THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv 29-

May-

15

31-

May

-16

1-

Dec

-16

US20160348

132

TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS Not Available 18-

May-

04

11-

Aug

-16

1-

Dec

-16

US20160348

115

CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity Not Available 27-

Sep-

06

26-

May

-16

1-

Dec

-16

US20160348

110

NUCLEIC ACID CHEMICAL MODIFICATIONS Not Available 2-

Mar-

09

11-

Aug

-16

1-

Dec

-16

US20160347

816

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER Not Available 15-

Apr-

11

29-

Feb

-16

1-

Dec

-16

US20160347

814

VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES Not Available 11-

Sep-

13

10-

Mar

-16

1-

Dec

-16

US20160347

784

NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF Not Available 6-Jul-

09

27-

May

-16

1-

Dec

-16

US20160346

309

TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS Not Available 1-

Jun-

07

21-

Dec

-15

1-

Dec

-16

US20160340

713

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID Not Available 6-

Oct-

06

20-

May

-16

24-

Nov

-16

US20160340

319

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Not Available 6-

Feb-

13

5-

Aug

-16

24-

Nov

-16

US20160339

097

CORONAVIRUS PROTEINS AND ANTIGENS MJ Biologics, Inc. 7-

Feb-

14

4-

Aug

-16

24-

Nov

-16

US20160338

998

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF 3-V Biosciences, Inc. 20-

Dec-

13

19-

Dec

-14

24-

Nov

-16

US20160333

356

OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY Not Available 3-

Mar-

11

28-

Jul-

16

17-

Nov

-16

US20160333

089

Antigenic GM-CSF Peptides and Antibodies to GM-CSF Not Available 8-

Feb-

06

18-

Jul-

16

17-

Nov

-16

US20160333

076

NEUTRALIZING GP41 ANTIBODIES AND THEIR USE The United States of America, as represented by the Secretary, Department of Health and Human Serv 7-

Nov-

11

2-

Aug

-16

17-

Nov

-16

US20160331

828

NUCLEIC ACID VACCINES Moderna Therapeutics, Inc. 23-

Apr-

14

5-

Apr

-16

17-

Nov

-16

US20160331

816

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS Not Available 18-

Oct-

13

18-

Apr

-16

17-

Nov

-16

US20160331

758

TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE Not Available 1-

Aug-

08

21-

Dec

-15

17-

Nov

-16

US20160327

506

CAPACITIVE LIQUID CRYSTAL BIOSENSORS Not Available 6-

May-

15

5-

May

-16

10-

Nov

-16

US20160327

484

A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST HYDROLYSATE AND ITS USE Not Available 30-

Dec-

13

18-

Dec

-14

10-

Nov

-16

US20160326

598

METHODS AND COMPOSITIONS FOR PROSTATE CANCER METASTASIS Not Available 25-

Mar-

11

27-

May

-16

10-

Nov

-16

US20160326

325

POWDERED POUCH AND METHOD OF MAKING SAME Not Available 16-

Apr-

12

19-

Jul-

16

10-

Nov

-16

 

US20160326

233

NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGEN Not Available 16-

Jan-

14

15-

Jan

-15

10-

Nov

-16

US20160326

141

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS Not Available 7-

Jan-

14

7-

Jan

-15

10-

Nov

-16

US20160325

283

BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS Not Available 30-

Mar-

09

18-

Jul-

16

10-

Nov

-16

US20160324

834

Use of mTOR Inhibitors to Enhance T Cell Immune Responses Not Available 5-

Aug-

08

16-

May

-16

10-

Nov

-16

US20160320

390

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES Not Available 1-

May-

15

1-

May

-15

3-

Nov

-16

US20160318

985

Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored GM-CSF and IL-4 Conjugates Not Available 29-

Apr-

15

29-

Apr

-16

3-

Nov

-16

US20160318

861

NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. 30-

Apr-

15

2-

May

-16

3-

Nov

-16

US20160317

647

NUCLEIC ACID VACCINES Moderna Therapeutics, Inc. 23-

Apr-

14

1-

Apr

-16

3-

Nov

-16

US20160317

637

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF Not Available 7-

Jan-

14

7-

Jan

-15

3-

Nov

-16

US20160317

496

METHODS OF TREATING CANCER AND OTHER DISORDERS Not Available 12-

Nov-

10

27-

Jun

-16

3-

Nov

-16

US20160317

458

Lipids and Lipid Compositions for the Delivery of Active Agents Not Available 19-

Dec-

13

17-

Dec

-14

3-

Nov

-16

US20160312

276

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION Not Available 23-

Apr-

15

21-

Apr

-16

27-

Oct-

16

US20160311

886

Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging Not Available 24-

Jan-

05

12-

Jul-

16

27-

Oct-

16

US20160311

835

NOVEL ANTIBIOTICS Not Available 26-

May-

11

30-

Nov

-15

27-

Oct-

16

US20160311

816

COMPOSITIONS AND METHODS FOR INHIBITING KINASES Not Available 23-

Apr-

15

22-

Apr

-16

27-

Oct-

16

US20160311

759

Lipids and Lipid Compositions for the Delivery of Active Agents Not Available 19-

Dec-

13

17-

Dec

-14

27-

Oct-

16

US20160310

511

Myxovirus Therapeutics, Compounds, and Uses Related Thereto Not Available 24-

Oct-

11

7-

Jul-

16

27-

Oct-

16

US20160305

936

DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY Not Available 13-

Jul-10

18-

Feb

-16

20-

Oct-

16

US20160304

954

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS Not Available 11-

Dec-

13

11-

Dec

-14

20-

Oct-

16

US20160304

942

Enhanced Methods of Ribonucleic Acid Hybridization Not Available 6-

Dec-

13

5-

Dec

-14

20-

Oct-

16

US20160304

904

Directed Evolution and In Vivo Panning of Virus Vectors Not Available CO 1 1 28-

Jun

-16

20-

Oct-

16

US20160304

883

ARTIFICIAL NUCLEIC ACID MOLECULES CureVac AG 30-

Dec-

13

28-

Jun

-16

20-

Oct-

16

US20160304

882

METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS GenVec, Inc. 10-

Nov-

05

27-

Jun

-16

20-

Oct-

16

US20160304

586

PROCESS FOR PREPARING INFLUENZA VACCINES Crucell Holland B.V. 5-

Dec-

13

4-

Dec

-14

20-

Oct-

16

US20160304

579

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION Not Available 30-

Jun-

11

29-

Feb

-16

20-

Oct-

16

US20160304

472

Hydrazide Containing Nuclear Transport Modulators and Uses Thereof Not Available 29-

Jul-11

13-

Nov

-15

20-

Oct-

16

US20160303

194

Compositions And Method For Treatment Of Inflammatory Bowel Disease Not Available 2-

Jun-

11

21-

Apr

-16

20-

Oct-

16

US20160303

052

MODULAR PARTICLES FOR IMMUNOTHERAPY Not Available 1-

Nov-

13

31-

Oct

-14

20-

Oct-

16

US20160299

141

NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS Biolog Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH 8-

Apr-

15

1-

Apr

-16

13-

Oct-

16

US20160298

179

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS CapitalBio Corporation 5-

Dec-

13

2-

Dec

-14

13-

Oct-

16

 

US20160296

617

Immunogenic Composition for MERS Coronavirus Infection Not Available 1-

Mar-

13

28-

Feb

-14

13-

Oct-

16

US20160296

616

IMMUNOGENIC COMPOSITIONS AND USES THEREOF Not Available 25-

Mar-

15

25-

Mar

-16

13-

Oct-

16

US20160295

844

GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF Not Available 13-

Apr-

15

12-

Apr

-16

13-

Oct-

16

US20160292

393

SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOF Not Available 24-

Oct-

13

13-

Apr

-16

6-

Oct-

16

US20160289

740

METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING Not Available 30-

Mar-

15

29-

Mar

-16

6-

Oct-

16

US20160289

191

ORGANIC COMPOUNDS NOVARTIS AG 27-

Jun-

08

9-

Oct

-15

6-

Oct-

16

US20160288

121

Slip Chip Device and Methods Not Available 24-

Mar-

09

25-

May

-16

6-

Oct-

16

US20160287

697

INJECTABLE VACCINE COMPOSITION NITTO DENKO CORPORATION 3-

Oct-

13

2-

Oct

-14

6-

Oct-

16

US20160287

622

COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING PROTEIN-RNA INTERACTION Massachusetts Institute of Technology 18-

Nov-

13

7-

Nov

-14

6-

Oct-

16

US20160281

109

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

Not Available 28-

Oct-

05

10-

Jun

-16

29-

Sep

-16

US20160280

707

ALKOXY SUBSTITUTED IMIDAZOQUINOLINES Not Available 3-

Oct-

03

13-

Jun

-16

29-

Sep

-16

US20160279

237

ADJUVANT COMPOSITIONS AND RELATED METHODS Not Available 24-

Mar-

15

24-

Mar

-16

29-

Sep

-16

US20160279

193

IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY Not Available 6-

Nov-

13

6-

Nov

-14

29-

Sep

-16

US20160279

165

PULSE INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES Not Available 24-

Mar-

15

24-

Mar

-16

29-

Sep

-16

US20160279

163

Method of Treating Inflammation Not Available 1-

Apr-

10

3-

Jun

-16

29-

Sep

-16

US20160278

349

Immunocompromised Ungulates Not Available 27-

Oct-

08

23-

Mar

-15

29-

Sep

-16

US20160272

707

VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES Not Available 11-

Sep-

13

11-

Sep

-14

22-

Sep

-16

US20160271

241

BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR GENES AND METHODS FOR GENERATING THESE VIRUSES Stichting Dienst Landbouwkundig Onderzoek 21-

May-

13

21-

May

-14

22-

Sep

-16

US20160271

240

Tetanus Toxoid and CCL3 Improve DC Vaccines Duke University 14-

Nov-

13

14-

Nov

-15

22-

Sep

-16

US20160271

137

INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS Not Available 18-

Feb-

10

27-

Oct

-15

22-

Sep

-16

US20160267

244

METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS Not Available 8-

Aug-

08

19-

May

-16

15-

Sep

-16

US20160265

025

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF Not Available 23-

Dec-

05

20-

May

-16

15-

Sep

-16

US20160264

971

COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION Not Available 20-

Jul-09

9-

Oct

-15

15-

Sep

-16

US20160264

962

TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS Not Available 4-

Apr-

12

28-

Jul-

15

15-

Sep

-16

US20160263

156

RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND THEIR USE FOR THE TREATMENT OF LUNG DISEASE University of Pittsburgh – Of the Com monwealth System of Higher Education 7-

Nov-

13

6-

Nov

-14

15-

Sep

-16

US20160258

949

CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX PNEUMOCOCCUS SEROLOGY Not Available 9-

Oct-

13

9-

Oct

-14

8-

Sep

-16

US20160257

932

GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER POLYPEPTIDE Not Available 18-

Nov-

13

17-

May

-16

8-

Sep

-16

US20160257

653

Benzazepine Dicarboxamide Compounds Hoffmann-La Roche Inc. 6-

Mar-

15

4-

Mar

-16

8-

Sep

-16

 

US20160256

870

Slip Chip Device and Methods Not Available 24-

Mar-

09

25-

May

-16

8-

Sep

-16

US20160256

541

Cationic Oil-In-Water Emulsions Not Available 6-Jul-

10

11-

Mar

-16

8-

Sep

-16

US20160253

584

SPATIALLY ADDRESSABLE MOLECULAR BARCODING Not Available 27-

Feb-

15

26-

Feb

-16

1-

Sep

-16

US20160251

637

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS Not Available 19-

Nov-

09

11-

Mar

-16

1-

Sep

-16

US20160251

631

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES Novartis AG 9-

Sep-

04

9-

May

-16

1-

Sep

-16

US20160251

399

PEPTIDOMIMETIC MACROCYCLES Not Available 14-

Jan-

09

7-

Apr

-16

1-

Sep

-16

US20160251

362

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.P.A. 18-

Dec-

12

10-

May

-16

1-

Sep

-16

US20160251

319

CARBOXYLIC ACID COMPOUNDS Astrazeneca Aktiebolag 18-

May-

12

11-

May

-16

1-

Sep

-16

US20160250

326

Conjugates of GM-CSF and IL-7, and Compositions Thereof Not Available 14-

Nov-

11

18-

May

-16

1-

Sep

-16

US20160250

278

PEPTIDOMIMETIC MACROCYCLES Not Available 14-

Jan-

09

7-

Apr

-16

1-

Sep

-16

US20160250

168

ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS Not Available 3-

Oct-

12

3-

Mar

-16

1-

Sep

-16

US20160238

601

METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS Not Available 14-

Oct-

13

14-

Oct

-14

18-

Aug

-16

US20160238

600

METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES Merus B.V. 30-

May-

03

27-

Apr

-16

18-

Aug

-16

US20160237

455

CRISPR-RELATED METHODS AND COMPOSITIONS Editas Medicine, Inc. 27-

Sep-

13

26-

Sep

-14

18-

Aug

-16

US20160237

123

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS Not Available 23-

Jan-

08

4-

May

-16

18-

Aug

-16

US20160237

082

DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME Not Available 10-

Oct-

13

10-

Oct

-14

18-

Aug

-16

US20160235

840

Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same Not Available 12-

Dec-

11

26-

Feb

-16

18-

Aug

-16

US20160235

837

THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV) Not Available 16-

Oct-

13

16-

Oct

-14

18-

Aug

-16

US20160235

835

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE Seqirus UK Limited 10-

Feb-

09

27-

Jan

-16

18-

Aug

-16

US20160235

675

Technology for the Preparation of Microparticles Not Available 24-

Jul-07

24-

Mar

-16

18-

Aug

-16

US20160230

190

Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof Not Available 17-

Sep-

13

17-

Sep

-14

11-

Aug

-16

US20160229

904

Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use Not Available 6-

Feb-

15

5-

Feb

-16

11-

Aug

-16

US20160229

872

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

4-

Feb

-16

11-

Aug

-16

US20160229

864

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

4-

Feb

-16

11-

Aug

-16

US20160229

833

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 5-

Feb-

15

4-

Feb

-16

11-

Aug

-16

US20160228

540

NASAL MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION 3-

Oct-

13

2-

Oct

-14

11-

Aug

-16

US20160228

533

Use of EGFR Pathway Inhibitors to Increase Immune Responses to Antigens Emory University 23-

Sep-

13

23-

Sep

-14

11-

Aug

-16

US20160228

532

METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE FORMULATIONS Merck Sharp & Dohme Corp. 16-

Oct-

13

13-

Oct

-14

11-

Aug

-16

US20160228

463

BORON-CONTAINING SMALL MOLECULES Not Available 16-

Feb-

05

20-

Apr

-16

11-

Aug

-16

 

US20160222

414

CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSES Not Available 14-

Mar-

13

15-

Apr

-16

4-

Aug

-16

US20160222

072

Universal Protein Tag for Double Stranded Nucleic Acid Delivery Not Available 23-

Oct-

13

22-

Oct

-14

4-

Aug

-16

US20160222

023

NOVEL MONOTHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. 30-

Jan-

15

29-

Jan

-16

4-

Aug

-16

US20160222

010

4-AMINO-IMIDAZOQUINOLINE COMPOUNDS Hoffmann-La Roche Inc. 22-

Apr-

14

7-

Apr

-16

4-

Aug

-16

US20160221

994

Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Not Available 29-

Nov-

12

27-

Nov

-13

4-

Aug

-16

US20160220

664

ANTIGEN AND METHOD FOR PRODUCTION THEREOF Not Available 13-

Sep-

13

12-

Sep

-14

4-

Aug

-16

US20160220

595

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Not Available 11-

Sep-

13

10-

Sep

-14

4-

Aug

-16

US20160220

536

USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL­LIKE RECEPTOR OVEREXPRESSION Not Available 16-

Mar-

04

19-

Feb

-16

4-

Aug

-16

US20160215

282

SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES Not Available 28-

Jan-

15

20-

Jan

-16

28-

Jul-

16

US20160215

262

CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION Not Available 16-

Sep-

13

16-

Sep

-14

28-

Jul-

16

US20160213

776

ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS GlaxoSmithKline Biologicals SA 1-

Sep-

10

7-

Apr

-16

28-

Jul-

16

US20160213

773

MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION 3-

Oct-

13

2-

Oct

-14

28-

Jul-

16

US20160213

761

CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF Not Available 19-

Mar-

08

5-

Apr

-16

28-

Jul-

16

US20160213

647

COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION Not Available 28-

Jan-

15

27-

Jan

-16

28-

Jul-

16

US20160213

610

MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB Not Available 24-

Oct-

12

28-

Jan

-16

28-

Jul-

16

US20160207

980

FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES AMGEN INC. 5-

Sep-

13

5-

Sep

-14

21-

Jul-

16

US20160207

949

NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE Hangzhou DAC Biotech Co., Ltd 2-

Sep-

13

2-

Sep

-13

21-

Jul-

16

US20160207

900

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS PROZYMEX A/S 9-

Sep-

13

8-

Sep

-14

21-

Jul-

16

US20160206

729

IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS Not Available 19-

Sep-

13

19-

Sep

-14

21-

Jul-

16

US20160206

719

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY CureVac AG 22-

Feb-

13

5-

Apr

-16

21-

Jul-

16

US20160206

638

BORON-CONTAINING SMALL MOLECULES Not Available 16-

Feb-

05

5-

Apr

-16

21-

Jul-

16

US20160206

575

Inhibition of Biofilm Organisms NOVABIOTICS LIMITED 31-

Mar-

09

28-

Mar

-16

21-

Jul-

16

US20160202

258

B-CELL ANTIGEN PRESENTING CELL ASSAY University of Pittsburgh – Of the Com monwealth System of Higher Education 8-

Apr-

10

21-

Mar

-16

14-

Jul-

16

US20160201

110

DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES Not Available 9-

Jan-

15

17-

Nov

-15

14-

Jul-

16

US20160201

088

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR Not Available 17-

Dec-

01

30-

Mar

-16

14-

Jul-

16

US20160199

486

ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION Not Available 3-

Dec-

09

22-

Mar

-16

14-

Jul-

16

US20160199

449

METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON Hemispherx Biopharma, Inc. 21-

Aug-

13

21-

Aug

-14

14-

Jul-

16

 

US20160199

416

Induced Hepatocytes and Uses Thereof Not Available 26-

Nov-

14

25-

Nov

-15

14-

Jul-

16

US20160199

407

HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION THE UNIVERSITY OF IOWA RESEARCH FOUNDATION 25-

Jan-

08

17-

Dec

-15

14-

Jul-

16

US20160194

387

Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections Not Available 2-

Jan-

15

31-

Dec

-15

7-

Jul-

16

US20160194

322

SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS Not Available 25-

Nov-

03

14-

Mar

-16

7-

Jul-

16

US20160194

278

DITHIOL MUCOLYTIC AGENTS PARION SCIENCES, INC. 23-

Aug-

13

11-

Mar

-16

7-

Jul-

16

US20160193

603

SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE Not Available 29-

Jan-

10

5-

Aug

-15

7-

Jul-

16

US20160193

327

MUCOSAL VACCINE COMPOSITION NITTO DENKO CORPORATION 3-

Oct-

13

2-

Oct

-14

7-

Jul-

16

US20160193

321

MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS Novartis AG 11-

Sep-

06

5-

Nov

-15

7-

Jul-

16

US20160193

315

PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES Not Available 7-

Aug-

09

17-

Mar

-16

7-

Jul-

16

US20160192

658

HYDROGEN-CONTAINING ANTIMICROBIAL AGENT Not Available 13-

Aug-

13

5-

Aug

-14

7-

Jul-

16

US20160185

786

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS Not Available 30-

Dec-

14

29-

Dec

-15

30-

Jun-

16

US20160185

785

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS Not Available 30-

Dec-

14

29-

Dec

-15

30-

Jun-

16

US20160184

424

INTRANASAL VACCINATION DOSAGE REGIMEN Not Available 17-

Dec-

12

17-

Dec

-13

30-

Jun-

16

US20160184

334

BORON-CONTAINING SMALL MOLECULES Not Available 16-

Feb-

05

11-

Mar

-16

30-

Jun-

16

US20160177

337

METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR Not Available 16-

Jul-08

8-

Mar

-16

23-

Jun-

16

US20160177

336

Expression Tools for Multiprotein Applications Not Available 9-

Mar-

04

11-

Dec

-15

23-

Jun-

16

US20160175

433

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS Not Available 17-

Aug-

10

15-

Dec

-15

23-

Jun-

16

US20160175

394

Compositions and Uses of Lectins Emory University 12-

Feb-

10

11-

Dec

-15

23-

Jun-

16

US20160175

387

Use of Immune Suppressive Domains as Medicaments Not Available 10-

Apr-

13

10-

Apr

-14

23-

Jun-

16

US20160174

631

PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER, FORMULATIONS FORMING THE SAME, AND METHOD OF PRODUCING THEREOF Not Available 23-

Dec-

14

10-

Dec

-15

23-

Jun-

16

US20160168

203

Cyclic Antimicrobial Peptides NOVABIOTICS LIMITED 24-

Feb-

06

9-

Nov

-15

16-

Jun-

16

US20160168

101

NOVEL COMPOUNDS CHIESI FARMACEUTICI S.p.A. 15-

Dec-

14

27-

Nov

-15

16-

Jun-

16

US20160166

710

METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS CureVac AG 21-

Aug-

13

19-

Feb

-16

16-

Jun-

16

US20160166

676

Use of Immune Suppressive Peptides as Adjuvants Not Available 10-

Apr-

13

10-

Apr

-14

16-

Jun-

16

US20160160

258

MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS Not Available 26-

Feb-

03

8-

Feb

-16

9-

Jun-

16

US20160160

178

IMMUNOTHERAPY USING STEM CELLS Not Available 9-

Dec-

14

2-

Dec

-15

9-

Jun-

16

US20160159

927

IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V- R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS Not Available 5-

Dec-

14

7-

Dec

-15

9-

Jun-

16

US20160158

341

PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS Novartis AG 18-

Mar-

08

7-

Dec

-15

9-

Jun-

16

 

US20160158

340

INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS Not Available 27-

Jan-

06

4-

Dec

-15

9-

Jun-

16

US20160158

339

METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS Not Available 26-

Jul-13

24-

Jul-

14

9-

Jun-

16

US20160158

308

TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE CHILDREN’S HEALTHCARE OF ATLANTA, INC. 12-

Nov-

13

14-

Aug

-14

9-

Jun-

16

US20160158

294

Methods of Populating a Gastrointestinal Tract Not Available 4-

Feb-

13

4-

Feb

-14

9-

Jun-

16

US20160158

154

PROTEIN VESICLES AND METHODS OF MAKING AND USING THEREOF Not Available 5-

Dec-

14

7-

Dec

-15

9-

Jun-

16

US20160153

034

Rapid Epidemiologic Typing of Bacteria Not Available 19-

May-

08

11-

Nov

-15

2-

Jun-

16

US20160152

693

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES Ablynx N.V. 5-

Jun-

08

29-

Oct

-15

2-

Jun-

16

US20160152

676

HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS COLORADO STATE UNIVERSITY RESEARCH FOUNDATION 7-

Nov-

14

9-

Nov

-15

2-

Jun-

16

US20160152

667

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS Not Available 23-

Jan-

08

9-

Feb

-16

2-

Jun-

16

US20160152

596

Nuclear Transport Modulators and Uses Thereof Karyopharm Therapeutics Inc. 21-

Jun-

13

20-

Jun

-14

2-

Jun-

16

US20160151

399

BORON-CONTAINING SMALL MOLECULES Not Available 16-

Feb-

05

17-

Feb

-16

2-

Jun-

16

US20160146

806

RECEPTORS FOR B7-H4 Not Available 17-

May-

13

19-

May

-14

26-

May

-16

US20160146

786

Method of monitoring cellular trafficking of peptides Not Available 26-

Jun-

13

26-

Jun

-14

26-

May

-16

US20160145

246

NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Not Available 9-

May-

12

23-

Jun

-15

26-

May

-16

US20160144

061

Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides Not Available 15-

Jul-02

4-

Feb

-16

26-

May

-16

US20160139

143

DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY Not Available 2-Jul-

10

28-

Dec

-15

19-

May

-16

US20160137

702

GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES Not Available 12-

Sep-

07

7-

Aug

-15

19-

May

-16

US20160137

649

PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF Not Available 3-Jul-

13

1-

Jul-

14

19-

May

-16

US20160135

453

SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS Not Available 30-

Aug-

07

20-

Jan

-16

19-

May

-16

US20160130

367

GENERATION OF BINDING MOLECULES Merus B.V. 26-

Sep-

11

16-

Sep

-15

12-

May

-16

US20160130

345

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY Not Available 22-

Feb-

13

21-

Feb

-14

12-

May

-16

US20160130

265

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY Not Available 23-

Aug-

12

29-

Dec

-15

12-

May

-16

US20160129

110

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS AUTOIMMUNE TECHNOLOGIES, LLC 14-

Mar-

13

17-

Jul-

15

12-

May

-16

US20160129

104

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF Not Available 7-

Nov-

14

6-

Nov

-15

12-

May

-16

US20160129

095

Immunostimulatory Combinations Not Available 30-

Dec-

02

10-

Sep

-15

12-

May

-16

US20160128

937

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS Novartis AG 3-

Dec-

09

5-

Sep

-14

12-

May

-16

US20160122

412

COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND Not Available 15-

Mar-

13

16-

Mar

-14

5-

May

-16

 

US20160122

397

REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA Not Available 23-

Apr-

09

2-

Dec

-15

5-

May

-16

US20160122

312

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF Not Available 16-

Jul-13

16-

Jul-

14

5-

May

-16

US20160122

306

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER

MUCOSAL DISEASES

PARION SCIENCES, INC. 29-

May-

12

5-

Jan

-16

5-

May

-16

US20160116

462

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES Not Available 27-

Apr-

10

21-

Apr

-15

28-

Apr-

16

US20160115